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Abstract 
 
The extensive genetic variation in the lipooligosaccharide (LOS) core 
biosynthesis gene cluster, a majority of which occurs in the LOS outer core 
biosynthesis gene content present between lgtF and waaV, have led to the 
development of a classification system; with 8 classes (I-VIII) for Campylobacter 
coli (C. coli) LOS region and four groups (1-4) with 23 classes (A-W) for 
Campylobacter jejuni (C. jejuni) LOS region. The aim of this work was to 
characterise the C. jejuni and C. coli LOS biosynthesis loci with special emphasis 
on their classes’ distribution and also to determine the role of LOS in mediating 
the host immune response. Analysis of the LOS locus gene content in 50 C. 
jejuni clinical isolates and 703 publicly available C. jejuni genome sequences 
revealed that the class B (Group 1) was the most abundant LOS locus class in 
C. jejuni. Two novel C. jejuni LOS types were identified from the GenBank 
database which may have arisen due to interspecies and intraspecies LOS gene 
recombination. In silico analysis of LOS locus gene content in 564 publicly 
available C. coli genome sequences identified previously unknown LOS inner 
core biosynthesis genes; all were located between waaF and gmhA and 
occurred in 5 C. coli LOS locus types (I, II, III, V, VIII). It was also determined 
that class III is the most abundant LOS locus type in C. coli and the environmental 
niches are the major reservoirs of C. coli. Moreover, this work highlighted that 
live and heat killed cells of both C. jejuni and C. coli, as well as, extracted LOS 
activate the NLRP3 [Nucleotide binding oligomerisation domain (NOD) like 
receptors with pyrin domain–containing 3] inflammasome dependent signalling 
in a human monocytic cell line, THP-1. However, C. jejuni 11168 LOS mutant 
live cells and its modified LOS with altered lipid A and lack of LOS core 
oligosaccharides both stimulated significantly reduced Caspase-1 and IL-1β 
compared to the wild-type 11168 live cells and LOS, which indicated that 
variation in LOS structure can alter NLRP3 inflammasome activation. This work 
extends the understanding of the Campylobacter LOS locus classification 
system and determines that LOS plays an important role in the development of 
host immune response during Campylobacter infection.  
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CHAPTER 1 
Introduction 
 
1.1. Campylobacter  
Campylobacter, initially known as “Vibrio”, was observed for the first time in the 
large intestine of a child (Escherich, 1886) and subsequently, in an aborted 
sheep (McFaydean and Stockman, 1913). Later, Vibrio was reported as a cause 
of diarrhoea in humans (Levy, 1946; King, 1957). In 1963, Sebald and Veron 
found basic differences in the genomic DNA (gDNA) of Vibrio-like 
microorganisms and bacterial strains belonging to the Vibrio genus and therefore 
classified these Vibrio-like microorganisms in a new genus “Campylobacter” 
(Greek word; meaning: curved rod). Currently, this genus consists of 25 
Campylobacter species and 8 sub-species (Man, 2011).  
 
 
1.1.1. Physical aspects 
Campylobacter are Gram-negative rods (1.5-6.0 µm long and 0.2-0.5µm wide) 
which are either spiral curved or straight in shape with thin ends (Sebald and 
Veron, 1963; Man, 2011), as it can be seen in the microscopic images of 
Campylobacter jejuni (C. jejuni) 11168 and Campylobacter coli (C. coli) RM1875 
(Figure 1.1). These rods have flagella either at a single or both tapering ends for 
a cork-screw like motion (Yamamoto et al., 2013; Baldvinsson et al., 2014).  
 
                                      
 
Figure 1.1. Scanning electron micrographs showing the cell 
shape of C. jejuni 11168 and C. coli RM1875 (Current study) 
 
       C. jejuni 11168    C. coli RM1875 
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Campylobacter grow well in nutrient rich media in a microaerobic atmosphere (5-
10% CO2, 3-10% O2, and 85% N2) and at temperatures between 34 and 44 °C 
(Skirrow, 1977). Campylobacter are unable to grow below 30 °C and grow best 
at 42 °C (Konkel et al., 1998; Apel et al., 2012). In the presence of limited-oxygen, 
Campylobacter can utilise various compounds from the environment including 
fumarate, nitrate, nitrite, sulphite, trimethylamine-N-oxide, dimethyl sulfoxide, 
and hydrogen peroxides. Adaptation to use various compounds from the 
environment instead of oxygen for electron accepter dependent respiration help 
Campylobacter to survive in an oxygen-limited environment (Sellars et al., 2002; 
Myers and Kelly, 2005; Cameron et al., 2012). Campylobacter use these 
respiratory processes for energy preservation as well and do not oxidise or 
ferment carbohydrates for energy purposes (Mohammad et al., 2004). 
Campylobacter generally are non-spore forming and oxidase-positive 
microorganisms (Barrett et al., 1988).  
Under unfavourable growth conditions, spiral form Campylobacter cells may 
convert into coccoid forms and exhibit a viable, but non-cultureable state (Ng et 
al., 1985; Cappelier et al., 1999, Ziprin et al., 2003). Under strict anaerobic or 
hyperosmotic (2 % sodium chloride) conditions, Campylobacter cells appear as 
thin filaments with inhibition of DNA synthesis and growth (Sellars et al., 2002; 
Cameron et al., 2012). In addition, long-term storage and frequent sub-culturing 
in the laboratory can also affect Campylobacter physiology and motility traits. 
This is supported by the characterisation of a Whole Genome (WG) sequenced 
variant of C. jejuni 11168, where this variant was straight in shape and had 
reduced motility in comparison to the spiral-shaped and highly motile original 
strain (Gaynor et al., 2004).   
 
1.1.2. Genetic features  
C. jejuni 11168 in C. jejuni species (1.64 MB; Parkhill et al., 2000) and RM2228 
in C. coli species (1.68 MB; Fouts et al., 2005) were the first sequenced isolates. 
Subsequently, C. jejuni RM1221 (1.77 MB), C. jejuni 81-176 (1.62 MB), C. coli 
15-537360 (1.7MB), C. coli N29710 (1.67 MB) and other Campylobacter species 
related strains such as C. upsaliensis RM3195 (1.66 MB), C. lari RM2100 (1.53 
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MB), C. fetus 82-40 (1.77 MB), and C. geochelonis RC7 were also WG 
sequenced (Fouts et al., 2005;  Hofreuter et al., 2006; Miller et al., 2008; Pearson 
et al., 2013; Chen et al., 2013; Fitzgerald et al., 2014; Piccirillo et al., 2016). All 
of these sequenced Campylobacter strains had a small genome size (~1.5-1.8 
MB) in comparison to other enteropathogens such as Escherichia coli (E. coli), 
whose genome size is ~4.5 MB (Casale et al., 2018). The WG sequencing of 
Campylobacter strains has revealed many unique features which are commonly 
present in the genome of almost every species of the genus “Campylobacter”. 
The genome of almost all Campylobacter species contains a few phage-
associated and repeat sequences, but many phase variable genes (Parkhill et 
al., 2000; Dorrell et al., 2001; Prendergast et al., 2004; Fouts et al., 2005; Bayliss 
et al., 2012). It has low GC content (28-38 %) and may harbour pseudogenes as 
well as CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) 
sequences (Park et al., 1991; Fouts et al., 2005; Pearson et al., 2013; Ghatak et 
al., 2017). It consists of highly variable gene regions and most of them are 
involved in the biosynthesis of cell-surface carbohydrates containing structures, 
[lipooligosaccharide (LOS) and capsular polysaccharide (CPS)], flagellum, and 
iron-uptake system (Parkhill et al., 2000; Fouts et al., 2005; Hofreuter et al., 
2006). The absence of transposable inserted sequence (IS) elements in the C. 
jejuni 11168 genome (Parkhill et al., 2000) and the presence of four large IS 
elements in the C. jejuni RM1221 genome (Fouts et al., 2005) suggest that the 
number of genomic IS elements varies between strains, even in those, which 
belong to the same Campylobacter species. Exceptionally, a fragment of plasmid 
sequence was found inserted in the gDNA of C. jejuni 81-176 next to the leucine 
tRNA genes (Hofreuter et al., 2006). 
The presence or absence of plasmids differs among Campylobacter strains. For 
example, C. jejuni 11168 and RM1221 do not harbour a plasmid, but C. jejuni 
81-176 contain two plasmids, pVir and pTet. C. coli RM2228, C. coli 15-537360, 
C. lari RM2100, and C. upsaliensis RM3195, all have one plasmid (Parkhill et al., 
2000; Fouts et al., 2005; Hofreuter et al., 2006; Pearson et al., 2013). 
Campylobacter plasmids may harbour genes for drug resistance. The plasmid 
pN29710 in C. coli N29710 contains multi-drug resistance genes, and gives 
resistance for gentamicin, kanamycin, streptomycin, streptothricin, and 
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tetracycline (Chen et al., 2013). Similarly, pCC178 plasmid in C. coli RM2228 
confers resistance against kanamycin, neomycin, tetracycline, oxytetracycline, 
and minocycline (Fouts et al., 2005). Campylobacter plasmids may also contain 
genes linked to the type-IV protein secretion system. This is evidenced by the 
presence of type-IV secretion system related proteins encoding genes in C. jejuni 
81-176 pVir plasmid and C. coli 15-537360 cryptic plasmid (Hofreuter et al., 
2006; Pearson et al., 2013).   
 
1.1.3.  Reservoirs  
Campylobacter species including C. jejuni, C. coli, C. lari, C. fetus, C. 
upsaliensis, C. hypointestinalis, C. helveticus, C. lanienae, and C. mucosalis are 
mostly found in warm-blooded animals (Table 1.1). However, some 
Campylobacter species, such as, C. fetus and C. geochelonis can also occur in 
cold-blooded reptiles (lizard, tortoise, and snake) (Wang et al., 2015; Piccirillo et 
al., 2016). Interestingly, the most common species of Campylobacter, C. jejuni, 
has also been found in Antarctic penguins and fur seals (Broman et al., 2000). 
Chicken is the main reservoir of Campylobacter who colonise Campylobacter in 
its intestines after hatch, usually at the age of 2-5 weeks (Neill et al., 1984; 
Humphrey et al., 1993; Berndtson et al, 1996). In addition to livestock, 
Campylobacter isolates can be also be present in non-livestock niches (such as 
the environment), which may be agricultural or non-agricultural (Champion et al., 
2005; Wilson et al., 2008; Sheppard et al., 2010, 2013). 
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Table 1.1: Known Reservoirs of Campylobacter spp. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Campylobacter spp. 
 
Reservoirs 
 
Reference 
 
C. jejuni Chicken, dog, wild-
birds (duck, American 
crow, gull), monkey, 
cat, turkey, cow, 
sheep, Antarctic 
penguin, and fur seal 
Broman et al., 2000; 
Moore et al., 2004; 
Workman et al., 2005; 
Inglis et al., 2005; 
Rahimi et al., 2010; 
Weis et al., 2014 
C. coli Chicken, dog, wild-
birds, monkey, pig, 
turkey, cow, sheep 
Workman et al., 2005; 
Rahimi et al., 2010; 
Weis et al., 2014 
C. lari American crow, gull Moore et al., 2004; 
Weis et al., 2014 
C. fetus Duck, turtle, lizard, 
snake 
Luechtefeld et al., 1980; 
Wang et al., 2015 
C. upsaliensis Dog, cat Fouts et al., 2005; 
Workman et al., 2005 
C. geochelonis Western Hermann’s 
tortoise 
Piccirillo et al., 2016 
C. hypointestinalis Pig, cow Gebhart et al., 1985 
C. helveticus Cat Workman et al., 2005 
C. lanienae Cow Inglis et al., 2005 
C. mucosalis Pig Roberts et al., 1980 
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1.1.4. Transmission 
Soil and surface water at farm houses, contaminated with faeces of 
Campylobacter colonised animals or birds, are the two major environmental 
factors, which are considered responsible for animal-to-animal or animal-to-bird 
Campylobacter transmission (Ross and Donnison, 2006; Denis et al., 2011; Weis 
et al., 2014; Smith et al., 2016). Chicken flocks have mostly been found colonised 
with Campylobacter when other farm animals, such as cow and sheep, are 
present in the close proximity of poultry houses and old litter of these animals 
remain dispersed in the soil of poultry farms (Neill et al., 1984; Ahmed et al., 
2013). The farm environment does not only facilitate Campylobacter 
transmission from farm animals to chicken flocks, but also to other animals (dog, 
cat) and wild-birds (gulls, crow) (Wilson et al., 2008; Whiley et al., 2013; 
Bronowski et al., 2014). Subsequently, circulation of Campylobacter 
contaminated surface water in drinking water (typically untreated or non-
chlorinated) can transmit Campylobacter to humans (Kuusi et al., 2004; Uhlmann 
et al., 2009; Rosef et al., 2010), but at a low rate (Denis et al., 2011).  
Poultry flocks contaminated with approximately 109 Campylobacter are 
considered as a major source of Campylobacter transmission to humans 
(Atanassova and Ring, 1999; Newell and Fearnley, 2003). At slaughter time, 
Campylobacter present in the chicken intestine comes in contact with meat and 
further survives during retail meat processing. Campylobacter can then transmit 
to humans if this contaminated meat remains partially cooked or is consumed in 
its raw state (Zhao et al., 2001; Rahimi et al., 2010). It is considered, that a whole 
chicken can contain Campylobacter cells in the range of 350-107 (Hood et al., 
1988) and 500-800 cells can be a sufficient infectious dose for humans (Black et 
al., 1988). Feeding of raw meat to pets (specifically dogs) can also transmit 
Campylobacter from farm animals to pets and then pets to humans (Lenz et al., 
2009; Gras et al., 2013). In addition to meat, consumption of dairy products 
including unpasteurized milk from these animals can also contribute in 
Campylobacter transmission to humans (Levy, 1946; Robinson, 1981). 
Currently, no evidence of human-to-human Campylobacter transmission is 
available (Nichols, 2005). 
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The rate of Campylobacter colonisation in poultry flocks as well as 
Campylobacter infection in humans remains high during the summer (May to 
June) (Louis et al., 2005; Meldrum et al., 2005), which may occur due to 
increased fly populations in summer (Berndtson et al, 1996; Nichols, 2005). The 
presence of flies in the environment is another contributor to Campylobacter 
transmission between animals and humans (Nichols, 2005). The following figure 
1.2 represents the routes of Campylobacter transmission, important for infection 
in humans. 
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Figure 1.2: Campylobacter transmission routes; linking Campylobacter 
transmission from different Campylobacter reservoirs to humans. 
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1.2. Campylobacter Infection  
Campylobacter is a worldwide foodborne pathogen, associated with human 
gastroenteritis (EFSA, 2010; CDC, 2011; WHO, 2018). In comparison to other 
Campylobacter species, C. jejuni and C. coli are highly prevalent in 
Campylobacter reservoirs, specifically in chickens, and account for 
approximately 99% of all Campylobacter infections in UK and USA (Zhao et al., 
2001; Louis et al., 2005; Rahimi et al., 2010). Other Campylobacter species such 
as C. hyointestinalis and C. fetus can also cause infection in humans (Gebhart 
et al., 1985; Wang et al., 2015). 
Campylobacter infection commonly presents itself as an acute, self-limiting 
gastroenteritis with various non-specific symptoms including watery or bloody 
diarrhoea, abdominal pain, headache, fever, chills, and dysentery (van 
Spreeuwel et al., 1985; Black et al., 1988; Perkins and Newstead, 1994). 
Interestingly, Campylobacter infection has a different clinical manifestation in 
developed and developing countries and the reasons behind this geographical 
difference are unknown. In developed countries, illness is characterised by 
bloody diarrhoea with mucus and occurs mostly in young adults, whereas, in 
developing countries, it causes watery diarrhoea and occurs mostly in children 
of age < 5 years (van Vliet and Ketley, 2001; Masanta et al., 2013). Symptoms 
begin to develop after 24-72 hours of infection and last for 5 to 7 days (van 
Spreeuwel et al., 1985; Black et al., 1988; van Vliet and Ketley, 2001). After 72 
hours, stools containing leukocytes and erythrocytes together with 8-10 bowel 
movements are the two major signs of severe Campylobacter infection (Black et 
al., 1988; Samie et al., 2007).  
 
1.2.1. Post-infection effects 
It is hypothesised that Guillain-Barré Syndrome (GBS), Miller Fisher Syndrome 
(MFS), Reiter’s arthritis, and irritable bowel syndrome are the post-infectious, 
long-term consequences of Campylobacter infection (Endtz et al., 2000; 
McCarthy and Giesecke, 2001; Janseen et al., 2008). In GBS, cranial nerves 
extending from brain to various areas of the head and neck are affected, which 
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further develop difficulty in walking, muscle weakness, and muscle pain. MFS, a 
variant of GBS, is characterised mainly by paralysis of eye muscles and 
problems with balance and coordination (Nachamkin et al., 1998). 
 Almost 25-40% of GBS patients have been found with C. jejuni infection 1-3 
weeks prior to the onset of illness. This is supported with the high expression of 
Penner heat-stable serotypes, HS: O19 and HS: O41, in GBS patients. High 
numbers of these serotypes have also been observed in non-GBS patients or 
patients with gastroenteritis only (Endtz et al., 2000). Therefore, it has been 
suggested that Campylobacter infection is not a sole contributor to GBS onset. 
Other host/bacterial factors, for instance, host immune status and concurrent 
infections in the host, are also involved in GBS progression (Janseen et al., 
2008). In addition, vaccines administrated for rabies, oral polio, influenza, 
measles, tetanus toxoid, and hepatitis B administration can also contribute to the 
GBS development (Baxter et al., 2012). These post-infection complications occur 
rarely in humans (~1 to 8 per 1000 individuals) and typically appear in immune 
compromised individuals, such as, individuals with HIV infection  (McCarthy and 
Giesecke, 2001; Janseen et al., 2008). 
 
 
1.2.2. Epidemiology 
The annual estimated number for Campylobacter infection cases is 400-500 
million worldwide and 71 per 100,000 population in the European Union alone 
(Jeon et al., 2010; Magana et al., 2017). As Campylobacter infection is self-
limiting, reported incidences are likely to be under-estimates of the true disease 
burden of infection (Allos, 2001). The actual incidence rate is thought to be 10-
100 times higher than the reported cases of Campylobacter infection (Guerry et 
al., 2012). The estimates of reported incidences of Campylobacter infection 
cases per 100,000 of the population of several developed and developing 
countries are given in figure 1.3, indicating epidemiology of Campylobacter 
infection varies from region to region. 
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Figure 1.3: An overview of worldwide epidemiology of Campylobacter infection 
Average, reported incidences of gastroenteritis cases in Canada (Le´vesque et al., 2013), 
United Kingdom (Louis et al., 2005), Iceland (Stern et al., 2003), Germany (Schielke et al., 
2014), Norway (Sandberg et al., 2006), Ireland (Foley and Mckeown, 2006), China (Jun et 
al., 2013), Bangladesh (Islam et al., 2011), Kuwait (Ismail et al., 1998), and other countries 
(Pitkanen and Hanninen, 2017). 
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1.2.3. Prevention measures and treatment  
Public awareness related to food handling, cooking of meat at appropriate 
temperatures, and the avoidance of drinking unpasteurized milk or untreated 
water is crucial to decrease the incidence rate of Campylobacter infection. 
Maintenance of food hygiene measures in the kitchen, slaughter houses, and 
food processing units can also reduce the potential cross-contamination of 
Campylobacter (Humphrey et al., 2001; Zhao et al., 2001; Humphrey, 2006; 
Rahimi et al., 2010).  
Campylobacter infection is a self-limiting disease with an incubation period of 5-
7 days and therefore, clinical treatment is not required (van Spreeuwel et al., 
1985; Black et al., 1988; Perkins and Newstead, 1994). A homemade solution of 
table sugar with water to patients with mild diarrhoea and commercially available 
oral solutions to patients with severe diarrhoea can be given to overcome the 
loss of body fluids and electrolytes (Mackenzie & Barnes, 1988). Antibiotics are 
recommended mostly for very young children (< 2 years of age), pregnant, and 
immunocompromised patients, but a risk of antibiotic resistance development in 
Campylobacter always remains present (Funke et al, 1994; Mamelli et al, 2003; 
Eiland and Jenkins, 2008).  
Various flagellum-secreted proteins based vaccines (C. jejuni 81-176 FlaC, C. 
jejuni 81-176 FspA1, and C. jejuni CG8486 FspA2) and a conjugated capsule 
polysaccharide vaccine, CPS (81-176)-CRM (197), have been experimentally 
tested in mice (Baqar et al., 2008; Monteiro et al., 2009). A recombinant protein 
vaccine, ACE 393, was tested in volunteers (phase-II clinical trials), but remained 
unsuccessful as it did not provide the adequate immunity. Despite these 
experiments and efforts, no commercial vaccine has been developed for 
Campylobacter to date and this is largely due to the versatile and diverse nature 
of Campylobacter physiology and genomics (Riddle and Guerry, 2016).  
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1.3. Campylobacter Virulence in Humans 
1.3.1. Colonisation in the GI tract 
The main areas of Campylobacter localisation in humans is the lower GI tract, 
which includes the small intestine (ileum and jejunum), caecum, and colon (van 
Spreeuwel et al., 1985; Black et al., 1988). The GI tract in humans structurally 
consists of four cell layers: the mucosa, submucosa, muscularis externa, and 
serosa. The mucosa is the innermost layer which is further divided into the 
epithelium [a single layer of mucosal epithelial cells or intestinal epithelial cells 
(IECs)], lamina propria (a layer of connective tissues), and muscularis mucosae 
(a thin layer of smooth muscles). The mucosal epithelium of the small intestine 
consists of villi or crypts (finger-like projections), enriched with mucus secreting 
goblet cells. Campylobacter cells colonise the mucus layer and crypts in high 
numbers, rather than the intestinal lumen, due to the nutrients availability for 
maximal growth and low concentration of oxygen in this layer (Apel et al., 2012; 
Stahl and Vallance, 2015). The highly viscous mucus layer is mainly composed 
of mucin glycoproteins; proteins attached with L-fucose, galactose, sialic acid, 
N-acetyl galactosamine, N-acetyl glucosamine and mannose (Tu et al., 2008, 
Bäumler and Sperandio, 2016). Campylobacter utilises the mucin components 
(L-serine and L-fucose) by putative mucin-degrading enzymes as a source of 
energy (Tu et al., 2008; Stahl and Vallance, 2015; Bäumler and Sperandio, 
2016). 
  
1.3.2. Motility and chemotaxis 
Campylobacter flagellum filaments act as adhesins, develop strong host-
bacterial interaction, and help bacteria to colonise the viscous mucus layer of the 
human GI tract (Wösten et al., 2010; Yamamoto et al., 2013; Baldvinsson et al., 
2014). C. jejuni mutant cells (with paralysed flagella) were found only at 103/gram 
cecal content in comparison to the wild-type (WT) cells, which colonised up to 
109/gram cecal content (Baldvinsson et al, 2014).  
                                                                                                                                                        28 
 
Campylobacter cells sense chemoattractants (bile, L-fucose of mucin, amino 
acids, and salts of the organic acids) and chemorepellents within their 
surroundings via chemoreceptors. Campylobacter chemoreceptors (Tlp1, Tlp4, 
Tlp7, and Tlp10) have been divided into three groups (A. B, and C) based on 
their structural differences and affinity for ligands (chemoattractants) (Yamamoto 
et al., 2013; Baldvinsson et al, 2014). Binding of ligands to Campylobacter 
chemoreceptors initiate signal transduction in chemoreceptors, which further 
develops an interaction between chemoreceptors and flagellum. Consequently, 
Campylobacter flagellum receives a signal to move either clockwise or anti-
clockwise in order to achieve movement or chemotaxis, which may be towards 
the favourable environment or away from the unfavourable conditions (Tareen et 
al., 2010; Rahman et al., 2014; Reuter et al., 2019). 
 
1.3.3. Adherence and invasion 
Campylobacter crosses the mucus layer and adheres to the microvilli present on 
the apical surface of the epithelium cell layer (Monteville et al., 2003; O Cróinín 
and Backert, 2012). Following adherence, Campylobacter invades into the 
epithelial cells without changing the transepithelial electrical resistance and 
migrates either via transcellular translocation (apical endocytosis) or paracellular 
translocation (Hu et al., 2008; Backert et al., 2013). During transcellular 
translocation, disruption and subsequent accumulation of the host cell 
cytoskeletal proteins (microtubule-associated dynein and microfilament actin 
proteins) is a prerequisite of the Campylobacter entry process (Monteville et al., 
2003; Hu et al., 2008). In contrast, simultaneous cell membrane engulfment of 
bacteria into an endosome is thought to occur in order to initiate paracellular 
translocation (Hu et al., 2008). The actual mechanism behind endocytosis before 
the paracellular migration is not known (O Cróinín and Backert, 2012). 
Transcellular translocation is achieved generally via two mechanisms, zipper and 
trigger. The zipper-mechanism is more common in Listeria in which bacterial 
adhesins or invasins bind with the host cell receptors and disrupt the cytoskeletal 
proteins. The cytoskeleton protein-mediated zippering of host cell membrane 
causes the engulfment of interacting bacterial cells. In contrast, the trigger-
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mechanism is more common in Salmonella, where a bacterial cell releases many 
proteins into a host cell via type-III and type-IV protein secretion systems to 
trigger the disruption of host cell cytoskeletal proteins (O Cróinín and Backert, 
2012). The triggered signalling pathways in the host cell subsequently induce 
membrane ruffling for the internalisation of in-contact bacterial cell (Watson and 
Galan, 2008; O Cróinín and Backert, 2012).  
Campylobacter utilise both types of mechanisms, zipper and trigger, for its 
transcellular translocation or apical endocytosis (Figure 1.4) (O Cróinín and 
Backert, 2012). The Campylobacter adhesins including JlpA (Jejuni lipoprotein 
A; 42.3 kDa lipoprotein), Fn (Fibronectin; 220kDa glycoprotein), FlpA (Fn-binding 
protein), CadF (Cadherin-Fn binding protein; 37 kDa), Cbf-1 (Cell binding factor 
1; 28 kDa), KpsE and KpsM (capsule biosynthesis proteins), and glycans 
(specifically LOS) use the zipper mechanism as they bind to the specific host cell 
membrane proteins and induce endocytosis (Bacon et al., 2001; Jin et al., 2001; 
Monteville et al., 2003; O Cróinín and Backert, 2012; Rubinchik et al., 2012). It 
is considered that Campylobacter may decorate adhesins onto the cell surface 
in the form of pili that come in contact with host cells (Jin et al., 2001). An example 
of utilisation of the trigger-mechanism in Campylobacter is the secretion of 
several virulence associated, mainly Campylobacter invasion antigens (Cia; 
CiaB, CiaC, CiaI), by the flagellum into the host cells in order to facilitate the 
invasion process (Guerry, 2007; Hu et al., 2008; Wösten et al., 2010; 
Baldvinsson et al., 2014). The mechanism linking flagellum structural elements 
to endocytosis has not been fully explored yet. However, it has been observed 
that C. jejuni flagellum secreted CiaC recruits Rac1, a Rho GTPase, responsible 
for the cytoskeletal disruption in a host cell (Konkel et al., 2013).  
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Figure 1.4: A representation of zipper (A) and trigger (B) routes in C. jejuni, 
causing its translocation into a host cell (Reproduced from O Cróinín and Backert, 
2012). 
Yellow arrows in electron micrograph in figure 1.4 (A) represent invasion of C. jejuni 
cells into host cells with “zipper” mechanism. Yellow arrow in electron micrograph in 
figure 1.4 (B) shows invasion of a C. jejuni cell into host cells with “trigger” mechanism. 
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1.3.4. Intracellular survival 
After internalisation, Campylobacter cells reside in the vacuolar compartment or 
Campylobacter-containing vacuoles (CCVs) within the host cells (Hu et al., 2008; 
Watson and Galan, 2008). Golgi vacuolar compartments contain an acidic 
mixture to lyse the bacterial cell (Watson and Galan, 2008). CCVs are structurally 
and functionally different from the Golgi-vesicles and protect the enclosed 
bacteria from the action of lysosomes (Watson and Galan, 2008). CCVs fuse 
with the epithelial basolateral layer and consequently, bacteria exit from the host 
cell (basolateral exocytosis) subepithelially (Hu et al., 2008; Watson and Galan, 
2008). Inflammation and destruction of epithelial cells is an important aspect of 
Campylobacter infection which causes an imbalance in fluid transport across the 
GI tract and develops severe diarrhoea in host (Friis et al., 2009).  
 
1.3.5. Toxin production 
Toxins are defined as high molecular weight proteins which are secreted by 
Campylobacter cells inside the host IECs to cause cellular damage (Guerrant et 
al., 1987; Whitehouse et al., 1998). All Campylobacter strains do not produce the 
Cytolethal Distending Toxins (CDTs) (AbuOun et al., 2005), and their expression 
and activity may also vary among strains for unknown reasons (Wassenaar, 
1997). Campylobacter CDTs share structural similarity with the Vibrio cholerae 
toxin and E. coli heat-labile toxin. Generally, these types of toxins enter into the 
host cells via cell receptors and induce signalling to increase the intracellular 
level of cAMP (Wassenaar, 1997). Increase in cAMP affects the intracellular ion 
instability which leads to excess secretion of fluid from the damaged IECs 
(Wassenaar, 1997). Accumulation of fluid in intestinal cells has been proposed 
as a reason for diarrhoea development during Campylobacter infection (Guerrant 
et al., 1987; Whitehouse et al., 1998).  
Campylobacter CDTs treated HeLa cells have been observed with cell 
apoptosis, chromatin condensation, and nuclear fragmentation after 2-3 days of 
treatment. This is due to inactivation of a cyclin-dependent kinase (CDK-1) by its 
phosphorylation at a tyrosine-15 residue, which further arrests the cell in G2-
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phase and induces apoptosis. This mechanism can be employed in the non-
differentiated IECs and crypts where Cdc-2 inactivation can affect the cells’ 
maturation into fully functional epithelial cells (Whitehouse et al., 1998). 
Production of immature and non-functional cells with less absorptive properties 
can then majorly contribute to the progression of diarrhoea in humans 
(Whitehouse et al., 1998; van Vliet and Ketley, 2001). In addition to inducing ion 
instability and apoptosis in a host cell, Campylobacter toxins with haemolysin 
domains and phospholipase activity are also thought to be responsible for pore 
formation in erythrocytes and haemolysis (Guerrant et al., 1987; Grant et al., 
1997).  
 
1.3.6. Other virulence factors  
As discussed above, endocytosis and exocytosis of Campylobacter as well as 
Campylobacter CDTs facilitated ion instability, cell apoptosis, and pore formation 
in host cells are the key virulence factors. Iron acquisition, flagellum 
glycosylation, and stress regulating mechanisms are the other virulence factors, 
which help Campylobacter to survive inside the human body. The actual free iron 
(Fe2+) bioavailability in mammalian cells is approximately 10−18 M to 10−24 M, 
which is insufficient for optimum bacterial cell growth (Palyada et al., 2004). 
Campylobacter have evolved various mechanisms to uptake iron (Fe2+) from the 
host iron (Fe3+)-binding compounds (siderophores: enterochelin, ferrichrome, 
and rhodotorulic acid) and iron (Fe3+)-containing compounds (haem and ferri-
transferrins) in order to attain the required concentration of iron (10−7 M) (Miller 
et al., 2009). In addition, the post-translational modifications or O-linked 
glycosylation of flagella filaments and other flagellar components also contribute 
to the Campylobacter virulence (Guerry, 2007; Baldvinsson et al., 2014). 
Moreover, oxidative stress decreasing proteins, such as, superoxide dismutase 
(SodB), catalase (KatA), alkyl hydroperoxide reductase (AhpC), ferredoxin 
regulator protein (Fdx), thiol peroxidases, and cytochrome C peroxidases as well 
as heat shock proteins including GroESL, DnaJ, DnaK, and ClpB regulate the 
stress response and help Campylobacter to cope with the stressful environment 
inside the host (Konkel et al., 1998; Palyada et al., 2004, 2009; Apel et al., 2012).  
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1.4. Immune Responses against Campylobacter Infection  
1.4.1. Chicken immune responses  
Campylobacter is commensal in poultry because it modifies its physiological 
state during colonisation in the chicken intestine and does not produce any 
disease symptoms in chickens (Woodall et al., 2005). Campylobacter is not a 
harmless commensal in chickens as it stimulates the innate and adaptive 
immune responses in almost all types of chicken breeds. However, the extent of 
harm posed by Campylobacter may vary among different breeds of chickens 
(Humphrey et al., 2014). Chickens become infected with Campylobacter at the 
age of 2-3 weeks. Due to a lack of a fully developed adaptive immune system at 
this age, maternal antibodies, already passed from hens to chicks, provide 
protection against Campylobacter (Sahin et al., 2003; Shoaf-Sweeney et al., 
2008). Maternal antibodies against the Campylobacter flagellar proteins, outer 
membrane proteins and LOS were observed in new-born chicks (Shoaf-
Sweeney et al., 2008). After developing an adaptive immune system at the age 
of 6-7 weeks, chickens produce antibodies against Campylobacter cellular 
components, such as outer membrane proteins and flagellum (Cawthraw et al., 
1994; Shoaf-Sweeney et al., 2008). However, circulation of maternal antibodies 
as well as development of adaptive immune B-cells play a limited role in the 
clearance of Campylobacter cells from the chicken intestines (Sahin et al., 2003; 
Lacharme-Lora et al., 2017). It is proposed that Campylobacter avoids rapid 
clearance in the chicken intestine due to the adaptation to a novel colonisation 
mechanism, where it continues short-term invasion of chicken IECs followed by 
escape from these cells (van Deun et al., 2008).  
 
1.4.2. Human innate immune responses 
The nucleotide-binding oligomerisation domain (NOD) proteins are the IECs 
intracellular pattern recognition receptors (PRRs) which directly recognise the 
microbe associated molecular patterns (MAMPs) of Campylobacter and induce 
the release of antimicrobial peptides (AMPs) including human beta-defensins 2 
(hBD-2) ( Zilbauer et al., 2007). The hBD-2 are bactericidal as they disrupt the 
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Campylobacter cell wall integrity (Zilbauer et al., 2005). In addition, NOD-1 
binding to Campylobacter MAMPs (Campylobacter toxins or adhesins) also 
promotes the secretion of a chemokine, interleukin- 8 (IL-8) from the human IECs 
(Hickey et al., 2000; Jin et al., 2003; Zilbauer et al., 2007) by the MAPK signalling 
pathway (Watson and Galan, 2005; John et al., 2017). The secreted IL-8 recruits 
the innate immune cells, specifically neutrophils, macrophages, and dendritic 
cells (DCs) at the site of infection. The accumulated DCs internalise the 
Campylobacter cells and become mature after the expression of cell surface co-
stimulatory molecules (CD40, CD80, and CD86). Subsequently, mature DCs 
produce different pro-inflammatory cytokines, including IL-1, IL-6, IL-8, IL-10, IL-
12, gamma interferon (IFN-γ), and tumour necrosis factor α (TNF-α) (Hu et al., 
2006; Murphy et al., 2011, Malik et al., 2014).  
Toll-like receptor (TLR)-2 are other IECs cell-surface PRRs which recognise the 
C. jejuni MAMPs and consequently, induce IL-6 secretion from IECs (Friis et al., 
2009). Different cellular constituents of Campylobacter such as lipoproteins (bind 
TLR-1/2/6), LOS (bind TLR-4), DNA, capsule, cell wall polysaccharides, flagella, 
and CDT can bind to TLRs in human immune cells to activate them (Hickey et 
al., 2000; Jin et al., 2003; Andersen-Nissen et al., 2005; Hu et al., 2006; de Zoete 
et al., 2009; Stephenson et al., 2013; Stahl et al., 2014). TLR signalling leads to 
the activation and translocation of NFKß to the nucleus to induce the transcription 
of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β (Wesche et al., 
2001; Verstak et al., 2009). In addition to NOD-1 and TLR dependent signalling, 
human serum or complement proteins also play an important role in C. jejuni 
infection (Bar, 1988; Keo et al., 2011). 
Human monocytes undergo apoptosis following infection with Campylobacter 
(Hickey et al., 2005; Wassenaar et al., 1997), however, macrophages rapidly kill 
Campylobacter cells subsequent to their internalisation (Wassenaar et al., 1997; 
Watson and Galán, 2008; Heikema et al., 2013). Campylobacter viability is not 
very important for macrophage infection as Campylobacter cellular components 
detached from killed Campylobacter cells can also bind to macrophage receptors 
(Stephenson et al., 2013; Bouwman et al., 2014; Korneev et al., 2018), which 
further induce cell signalling pathways and the secretion of pro-inflammatory 
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cytokines. For example, C. jejuni lipoproteins induce the production of TNF-α and 
IL-6 in macrophages (Jin et al., 2001; Shang et al., 2016). In addition to 
cytokines, protein complexes or NLRP3 [Nucleotide binding oligomerisation 
domain (NOD) like receptors with pyrin domain–containing 3] inflammasomes, 
also accumulate in the cytosol of human macrophages in response to the 
Campylobacter infection (Bouwman et al., 2014).  
 
1.4.3. Human adaptive immune responses 
During Campylobacter infection, DCs-derived cytokines, IL-12 and IL-10 in 
particular, stimulate the proliferation of CD4+ T-cells and their secretion of IFN-γ, 
IL-22 and IL-17 from these T-cells. In addition, DC-derived cytokines also 
contribute to the development of B lymphocytes in a T cell-independent manner 
(Hu et al., 2006; Edwards et al., 2010; Fimlaid et al., 2014; Malik et al., 2014). 
Antibodies against the Campylobacter toxins, flagella, LOS, and major outer 
membrane proteins, have been observed previously in human serum (Blaser et 
al., 1984; Kirimat et al., 1989; Godschalk et al., 2007). In the acute phase of 
infection (7 days post-infection), the level of serum antibodies, IgA and IgM, 
increase in serum (Strid et al., 2001). In the convalescent phase of infection (1 
week – 2 months), IgG also begins to circulate in the blood (Cawthraw et al., 
2000; 2002). These serum antibodies are detectable in the serum and faeces of 
Campylobacter infected patients (Lane et al., 1987). IgA and IgM decline over 
time. In contrast, IgG present in serum as well as serum IgG expelled into saliva, 
remain persistent inside the host for long time period (~ 1 year) and provide 
protection against subsequent Campylobacter infection (Cawthraw et al., 2000; 
2002).  
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1.5. Campylobacter LOS  
 
The lipopolysaccharides (LPS) present in the outer-cell membrane of Gram-
negative bacteria generally contain lipid A, core saccharides, and O-chains (a 
set of repeating saccharides). However, Gram-negative bacteria related to 
Neisseria, Haemophilus, and Campylobacter species lack LPS in the outer-cell 
membrane. Instead, they possess LOS with the composition of lipid A and core 
saccharides only (Mandrell et al., 1992; Moran, 1997; Duncan et al., 2009). In 
comparison to LPS, LOS are low-molecular weight biological molecules with the 
lack of O-chains (Moran, 1997). Other Campylobacter cell-surface structures 
include CPS, O-linked glycosylated flagellum, and N-linked glycoproteins. LOS, 
CPS, and O-linked glycans (mainly flagellar glycans) are variable among 
different strains, while, N-linked glycoproteins remain conserved (Karlyshev et 
al., 2005). The glycome comprising these four types of carbohydrates containing 
conjugate molecules are synthesised by more than 8 % of the genome in C. 
jejuni 11168 (Parkhill et al., 2000). 
 
 
1.5.1. The biosynthesis of LOS in Campylobacter and its comparison to 
LPS biosynthesis in E. coli  
 
Acyl transferases (encoded by genes, lpxA, lpxD) facilitate the attachment of two 
acyl chains to Uridine Di-Phosphate N-acetyl glucosamine (UDP-GlcNAc) and 
initiate the biosynthesis of LPS-lipid A in E. coli. The acylated UDP-GlcNAc is 
then deacylated and phosphorylated respectively by UDP-3-O-acyl-N-acetyl 
glucosamine deacetylase (lpxC) and UDP-2, 3-diacylglucosamine 
diphosphatase (lpxH) to form lipid X. Two lipid X molecules combine by lipid A 
disaccharide synthase (lpxB) and the produced disaccharide complex is then 
phosphorylated by tetraacyldisaccharide 4’ kinase (lpxK) to form lipid IVa. This 
lipid IVa is known as the lipid A backbone (Figure 1.5) (Emiola et al., 2015). The 
lipid A backbone in C. jejuni contains a 3-diamino-2, 3-dideoxy-D-glucopyranose 
linked to 2-amino-2-deoxy-D-glucose (GlcN), whereas, C. coli lipid A backbone 
consists of two GlcN (Culebro et al., 2016). Subsequently, in E. coli, two 3-deoxy-
D-manno-octulosonic acid (abbreviated KDO) molecules are joined to the lipid A 
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backbone by 3-deoxy-D-manno-octulosonic acid transferase (waaA) (Figure 1.5 
& 1.6A; Emiola et al., 2015). Similarly, lipid A biosynthesis lauroyl acyltransferase 
(waaM) in Campylobacter adds one KDO molecule to the backbone of lipid A 
(Figure 1.6B; Karlyshev et al., 2005). E. coli LPS-lipid A generally consists of 4 
hydroxyl-linked acyl chains and 2 amide-linked acyl chains, whereas, the LOS-
lipid A in most of the Campylobacter strains consists of 2 hydroxyl-linked acyl 
chains and 4 amide-linked acyl chains (Moran, 1997).  
 
The O-antigen of E. coli LPS is synthesised in the cytoplasmic side of the inner 
cell membrane by the addition of 3-5 monosaccharides to undecaprenol-PP 
(Emiola et al., 2015). Following synthesis, it is translocated to the periplasmic 
side of the inner membrane where a chain of repeating monosaccharide units is 
attached to already ligated 3-5 monosaccharides. Similarly, E. coli LPS lipid A 
and core are synthesised in the cytoplasmic side of inner cell membrane and 
later, translocate to the periplasmic side. In the periplasm, the lipid A-core 
assembles with O-antigen by O-antigen polymerase and finally, a complete 
synthesised LPS structure is decorated on the outer-cell membrane (Figure 1.5). 
Likewise, Campylobacter LOS lipid A and core are synthesised in the 
cytoplasmic side of inner cell membrane from where they are translocated to the 
periplasm and finally, to the outer cell membrane. The process of LOS 
biosynthesis and translocation is accomplished to further complete the synthesis 
of outer cell membrane (Whitfield and Trent, 2014; Simpson et al., 2015). 
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Figure 1.5: Biosynthesis of E. coli LPS and its translocation from inner membrane to outer membrane. 
O-antigen backbone (undecaprenol-PP with 3-5 saccharides), as well as, lipid A-core saccharides are synthesised in the cytoplasmic side of the inner 
cell membrane. Then these complex biological molecules flip towards the periplasmic side of the inner cell membrane, where they join together to form 
a complete LPS structure. LPS after synthesis are translocated to the outer cell membrane to build this membrane. 
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The core biosynthesis gene clusters involved in the biosynthesis of E. coli K12 
LPS core and C. jejuni 11168 LOS core have been demonstrated respectively 
(Figures, 1.6A and 1.6B). The inner core of C. jejuni 11168 LOS has two heptose 
and two glucose molecules in contrast to three heptose containing inner core of 
E. coli K12 LPS. The process of addition of first two heptoses to lipid A-KDO is 
similar in both E. coli and C. jejuni, where heptosyltransferase-I (waaC) adds the 
first heptose (Hep-I) to KDO and heptosyltransferase-II (waaF) catalyses the 
addition of a second heptose (Hep-II) to Hep-I (Klena et al., 1998; Kanipes et al., 
2004; 2006; Emiola et al., 2015). In C. jejuni 11168, two glucose molecules are 
added to Hep-I and Hep-II by lgtF (cj1135) encoded putative two-domain 
glucosyltransferase (Gilbert et al., 2002). Hep-1 and Hep-II in C. jejuni 11168 are 
synthesised by four LOS genes including gmhA (phosphoheptose isomerase), 
waaE (D-glycero-beta-D-manno-heptose-7-phosphate kinase), waaD (ADP-L-
glycero-D-manno-heptose-6-epimerase), and gmhB (dephosphatase) that add 
into the inner core of LOS. Unlike to the inner core, the outer core of LPS and 
LOS varies among E. coli as well as C. jejuni strains (Parker et al., 2005; Emiola 
et al., 2015). The outer core of C. jejuni 11168 is synthesised by 
glycosyltransferases (cj1136, cj1137, and cj1138), N-acetyl galactosaminyl 
transferase (cgtA/neuA1), sialyltransferase (cst-III), and galactosyltransferase 
(wlaN) (Gilbert et al., 2000; Linton et al., 2000; Gilbert et al., 2002; Guerry et al., 
2002; Karlyshev et al., 2005; Javed et al., 2012). The presence of cst-III, neuA1, 
neuB1, and neuC1 in the LOS biosynthesis cluster leads to the development of 
sialic acid containing LOS structural epitopes or human gangliosides mimics in 
C. jejuni 11168 (Gilbert et al., 2000; Gilbert et al., 2002; Guerry et al., 2002). 
Finally, the figure 1.6 (A) and figure 1.6 (B)  demonstrate that each LOS 
biosynthesis gene produces an individual enzyme either for the monosaccharide 
biosynthesis or addition of a particular monosaccharide to the LOS structure, 
explaining that LOS structures are synthesised at the genetic level (Karlyshev et 
al., 2005; Parker et al., 2005, 2008; Iwata et al., 2013).  
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Figure 1.6 (A): A representation of E. coli K12 LPS core biosynthesis gene cluster and its LPS structure. Each arrow represents an individual LPS core 
biosynthesis gene and its direction indicates the direction of gene transcription. A purple coloured gene catalyses the addition of KDO molecules to lipid A. Each 
orange coloured gene encoding enzyme catalyses the addition of a specific monosaccharide to LPS inner core structure. Each green coloured gene encoding 
enzyme catalyses the addition of sugars to LPS outer core structure.      
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Figure 1.6 (B): A representation of C. jejuni 11168 LOS core biosynthesis gene cluster and its LOS structure. Each arrow represents an individual LOS 
core biosynthesis gene and its direction indicates the direction of gene transcription. A purple coloured gene catalyses the addition of a KDO molecule to lipid 
A. Each orange coloured gene encoding enzyme catalyses the addition of a specific monosaccharide to LOS inner core structure. Each green coloured gene 
encoding enzyme catalyses the addition of sugars to LOS outer core structure. LOS genes, gmhA, waaE, waaD, and gmhB, synthesise heptoses for inner core, 
whereas, neuB1, neuC1 and cgtA/neuA1 synthesise sialic acid to incorporate in the outer core. 
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1.5.2. Classification of C. jejuni and C. coli LOS biosynthesis gene clusters 
The LOS inner core biosynthesis genes present upstream (waaC, waaM, and 
lgtF) and downstream (waaV, waaF, gmhA, waaE, waaD, gmhB, and cj1153) 
within the LOS biosynthesis gene cluster occur in the same order in almost all C. 
jejuni and C. coli strains. This is the reason that the inner LOS core is structurally 
similar in almost all Campylobacter strains (Gilbert et al., 2002; Karlyshev et al., 
2005; Richard et al., 2013). However, the LOS biosynthesis gene cluster 
extending from lgtF and waaV varies among C. jejuni and C. coli strains as this 
region may incorporate new genes or delete the existing genes. This region of 
the LOS biosynthesis cluster is involved in the biosynthesis of LOS outer core, 
hence, variations in this region cause modifications in the LOS outer core 
structure. The gene insertion or deletion events in this LOS biosynthesis region 
give rise to a new locus organisation or type in Campylobacter strains (Parker et 
al., 2005, 2008). As an example, the development of C. jejuni LOS type F derives 
from type D following a gene deletion event and type L derived from type G after 
insertion of two genes (Figure 1.7). A specific organisation of LOS genes named 
with an alphabetical letter is known as one C. jejuni class, and a Roman numeral 
is known as one C. coli LOS class. Previously known C. jejuni LOS classes (A 
through W) and C. coli LOS classes (I-VIII) are highlighted, respectively, in Table 
1.2 and Table 1.3 (Gilbert et al., 2002; Parker et al., 2008; Richard et al., 2013).  
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Figure 1.7: Development of new C. jejuni LOS types following the occurrence of gene deletion or insertion events in the 
LOS biosynthesis gene cluster.   
Deletion of ORF17 from C. jejuni LOS biosynthesis gene cluster type D establishes LOS class F and insertion of ORF47 and ORF48 in LOS class G leads 
to the development of LOS class L. Coloured boxes: LOS genes, likely to vary between C. jejuni strains. White boxes: LOS genes, commonly present in C. 
jejuni strains (Reproduced from Parker et al., 2008)
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Table 1.2: Previously known C. jejuni LOS types or classes (Gilbert et al., 2002; Parker et al., 2005, 2008; Richard et al., 2013) 
          LOS genes commonly present in C. jejuni are illustrated with black colour and LOS genes, likely to vary among strains, are presented with pink colour. 
 
 
LOS 
class 
 
Reference C. 
jejuni strain 
 
Accession no. 
(Sequencing level) 
 
Gene content present between lgtF and waaV LOS biosynthesis genes  
 
 
A 
 
 
RM1048/ 
ATCC43432 (A1) 
RM1556/ 
ATCC43438 (A2) 
AF215659 (Partial) 
 
AF400048 (Partial) 
      
                  
B RM1050/ 
ATCC43449 (B1) 
RM1052/ 
ATCC43456 (B2) 
AF401529 (Partial) 
 
AF401528 (Partial)        
   
C 
 
11168 AL 111168 (WGS) 
     
D RM3418 EU404109 (Partial) 
   
E 
 
81116 
 
CP000814 (WGS) 
 
 
F RM1221 CP000025 (WGS) 
 
G RM1555/ 
ATCC 43437 
AY436358 (Partial) 
 
 
H RM1553/ 
ATCC43435 
EU404106 (Partial) 
 
 
I RM1850 EU 404107 (Partial) 
 
 
J RM1508 
 
EU 404104 (Partial) 
 
 
 
 
  cj1136   cgtA    wlaN    cst     neuB1   neuC1 neuA1  cj1144  
 
 
  cj1136   cgtA    wlaN    cst     neuB1   neuC1 neuA1  cj1144  
 
 
  cj1136   cgtA    wlaN    cst     neuB1   neuC1 neuA1  cgtA-II  cj1144  
 
  cj1136   cgtA    wlaN    cst     neuB1   neuC1 neuA1  cgtA-II  cj1144 
 
 
 
  cj1136 cj1137 cj1138   wlaN    cst     neuB1  neuC1  cgtA/neuA1  cj1145  
 
 
   ORF17   cgtH     cgtG   cgtE   cj1145  
 
 
  ORF21 ORF22 ORF23 ORF24 ORF25 ORF26 ORF27 ORF28 ORF29 ORF30 ORF31 ORF32 ORF33 ORF34 
 
 
                cgtH     cgtG   cgtE   cj1145  
 
                             ORF35 ORF36 ORF37 cj1145 ORF38       
 
 
 ORF21 ORF22 ORF23 ORF24 ORF25 ORF26’ ORF27 ORF29 ORF30 ORF31 ORF32 ORF33 ORF34  
 
 
         ORF17  cgtH    cgtG   cgtE ORF40 ORF41 ORF42 ORF43 ORF44 ORF45       
 
 
                    cgtH   cgtG   cgtE    ORF40 ORF42 ORF43 ORF44 ORF45      
lgtF 
46 
 
K RM1861 
 
EU410350 (Partial)
  
 
L RM3435 EU404111 (Partial) 
 
M* RM1503  
 
EF140720 (Partial) 
 
 
 
 
N RM2095 
 
AY816330 (Partial) 
 
 
O RM3423 EF143352 (Partial) 
 
P GB4 AY943308 (Partial) 
 
Q RM3437 EU 404112 (Partial) 
 
R GC149 AY962325 (Partial) 
 
 
S RM3419 EU 404110 (Partial) 
 
 
T LMG23223 AIOC00000000 
(WGS; contig 1) 
 
U 2008-979 AIOU00000000 
(WGS; contigs 12, 
88) 
 
V 2008-1025 AIOP00000000 
(WGS; contigs 26, 
57, 134) 
 
W* M1 CP001900 (WGS) 
 
 
 
* Class M and Class W possess LOS genes exceptionally outside the defined LOS outer core biosynthesis gene region (lgtF-waaV).  
   WGS: Whole-genome sequence 
 
 
 
 
               ORF17  cgtH   cgtG   ORF49 ORF50     
 
 
 
                             ORF36 ORF37 ORF47 ORF48 cj1145       
 
 
               ORF17  cgtH   ORF38     
 
 
 
  ORF21 ORF22 ORF23 ORF24 ORF25 ORF26 ORF27 ORF29 ORF30 ORF31 ORF32 ORF33 ORF34  
 
 
 ORF21 ORF22 ORF23 ORF24 ORF25 ORF26’ ORF27 ORF28 ORF29 ORF30 ORF31 ORF32 ORF33 ORF34 
 
 
               ORF17  cgtH   cgtG    cgtE  ORF46  cj1145     
 
 
   cj1136   cgtA    wlaN    cst     neuB1  neuC1 neuA1  cj1145 
 
 
 
 
                               cgtH   cgtG ORF40 ORF41 ORF42 ORF43 ORF44 ORF45       
 
 
                                         ORF37 ORF38  
 
  
 
    ORF21  ORF22 ORF23 ORF24  M1118  M1119  M1120   ORF24   ORF27 ORF29   ORF30 ORF31 ORF32 ORF33  ORF34   waaV   waaF   M1130  M1131 
 
 
 
 
    waaM  ORF51 cj1135  ORF17   cst    neuB1  neuC1 neuA1  cj1144 
 
 
 
                                            wlaN  ORF37 ORF48 cj1145 ORF38  
 
 
  cj1136   cj1137   wlaN    cst     neuB1  neuC1  cgtA/neuA1  cj1145 
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                                                          Table 1.3: Previously known C. coli LOS classes (Richard et al., 2013) 
            LOS genes, commonly present in C. coli, are illustrated with black colour and LOS genes, likely to vary among strains, are presented with brown colour. 
LOS 
class 
C. coli reference 
strain 
Accession no. 
(Sequencing level) 
 
 Gene content present between lgtF and waaV LOS biosynthesis genes  
 
 
I LMG2336 
AINM01000000 (WGS; 
Contig 29)  
II 202/04 
AINH01000000 (WGS; 
Contig 4)  
III LMG23341 
AINN01000000 (WGS; 
Contig 20)  
IV 1948 
AINE00000000 (WGS; 
Contig 24)  
V 1957 
AINF01000000 (WGS; 
Contig 1)  
VI 1148 
AIMX00000000 (WGS; 
Contig 1)  
VII LMG9853 
AINR00000000 (WGS; 
Contig 1)  
VIII H9 
AINV01000000 (WGS; 
Contig 11)  
lgtF 
48 
 
1.5.3. Campylobacter LOS as a virulence determinant 
 
LOS is an integral part of the outer cell membrane. It does not only maintain the 
integrity of the cell membrane structure, but also acts as a barrier for those 
molecules which are transported through the cell membrane (Karlyshev et al., 
2005). For example, antibiotic permeability into the cell increases due to 
alteration in LOS structures, possibly because LOS structural changes decrease 
the cell membrane hydrophobicity. This is the reason that mutants of 
Campylobacter LOS genes are highly susceptible to some antibiotics, 
specifically to erythromycin (Kanipes et al., 2004; Jeon and Zhang, 2009; 
Marsden et al., 2009). In addition to providing a barrier to antibiotics, LOS also 
confers resistance to Campylobacter cells against the human serum proteins 
including polymyxin B, α-defensins, cathelicidins and bactericidal/permeability-
increasing proteins (Marsden et al., 2009; Keo et al., 2011). DNA uptake into a 
bacterial cell is an outer cell membrane-dependent process. Therefore, LOS 
modification in the outer cell membrane may also affect Campylobacter’s ability 
to uptake foreign DNA or its characteristic of natural transformation (Jeon and 
Zhang, 2009; Marsden et al., 2009). 
Campylobacter LOS mediate the interaction between the host and bacterial cell. 
The Campylobacter LOS terminal N-acetyl galactosamine residues bind with the 
human macrophage galactose-type lectin receptors in order to enhance the 
bacterial interaction with human macrophages (van Sorge et al., 2009). Similarly, 
Campylobacter LOS sialic acid residues bind to TLR-4 and sialoadhesin 
receptors present on the human macrophage cell surfaces (Klaas et al., 2012; 
Heikema et al., 2013; Stephenson et al., 2013). Campylobacter LOS sialic acid 
residues are also ligands of Sialic-acid binding immunoglobulin-like lectins 
(Siglecs) present on human monocytes and natural killer cells (Avril et al., 2006). 
Mutants of Campylobacter LOS genes (galE, cj1136, and waaF), in comparison 
to respective WT strains have showed reduced adherence and invasion into host 
IECs (Fry et al., 2000; Kanipes et al., 2004; Javed et al., 2012), which might be 
due to reduced interaction between host cell receptors and altered LOS 
structures. A mutant of C. jejuni 11168, lacking the core oligosaccharides in its 
LOS structures, was unable to invade Caco-2 cells, indicating the importance of 
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LOS in Campylobacter invasion into host cells (Marsden et al., 2009). Thus, LOS 
structures present on the Campylobacter cell surfaces develop interaction with 
host cells to further facilitate the adherence, invasion, endocytosis and 
translocation of Campylobacter into host cells (Fry et al., 2000; Marsden et al., 
2009; Louwen et al., 2012).  
Campylobacter LOS are stimulators and mediators of human immune cells. DC-
expressed Siglec-7 receptor interaction with α-2, 8-linked sialylated LOS induces 
the type-1 helper T cells (Th1) polarisation, whereas, its interaction with α-2, 3-
linked sialic acid induces a type-2 helper T cells (Th2) development. Hence, LOS 
structures mediate the DCs-dependent differentiation of ThO cells into Th1 or Th2 
cells (Hu et al., 2006; Bax et al., 2011). Moreover, variable LOS-outer core 
structures (displayed in figure 1.8) help Campylobacter to escape from the host 
immune system as they mimic the GM1, GM2, GM3, GD3 and GD1a containing 
human gangliosides (Ang et al., 2002). For this reason, antibodies produced 
against the LOS structural epitopes do not only bind to LOS structures, but also 
to human gangliosides. The cross-reactivity of anti-LOS antibodies with human 
gangliosides leads to the development of GBS or MFS in humans (Nachamkin 
et al., 1998; Endtz et al., 2000; McCarthy and Giesecke, 2001). It is proposed 
that C. jejuni LOS triggers the NFKß pathway via TLR signalling in CD14+ DCs 
and macrophages to stimulate cytokine production from these cells (Huizinga et 
al., 2013; Stephenson et al., 2013). Increase in the expression of DC-derived 
cytokines, such as IFN-ß, TNF-α, and IL-12, induces the proliferation of human 
mucosal B-lymphocytes in a T cell-independent manner. Subsequently, B-
lymphocytes then produce the cross-reactive antibodies in GBS patients post-
infection with Campylobacter. This links C. jejuni sialylated LOS structures with 
B-cell mediated autoimmunity in GBS patients (Kuijf et al., 2010; Huizinga et al., 
2013).  
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Figure 1.8: C. jejuni LOS structures and their corresponding human 
ganglioside mimics (Reproduced from Ang et al., 2002)
Structure of C. jejuni LOS                        Corresponding ganglioside-mimic 
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1.6. Aims and Objectives 
The aim of this research project is to characterise the LOS biosynthesis gene 
clusters involved in cell-surface LOS biosynthesis in C. jejuni and C. coli. To 
achieve this primary aim, this thesis has four following aims and objectives 
1) To analyse the extent of gene content variation in the C. jejuni LOS 
biosynthesis gene cluster by using a molecular typing method (Chapter 3).  
 Validate PCR as a LOS locus genotyping assay  
 Identify LOS locus type in clinical C. jejuni isolates by using PCR  
 Analyse LOS core of C. jejuni clinical isolates 
 
2) To validate a pipeline to use for C. jejuni LOS locus typing, and analyse the 
extent of gene content variation in C. jejuni and C. coli LOS biosynthesis gene 
clusters in silico (Chapter 4). 
 Identify LOS locus type in C. jejuni online sequences by using 
Megablast and Galaxy pipeline 
 Identify LOS locus type C. coli online sequences by using Megablast 
and WG sequencing of a clinical C. coli strain  
 Evaluate C. jejuni and C. coli LOS loci distribution in different 
Campylobacter niches 
 Determine novel genes in C. jejuni and C. coli LOS biosynthesis loci 
 
3) To determine the impact of LOS gene deletion on C. coli LOS structure and 
cell function (Chapter 5).  
 Validate a rpsL-based mutagenesis strategy  
 Construct and characterise a C. coli LOS biosynthesis gene region 
deletion mutant 
 
4) To determine how variation of the LOS structures in C. jejuni and C. coli 
impacts upon infection of host cells in vitro (Chapter 6).  
 Measure induction of IL-1β and Caspase-1 in THP-1 cells following 
stimulation with extracted LOS from Campylobacter strains  
 Measure induction of IL-1β and Caspase-1 in THP-1 cells following 
infection with Campylobacter strains  
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CHAPTER 2 
Materials and Methods 
 
Materials  
2.1. Bacterial Culture Media  
All culture media were prepared by dissolving an appropriate amount of media 
in distilled water and sterilising at 121 °C for 15-20 minutes under 15 psi pressure 
in an autoclave (Dixons, Sussex, UK). Agar was cooled to 55 °C, poured into a 
petri dish (Scientific Laboratory Supplies, Nottingham, UK) under aseptic 
conditions, and allowed to solidify. If required, supplements were added after 
cooling the agar to 55 °C. 
 
2.1.1. Mueller-Hinton agar and Mueller-Hinton broth 
Mueller-Hinton agar (MHA; Oxoid Limited, Basingstoke, UK) media (38 g) 
containing 3 g beef dehydrate, 17.5 g casein hydrolysate, 1.5 g starch and 17 g 
agar was dissolved in 1 L of water. After autoclaving and cooling the media to 55 
°C, 5% (v/v) defibrinated horse blood (Oxoid Limited) was added to it. 
Subsequently, vancomycin and trimethoprim with final concentrations (as 
specified in Table 2.1) were added to MHA to select Campylobacter. 21 g of 
Mueller-Hinton Broth (MHB; Oxoid Limited) containing 2 g beef dehydrate, 2 g 
starch and 1.5 g casein hydrolysate was dissolved in 1 L water to prepare MHB.  
 
2.1.2. Campylobacter blood-free charcoal agar  
Campylobacter blood-free charcoal agar base (22.75 g; Oxoid Limited) 
containing 4 g bacteriological charcoal, 3 g casein hydrolysate, 1 g sodium 
deoxycholate, 0.25 g ferrous sulphate, 0.25 g sodium pyruvate and 12 g agar 
was dissolved in 500 mL of distilled water. Subsequently, vancomycin and 
trimethoprim with final concentrations as specified in Table 2.1 were added to 
the media to select Campylobacter.  
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2.1.3. Luria-Bertani broth and Luria-Bertani agar  
Luria-Bertani broth (LB broth; 25 g; Scientific Laboratory Supplies) was 
suspended in 1 L of distilled water (Bertani, 1951) to prepare LB broth. LB broth 
contents per L were 10 g tryptone, 5 g yeast extract and 10 g sodium chloride. 
To prepare Luria-Bertani agar (LB agar; Scientific Laboratory Supplies), 40 g LB 
agar was dissolved in 1 L of distilled water. All contents of LB agar per L were 
the same as LB broth with the addition of 15 g agar. After sterilisation, antibiotics 
were added to LB media according to the requirements (see Table 2.1). X-Gal 
(5-Bromo-4-chloro-3-indol-β-D-galactoside; Thermo Scientific, Loughborough, 
UK) dissolved in dimethylformamide (DMF) and IPTG (isopropythio-β-D-
galactoside; Thermo scientific) dissolved in water, both at the final concentration 
of 20 µg per mL, were added into LB agar before pouring it into plates. X-
gal/IPTG LB agar plates were used for blue-white screening of bacterial colonies.  
 
2.1.4. Soft motility agar  
Brain Heart Infusion broth (BHI broth; 37 g; Oxoid) containing 12.5 g brain 
infusion solids, 5 g beef heart infusion solids, 10 g proteose peptone, 2 g glucose, 
5 g sodium chloride and 2.5 g disodium phosphate was dissolved in 1 L distilled 
water. To prepare the soft motility agar plates, 0.25% (w/v) bacteriological agar 
(Oxoid) was added into BHI broth and poured into petri plates after sterilisation. 
Soft motility agar plates were dried at room temperature for at least 24 hours 
prior to use. 
 
 
 
2.2. Antibiotics 
Stock solutions of antibiotics (Sigma-Aldrich, Dorset, UK) were prepared by 
dissolving in the appropriate solvents and stored at 4-20 °C in the dark. All water 
soluble antibiotic stock solutions were filter sterilised after preparation using 0.20 
µm filters (Minisart Plus). Solvent, stock concentration and final working 
concentrations used are given in Table 2.1.  
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Table 2.1: Antibiotics used in this study 
 
 
 
 
 
 
 
 
 
 
2.3. Buffers and Solutions 
Buffers and solutions were sterilised after preparation under 15 psi pressure at 
121 °C for 15-20 minutes in an autoclave, where needed. 
 
2.3.1. TAE (Tri-Acetate-EDTA) buffer 
TAE buffer (50x; ready to use) was purchased from Fisher Scientific and 1x TAE 
buffer was prepared by adding 20 mL of 50x TAE buffer to 980 mL distilled water 
for agarose gel electrophoresis. 
 
2.3.2. Western blot transfer buffer 
Sodium Dodecyl Sulfate (SDS; 1 g) was dissolved in 500 mL sterile distilled 
water. Then 100 mL 10 x Running buffer [0.25 M Tris (Sigma-Aldrich, UK) and 
1.9 M glycine (Fisher Scientific, UK) dissolved in 1L distilled water] and 200 mL 
methanol were added and final volume was made up to 1 L. 
 
2.3.3. 1X Phosphate Buffered Saline (PBS) 
PBS solution was prepared by dissolving PBS tablets (Oxoid Limited) in distilled 
water. One tablet was used per 100 mL volume of distilled water. 
 
2.3.4. 5M NaCl 
NaCl (292.2 g; Sigma Aldrich) was dissolved in 700 mL of distilled water, total 
volume of solution was made up to 1 L with distilled water, and sterilised.  
 
Antibiotics 
 
 
Solvent 
 
Stock 
concentration 
(mg/mL) 
Final working 
concentration 
(µg/mL) 
Ampicillin sodium salt water 100 100 
Vancomycin hydrochloride 50% (v/v) ethanol 10 10 
Trimethoprim 50% (v/v) ethanol 5 5 
Chloramphenicol 100% ethanol 20 20 
Streptomycin sulphate salt water 100 100 
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2.3.5. CTAB/NaCI solution 
NaCl (4.1 g) was dissolved in 80 mL water to make 0.7 M NaCl solution. 10 g 
CTAB (hexadecyltrimethyl ammonium bromide; Sigma Aldrich) was dissolved 
into 0.7 M NaCl solution slowly to make CTAB/NaCI solution. The solution was 
stirred and heated to 60 °C to dissolve the CTAB.  
 
 
2.3.6. Solutions for Tricine Polyacrylamide Gel Electrophoresis  
2.3.6.1. Spacer and resolving buffer 
To make the spacer buffer, 15.12 g Trizma base (Sigma-Aldrich) was dissolved 
in 50 mL sterile distilled water, the pH was adjusted to 6.8, and the final volume 
was made up to 100 mL with sterile distilled water. For the resolving buffer, 22.78 
g Trizma base was dissolved in 50 mL sterile distilled water, pH 8.8, and a final 
volume was made up to 100 mL with sterile distilled water.  
 
2.3.6.2. Running buffer 
To make 1X running buffer, 10X running buffer (recipe given above in section 
2.3.2) was diluted and 0.1% (w/v) SDS (Fisher Scientific) was added.  
 
2.3.6.3. 10% Ammonium Persulphate (APS)  
APS (0.1 g; Sigma-Aldrich) was dissolved in 1 mL of sterile distilled water. 
 
 
2.3.7. Solutions for LOS gel silver staining 
2.3.7.1. Gel fixing solution 
Methanol (100 mL; Fisher Scientific), acetic acid (24 mL; Sigma-Aldrich) and 
formaldehyde (100 µL; Fisher Scientific) were added to 76 mL sterile distilled 
water to prepare 200 µL of fixing solution. 
 
2.3.7.2. Wash solution (35% ethanol) 
Molecular biology grade ethanol (>99.5%; 36.5 mL; Fisher Scientific) was 
dissolved in 63.5 mL sterile distilled water.  
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2.3.7.3. Sanitiser solution 
Sodium thiosulfate (0.04 g; Sigma-Aldrich) was dissolved in 200 mL sterile 
distilled water. 
 
2.3.7.4. Silver stain solution 
Silver nitrate (0.4 g; Fisher Scientific) and formaldehyde (152 µL) were added to 
200 mL sterile distilled water. 
 
2.3.7.5. Gel developer 
Sodium carbonate (24 g; Fisher Scientific), 0.02% (w/v) sodium thiosulfate (8 
mL) and formaldehyde (200 µL) were added to 392 mL sterile distilled water to 
prepare the 400 mL of gel developer.  
 
2.3.7.6. Stop solution 
To make the 200 mL stop solution, 100 mL methanol and 24 mL glacial acetic 
acid were added to 76 mL sterile distilled water. 
 
 
2.4. THP-1 Cell Line 
The human monocytic cell line THP-1, derived from the peripheral blood of a 1 
year old male with acute monocytic leukaemia (Tsuchiya et al., 1980), was 
purchased from the European Collection of Authenticated Cell Cultures (ECACC; 
Catalogue no. 88081201). 
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Methods 
 
2.5. Collection of Bacterial Strains  
Campylobacter clinical isolates, given in Table 2.2, were collected from 
Northampton General Hospital (NGH), Northampton, UK, in a 12 month period 
from November 2015-2016. From anonymised clinical samples from NGH, 
bacterial isolates were collected by swabbing from already cultured Charcoal-
Cefoperazone-Deoxycholate Agar (CCDA) plates. Amines and charcoal swabs 
(Thermo Fisher Scientific) were used for collection and transportation of 
Campylobacter isolates. Bacterial isolates were cultured again within 24 hours 
of collection. Campylobacter strains obtained from National Culture Type 
Collection (NCTC, Colindale) and American Type Culture Collection (ATCC) 
were used as reference strains throughout the project. In addition, genomic DNA 
(gDNA) of three C. jejuni strains, RM1048, RM1556 and RM1555, obtained from 
the United States Department of Agriculture Research Service, USA, were also 
used in this study.  
 
2.6. Bacterial Cell Culture 
 
2.6.1. Bacterial growth conditions 
Campylobacter strains were grown on MHA plates at 37 °C for 24-48 hours under 
a microaerobic atmosphere of 5% O2, 10% CO2 and 85% N2. The microaerobic 
environment was provided by either using the CampyGen sachets (Oxoid 
Limited) in 2.5 L air-tight jars or BOC gas mixture (2% H2, 5% O2, 10% CO2 and 
83% N2) in a Whitley G2 workstation (Don Whitley Scientific). 
E. coli strains were grown at 37 °C under aerobic conditions either on LB agar 
plates or in LB broth with shaking. 
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        Table 2.2. Campylobacter isolates used in this study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Clinical isolate 
2 University of Liverpool, UK  
3 University of Leicester, UK 
4 NCTC, Public Health England, UK 
5 University of Helsinki, Finland 
6 University of Northampton, UK 
 
 
No. C. jejuni strain No. C. jejuni strain No. C. coli strain 
 
1 CJ101 35 ME112946R1 1 2210891 
2 CJ41 36 ME112990Z1 2 RM18754 
3 CJ121 37 ME113179J1 3 763395 
4 CJ131 38 ME113090Y1   
5 CJ181 39 7511   
6 CJ231 40 926491   
7 S11 41 366701   
8 S21 42 CJ31111   
9 1011 43 375311   
10 1021 44 342181   
11 1031 45 348061   
12 1041 46 386251   
13 1051 47 345651   
14 1061 48 386081   
15 Moulton6 49 444061   
16 13362 50 452831   
17 927401 51 419991   
18 926911 52 409731   
19 925401 53 471851   
20 927171 54 398641   
21 93133Y1 55 603191   
22 CJ201 56 602381   
23 93084N1 57 543861   
24 926611 58 507021   
25 1129901 59 596531   
26 1187151 60 515851   
27 1189731 61 928381   
28 5121 62 928711   
29 1210971 63 111683   
30 1187181 64 81-1763   
31 93941P1 65 811163   
32 11168Δ32-523    66 RM12213   
33 ME1132621    67 40315   
34 ME112938s1     
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2.6.2. Bacterial strain storage 
MicrobanksTM (PRO-LAB Diagnostics) were inoculated with bacterial colonies 
from an overnight culture. Vials were inverted 4-5 times for rapid bonding of 
bacteria with porous bead surfaces. The cryopreservative solution was aspirated 
from each vial and stored at -80 °C. To prepare a fresh culture, the vial was kept 
cold on ice and a single bead was removed from the vial under aseptic conditions 
and used to directly inoculate a suitable fresh culture medium.  
 
 
2.7. Mammalian Cell Tissue Culture 
2.7.1. Cell counting and viability using a disposable haemocytometer 
THP-1 cell suspension (100 µL) was aseptically transferred into an Eppendorf 
and 10 µL of it was mixed with 10 µL of 0.4% trypan blue (Gibco™) with pipetting. 
10 µL of trypan blue treated cell suspension was gently injected into the counting 
chamber of disposable haemocytometer with pipette and examined under the 
inverted microscope (Nikon TMS 0.3 A). Cells were counted in 4 sets of 16 corner 
squares by using 10x objective of the inverted microscope. The average value 
of cell count from 4 sets of 16 corner squares was multiplied by 104 and then 
multiplied by 2 (dilution factor) to determine the number of live cells in the original 
cell suspension. 
 
 
2.7.2. Cryopreservation and revival of suspension THP-1 cells  
THP-1 cell suspension with >80% viable cells was transferred into a 50 mL tube 
and centrifuged at 100 x g for 5 minutes. The supernatant was removed and the 
cell pellet was dissolved in 1 mL of freezing media [95% (v/v) FBS + 5% (v/v) 
DMSO]. Cells in freezing media were transferred to a 1 mL cryovial. The cryovial 
was immediately placed in a CoolCell (Thermo Scientific™) and kept at -80 °C. 
After 24 hours, the cryovial was removed from the CoolCell and immediately 
stored at -80 °C.  
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For revival of the suspension of THP-1 cells, a cryovial was removed from the -
80 °C freezer and snap-thawed in a 37 °C water bath for 1 minute. The cell 
suspension was transferred into a 50 mL tube containing 10 mL of pre-warmed 
cell culture media by pipetting. Subsequently, cells were centrifuged at 80 x g for 
5 minutes, the supernatant was discarded and the pellet was suspended in 10 
mL of cell culture media. Cell culture media containing cells was transferred into 
a culture flask (T25; Sarstedt). Flasks were incubated in a 37 °C humidified 
incubator in a vertical position for 15-20 days or until the cells reach the 
exponential phase of growth.  
 
 
2.7.3. Tissue culture and differentiation of THP-1 cells  
The THP-1 cell line was cultured in RPMI 1640 medium (Gibco®, Life Sciences) 
containing 10% (v/v) FBS (Gibco®, Life Sciences) at 37 °C in a 5% CO2 
humidified incubator (Eppendorf). For passaging the suspension cells, cells were 
counted and a volume of media required to dilute the culture to the recommended 
seeding density was calculated. The calculated volume of pre-warmed complete 
growth medium was added into the culture flask and kept at 37 °C in a 5% CO2 
humidified incubator. Cells were passaged every 3-4 days with a typical split ratio 
of 1:10 to minimise the accumulation of cell debris and metabolic waste by-
products in suspension cell cultures.  
To differentiate the THP-1 cells, cells were counted, centrifuged at 100 x g for 5 
minutes and resuspended in cell culture medium supplemented with a final 
concentration of 100 ng/mL phorbol 12-myristate 13-acetate (PMA; Sigma). 
THP-1 cells were seeded into 12-well tissue culture plates (Eppendorf) at a 
density of approximately 1×106 cells per well and incubated for 48 hours at 37 °C 
in 5 % CO2 humidified incubator. After incubation, PMA-containing medium was 
aspirated and adherent, differentiated cells (macrophages) were washed once 
with culture medium. Differentiated cells were then incubated in culture medium 
without PMA for an additional 24 h prior to inoculation.  
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2.7.4. Inoculation of THP-1 cells with live bacteria, lysates or purified 
lipooligosaccharides 
Lipooligosaccharides were extracted from Campylobacter cells using the hot-
phenol method (specified in section 2.15.1) and whole cell lysates were used to 
stimulate the IL-1β secretion in THP-1 cells with procedures as described 
previously (Siegesmund et al., 2004). To prepare Campylobacter whole cell 
lysates, Campylobacter cells were harvested from one overnight cultured plate, 
washed twice in PBS and resuspended in PBS to a final OD600 of 1. The 
suspended bacterial cells were heat killed at 65 °C for 30 minutes and lysed by 
using sonicator (nusonics). After sonication (six times 30 second bursts and 30 
second pause), the cells were centrifuged at 15,000 x g for 20 minutes at 4 °C. 
The whole cell lysate was collected in a new tube, filter sterilised and stored at -
20 °C. The total protein in the bacterial whole cell lysates was then quantified 
(section 2.16.1) and lysates equivalent to ~25 µg protein were added to THP-1 
cell culture. 
To infect the differentiated THP-1 cells with live bacteria, Campylobacter cells 
were harvested from an overnight cultured plate, washed once in PBS and 
resuspended in RPMI 1640. The optical density (O.D600) of bacterial suspensions 
was adjusted to 0.8, which was almost equivalent to 2x109 C. jejuni 11168, 
2x1010 C. coli RM1875 or 8x108 C. coli 76339 colony forming units (CFU). These 
pre-determined CFU were checked again by serially diluting and plating the 
bacterial suspensions. The multiplicity of infection (MOI; number of live 
Campylobacter cells required per THP-1 cell infection) was calculated by using 
the following formula and achieved by adding the appropriate volume of bacterial 
suspensions in THP-1 cells  
                                           MOI = CFU of bacteria used for infection 
                                                                Number of THP-1 cells  
The assay was carried out for 12 hours after the addition of either live bacteria, 
lysates or purified LOS and cell culture media from the culture plate was collected 
after 12 hours for further analysis. For the inhibition of K+ channels and Caspase-
1, THP-1 cells were incubated respectively with 50 µM glyburide (soluble in 
DMSO; Fisher Scientific, UK) and 10 µM N-benzyloxycarbony-Val-Ala-Asp (O-
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methyl)-fluoromethylketone (Z-VAD-FMK; a Caspase-1 inhibitor soluble in 
DMSO; Invitrogen) for 3 hours prior to infecting them with live or killed bacterial 
lysates. THP-1 cell culture with E. coli O111:B4 purified Lipopolysaccharides 
(LPS; Sigma-Aldrich LPS25) was used as a positive control and THP-1 cell 
culture with PBS only was used as a negative control in all THP-1 inoculation 
assays.  
 
 
2.8. Nucleic Acid Isolation from Bacterial Cells 
The CTAB gDNA extraction method was used for large-scale DNA extraction, 
whereas, DNeasy Blood and Tissue kit (Qiagen) was used for small-scale DNA 
extraction. High quality and ultra clean DNA, required for either WG sequencing 
or LOS gene deletion screening PCR assays, was isolated by using the 
UltraClean® Microbial DNA Isolation Kit.   
 
2.8.1. Extraction of gDNA using CTAB method 
 
The previously described the CTAB gDNA extraction method was followed with 
few modifications for gDNA extraction from Campylobacter isolates (Dasti et al., 
2007). Bacterial cells were collected from four cultured plates with 10 mL PBS. 
The mixture was centrifuged at maximum speed for 10 minutes, and 9.5 mL of 
PBS was added to suspend the cell pellet. To lyse the cell suspension, 2 mL of 
10% (w/v) SDS (Sigma-Aldrich), 100 µL of 20 mg/mL proteinase K (Qiagen) and 
20 µL of 10 mg/ml RNase A (Qiagen) were added. The solution was mixed by 
inverting 4-5 times and incubated for 1 hour at 37 °C. After this incubation, 1.8 
mL of 5 M NaCI and 1.5 mL of CTAB/NaCI were added to the lysed cell 
suspension and the sample was incubated at 65 °C for 20 minutes. 
Chloroform:isoamyl alcohol (24:1; Sigma-Aldrich) was added to the suspension 
in a 1:1 ratio to isolate the DNA into the aqueous layer. The mixture was 
transferred to 50 mL phase lock gel tubes (Scientific Laboratory Supplies) and 
centrifuged in order to separate the aqueous layer and organic solvent layer at 
3,020 x g at 4 °C for 20 minutes. The gDNA was extracted from the aqueous 
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layer with 0.7 volumes of room temperature isopropanol. The DNA was collected 
with a clean glass Pasteur pipette into a collection tube, washed with 70% (v/v) 
ethanol to precipitate the DNA, and air dried. After drying, the DNA was 
resuspended in 750 µL of sterile distilled water. 
 
2.8.2. DNA extraction using DNeasy Blood and Tissue Kit  
The protocol provided by the DNeasy Blood and Tissue kit (Qiagen) 
manufacturer was followed. Briefly, ~1 x 109 Campylobacter cells from an 
overnight cultured plate were harvested in 1 mL PBS and centrifuged at 
maximum speed for 1 minute. The cell pellet was suspended in 180 µL of ATL 
buffer (SDS solution) and 20 µL of supplied proteinase K (20 mg/mL), mixed and 
incubated at 56 °C for 3 hours. After incubation, 4 µL of RNase (100 mg/mL) was 
added to the cell suspension and kept at room temperature for 2 minutes. Then, 
200 µL of AL buffer and 200 µL of molecular biology grade ethanol (>99.5%) 
were added together and the mixture was transferred to the supplied DNeasy 
Mini Spin column. The column was centrifuged for 1 minute and the flow-through 
was discarded. The column was then sequentially washed with 500 µL of Wash 
Buffer AW1 and 500 µL of Wash Buffer AW2 and the flow-through was discarded 
after every washing step. The column was re-centrifuged for 1 minute to remove 
the residual ethanol. The column was then placed into a clean Eppendorf, 100 
µL sterile distilled water was applied to the centre of column, left for 1 minute, 
and finally centrifuged for 1 minute to elute the gDNA. 
 
2.8.3. DNA extraction using UltraClean® Microbial DNA Isolation Kit 
The protocol provided by the UltraClean® Microbial DNA Isolation kit (MO BIO 
Laboratories, Inc.) manufacturer was followed. Briefly, ~1 x 109 cells from an 
overnight cultured plate were harvested in 1 mL PBS and centrifuged at 
maximum speed for 1 minute. The cell pellet was resuspended in 300 µL of 
MicroBead solution and 50 µL of solution MD1, gently vortexed, and incubated 
at 70 °C for 1 hour. The cell suspension was centrifuged for 1 minute, the 
supernatant was collected into a new tube and mixed with 100 µL solution MD2. 
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The mixture was centrifuged again for 1 minute. The supernatant, collected into 
a fresh tube, was mixed with 100 µL of solution MD3 and transferred to spin filter. 
The column was centrifuged for 1 minute and the flow-through was discarded. 
The column was then washed with 300 µL of wash solution MD4, centrifuged for 
1 minute, and then re-centrifuged for 1 minute to remove the traces of wash 
solution. To elute the ultraclean gDNA, the column was placed into a clean 
Eppendorf, 50 µL sterile distilled water or EB buffer (10 mM Tris-HCl pH 8.5) was 
applied to the centre of the column, left for 1 minute, and finally centrifuged for 1 
minute.  
 
 
2.8.4. Isolation of plasmid DNA using QIAprep Miniprep Kit 
The protocol provided by the QIAprep Spin Miniprep kit (Qiagen) manufacturer 
was followed. Briefly, an overnight E. coli culture of up to 5 mL was harvested by 
centrifugation at 7,000 x g for 3 minutes at room temperature. The cell pellet was 
suspended in 250 µL of the cell suspension buffer P1 (50 µg/mL RNase A, 50 
mM Tris-HCI; pH 8.0, 10 mM EDTA, and lyseblue). Then 250 µL of the lysis 
buffer P2 [0.2 M NaOH and 1% (w/v) SDS] was added, mixed thoroughly until 
the solution turned blue, and the mixture was incubated at room temperature 
(15–25 °C) for 5 minutes. 350 µL of the neutralization and binding buffer N3 (4 
M guanidine hydrochloride and 0.5 M potassium acetate, pH 4.2) was 
then immediately added and mixed thoroughly until the solution became 
colourless. The solution was centrifuged at 18,000 x g for 10 minutes and the 
supernatant was transferred to the QIAprep 2.0 spin column by pipetting. The 
column was centrifuged for 30-60 seconds and the flow-through was discarded. 
The column was then washed with 0.75 mL wash buffer PE (20 mM NaCl2mM, 
Tris-HCl pH 7.5, and 80% ethanol) and the flow-through was discarded after 
centrifugation for 30-60 seconds. Each column was re-centrifuged for 1 minute 
to remove residual buffer PE. To elute the plasmid DNA, the column was then 
placed into a clean Eppendorf and 30-50 µL sterile distilled water was applied to 
the centre of the column, left for 1 minute, and finally centrifuged at 18,000 x g 
for 1 minute.  
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2.8.5. RNA extraction using PARISTM Kit 
The protocol provided by the manufacturer in the PARISTM kit (Life 
Technologies™) was followed. Briefly, Campylobacter cells from an overnight 
cultured plate were harvested with 1 mL PBS in an RNase-free 2 mL tube and 
centrifuged at 7,000 x g for 3 minutes at 4 °C. Cells were washed once by 
resuspending in 1 mL PBS and re-pelleted via centrifugation. The supernatant 
was removed and 500 µL of ice-cold cell disruption buffer was added to the cell 
pellet to lyse the cells. Cells were completely lysed in the cell disruption buffer 
by vigorous pipetting. 500 µL of 2X lysis/binding solution was added to the lysed 
cells mixture and mixed gently by inverting the tube several times. Visible cell 
debris was removed by spinning at 10,000 x g for 1 minute. To purify the RNA, 
500 µL of 100% (v/v) molecular biology grade ethanol was added and mixed 
gently by inverting the tube several times. The sample mixture (~2 mL) was 
transferred to a supplied filter cartridge by pipetting. The filter cartridge was then 
centrifuged for 60 seconds and the flow-through was discarded. The filter 
cartridge was sequentially washed once with 0.75 mL wash solution 1 and twice 
with 0.5 mL wash solution 2/3, with the flow through being discarded after each 
spin. The filter cartridge was re-centrifuged for 1 minute to remove the traces of 
wash solution 2/3. To elute the total RNA, the column was then placed into a 
clean RNase-free collection tube, 50 µL elution solution (preheated to 95 °C) was 
applied to the centre of column, left for 1 minute, and finally centrifuged for 1 
minute. All samples, used for RNA extraction, were kept cold on ice between 
each step and each centrifugation step was carried out at 4 °C. 
Following the RNA extraction, all RNA samples contaminated with gDNA were 
cleaned up by following the protocol provided by the DNA-free™ kit (Invitrogen) 
manufacturer. Briefly, the contaminated RNA sample was mixed with 5 µL 10X 
DNase buffer and 0.5 µL rDNase and incubated for 30 minutes at 37 °C. Then 
0.5 µL rDNase was added again and sample was incubated again for 30 minutes 
at 37 °C. After incubation, 0.25 µL DNase inactivation reagent was added. The 
sample was incubated for two minutes at room temperature with occasional 
vortexing. The sample was centrifuged at 10,000 x g for 10 min and the 
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supernatant containing clean RNA was transferred to a new RNase-free 
collection tube.  
 
 
2.9. Analysis of Nucleic acid Quality and Integrity 
The concentration and quality of gDNA, plasmid DNA and RNA in nanograms 
(ng) per µL of sample was determined using Nanodrop 2000 spectrophotometer 
(Thermo Scientific).  
DNA quality and integrity was also analysed by agarose gel electrophoresis. 
Agarose gels (1%) were prepared by dissolving agarose (1g; Sigma-Aldrich) in 
100 mL of 1X TAE buffer and heating the mixture until it had dissolved 
completely. The agarose solution was cooled to 50 °C and 5 µL SYBR® safe 
stain (10,000X; Invitrogen) per 100 mL of agarose solution was added. DNA 
samples were then prepared by the addition of 5X loading dye (Bioline Reagents 
Ltd) prior to loading. DNA samples and molecular weight markers of known 
concentration were loaded on a gel. Hyperladder I (200bp to 10kb; Bioline 
Reagents Ltd) or Hyperladder IV (100bp to 1kb; Bioline Reagents Ltd) were used 
to determine the DNA size and concentration of unknown samples. The gel was 
run at 80-150 V depending upon the DNA size until the loading dye had travelled 
approximately 1 inch up from the bottom of gel. Loaded DNA was visualised by 
using G: Box (Syngene) and photographed under UV light.  
 
 
2.10. Purification of DNA Fragments 
 
2.10.1. Purification of DNA using MinElute Gel Extraction Kit 
The MinElute kit (Qiagen) was used to clean DNA fragments of up to 4kb in 
length. Each DNA band was excised from the agarose gel with a clean, sharp 
scalpel and the gel slice was weighed. 1 volume of gel was mixed with 3 volumes 
of buffer QG (5.5 M guanidine thiocyanate and 20 mM Tris HCl, pH 6.6), for 
example, 100 mg of gel into 300 µL of buffer QG. Mixture was incubated at 50 
°C for 10 minutes to dissolve the gel. An equal volume of 100% (v/v) isopropanol 
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was added to the mixture and incorporated by inversion. The mixture was 
transferred to the MinElute spin column and passed through by centrifugation. 
500 µL of buffer QG and then 750 µL of buffer PE (10 mM Tris-HCl, pH 7.5 and 
80% ethanol) were passed through the column by centrifugation, with the flow 
through being discarded after each spin. The column was re-centrifuged for 1 
minute to remove any excessive residual ethanol from buffer PE. Finally, 10 µL 
of sterile distilled water was directly applied to the column membrane to elute 
bound DNA.  
 
2.10.2. Purification of DNA using QIAquick PCR Purification Kit 
The QIAquick PCR purification kit (Qiagen) was used to clean the DNA 
fragments in PCR or restriction enzyme reaction mixtures (or fragments over 
4kb). One volume of reaction mixture and 5 volumes of buffer PB were mixed 
into a clean centrifuge tube. The mixture and 750 µL of buffer PE (10 mM Tris-
HCl, pH 7.5 and 80% ethanol) were consecutively passed through the QIAquick 
column, with the flow through being discarded after each spin. The column was 
centrifuged for 1 minute to remove any excessive residual ethanol from buffer 
PE. Finally 30-50 µL of sterile distilled water was directly applied to the column 
membrane to elute bound DNA.  
 
2.11. Enzymatic Manipulation of DNA 
 
2.11.1. Restriction endonuclease digestion of DNA 
Restriction endonucleases and buffers were purchased from New England 
Biolabs (NEB) or Thermo Scientific and the procedure for DNA restriction was 
carried out according to the manufacturers’ protocols. Typically, a reaction with 
a maximum total volume of 50 µL including nuclease-free water, restriction 
enzyme buffer, 0.5-1 µg DNA, 5-10 units restriction enzyme was incubated at 37 
°C for 1 hour to carry out DNA digestion. A positive control (digestion mixture 
with control DNA) and a negative control (digestion mixture with no enzyme) 
were also included. 
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2.11.2. DNA ligation  
T4 DNA Ligase (Invitrogen) was used according to the instructions given by the 
manufacturer. Briefly, a reaction mixture with a maximum size of 20 µL was 
prepared containing 4 µL 5X ligase buffer [250 mM Tris-HCl (pH 7.6), 50 mM 
MgCl2, 5 mM ATP, 5 mM Dithiothreitol (DTT), 25% (w/v) polyethylene glycol-
8000], insert DNA and vector DNA in a Molar ratio of 3:1, distilled water, and T4 
DNA ligase (2 Units). The reaction mixture was incubated overnight in PCR 
machine at 26 °C.  
 
 
 
2.12. Transformation of Bacterial cells with Plasmid DNA 
2.12.1. E. coli electrocompetent cells preparation for DNA transformation 
To prepare electrocompetent E. coli cells (Sambrook and Russell, 2001), 100 
mL of fresh LB broth was inoculated with 1 mL overnight E. coli culture and 
incubated at 37 °C with agitation until the OD600 nm of the culture was between 
0.4 - 0.6. The cell pellet was washed three times with decreasing amounts of ice-
cold, sterile, distilled water. Then, the cells were re-suspended in 10 mL of 10% 
(v/v) ice-cold, sterile glycerol. After washing with glycerol, harvested cells were 
dissolved in 1 mL of 10% glycerol and divided into 50 µL aliquots to make them 
ready to use either immediately or stored at -80 °C, after being snap frozen on 
dry ice. 
 
2.12.2. Electroporation of plasmid DNA into E. coli 
Plasmid DNA was electroporated into E. coli with a standard procedure as 
explained previously (Sharma and Schimke, 1996). Plasmid DNA and 
electrocompetent cells (2-5 µg in 50 µL of cell suspension) were carefully 
transferred to the bottom of an ice-cold electrocuvette (VWR International Ltd). 
Cells were electroporated at 2.5 kV, 5.90 ms with electroporator (Bio-RAD 
Micropulser) after 10 minutes incubation on ice. After electroporation, 
immediately cells were suspended into 1 mL of ready-to-use SOC (Super 
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Optimal broth with Catabolite repression; Invitrogen) media. The cuvette was 
inverted 2-3 times to mix the media with the cells. The mixture was then 
incubated with shaking for at least 1 hour at 37 °C. Cells were centrifuged and 
re-suspended in 200 µL of SOC media. Cells suspension was then spread on LB 
agar selection plates and bacterial colonies were counted to determine the 
transformation efficiency after 18-24 hours.  
 
2.12.3. Preparation of Electrocompetent Campylobacter cells 
For the preparation of electrocompetent Campylobacter cells (Miller et al., 1988), 
cells were harvested from two overnight cultured plates with 10 mL MHB and 
centrifuged at 1,500 x g for 10 minutes at 4 °C. Supernatant was removed and 
the cell pellet was sequentially washed four times in 50 mL, 25 mL, 10 mL and 5 
mL of ice-cold CEB buffer (15% (v/v) glycerol, 272 mM sucrose). The cells were 
finally resuspended in 200 µL of CEB and used straight away.  
 
2.12.4. Electroporation of plasmid DNA into electrocompetent 
Campylobacter cells 
Approximately 1.5-2 µg of plasmid DNA and 40 µL of electrocompetent cells 
were mixed in a sterile Eppendorf (Miller et al., 1988). The mixture was 
transferred to the bottom of an ice-cold electrocuvette and incubated on ice for 
10 minutes. Cells were electroporated at 2.5 kV, 5.90 ms with electroporator, 
suspended into 200 µL of SOC media, and immediately spread on plain MHA 
plate. After overnight incubation at 42 °C under microaerobic conditions, cultured 
cells were harvested in 2 mL MHB. An aliquot of 100 µL was cultured onto MHA 
supplemented with 20 µg/mL chloramphenicol and the remaining cell suspension 
was centrifuged for 1 minute. The cell pellet was dissolved in 100 µL of MHB and 
cultured onto MHA supplemented with 20 µg/mL chloramphenicol. 
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2.13. Polymerase Chain Reaction (PCR) 
 
2.13.1. Standard PCR 
Each Polymerase Chain Reaction (PCR) master mix was prepared after mixing 
the PCR reaction components in a clean, nuclease free Eppendorf, (Table 2.3 
and Table 2.4). Generally, PCR master mix with MyTaq™ red DNA polymerase 
(Bioline Reagents Ltd) and DreamTaq Green PCR master mix (Thermo 
Scientific) were used for standard PCRs. The reaction mixture was transferred 
to the PCR tubes in the correct volume and each reaction was carried out in a 
thermocyler (TECHNE) using appropriate cycling conditions. A typical PCR 
cycling profile is given in Table 2.5.  
 
      Table 2.3: A standard PCR reaction mix with MyTaq™ red DNA polymerase 
Component of PCR mix Volume (µL) Final Concentration 
Sterile distilled water Up to 20 µL - 
Forward primer stock solution (10 µM) 1 0.5 µM 
Reverse primer stock solution (10 µM) 1 0.5 µM 
MyTaq™ red DNA polymerase 0.25                ~1.25 Units 
gDNA  
Plasmid DNA 
variable 50-100 ng 
10-20 ng 
MyTaq™ red Reaction Buffer 
(includes 5 mM dNTPs, 15 mM MgCl2 & 
enhancers) 
 
4 
 
5X 
 
 
       Table 2.4: A standard PCR reaction mix with DreamTaq polymerase 
Component of PCR mix Volume (µL) Final Concentration 
Sterile distilled water Up to 25 µL - 
Forward primer stock solution (10 µM) 1 0.5 µM 
Reverse primer stock solution (10 µM) 1 0.5 µM  
Template DNA variable 50-100 ng 
DreamTaq Green Reaction Buffer 
(includes 1.6 mM dNTPs,  
4 mM MgCl2 & DreamTaq polymerase) 
 
12.5 
 
2X 
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                Table 2.5: A standard PCR amplification profile. 
PCR assay step Cycle Temperature 
(°C) 
Duration 
Initial template denaturation 
1 95 5min 
Template denaturation 
Primer annealing 
Primer extension 
 
25-40 
95 
45-65 
72 
30sec 
35sec 
30s – 3 min 
Final extension 1 72 5min 
 
 
2.13.2. Colony PCR  
Single bacterial colonies were picked with sterile loops and each colony was 
suspended in the same volume of sterile PCR grade water as required to make 
the PCR master mix (Costa et al., 1994). In PCR cycling conditions, the initial 
denaturation temperature and time were changed to 98 °C and 10 minutes, 
respectively. The other conditions were kept same as for the standard PCR 
protocol. 
 
2.13.3. cDNA synthesis and Real-Time PCR 
To synthesize cDNA, 1-2 µg gDNA-free RNA template was mixed with 4 µL of 
5X cDNA SuperMix (qScript™) in a sterile PCR tube and to a final volume of 20 
µL with nuclease-free grade water. The reaction was carried out in the PCR 
machine under the cycling conditions as specified in Table 2.6.  
 
Table 2.6: cDNA synthesis conditions 
Step Cycle Temperature 
(°C) 
Duration (minutes) 
Enzyme activation 1 25 5 
Enzyme reactivity 1 42 30 
Enzyme inactivation 1 85 5 
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The master mix for real-time PCR was prepared in a clean Eppendorf after 
mixing the PCR reaction components, as specified in Table 2.7. The reaction 
components were mixed by brief centrifugation and transferred in the correct 
volume to a 96-well PCR plate. The PCR plate was sealed with an optical 
adhesive cover and centrifuged at 18,000 x g for 15 seconds to spin down the 
contents and eliminate any air bubbles. Each PCR reaction was carried out in a 
StepOnePlus (Applied Biosystems) using the cycling conditions and dissociation 
curve conditions as specified in Table 2.8. A no template control (NTC) reaction 
containing all reaction components except cDNA was also included for each 
primer set.  
 
Table 2.7: Real-time PCR reaction mix  
Component of PCR mix Volume (µL) Concentration 
PowerUp™ SYBR Green master mix 10 2X 
Forward primer stock solution 0.12 600nM 
Reverse primer stock solution 0.12 600nM 
cDNA Variable           ~ 25ng/µl 
Sterile distilled water Up to 20 µL - 
 
               Table 2.8: Cycling and dissociation curve conditions 
Cycling conditions 
PCR assay step Cycle Temperature (°C) Duration 
UDG activation 1 50 2min 
Dual-Lock DNA polymerase 
activation 
1 95 2min 
Denature 
Anneal/Extend 
       40 95 
60 
15 sec 
1min 
Dissociation curve conditions 
Step Ramp rate Temperature Duration 
1 1.6 °C/sec 95 15sec 
2 1.6 °C/sec 60 1 min 
3 0.15 °C/sec 95 15 sec 
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The amplification efficiency of rpsL (reference gene) and flaA (target gene) 
specific primers was checked by a standard qPCR curve where Ct (Threshold 
cycle) values were plotted versus the C. coli RM1875 gDNA dilutions (0.0001 µg, 
0.001 µg, 0.01 µg, 0.1 µg, 1 µg) and it was confirmed that the correlation 
coefficient (R2) for the linear lines was 0.98-0.99. The 2-ΔΔCt (Livak) method was 
used for the analysis of qPCR results or quantification of flaA expression in test 
sample (gDNA from C. coli mutant strain) relative to the calibrator sample (gDNA 
from C. coli wild-type strain). The flaA gene expression was normalised against 
the rpsL gene expression. 
 
 
2.14. DNA Sequencing 
2.14.1. Sanger sequencing using Eurofins Mix2Seq Kit  
The protocol provided with the Eurofins Mix2Seq kit was followed for gene or 
PCR product sequencing. According to the protocol, 15 µL purified PCR product 
or plasmid DNA (1-15 ng/µL) was mixed with 2 µL of either forward or reverse 
primer stock solution (10 pmol/µL). 17 µL DNA/primer mix was pipetted into a 
Mix2Seq tube. The tube was tightly sealed with provided lid and sent to the 
Eurofins, Wolverhampton, U.K. for sequencing. Sequence data obtained online 
in FASTA format was analysed by Clone Manager software (Edition 9; Scientific 
& Educational Software).  
 
 
2.14.2. DNA submission protocol for WG sequencing 
The gDNA samples for WG sequencing were sent to MicrobeNG, University of 
Birmingham, UK. For gDNA sample submission, 2 mL screw cap tubes, each 
containing 50 µL of gDNA sample, were sealed, labelled with the supplied 
barcode labels and submitted for sequencing. Prior to sending the DNA samples, 
the following two steps were carried out. The results obtained were analysed by 
using Clone Manager as explained in section 2.19.  
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1) The gDNA was quantified with a Nanodrop and concentration of each 
sample was prepared at 100 ng/µL.  
2) The integrity gDNA was verified by running ~1µg DNA sample on a 0.75% 
(w/v) agarose gel.  
 
 
2.15. Assays for LOS Analysis 
 
2.15.1. Campylobacter LOS extraction  
A previously described LOS method was followed for LOS extraction from 
Campylobacter isolates (Apicella, 2008). Campylobacter cells were harvested 
from one overnight cultured plate in 1 mL sterile distilled water. Cells were 
washed once in 1 mL sterile water. Cells were centrifuged and resuspended in 
300 µL sterile water. The cells were lysed by heating at 95 °C for 10 minutes and 
1 µL of Proteinase K (20 mg/mL), DNase (Ambion Turbo DNase 2 units/µL) and 
RNase (20 mg/mL) was added to the lysed cell suspension. The mixture was 
incubated at 37 °C for 1.5 hours and 60 °C for 1.5 hours. After incubation, the 
cells were chilled on ice. Then 300 µL 90% aqueous phenol (pH 4.2, Fisher) was 
added and the mixture was incubated again at 60 °C for 10 minutes. The cells 
were centrifuged at 8,500 x g for 20 minutes at room temperature. The aqueous 
phase was carefully collected in a clean 15 mL tube. 1 mL 3M sodium acetate 
and 6 mL 95% ethanol were added to the tube and incubated at -20 °C overnight 
to precipitate the LOS. After this incubation, the mixture was centrifuged at 2,000 
x g for 40 minutes at 4 °C. The supernatant was discarded and the precipitated 
LOS pellet was resuspended in 100 µL distilled water and 6 mL 95% (v/v) 
ethanol. The LOS suspension was incubated again at -20 °C overnight and 
centrifuged at 2,000 x g for 40 minutes at 4 °C. After this incubation, the LOS 
pellet was either dissolved in 100 µL of sterile distilled water or lyophilized and 
stored at -80 °C. 
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2.15.2. LOS Tricine Polyacrylamide Gel Electrophoresis  
For LOS Tricine Polyacrylamide Gel Electrophoresis (PAGE), separating and 
stacking gels were made (Apicella, 2008) by mixing the components as specified 
in Table 2.9 below. 
 
Table 2.9: Mixtures for Separating and Stacking Gels 
Separating Gel Mix Stacking Gel Mix 
10.55 mL of 30% acrylamide solution 2 mL of 30% acrylamide solution 
3.95 mL of resolving buffer 2 mL of spacer buffer 
4.95 mL of sterile distilled water 15.6 mL of sterile distilled water 
0.3 mL of 1% (w/v) APS 0.3 mL of 1% (w/v) APS 
4 µL of Tetramethylethylenediamine (TEMED) 4 µL of TEMED 
 
The gel was placed in the running buffer (1X) filled Biorad mini-gel apparatus. 
Samples were prepared by mixing the LOS samples with 2X Laemmli Buffer 
(Biorad) in equal volumes and heating at 95 °C for 5 min. The samples were 
cooled down on ice and loaded on to the gel. The Spectra Multicolor Low range 
Protein Ladder (5 µL; Thermo Scientific) was also loaded on the gel and 
electrophoresis was performed at 80 V for 2-3 hours.  
 
 
2.15.3. Silver staining of LOS Tricine PAGE gel 
A previously established method (Tsai and Frasch, 1981) with few modifications 
and solutions described in section 2.3.7 were used for the silver staining of SDS-
PAGE LOS gels. Firstly, the gel was fixed overnight with gel fixing solution. After 
overnight fixation, the gel was washed 3 times with the wash solution for 20 
minutes each at room temperature. After washing, the gel was immersed in the 
sanitizer solution for 2 minutes and washed 3 times with sterile distilled water, 
each for 5 minutes. The gel was stained with silver stain solution for 20 minutes 
and washed again 2 times with sterile distilled water for 1 minute. The gel was 
developed with gel developer till LOS bands become visible. The gel 
development was stopped by immersing the gel into the stop solution.   
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2.15.4. Lectin blot  
The protocol for lectin blot was used as described previously (Sondej et al., 
2009). Briefly, Polyvinylidene difluoride (PVDF) membrane (Millipore) was pre-
wetted in methanol, rinsed in distilled water, and soaked in western transfer 
buffer for 10 minutes. The blot was set up from the bottom with   
a. Paper towel stack  
b. 4 x dry filter papers  
c. 4 x wet filter papers (transfer buffer)  
d. PVDF membrane  
 5 µL of LOS (~50 µg/µL) was transferred onto membrane by pipette and left to 
dry completely for 2 hours. 5 µL LPS extracted from E. coli DH5α and 5 µL sterile 
distilled water were also dotted on the membrane as positive and negative 
controls, respectively. The PVDF membrane was soaked in methanol for 2 
minutes, washed in PBST (PBS + 0.1% Tween) for 2 minutes and blocked with 
PBST + 1% BSA for 1 hour with shaking. The blocking solution was discarded 
and the membrane was immersed in biotinylated peanut lectin (Sigma-Aldrich; 
1:200 in the PBST-1% (w/v) BSA) for 1 hour. The membrane was washed 3 times 
with PBST for 10 minutes. Then the membrane was immersed in streptavidin-
horseradish peroxidase (Fisher Scientific; 1:200 in PBST-1% BSA) for 1 hour 
and washed again 3 times for 10 minutes. Solution A and B in the 
chemiluminescence detection kit (Thermo Fischer Scientific) were mixed in equal 
volumes and used to develop the membrane.  
 
2.16. Assays for Protein Analysis 
2.16.1. Total protein quantification  
To determine the total protein concentration in bacterial whole cell lysates, the 
protocol provided by the Pierce™ BCA Protein Assay Kit (Thermo Fisher 
Scientific) manufacturer was followed. By using the 1 mL ampoule of 2 mg/mL 
Bovine Serum Albumin (BSA), 8 standards were prepared with final BSA 
concentration of 2000, 1500, 1000, 750, 500, 250, 125 and 25 µg/mL. 100 µL of 
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the blank, each standard and unknown samples (whole cell lysate preps) were 
mixed with 2 mL of working reagent [50 mL of solution A (sodium carbonate, 
sodium bicarbonate, bicinchoninic acid and sodium tartrate in 0.1M sodium 
hydroxide) and 1 mL of solution B (4% cupric sulfate)]. The enzyme reaction was 
initiated by incubating the reaction mixtures at 37 °C for 30 minutes. After 
incubation, the absorbance was measured at 562 nm with a spectrophotometer. 
A standard curve was prepared by plotting the average measurement for each 
BSA standard along y-axis and standards concentration along x-axis and used 
to determine the total protein concentration of each unknown sample.  
 
2.16.2. Interleukin-1β Enzyme-linked Immunosorbent Assay 
The protocol provided by the Interleukin-1β (IL-1β) Enzyme-linked 
Immunosorbent Assay (ELISA) kit manufacturer (Thermo Fisher Scientific) was 
followed. Briefly, a 96-well Corning™ Costar™ 9018 ELISA plate was coated 
with 100 µL capture antibody diluted in 1X Coating Buffer, sealed and incubated 
overnight at 4 °C. Wells were aspirated and washed 3 times with 300 µL per well 
wash buffer (PBS + 0.05% (v/v) tween-20). Plates were soaked in the wash 
buffer for 1-2 minutes to increase the effectiveness of the washing solution. After 
each wash step, the plate was tapped several times against the paper towel to 
remove excess wash buffer. The wells were blocked with 200 µL of 1X ELISA 
diluent and incubated at room temperature for 1 hour. The wells were aspirated 
and washed with 300 µL per well wash buffer once. By using the provided stock 
solution of IL-1β, 8 standards were prepared with final IL-1β concentration of 
150, 75, 37.5, 18.7, 9.4, 4.7, 2.3 and 1.2 µg/mL.100 µL of blank (1X ELISA 
diluent), each standard and unknown sample (cell culture supernatant) in 
triplicates were added to the wells and incubated overnight at 4 °C for maximum 
sensitivity. The wells were aspirated and washed 3 times with wash buffer. 100 
µL detection antibody diluted in 1X ELISA Diluent was added to each well, 
sealed, and incubated at room temperature for 1 hour. The wells were aspirated 
and washed again 3 times with wash buffer. 100 µL avidin-horseradish 
peroxidase (250X) diluted in 1X ELISA diluent was added to each well and 
incubated at room temperature for 30 minutes. Wells were aspirated and washed 
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5 times with wash buffer. Then 100 µL of 1X tetramethylbenzidine solution was 
added to each well and incubated at room temperature for 15 minutes. After 
incubation, 50 µL of stop solution was added to each well to stop the reaction 
and plate was read at 415 nm with plate reader (BIORAD Model 680 XR).  
 
 
2.16.3. Caspase-1 ELISA  
The protocol provided by the Caspase-1 ELISA Kit (R & D Systems) 
manufacturer was followed. In brief, a 96-well microplate precoated with 
Caspase-1 specific capture antibodies was incubated with 50 µL of assay diluent 
in each well. Wells were aspirated. By using the provided stock solution of 
Caspase-1 (4000 pg/mL), 7 standards were prepared with final Caspase-1 
concentrations of 400, 200, 100, 50, 25, 12.5 and 6.25 µg/mL. 100 µL of blank 
(calibrator diluent), each standard and unknown samples (cell culture 
supernatants) in duplicates were added to the wells and incubated for 1.5 hours 
at room temperature. Wells were aspirated and washed 3 times with 400 µL per 
well wash buffer. 100 µL Caspase-1 antiserum was added to each well, and the 
plate was incubated for 30 minutes at room temperature. After 3 washes with 
wash buffer, 100 µL of human Caspase-1 conjugate was added to each well and 
incubated at room temperature for 30 minutes. Following another wash step, 200 
µL substrate solution was added to each well and incubated in dark at room 
temperature for 20 minutes. After incubation, 50 µL stop solution was added to 
each well to stop the reaction and plate was read with plate reader at 415 nm.  
 
2.16.4. Lactate dehydrogenase (LDH) release assay  
Supernatants were collected from THP-1 cell cultures after 12 hours of 
inoculation as specified in section 2.7.4 and LDH release assay was performed 
according to the protocol provided for the Cytotoxicity Detection Kit (Thermo 
Fisher Scientific) by the manufacturer. Briefly, 50 µL of complete cell culture 
media [RPMI + 10% (v/v) FBS] and 50 µL of cell culture supernatants was 
transferred to a 96-well flat-bottom plate in triplicate. 50 µL of reaction mixture 
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was added to each well and incubated in the dark at room temperature for 30 
minutes. After incubation, 50 µL stop solution was added to each well and mixed 
by gentle tapping. The plate was centrifuged for 5 minutes to remove any bubbles 
and the absorbance was measured with plate reader at 415nm. The mean 
absorbance value of complete cell culture media was subtracted from all other 
absorbance values to determine the LDH activity and subsequently, relative LDH 
release values were calculated by using the following formula.  
 Relative LDH release= LDH activity in unknown sample – LDH activity in negative control 
                                        LDH activity in positive control – LDH activity in negative control 
 
 
 
2.17. Assays for Phenotype Analysis of Campylobacter spp. 
 
2.17.1. Scanning electron microscopy 
For scanning electron microscopy (SEM), the procedure given in Yamamoto et 
al. (2013) was followed with a few modifications. In brief, agar blocks onto which 
Campylobacter colonies had grown were fixed with 3% (v/v) glutaraldehyde for 
2 hours at 4 °C and 1% osmium tetraoxide overnight at 4 °C. After fixation, agar 
plates were kept on a shaker for 1 hour at 4 °C. The floating colonies were 
collected in a sterile 50 mL tube. Then cells were dehydrated with a series of 
graded ethanol solutions (25%, 50%, 70%, 90% and 100% ethanol) and acetone 
solutions (25%, 50%, 70% and 100%) for 30 minutes each at room temperature. 
Bacterial cells were critically dried in a mixture of isoamyl alcohol and ethyl 
acetate (1:1), coated with gold-palladium, and examined using a Hitachi map 3D 
visualisation software in Hitachi S-3000 SEM.  
 
 
2.17.2. Growth assay 
A single colony was recultured on the MH agar plate at 42 °C under microaerobic 
conditions. Bacterial cells from the cultured plate were suspended in 15 mL MHB 
(starter culture) and used to inoculate the MHB culture (inoculated culture) to a 
standard value (0.05) of O.D600.  
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The inoculated cultures, containing 500 µL per well of a 12-well plate, were kept 
shaking at 42 °C for 48 hours under microaerobic conditions. During the 
incubation, samples were taken at different time points (0, 3, 6, 9, 12, 24, 36 and 
48 hours), serially diluted, and plated on MHA to count CFU. The log10 -
transformed CFU values were used to assess the growth rate of Campylobacter 
strains.  
 
2.17.3. Motility assay 
The motility assay was performed according to the procedure as explained 
previously (Cohn et al., 2007). Campylobacter cells from an overnight cultured 
plate were harvested in 15 mL MHB (starter culture) and adjusted to O.D600 of 
0.2. 2 µL of cell suspension was stabbed with a sterile pipette tip to the centre of 
pre-dried soft motility agar plate. Plates were incubated for 24 hours at 42 °C 
under the microaerobic conditions and the average motility was estimated by 
measuring the diameter of growth zone.  
 
2.18. Student’s t-test for Statistical Analysis  
Comparisons between the two experimental groups were performed by using the 
Student's t-test (Independent; equal variance t-test). Differences in the data 
mean values were considered significant with a value of alpha than 0.05 
considered statistically significant.   
 
2.19. Using Clone Manager for Designing Primers  
Clone Manager Professional Suite (Version 8; Scientific & Educational Software, 
Morrisville, USA), was used to design the C. jejuni LOS class specific PCR 
primers and other primers (given in Appendix-I), as well as, to look for the specific 
primers characteristics (Primers length=18-22 bp, GC content=40-60%, GC 
clamp=1, Stability>1, Tm=52-58 oC, Di-nucleotide repeats<4, Runs of single 
base<4, Cross Dimers<5, Self 3’ Dimers<2, and Hairpins=none). 
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2.20. Ethics 
Commercially available cell lines, horse blood, and human serum were used. 
Campylobacter isolates from anonymised clinical samples were collected by the 
Swab method under the sterile conditions from already cultured plates. No 
experimentation was carried out on humans during this research and this 
research did not involve the use of human tissues, fluids or DNA samples. 
Therefore, approval from any external body (such as NHS Research Ethics 
Committees) was not sought for this research. Ethical principles in relation to the 
research work were reviewed by the University Research Ethics Committee and 
no ethical issues were found to apply to this research. As such there were no 
ethical considerations for this study, however, approval from the University of 
Northampton’s Genetically Modified Organism Biosafety review committee and 
the Health & Safety Executive for Campylobacter mutagenesis was previously 
obtained. 
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CHAPTER 3 
 
Analysis of the Genetic Diversity of the C. jejuni 
Lipooligosaccharide Biosynthesis Locus by Molecular Typing 
  
3.1. Introduction  
 
3.1.1. Genetic diversity of C. jejuni LOS biosynthesis locus 
The WG sequencing of C. jejuni 11168 (1.64 MB; Parkhill et al., 2000), C. jejuni 
RM1221 (1.77 MB; Fouts et al., 2005), and C. jejuni 81-176 (1.62 MB; Hofreuter 
et al., 2006) has revealed that the C. jejuni genome is highly diverse. C. jejuni 
exhibits extensive diversity in its genome due to its natural competent property 
for DNA uptake (Wang and Taylor, 1989; Gilbert et al., 2004; Revez and 
Hänninen, 2012) and non-clonal population structure (Gilbert et al., 2004; Revez 
and Hänninen, 2012). In addition, low GC content (28-38%) and presence of 
bacteriophage-related genes in C. jejuni genome also facilitate the occurrence 
of genetic exchanges (Fouts et al., 2005; Parker et al., 2005). Interstrain genetic 
exchange and intragenomic genetic rearrangements in C. jejuni usually develop 
during the colonization of Campylobacter in chickens and humans (Prendergast 
et al., 2004; Phongsisay et al., 2006; Wilson et al., 2009). In addition to in vivo, 
genetic rearrangements also occur during in vitro experimental infection of 
chicken cells with Campylobacter at the rate of 1 x 109 – 8.3 x 108 (De Boer et 
al., 2002). 
 
The C. jejuni LOS biosynthesis gene region is a hotspot of genetic exchange in 
C. jejuni strains, which develops variation in C. jejuni LOS genetically, structurally 
and functionally (Gilbert et al., 2002; Parker et al., 2005; Mὓller et al., 2007; 
Godschalk et al., 2007). This region has been found to be strongly diverged in 
several C. jejuni strains compared to the first sequenced strain (C. jejuni 11168) 
(Dorrell et al., 2001; Gilbert et al., 2004). The GC content of this region is only 
22 to 28%, which is even lower than the GC content of the remaining genome 
(30%), indicating that variations within this region are most likely to involve the 
lengthy, AT rich DNA sequences (Parker et al., 2005).  
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The variation in the C. jejuni LOS biosynthesis gene region occur either due to 
mutations within the nucleotides of LOS biosynthesis gene sequences or 
recombination between LOS biosynthesis gene/gene regions, which are 
discussed in detail below. A single base or gene level variation within the LOS 
biosynthesis locus can modify the LOS genes encoded enzymes that are 
functional in LOS synthesis, which further leads to the development of variable 
LOS structures (Parkhill et al., 2000; Parker et al., 2008). Strains possessing the 
same LOS biosynthesis genes do not always express  phenotypically similar 
LOS structures because the LOS structures are determined not only by the gene 
content of the LOS biosynthesis gene cluster, but also by the presence of several 
mutations within this cluster (Parker et al., 2005). Hence, the genetic 
heterogeneity in LOS synthesis region determines the ultimate structure of LOS 
(Godschalk et al., 2007). 
 
3.1.1.1. Variation at the nucleotide level 
 
Nucleotide level variations within the LOS biosynthesis genes may occur due to 
the presence of homopolymeric tracts in these genes, which are the short 
sequence repeats and cause phase variation (gene switching) due to slip strand 
mispairing within these tracts (Linton et al., 2000; Gilbert et al., 2002). The 
presence of phase variable homopolymeric tracts affects the length of LOS 
biosynthesis genes (Guerry et al., 2002) and variation in LOS gene length 
significantly increases the rate of phase variation in C. jejuni (Bayliss et al., 
2012). A site directed mutagenesis of homopolymeric tract (G8  G11) in C. 
jejuni 11168 wlaN or change in the wlaN gene length increases the rate of phase 
variation ~10 fold in this gene (Bayliss et al., 2012).  
The LOS gene, wlaN, in C. jejuni 11168, C. jejuni 331 and C. jejuni 2500 with 8G 
homopolymeric tract produces a fully transcribed and functional gene product, β 
1, 3-galactosyltransferase (Linton et al., 2000; Mὓller et al., 2007; Semchenko et 
al., 2012). A phase-variable 9G homopolymeric tract in wlaN of these strains 
causes the premature translational termination and a non-functional gene 
product, which cannot add the terminal galactose in the LOS structure and 
consequently, converts GM1-like LOS epitope into a GM2 mimic (Linton et al., 
2000; Semchenko et al., 2012). In C. jejuni 224, double tracts (10A/9G; gene on 
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 10A/10G; gene off) in cj1144-45 also lead to the development of terminal α-
linked galactose lacking LOS structure (Semchenko et al., 2012). Another phase 
variable 10G tract was identified in cgtA in C. jejuni 81-176 (class B), which 
converts GM2 to GM3 in LOS structure (Guerry et al., 2002). Figure 3.1 illustrates 
the LOS structural modifications, which occur due to the phase variation in polyG 
tracts of C. jejuni 11168 wlaN and C. jejuni 81-176 cgtA. Phase variation in C. 
jejuni GC149 (class R) cgtA develops the expression of convertible human 
ganglioside (GT1a  GD3) mimics (Houliston et al., 2011). A 10G tract in C. 
jejuni GB27 cst-II and 9G tract in C. jejuni GB26 cst-II develop, respectively, a 
premature translation stop and a non-functional gene product (Godschalk et al., 
2006, 2007). As a result, cst-II encoded sialyltransferase cannot transfer sialic 
acid residues to these LOS structures and strains exhibit non-sialylated LOS 
(Godschalk et al., 2007). In addition, ORF23 with 9G or 10G tracts and ORF25 
with 8G or 9G tracts in C. jejuni 81116 (LOS locus type E) have also been 
observed (Parker et al., 2005).  
 
Sequence variation may also occur due to the single nucleotide mutations, which 
can inactivate the LOS biosynthesis genes without involving the phenomenon of 
phase variation. For example, missing A-base at position 1234 in lgtF (a LOS 
biosynthesis gene) alters the catalytic activity of its encoded enzyme, 
glycosyltransferase, in four C .jejuni strains (ATCC 43432, ATCC 43446, 
OH4382, and OH4384). As a result, the produced glycosyltransferase does not 
have the potential to catalyse the addition of ß-1, 2-glucose to Heptose-II during 
the LOS synthesis. Similarly, the last base alteration in Orf5/10 (cgtA/neuA1) in 
C .jejuni ATCC 43430 changes the amino acid (cysteine  tyrosine) which further 
leads to the production of a non-functional enzyme (Gilbert et al., 2002). The 
LOS gene, cgtA, with missing A-base at position 71 substitutes one amino acid 
in the cgtA encoding enzyme, N-acetyl galactosaminyl transferase, which further 
leads to the inactivation of N-acetyl galactosaminyl transferase in C. jejuni 
OH4382 and OH4384 and truncates the LOS structure (Gilbert et al., 2002). 
Similarly, a five base deletion from the cst-III gene of C. jejuni GB1 (possess LOS 
class B and sialylated LOS) alters the number of amino acids (294  219) in 
sialyltransferase and eventually, produces a non-sialylated LOS (Godschalk et 
al., 2007).  
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Figure 3.1. Phase variation in polyG homopolymeric tracts of C. jejuni 11168 wlaN and C. 
jejuni 81-176 cgtA.  
 
The wlaN gene in C. jejuni 11168 with 8G homopolymeric tract leads to the development of GM1-
like LOS structure. Phase variation of 8G into 9G removes the terminal galactose from GM1 and 
changes it into GM2. The cgtA gene in C. jejuni 81-176 with 10G tract develops GM2-like epitope 
in LOS structure and phase variation of 10G to 11G alters GM2 to GM3. 
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3.1.1.2. Variation at allele or gene level 
 
An insertion or deletion of a new LOS biosynthesis gene or gene regions into 
LOS locus can give rise to a different locus type (Parker et al., 2005, 2008). Only 
the portions of LOS biosynthesis genes or a deviation in gene (alleles) can also 
mutate to establish a new locus, such as, allele variation in cgtA and wlaN genes 
generate A and B subclasses including A1, A2, B1, B2 (Parker et al., 2005). In 
addition, disruption in resident LOS biosynthesis genes can also form a new 
class, for instance, disruption in class E ORF26 establishes the LOS locus class 
P (Parker et al., 2005). The developed new locus type can be variable both in 
gene content and gene organisation (Parker et al., 2005; Revez and Hänninen, 
2012). 
 
C. jejuni acquires new genes in its LOS biosynthesis region by horizontal gene 
transfer. The horizontal transfer of LOS biosynthesis genes from C. jejuni O4 
(GM1 strain) has been observed, which transformed C. jejuni 81116 (non-GM1 
strain) into a GM1-like LOS producing strain (Phongsisay et al., 2006). Similarly, 
a C. jejuni GB11 strain possessing class C locus acquired class A locus, identical 
to the LOS locus of C. jejuni ATCC 43446 (Gilbert et al., 2004). C. jejuni 81116 
and GB11, both were isolated from infected patients and horizontal gene transfer 
in these strains was found to have occurred during infection inside the human 
body (Gilbert et al., 2004; Phongsisay et al., 2006).  
 
LOS biosynthesis gene alleles cause alterations in the LOS structure. For 
instance, cst-II gene alleles lead to the expression of either threonine (Thr) or 
asparagine (Asn) at position 51 of the translated enzyme. As a result, the enzyme 
retains either a monofunctional (Thr  2, 3-sialyltransferase activity) or a 
bifunctional (Asn  2, 3- and 2, 8-sialyltransferase) activity and produces LOS, 
respectively, with one and two sialic acids (Figure 3.2; Gilbert et al., 2002).  
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Figure 3.2: Functional variation in sialyltransferase due to allele variation in cst-II 
 
Sialyltransferase with Thr at position 51 possesses mono-funtional activity and establishes α-2,3 
linkage to attach one sialic acid with LOS structure. Sialyltransferase with Asn at position 51 
exhibits bi-functional activity and forms α-2,3, as well as, α-2,8 linkage to join two sialic acids to 
LOS structure.  
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Variation in LOS locus gene content as well as in its gene organisation can also 
vary the cell-surface LOS structurally and functionally. It is not always the case 
that LOS structures belonging to the same LOS locus type present similar human 
ganglioside-like epitopes. C. jejuni 11168 and 520, both belong to class C, but 
C. jejuni 520 can produce a wider variety of human ganglioside mimics (GM1, 
GM2, asilo GM1, asialo GM2) than C. jejuni 11168 (GM1 and GM2) ( Semchenko 
et al., 2012). C. jejuni strains containing a type A LOS locus frequently present 
variable human ganglioside mimics including GM1a, GM1b, GD1a, and GD1b 
on cell surfaces (Nachamkin et al., 2002; Godschalk et al., 2004; Mortensen et 
al., 2009). GM1a-like in C. jejuni 11168 (class C), GQ1b-like in C. jejuni 81-176 
(Class B), Lewis type I-like in C. jejuni RM1503 (class M), and paragloboside/Pk 
antigens-like in C. jejuni RM1221 (class F) epitopes are typically presented in 
their LOS structures (Godschalk et al., 2004; Mortensen et al., 2009; Houliston 
et al., 2011). C. jejuni GC149 (class R) contains sialic acid biosynthesis genes 
and may present ganglioside like mimics (GT1a, GD3) as well as a hybrid form 
of ganglio and P-type antigens (Parker et al., 2008; Houliston et al., 2011). Other 
LOS classes such as D and E also possess human ganglioside-like LOS 
structures, but other than GM1, GD1 and GQ1b (Godschalk et al., 2004). Class 
P LOS have a lack of sialic acid and possess N-acetyl quinovosamine instead 
(Poly et al., 2008). The variable LOS structural epitopes or mimics presented by 
different C. jejuni LOS locus types are demonstrated in Table 3.1.  
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  Table 3.1. Variable LOS structures synthesised by different C. jejuni LOS locus types 
 
LOS locus 
class 
(Reference) 
LOS structural epitopes Mimicry 
A 
(Nachamkin et al., 
2002; Godschalk 
et al., 2004; 
Mortensen et al., 
2009) 
    
                         GM1/GM1a                                             GM1b                                 
       
          
                            GD1a                                                   GD1b 
                
 
Human Ganglioside 
Glycosphingolipid 
B 
(Godschalk et al., 
2004; Mortensen 
et al., 2009) 
                             
                               GQ1b   
 
Human Ganglioside 
Glycosphingolipid 
C 
(Linton et al., 
2000)                         
 
GM1     
 
                              
    
                                 
                    
                                  GM2 
 
Human Ganglioside 
Glycosphingolipid 
D 
(Godschalk et al., 
2004) 
Human ganglioside-like LOS structures other than GM1, GD1 & GQ1b 
(Unknown) Unknown 
E 
(Godschalk et al., 
2004) 
Human ganglioside-like LOS structures other than GM1, GD1 and GQ1b 
(Unknown) Unknown 
F 
(Houliston et al., 
2011) 
 
                    Paragloboside                                         P1 antigen                                              
       
 
                   Partial P1/GB4                                    Partial P1/GB3                                         
                   
 
P1 Blood Group  
Glycosphingolipid 
 
Partial  P1 Blood 
Group  
Glycosphingolipid  
 
Partial Human 
Ganglioside 
Glycosphingolipid 
M 
(Houliston et al., 
2011) 
 
                  Sialyl- Lewis (I) Type   
 
Lewis Type-1  
Glycosphingolipid 
P 
(Poly et al., 2008) 
Non-sialylated LOS with N-acetyl quinovosamine No mimics  
R 
(Houliston et al., 
2011) 
                 
 
                                             GD3   
 
                                            GT1b   
                    
 
 
               
                Partial P1/ Partial  GM1 
Human Ganglioside 
Glycosphingolipid 
 
 
Partial  P1 Blood 
Group  
Glycosphingolipid  
 
 
Partial Human 
Ganglioside 
Glycosphingolipid 
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3.1.2. Correlation of LOS classes with Campylobacter virulence 
The expression of variable cell surface LOS structures as a consequence of 
genes deviation in the LOS locus in C. jejuni is considered as an important 
virulence factor and may have direct connection with the progression of different 
neuronal disorders (Mὓller et al., 2007). For example, C. jejuni strains with LOS 
locus class A and variable human ganglioside mimics (GM1a, GM1b, GD1a, and 
GD1b) trigger GBS post-infection in Campylobacter infected patients 
(Nachamkin et al., 2002; Godschalk et al., 2004, 2007; Mortensen et al., 2009). 
Whereas, C. jejuni strains with LOS class B and corresponding GQ1b-like LOS 
structures are likely to develop MFS in Campylobacter infected patients 
(Godschalk et al., 2007; Islam et al., 2014). There is no doubt, genetic diversity 
within the LOS locus plays an important role in the Campylobacter virulence, as 
evidenced by the development of GBS or MFS post infection, however, this is 
not related to the development of diarrhoea or abdominal pain (Mortensen et al., 
2009; Ellström et al., 2013). Neural diseases in humans do not develop only as 
a consequence of the Campylobacter infection, but other bacterial or host 
specific risk factors also help in stimulating the anti-gangliosides antibodies 
(Revez and Hänninen, 2012; Islam et al., 2014). In the following figure 3.3, 
various factors are given, which may vary among C. jejuni strains or infected 
individuals and build complexity in GBS development (Mὓller et al., 2007; 
Godschalk et al., 2007). 
A strong link between the LOS biosynthesis gene variation and the invasion 
potential of C. jejuni strains in vitro has been identified previously. LOS class A, 
B and C (sialylated LOS) possessing C. jejuni strains show high potential of 
invasion into Caco-2 and INT407 cells compared to class D and E (non-
sialylated) retaining C. jejuni strains (Guerry et al., 2002; Mὓller et al., 2007; 
Habib et al., 2009). Moreover, resistance of C. jejuni strains to antibiotics and 
human serum has also been considered as an attribute of the LOS locus 
variation. LOS locus class B possessing C. jejuni strains were found highly 
resistant to ciprofloxacin in comparison to those which had either LOS locus 
class A or C (Mortensen et al., 2009).  
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Figure 3.3: Different variable factors causing complexity in GBS development 
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3.2. Aims and Objectives  
Based on the strong relationship between the variable LOS synthesis region and 
C. jejuni virulence, the current study aims to analyse the extent of gene variation 
in the C. jejuni LOS biosynthesis gene cluster. To achieve this aim, PCR as a 
LOS locus genotyping assay will be validated to use for the identification of LOS 
locus type in clinical C. jejuni isolates. The data obtained from the PCR typing of 
the LOS locus in clinical isolates will be used further to determine the frequency 
of C. jejuni LOS genotypes among the C. jejuni clinical isolates. 
To examine the prevalence of various C. jejuni LOS locus genotypes in a clinical 
cohort, 122 C. jejuni clinical strains, isolated from faecal samples of 
Campylobacter infected patients, were collected from the Northampton General 
Hospital, Northampton, UK. Only 50% of the 122 C. jejuni isolates were able to 
be cultured. It is previously known that Campylobacter cells can undergo a viable 
but non-culturable state during passage in the laboratory (Cappelier et al., 1999; 
Ziprin et al., 2003). Therefore, it might be possible that the remaining 50% strains 
either had the non-cultureable state or died by the time they were cultured. 
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3.3. Results 
3.3.1. Validation of PCR as a LOS locus genotyping assay  
A PCR based screening method was used to genotype the LOS core 
biosynthesis gene clusters or loci of C. jejuni clinical isolates. This method was 
initially applied by Gilbert et al. (2002) and later, has been used in other studies 
(Parker et al., 2005; Marsden, 2007; Parker et al., 2008; Habib et al., 2009; 
Ellström et al., 2013). The PCR based LOS typing method used in this study 
differs from the previous established methods on the basis of the primer design 
strategy. This strategy involves the designing of primers that span the junction of 
two adjacent LOS genes and are specific to two genes rather than a single gene 
only, indicating the exact location of genes within the cluster. 
Twenty-three LOS class specific primer pairs, as detailed in Table 1 in Appendix-
I, were designed by using the WG or partial LOS biosynthesis gene region 
sequences of established reference C. jejuni strains. In addition to 23 primers 
pairs, two sets of control primers (1 and 2) were also designed for the 
amplification of two core LOS genes (waaM and waaV). These two genes are 
present in all C. jejuni LOS classes (Parker et al., 2005) and therefore, selected 
for designing the control primers. In LOS classes for which more than one 
reference C. jejuni strains were known previously, LOS gene nucleotide-level 
differences between the strains were considered to design the class-specific 
primers. Only that sequence range of a LOS gene was selected for designing 
primers which was present across all reference C. jejuni strains without any base 
variation.  
The primer binding capacity as well as correct location of primers binding to the 
genomic DNA (gDNA) of reference C. jejuni strains were confirmed by looking at 
the size of PCR products. C. jejuni reference strains (n=9) with LOS locus types, 
A1, A2, B1, B2, C, E, F, G, H, O & P, were available and therefore these LOS 
classes specific primer pairs (A1, A2, B1, B2, C, F, 26EO, 28EP, 26HP, G) were 
tested (Figure 3.4). Primer pairs designed for other LOS classes could not be 
verified due to the unavailability of suitable reference C. jejuni reference strains.  
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Primer specificity for a single LOS class was confirmed by testing each designed 
primer pair against the collection of 9 C. jejuni reference strains belonging to 
different classes. Figure 3.5 represents that LOS class C specific primer pair was 
only specific to template DNA, which was derived from a LOS locus class C 
containing C. jejuni 11168 strain. It did not bind to gDNA of other C. jejuni strains 
including RM1048 (class A1), RM1556 (class A2), 101 (class B1), 81-176 (class 
B2), 81116 (class E), RM1221 (class F), RM1555 (class G) and 4031 (class P). 
Similarly, where possible, other primer pairs were also tested to determine their 
specificity for a single LOS class (data not shown). The primer pair was 
redesigned and retested if it showed specificity for more than one LOS class.  
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Figure 3.4: The PCR products of expected sizes amplified with C. jejuni LOS class 
specific primer pairs (A1, A2, B1, B2, C, F, 26EO, 26’HP, 28EP, and G).  
The PCR product size in bp expected for LOS classes, LOS class/classes identifiable with 
primers, and C. jejuni reference strains used for PCR assay are specified. A 100 bps to 1kb 
hyperladder, on both sides of gel photograph, was used to estimate the size of DNA bands. 
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Figure 3.5:  The specificity of primer pair/set C for LOS Class C related C. jejuni reference 
strain (11168) when tested with other LOS classes associated C. jejuni strains 
A 100 bps to 1kb hyperladder, on both sides of gel, was used to estimate the size of DNA bands. 
 
 
 
 
 
 
 
 
931 bps 
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3.3.2. Genotyping of C. jejuni clinical isolates by using PCR 
PCR with optimised and validated primer sets was performed to determine the 
LOS class of each clinical C. jejuni isolate. DNA from C. jejuni isolates was 
extracted and the origin of DNA only from C. jejuni strains was confirmed by 
performing PCR reactions (PCRs) with waaM and waaV LOS gene specific 
control primers.  
The collection of 62 C. jejuni gDNA samples was then subjected to a number of 
PCRs sets; each set of PCRs contained one pair of primers to use against all 
gDNA samples. The results of PCRs performed with primer C and all gDNA 
samples have been shown in figure 3.6 as an example, where PCR products of 
expected size (931 bps) in reactions: 6, 12, 20, 22, 30, 33, 42, 44, 47, 50, 55 & 
57, confirmed the presence of LOS locus type C respectively in C. jejuni CJ23, 
104, 92717, CJ20, 118718, ME113262, CJ3111, 34218, 34565, 45283, 60319 
and 54386. The remaining C. jejuni strains, negative for LOS Class C, did not 
show any band. A reference C. jejuni strain, if available, was included as a 
positive control in each PCR assay whereas a C. jejuni 11168Δ32-52 mutant 
strain lacking the LOS biosynthesis variable region (Marsden et al., 2009) was 
used as a negative control. A negative control for the PCR reaction was also 
included in each set of PCRs. In the same way, PCRs with all gDNA and other 
optimised primers, A1, A2, B1, B2, E, F, G, H, O, and P were performed (data 
not shown). 
The reference strains with LOS classes D, I, J, K, L, M, N, Q, R, S, T, U, V, and 
W, were not available and therefore, the annealing temperature of the primer 
pairs specific to these classes could not be optimised. PCRs with such type of 
non-optimised primer pairs were carried out at annealing temperature 5 °C below 
the primers’ theoretical melting temperatures. The presence of any specific or 
non-specific PCR product band was further confirmed by repeating the assay at 
a range of annealing temperatures (45°C to 65 °C).  
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Figure 3.6: Typical results obtained by performing PCR genotyping (class C).  
PCR reactions with all C. jejuni clinical strains’ gDNA and LOS class C specific primer “C” were 
performed. Numbers from 1 to 61 represent individual C. jejuni isolates or their gDNA. C. jejuni 11168 
strain as a positive control for PCRs (+). Negative control (a PCR reaction containing all reaction 
contents except gDNA) was used (-). PCR with C. jejuni mutant strain 11168Δ32-52 or sample 32 
was an additional negative control. A 100bp to 1kb hyperladder was used to estimate the size of 
PCR products. 
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All PCRs were performed at least three times and the results obtained were also 
verified by Sanger sequencing of PCR products and analysis of sequenced data. 
The PCR and sequencing results have been summarised in Table 3.2, which 
were used to assign a specific LOS class to each C. jejuni isolate. 50 clinical C. 
jejuni isolates were LOS classified. 6 of 50 classified C. jejuni strains including 
54386, S2, 92691, 118973, 118715 and 93133Y were positive for more than one 
LOS class. Typical PCR results of two C. jejuni strains, 54386 and 118973, 
positive for two LOS classes are illustrated in figure 3.7.  
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Table 3.2: Summary of C. jejuni LOS locus typing and PCR products’ sequencing results 
No. Clinical 
C. jejuni 
strain 
 
           PCR with optimised primers      
 
A1     A2    B1    B2   C   26EO  F    G 
                                                               26HP  
                                                                          28EP 
                                                                
PCR 
with 
other 
primers 
PCR product 
seq. identity 
(%) 
Seq. compatible 
reference strain 
& LOS genes 
Identified 
LOS Class 
1 CJ10 + - - - - - - - - - - 99         RM1048 cgtA & cgtB A1 
2 CJ4 - - - + - - - - - - - 98 81-176  cgtA & cgtB B2 
3 CJ12 - - - - - - - - - - -   Unknown 
4 CJ13 - + - - - - - - - - - 98 RM1556 cgtA & cgtB A2 
5 CJ18 - + - - - - - - - - - 97 RM1556 cgtA & cgtB A2 
6 CJ23 - - - - + - - - - - - 96 11168 neuA1 & neuC1 C 
7 S1 - - - - - - + - - - - 95 RM1221 cgtD & waaV F 
8 S2 - - - - - - - - + + -   H/P 
9 101 - - + - - - - - - - -   B1 
10 102 - - - - - - - - + + -   P 
11 103 - - - - - + - - - - -   O 
12 104 - - - - + - - - - - - 98 11168 neuA1 & neuC1 C 
13 105 - - - - - - - - + - -   H 
14 106 - - - - - - - - + + -   P 
15 Moulton - - - - - - - - - - -   Unknown 
16 1336 - - - - - - - - - - -   Unknown 
17 92740 - - - - - - - - + + - 99 
4031 
Orf27 & Orf28 
P 
18 92691 - + + - - - - - - - -   A2/B1 
19 92540 - - - - - - - - + - -   H 
20 92717 - - - - + - - - - - - 98 11168 neuA1 & neuC1 C 
21 93133Y - - - - - - - - + + -   H/P 
22 CJ20 - - - - + - - - - - - 97 11168 neuA1 & neuC1 C 
23 93084N - - - + - - - - - - - 99  B2 
24 92661 - - - - - - - - + + - 98  P 
25 112990 - - - - - - - - - - -   Unknown 
26 118715 - - - - - - - - + + - 98 
4031 
Orf27 & Orf28 
H/P 
27 118973 - + - + - - - - - - - 94 99 
RM1556 
cgtA & cgtB 
81-176 
cgtA & cgtB 
A2/B2 
28 512 - - - - - - - - - - -   Unknown 
29 121097 - - - + - - - - - - - 99 81-176 cgtA & cgtB B2 
30 118718 - - - - + - - - - - - 98 11168 neuA1 & neuC1 C 
31 93941P - - - - - - - - - - -   Unknown 
32 AT large mutant - - - - - - - - - - -   -ive control 
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33 ME113262 - - - - + - - - - - - 99 11168 neuA1 & neuC1 C 
34 ME112938 - - - - - - - - - - -   Unknown 
35 ME112946 - - - + - - - - - - -   B2 
36 ME112990 - - - - - - - - - - -   Unknown 
37 ME113179 - - - + - - - - - - - 95  B2 
38 ME113090 - - - - - - - - - - -   Unknown 
39 
751 - - - - - - - - - - -   Unknown 
40 92649 - - - - - - - - + + -   P 
41 36670 - - - - - - + - - - - 96  F 
42 CJ3111 - + - - - - - - - - -   A2 
43 37531 - + - - - - - - - - -   A2 
44 34218 - - - - + - - - - - - 98 11168 neuA1 & neuC1 C 
45 34806 - - - + - - - - - - - 98 81-176 cgtA & cgtB B2 
46 38625 - - - - - - - - + + - 99 
4031 
Orf27 & Orf28 
P 
47 34565 - - - - + - - - - - - 99 11168 neuA1 & neuC1 C 
48 38608 - - - - - + - - - - -   E 
49 44406 - - - + - - - - - - -   B2 
50 45283 - - - - + - - - - - - 99 11168 neuA1 & neuC1 C 
51 41999 - - - + - - - - - - - 99 81-176 cgtA & cgtB B2 
52 40973 + - - - - - - - - - - 98 RM1048 cgtA & cgtB A1 
53 47185 - - - - - - - - + + -   P 
54 39864 - - - - - - - - + + -   P 
55 60319 - - - - + - - - - - -   C 
56 60238 - - - - - - - - - - -   Unknown 
57 54386 - - - + + - - - - - - 98 98 
81-176 
cgtA & cgtB B2/C 
58 50702 - - - - - - + - - - - 92 RM1221 cgtD & waaV F 
59 59653 + - - - - - - - - - - 98 RM1048 cgtA & cgtB A1 
60 51585 - - - - - - - - + - -   H 
61 92838 - - + - - - - - - - -   B1 
62 92871 - - + - - - - - - - -   B1 
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Figure 3.7: The PCR positive results for C. jejuni isolates, 57 and 27, which were 
assigned to more than one LOS class.  
(A). C. jejuni 54386 (isolate 57) was positive for LOS classes, C and B2.  
(B). C. jejuni 118973 (isolate 27) was positive for LOS classes, A2 and B2.  
C. jejuni 11168 (class C), C. jejuni RM1556 (class A2) and C. jejuni 81-176 (class B2) were 
used as positive control for PCRs. PCRs containing all reaction contents except gDNA were 
used as negative controls. A 100bp to 1kb hyperladder was used to estimate the size of PCR 
products. 
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3.3.3. Evaluation of the C. jejuni LOS loci distribution at clinical level  
Figure 3.8 presents the distribution of C. jejuni LOS locus classes (A-W), 
subclasses (A1, A2, B1, B2) and LOS groups (1-4) in a C. jejuni collection, built 
up from C. jejuni infection cases in Northampton, UK. 28 (56%) C. jejuni strains 
were identified as belonging to LOS class A1 (n=3; 6%), A2 (n=4; 8%), B1 (n=3; 
6%), B2 (n=8; 16%), C (n=10; 20%) and therefore were members of LOS group 
1. 16 of 50 (32%) of classified strains were positive for either class E (n=1; 2%), 
H (n=3; 6%), O (n=1; 2%) or P (n=8; 16%), and therefore, belonged to LOS group 
2. LOS class P with 16% was the most frequently represented class within group 
2. Only 3 (6%) C. jejuni strains were positive for LOS group 3 related class F. No 
C. jejuni strain associated with other classes of LOS group 3 (D, K, Q, N, I, S, J) 
was identified. In addition, C. jejuni strains with LOS group 4 related classes, L, 
G, T, & U, were also not observed among the clinical C. jejuni isolates. The 
hierarchy of LOS groups was group 1 (62%) > group 2 (32%) > group 3 (6%) > 
group 4, indicating the occurrence of group 1 related C. jejuni strains in a high 
proportion at clinical level. Figure 3.9 further illustrates that the hierarchy of LOS 
locus ABC classes within group 1 was class B (n=11) > class C (n=10) > class A 
(n=7), as well as, high frequency of class P (n=8) and F (n=3) respectively in 
group 2 and group 3.  
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Figure 3.8: The distribution of C. jejuni LOS locus classes (A-W), subclasses (A1, A2, B1, 
B2) and LOS groups (1-4) from clinical isolates. 
 
Each segment of inner circle specify the total number of C. jejuni isolates (50) used for the PCR 
based typing assay. The frequency of C. jejuni isolates classified for each particular LOS 
class/group is mentioned in numbers (n out of 50) on the top of each inner circle segment and 
presented with ribbon width. The frequency of a C. jejuni LOS class/group in percent is mentioned 
with each outer circle segment and represented by the orange or colourful blocks. Ribbon ends 
link each C. jejuni LOS class to its related LOS group. 
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Figure 3.9: The distribution of C. jejuni LOS locus classes (A-W) within the LOS groups 
(1-4) from clinical isolates  
 
The class B in LOS group 1 (green), class P in LOS group 2 (light Blue) and class F in LOS 
group 3 (dark Blue) were highly prevalent. The hierarchy of LOS classes within the Group 1 was 
class B > class C > class A. 
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3.3.4. Analysis of LOS core of C. jejuni clinical isolates  
 
LOS samples extracted from C. jejuni clinical isolates were examined on 16% 
silver stained SDS-PAGE gels. Figure 3.10 (A) represents that CJ10 (class A1), 
CJ18 (class A2), 59653 (class A1), 37531 (class A2), and 40973 (class A1), and 
all C. jejuni strains with type A had LOS of almost same size (~12 kDa). Similarly, 
C. jejuni stains, 101 (class B1), ME113179J (class B2), 34806 (class B2), and 
41999 (class B2) showed the LOS of almost same size (~13 kDa) and 
comparable to the LOS of class B reference strain, C. jejuni 81-176 (Figure 3.10 
B). The LOS from class C associated strains (11168, 34565, 60319, 34218, 
45283, CJ20, 92717, 104, CJ23), classes E, H, O & P linked strains (103, 51585, 
92540, 47185, 38608, and 92649), and class F containing strains (RM221, 
36670, 60238) are also presented respectively in figure 3.10 C, D & F. These 
results suggested that C. jejuni strains linked to the same LOS locus class or 
type express LOS structures of almost equal molecular weight on their cell 
surfaces and the size of LOS does not change even with the possession of 
different LOS locus subclasses.   
The LOS structures were variable within different classes of a same LOS group. 
For instance, C. jejuni 92540 type H LOS and C. jejuni 92649 type P LOS had 
different sizes, although these both classes belonged to the same LOS group 
(Group 2; Figure 3.10 E). These results indicate that LOS size can vary between 
strains belonging to different LOS classes and do not significantly vary between 
strains of a same LOS class. The LOS structures could be variable even between 
the strains of a same class but these minor structural differences were unable to 
detect on SDS-PAGE gels.   
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Figure 3.10: Analysis of LOS by SDS PAGE. LOS extracts from the clinical C. jejuni strains on 
silver stained 16% (v/v) SDS-PAGE gels. Multi-colour low range protein ladder (1.7- 40 kDa) was 
used to predict the size of LOS bands.  
(A): C. jejuni strains, CJ10 (class A1), CJ18 (class A2), 59653 (class A1), 37531 (class A2), 
40973 (class A1), showed LOS of ~12 kDa.  
 
(B): C. jejuni strains, 101 (class B1), ME113179J (class B2), 34806 (class B2), 41999 (class 
B2), showed LOS of ~13 kDa, comparable to the LOS of class B reference strain, C. jejuni 81-
176. 
 
(C): C. jejuni strains including 34565, 60319, 34218, 45283, CJ20, 92717, 104, CJ23 showed 
LOS of ~11-12 kDa, comparable to the LOS of class C reference strain, C. jejuni 11168. 
  
(D): C. jejuni strains, 103 (class O), 51585 (class H), 92540 (class H), 47185 (class P), 38608 
(class E), and 92649 (class P), showed LOS of ~14-15 kDa.  
 
(E): Difference in type H (~15 kDa; C. jejuni 92540) and type P (~14.5 kDa; C. jejuni 92649) 
LOS. 
 
(F): C. jejuni 36670 and C. jejuni 60238 showed LOS of ~12 kDa, comparable to class F 
reference strain, C. jejuni RM1221. 
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3.4. Discussion  
LOS classes from A through F were known for C. jejuni initially (Gilbert et al., 
2002; Parker et al., 2005). Karlyshev et al. (2005) primarily categorised these 
known C. jejuni LOS classes into four groups and included LOS classes A, B, C 
in Group 1, LOS class E in Group 2, LOS class D and F in Group 3, and LOS 
class G in Group 4. Later, Parker et al. (2008) identified 11 more C. jejuni LOS 
classes including I, J, K, L, M, N, O, P, Q, R, and S. Subsequently, Richard et al. 
(2013) found C. jejuni strains with novel LOS loci and established 4 more LOS 
classes including T, U, V and W. The novel LOS loci identified in the latter two 
studies have never been classified into the LOS groups. To better understand 
the prevalence of C. jejuni LOS groups and groups related LOS classes, the 
present study has simplified the LOS classification system. Figure 3.11 is a 
representation of a simplified C. jejuni LOS locus classification system, where 
various already known LOS classes have been added into the pre-established 
LOS groups on the basis of sharing the similar LOS biosynthesis gene content. 
Group 1 includes all those LOS locus types, A, B, C, R, M and V, which contain 
the sialic acid synthesis genes whereas the other three groups have LOS loci 
with no sialic acid genes. Based on the similarity of LOS loci (H, O, P and W) to 
locus E, these four classes are added into group 2. Further, K, Q, N, I, J, and S 
in LOS group 3 and L, G, T, and U in LOS group 4 are assimilated.  
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                Figure 3.11: Simplified C. jejuni LOS locus classification system. 
LOS classes, classified into already established four groups on the basis of sharing the similar LOS biosynthesis gene content (highlighted in grey coloured boxes). 
Genes are numbered according to the Parker et al. (2005) numbering system. Pink arrows: commonly present genes in all LOS classes; Blue Arrows: variable LOS 
genes. Arrow direction represents the direction of gene transcription (Adapted from Karlyshev et al., 2005).
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In the present study, 6% of C. jejuni clinical strains possessed LOS locus 
subclass B1 and 16% had subclass B2. Altogether, 22% (n=11) of the analysed 
50 C. jejuni clinical isolates were found with LOS class B, indicating the class B 
as the most common LOS class among these isolates. This was in line to a 
previous study (Islam et al., 2009), who observed high prevalence of C. jejuni 
LOS locus class B in enteritis patients [46% (n=18) of analysed 39 C. jejuni 
strains] and GBS patients [28% (n=2) of analysed 7 C. jejuni strains]. Another 
recent study also described the class B as the most frequent class in enteritis 
patients after identification of 40% (n=68) of 152 C. jejuni strains with LOS locus 
class B (Islam et al., 2018).  
In the current study, 20% of analysed C. jejuni strains had LOS class C, 
specifying the class C as the second most abundant LOS type in the clinical 
cohort. The high frequency of LOS class B (22%) higher than class C (20%), 
observed in this study, is concordant with C. jejuni LOS locus class distribution 
data of Quinones et al. (2007), who LOS typed poultry C. jejuni strains using 
microarray and class-specific probes and reported class B (37%) > class C 
(16%). Many other studies have described the LOS class C as the major class 
of C. jejuni LOS biosynthesis locus (Marsden, 2007; Ellström et al., 2013, 2016). 
However, in comparison to the high prevalence of LOS class C (42%) in clinical 
isolates in Sweden (Ellström et al., 2016), a very small number of clinical strains 
(2%) in Bangladesh had association with LOS locus C (Islam et al., 2014). Most 
of the GBS-related C. jejuni strains in Bangladesh and China possessed the LOS 
locus class A rather than class C (Islam et al., 2009; Jiang et al., 2010; Islam et 
al., 2014), suggesting that C. jejuni LOS class distribution may vary 
geographically. 
According to the current findings, the trend of LOS classes within group I was 
class B (22%) > class C (20%) > class A (14%), which was different from 
previously found trends of these three classes in Marsden. (2007) [class C (19%) 
> class B (10%) > class A (2%)] and Ellström et al. (2016) [class C (42%) > class 
B (12%) > class A (3%)]. However, a general trend of LOS groups distribution at 
clinical level (group 1 > group 2 > group 3 > group 4) observed in the current 
study was comparable to Marsden. (2007), Quinones et al. (2007), Ellström et 
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al. (2016) and Islam et al. (2018). A comparison of current findings of C. jejuni 
LOS loci distribution with previous studies has been presented in figure 3.12 (A). 
In this comparison, it is noticeable that the hierarchy of LOS group prevalence 
remains similar among both human and poultry derived C. jejuni isolates. This 
also indicates that the LOS locus type A in GBS patients and B and C genotypes 
in clinical/enteritis patients are highly predominant. A representation of LOS ABC 
types’ combined frequency in different populations of C. jejuni isolates (which 
may be humans or poultry), observed in current and previous studies, is also 
given in figure 3.12 (B). This indicates that approximately 50–65% strains in most 
of the clinical/enteritis associated C. jejuni populations and more than 80% 
strains in GBS linked C. jejuni populations, belong to LOS classes A, B or C.   
Previous studies have described that a high prevalence of group 1 related ABC 
classes might happen due to the distinctive ability of the group 1 related strains 
to synthesise the sialylated LOS structures, which are beneficial for 
pathogenesis (Gilbert et al., 2002; Parker et al., 2005; Habib et al., 2009). For 
instance, LOS class A with the appearance of GM1-like LOS sub-structures is 
more likely to develop GBS whereas class B with GQ1b-like LOS sub-structures 
are linked with MFS development (Godschalk et al., 2007; Islam et al., 2014). 
According to the results of the present study, B2 and C are the most common 
LOS types in this population of C. jejuni. It might be due to this fact that both of 
LOS locus types exhibit high phase variations at the gene sequence level and 
produce heterogenous ganglioside mimics, advantageous for pathogenesis. 
Previously, phase variations in class B2 containing C. jejuni strain, 81-176 
(altering GM2  GM3  GD in LOS) and class C possessing C. jejuni strain, 
11168 (modifying LOS GM1  GM2) have been observed (Guerry et al., 2002; St 
Michael et al., 2002). It is noticeable that the rate of GBS and MFS in 
Campylobacter infected patients is very low (Nachamkin et al., 2002; Mortensen 
et al., 2009) despite high predominance of GBS/MFS associated LOS classes A, 
B, and C, at the clinical level, supporting the fact that some other factors in 
addition to LOS structures contribute in the development of these neural 
diseases.   
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Figure 3.12: (A) A comparison of current findings of C. jejuni LOS loci distribution with previous studies. (B) The combined frequency of LOS 
types A, B, and C, present in different C. jejuni populations (human or poultry)  
The combined frequency of classes ABC present in the range of 50–65% is represented by a green bubble. The combined frequency of classes ABC lying 
out of the range of 50–65% is illustrated by a grey bubble. The overlapping of green and grey bubbles shows that both bubbles belong to the same study. 
ENT: C. jejuni isolates from enteritis patients; GBS: C. jejuni isolates from GBS patients; Chick: C. jejuni isolates from chicken. BB infection: C. jejuni 
isolates from patients with Blood Borne infections.
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Interestingly, other LOS classes of group 1 (R, V and M), also contain genes for 
the biosynthesis of sialylated LOS structures (Parker et al., 2008; Richard et al., 
2013), but they were not found in the collection of C. jejuni clinical isolates. It 
might be because class R containing strains do not produce GBS related 
ganglioside mimics (GM1, GM2, GD1, GD2) and class M does not produce the 
ganglioside mimicking LOS structures at all despite having sialic acid 
biosynthesis genes (Houliston et al., 2011). 
LOS group 2 was the second most predominant group with a high prevalence of 
LOS class P (16%). However, LOS class H has been reported previously as the 
most abundant class within the group 2 (Quinones et al., 2007, Ellström et al., 
2016). The fact is both LOS class P and H share the almost similar gene content 
except for two LOS biosynthesis genes (Orf 26’ and Orf28) (Parker et al., 2008; 
Jiang et al., 2010) and therefore, a few studies have never considered these 
classes as two distinct classes (Habib et al., 2009; Islam et al., 2014). To clearly 
differentiate between the LOS group 2 related classes, three sets of primers 
26EO (for LOS class E and O), 26’HP (for class H and P) and 28EP (for class E 
and P) were designed in this study. Despite designing of class specific primers 
and testing these primers with reference strains, 81116 and 4031, a few clinical 
C. jejuni gave a mixed signal for LOS class H and P. In this case, PCR products 
obtained with class H and P specific primers were further sequenced and 
sequencing data was interpreted to assign a single class to each strain.  
LOS group 2 loci related strains appeared in abundance among a small 
population of C. jejuni from the enteritis cases, although they lack the sialic acid 
biosynthesis genes and are likely to produce the non-sialylated LOS structures 
(Parker et al., 2008; Poly et al., 2008). This might be due to the presence of sialic 
acid biosynthesis LOS genes somewhere else in the genome of these strains 
rather than specifically in the LOS locus. This notion is evidenced by the 
presence of ganglioside-like structures other than GM1 or GQ1b in LOS locus E 
associated C. jejuni strains (Godschalk et al., 2004). Subsequently, only 6% of 
C. jejuni strains were identified with the group 3 related LOS class F which was 
relatively similar to the findings of Quinones et al. (2007). Six C. jejuni strains 
were positive for more than two LOS classes which can take place due to co-
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infection in patients with multiple C. jejuni strains. The co-infection occurrence 
with multiple C. jejuni strains has been previously observed in GBS patients 
(Godschalk et al., 2006). Another reason could be occurrence of interstrain or 
intrastrain LOS gene recombination during infection as it has been observed 
previously by Gilbert et al. (2004) and Phongsisay et al. (2006). 
C. jejuni strains with the same LOS locus type expressed LOS structures of 
almost equal molecular weight. These results were identical to previous findings 
where two C. jejuni strains, 331 and 421, both with LOS class C had the LOS 
structures of similar size (Semchenko et al., 2012). However, LOS were variable 
between different classes of the same group, such as, LOS class H and P both 
belonged to the same group but their LOS appeared with slightly different 
molecular weights. The sizes of C. jejuni class H related LOS (~15 kDa) and 
class P linked strain LOS (~14.5 kDa) were found similar to class H and P 
associated LOS sizes reported in a previous study (Jiang et al., 2010), indicating 
that the size of LOS structures may vary with the change of locus type or even a 
single LOS biosynthesis gene of LOS locus. The work related to the LOS 
phenotypic characterisation was carried out by SDS-PAGE, which was not 
sufficient to fully explore the LOS structure and establish its link with LOS locus 
genotype. Another limitation of this work is that, the final LOS structure cannot 
be truly predicted by a particular LOS locus type as minor sequence variation in 
LOS biosynthesis genes can greatly impact the synthesis of LOS structure 
(Parker et al., 2005).   
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3.5. Conclusion 
This study is the first description of the abundance of LOS subclasses (B2 > A2 
> B1 > A1) in the clinical isolates of C. jejuni. The hierarchy of LOS group 
prevalence was group 1 > group 2 > group 3 > group 4 and trend of LOS classes 
within the group 1 was class B > class C > class A. C. jejuni isolates were most 
frequently assigned to group 1 related LOS locus types, B2 and C, which can 
happen due to the fact that these two loci have the potential of varying the human 
ganglioside-like LOS structural epitopes. Compared to the high proportion of C. 
jejuni isolates with LOS loci (A, B and C), the prevalence of strains with the other 
three group 1 related and sialic acid biosynthesis genes containing loci (R, V and 
M) was almost negligible. The reasons for this remain unclear, but it might be 
due to the lack of GM1-like ganglioside mimicking LOS structures in R and M 
loci, indicating the importance of LOS in Campylobacter pathogenesis. Finally, 
this study extends our understanding of the LOS locus classification system and 
represents an overview of the frequency of various LOS locus genotypes in 
clinical C. jejuni isolates.  
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CHAPTER 4 
 
In Silico Analysis of the Genetic diversity of the 
Lipooligosaccharide Biosynthesis Locus in C. jejuni and C. coli 
 
4.1. Introduction  
4.1.1. The use of bioinformatics in the present study  
Initially, the term bioinformatics was defined as “the computational methods for 
comparative analysis of genome data” (Hogeweg, 2011). This definition also 
summarises the application of bioinformatics in the current study, where 
computational tools were applied to compare the gene sequences and measure 
the similarity between them. The process of comparing the gene sequences or 
finding a series of similar character patterns with the same arrangement in the 
compared sequences is known as sequence alignment. The sequence alignment 
may be pairwise (performs between two sequences at a time) or multiple 
(performs between more than two sequences) (Pearson and Lipman, 1988). 
GenBank is comprehensive and the most common database which contains 
nucleotide sequences from more than 260, 0000 species and is publicly available 
around the world at no cost over the Internet (Benson et al., 2007). 
Campylobacter WG sequences available in GenBank, submitted either by the 
individual laboratories or large scale sequencing projects, were selected for the 
current study.  
 
4.1.1.1. Multiple alignment using fast Fourier transform (MAFFT) 
A bioinformatic tool, MAFFT, at the MAFFT server 
<http://mafft.cbrc.jp/alignment/server/large.html>, was first introduced in 2002 to 
perform multiple sequence alignments (Katoh et al., 2002). The following 3 steps 
explain the procedure in detail which are implemented by MAFFT to perform a 
sequence alignment using the Needleman–Wunsch and Fast Fourier Transform 
(FFT) algorithms. 
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Step 1 - Building a guide tree: MAFFT Needleman–Wunsch algorithm initially 
look for the k-mers (pairs of identical 6 nucleotide long strings), determines the 
pairwise percent identity score, and measures the similarity between k-mers 
(Needleman and Wunsch, 1970). The approximate number (Tij) of k-mers 
shared by every pair of input sequences (sequence i and sequence j) is counted. 
Subsequently, k-mer numerical value for each pair is converted into a distance 
value (distance between two sequences in a single pair; Dij) using the following 
formula and mathematical calculations (Kotah et al., 2002).  
Dij = 1 – [ Tij/min (Tii, Tjj) ] 
An UPGMA (Unweighted Pair Group Method with Arithmetic Mean) guide tree is 
constructed using the calculated distance values or a matrix of pairwise 
distances between all sequences (Lassmann and Sonnhammer, 2005; Katoh 
and Toh, 2008). The first two nodes (let’s suppose A & B) of the tree are joined 
based on the shortest distance value and represent the two closely related or 
similar sequences. Further new nodes are defined and established by the 
MAFFT to build a guide tree. A new node (for example, node C) is defined with 
the smallest value of the remaining distance values. The sequence at node C 
will have high similarity to the sequences incorporated at node A and B. Node C 
is established within the tree at the specific distance from the adjacent two nodes, 
A and B. This specific distance is determined by the arithmetic mean value of 
distance values of A and B. In this manner, the process of defining and 
establishing the nodes eventually construct a tree. The initial tree formed in this 
step is known as a guide tree (Kotah et al., 2002; Katoh and Toh, 2007, 2008). 
Step 2 - Progressive alignment based on the guide-tree branching: The 
guide tree dictates the order of further pairwise alignments. Once the guide tree 
is built, multiple alignment progressively starts building up, where multiple 
sequence alignment is assembled by accumulating the sequences to the 
alignment one by one following the branching order of guide tree. Branches and 
alignments, both are developed first between the most closely related sequences 
and then, distant ones are gradually added (Kotah et al., 2002; Katoh and Toh, 
2008; Yamada et al., 2016). 
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Step 3 - Group-to-group alignment based on FFT and refining: MAFFT has 
a function of group-group alignment, similar to the profile-profile alignment of 
Clustal W, where a group or profile is a subset of multiple alignments. MAFFT 
incorporates the fast Fourier transform (FFT) algorithm in addition to dynamic 
programming or Needleman–Wunsch algorithm (Thompson et al., 1994; Katoh 
et al, 2002). Within the group-group alignment, each pair of aligned sequences 
is converted to a 2D wave (containing frequencies of nucleotides {A, C, G, T}) 
and correlation between two waves is rapidly computed using FFT. A sequence 
pair with longer length and maximum identity gives a high signal or peak in 
comparison to a less similar and short length sequence. In addition to measuring 
the sequences similarity, the FFT algorithm also performs an approximate 
distance calculation which are further used to complete a phylogenetic tree. This 
FFT phase is fast and takes less time to complete in comparison to the dynamic 
programming phase (first two steps) (Katoh et al., 2005; Katoh and Toh, 2008).  
 
4.1.1.2. Using MAFFT for the classification of C. jejuni LOS locus 
The Galaxy web based platform <http://usegalaxy.org> consists of different 
bioinformatics related tools to access all these simultaneously on the same 
platform and to produce reproducible results (Goecks et al., 2010; Afgan et al., 
2018). In this study, MAFFT (version 7) in combination with other bioinformatics 
tools (as demonstrated in figure 4.1) was used at the Galaxy platform rather than 
utilising it through its own server. MAFFT alignment tree is built by this workflow 
as its output, where unclassified sequences belonging to a particular group are 
clustered together and within this cluster tree branches link each unclassified 
sequence to an individual, reference LOS locus type. 
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         Figure 4.1: A Galaxy workflow designed for the classification of C. jejuni LOS locus 
This workflow estimated and extracted a ~65 kb specific sequence (1064895-1130000) from every sequence in the collection of C. jejuni unclassified WG sequences. 
The extracted sequences (predicted to contain the LOS locus sequences) were collapsed. A set of collapsed sequences and a set of LOS class sequences (reference 
or previously known) are concatenated in tabular format and aligned in FASTA format using MAFFT.
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The bioinformatics based approach has been used previously for the LOS 
genotyping of Campylobacter sequences (Culebro et al., 2018). In this study, C. 
jejuni and C. coli sequences publically available in European Nucleotide Archive 
were mapped against a set of reference LOS genes using the ReMatCh 
framework v3.2 <https://github.com/B-UMMI/ReMatCh>. This framework 
extracted the raw reads in fastq format, mapped the reads of the LOS locus 
against the reference using Bowtie237, and performed the variant calling using 
Samtools and ReMatCh Single Nucleotide Polymorphism call criteria. A locus 
was considered to be present in an unclassified sequence if 70% of the target 
reference sequence with ≥80% nucleotide identity aligned with the query 
sequence (Culebro et al., 2018). 
 
 
4.1.1.3. Mega Basic Local Alignment Search Tool (Megablast)  
Megablast searches for the conserved regions in a query sequence, where a 
single pair alignment process can produce many subsequence alignments in the 
results (local alignment) (Benson et al., 2007; Camacho et al., 2009; Chen et al., 
2015). However, MAFFT optimises the alignment across the whole query 
sequence, which may include the regions of low similarity (global alignment) 
(Kotah et al., 2002; Katoh and Standley, 2013).  
Megablast works by using the dynamic programming method where the Smith-
Waterman algorithm is used to convert a large query sequence into small 
sequences (bits), pair these bits with similar bits found in the DNA databases, 
and mathematically assign a score to every bit pair. Subsequently, a scoring 
matrix is constructed based on the bits scores and high scoring optimal alignment 
is detected to report (Pertsemlidis and Fondon, 2001). Three steps given in figure 
4.2 explain the procedure in detail which is implemented by the Megablast Smith-
Waterman algorithm to perform a sequence alignment.   
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                Figure 4.2. Schematic of a Blast search 
                (Reproduced from Camacho et al., 2009). 
Set-up stage: Megablast masks the short, periodic nucleotide repeats from the query sequence, 
scans the DNA database to find those sequences which score at least threshold (T, a Blast 
parameter pre-defined by the user) and builds a library of those sequences which resemble to 
the query sequence (lookup table). 
Scanning step: Megablast seeks short word pairs (hits) typically 28 nucleotides long, which 
occur both in the query sequence and lookup table. Subsequent to seeding the hits, each hit or 
paired sequence is extended in both directions as long as its associated score continues to 
increase. Consequently, a segment of sequences with extended matching or alignment is 
produced, which is known as ungapped extensions of short word pairs or high scoring segment 
pair (HSP). An HSP with the highest score whose alignment cannot be further enhanced by 
lengthening or shortening is termed as a maximal-scoring segment pair (MSP). MSPs with the 
high level of similarity gains higher score than MSPs with low nucleotide similarity. MSPs 
possessing the highest score combine to trigger a gapped alignment (“gap” refers to the maximal 
uninterrupted run of spaces in a single sequence), which is then considered to report as the Blast 
output. The score of combined MSPs is sum up to report as a final alignment score (i.e. identity 
score in the Blast output). 
Trace-Back stage: Megablast look up once again for the approximate matches within each MSP 
composition, corrects the positions of incorrect base deletions or insertions saved in the 
alignments during this phase. 
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4.1.1.4. Using Megablast for the classification of C. jejuni and C. coli LOS 
loci  
The Blastn (Basic Local Alignment Search Tool for nucleotides) program is 
provided by National Center for Biotechnology Information at the Blastn server 
<https://blast.ncbi.nlm.nih.gov> which directly approximates the alignment 
between the two nucleotide sequences to measure and optimise the identity 
between them (Altschul et al., 1990). Megablast is an improvement of the existing 
Blastn program which is used specifically to detect the very similar nucleotide 
sequences between a query sequence and database sequences (subject 
sequences) (Benson et al., 2007; Camacho et al., 2009; Chen et al., 2015). In 
comparison to Blastn, Megablast is ten times faster, scans a large number of 
queries at one time, and can efficiently manipulate much longer DNA sequences 
originated from the same species (McGinnis and Madden, 2004; Kaur et al., 
2008). Therefore, in the current study, alignment of an individual query sequence 
against all genes (present in all previously known LOS classes) was determined 
by performing Megablast repeatedly at its server <https://blast.ncbi.nlm.nih.gov> 
rather than the Blastn. A LOS gene was defined as present if ≥80% of the query 
sequence was effectively mapped to the reference LOS gene sequence and had 
≥80% nucleotide identity to the reference LOS gene sequence. Subsequently, 
based on the predictions for the presence or absence of distinct LOS genes, 
combination of LOS genes or a LOS class was identified, and assigned to a 
particular C. jejuni or C. coli WG sequence.  
Megablast can detect the accession number for a complete WG                                                            
sequence and utilise it to find a query sequence. In contrast, Megablast is unable 
to incorporate the accession number of a contig-level or draft WG sequence. In 
this case, Megablast detects the contig unique ID number or sub accession 
number to find the query sequence. This means, a draft WG sequence with 100 
contigs will produce 100 query sequences in the Megablast program. Thus, to 
reduce the burden of query sequences, contig numbers containing the LOS 
biosynthesis gene sequence were identified for all draft C. jejuni sequences. For 
this purpose, all sequenced contigs associated with each single strain sequence 
were aligned against the two reference LOS genes (waaC and waaF) sequences 
using Megablast, and subsequently, only identified LOS biosynthesis cluster 
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sequence containing contigs were used further for the LOS classification 
analysis. Thus, complete and annotated sequences were subjected only once 
and draft sequences twice to the Megablast.  
In this study, Megablast was used to validate the Galaxy workflow and its 
classified C. jejuni sequences (complete and annotated), as well as, to classify 
those sequences of C. jejuni (draft) or C. coli (complete & draft) which could not 
be classified in Galaxy. Previously, 234 Acinetobacter baumannii genome 
sequences were extracted from the MLST database and their associated LOS 
outer core locus type was identified using Blastn (pairwise alignment between an 
unclassified sequence and one of the reference OCL1, OCL2 and OCL3 
sequences). 9 Novel LOS outer core biosynthesis locus types (OCL4 - OCL12) 
of Acinetobacter baumannii were identified and OCL1 type was found to be most 
abundant in the MLST database of Acinetobacter baumannii using Blastn 
(Kenyon et al., 2014). 
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4.2. Aims and Objectives 
This study aims to validate the use of the designed in silico Galaxy workflow for 
the classification of the C. jejuni LOS biosynthesis locus. For this purpose, 
complete online sequences of C. jejuni (n=125) classified by Galaxy workflow 
were compared with those 125 sequences which were classified using the 
Megablast. The designed Galaxy workflow was unable to classify the draft C. 
jejuni sequences, therefore, this study also aims to classify the draft C. jejuni 
sequences (n=578) using Megablast. Further, this study also aims to compare 
the distribution of C. jejuni LOS genotypes present within the GenBank database 
of C. jejuni sequences [complete (n=125) and draft (n=578)] with the frequency 
of C. jejuni LOS genotypes in a collection of 50 C. jejuni clinical Northampton 
General Hospital (NGH) isolates (previously identified in Chapter 3).  
C. coli LOS locus class II contains cst-IV (a homologues of sialic acid 
biosynthesis gene, cst-II) and class III consists of a pseudogenized cst-IV, which 
are responsible for the transfer of sialic acid residues to the outer core of LOS 
structure (Culebro et al., 2018; Kolehmainen et al., 2019). This might be a reason 
of occurrence of C. coli strains in GBS patients (Wulffen et al., 1994; van Belkum 
et al., 2009). The relation between different C. coli LOS locus structures and 
virulence is not fully established yet (van Belkum et al., 2009). The reasons 
behind it is the presence of a wide variety in C. coli LOS biosynthesis locus type 
(I-VIII)/LOS structures and availability of limited knowledge of C. coli LOS 
structures (Richard et al., 2013; Kolehmainen et al., 2019). Therefore, to focus 
future research at the specific, predominant C. coli LOS structures only, it is very 
important to identify those LOS locus types, which have been dominantly evolved 
and are frequently present in C. coli as the result of natural selection. Thus, this 
study also aims to determine the frequency of C. coli LOS types present in the 
worldwide GenBank database of C. coli sequences [complete (n=22) and draft 
(n=542)]. 
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4.3. Results 
 
4.3.1. LOS locus typing of C. jejuni GenBank sequences using Megablast 
and Galaxy MAFFT alignment tools  
Complete C. jejuni sequences (n=125) and contig-level C. jejuni sequences 
(n=578) of high quality (with >20x coverage) available in GenBank were 
subjected to Megablast and the LOS class associated with each sequence was 
determined. The accession numbers of both complete and draft sequences as 
well as identified contig numbers of all draft sequences containing LOS 
biosynthesis region are reported (Table 1 in Appendix-II). Megablast was 
performed repeatedly (taking a manual approach) to determine the alignment of 
C. jejuni unknown or query sequences against all reference LOS gene 
sequences. The identity score (similarity between the two sequences in the form 
of percentage; cut-off value 80%) and query cover (percent of query sequence 
identical to the subject sequence) confirmed the presence of a particular LOS 
gene sequence in the given query sequence. On the basis of the presence or 
absence of LOS gene or LOS genes’ combination in a query sequence, an 
individual LOS class from extant C. jejuni LOS classes was identified and 
assigned to the query sequence. Using this manual Megablast pairwise 
alignment approach, sequences of 400 C. jejuni strains were assigned to LOS 
group 1 related classes, 214 to LOS group 2 related classes, 73 to LOS group 3 
related classes, and only 16 to LOS group 4 related classes, were associated 
(Table 1; Appendix-II).   
The LOS class identification process for 125 complete C. jejuni sequences was 
also carried out using the Galaxy multiple alignment workflow. Altogether 81 of 
125 sequences were linked to LOS groups (leaving 44 of 125 unclassified) and 
39 of 81 were further associated with LOS classes using Galaxy MAFFT 
alignment trees (Figure 4.3). The same LOS group or class was also determined 
for each of these 81 sequences using Megablast, validating the use of Galaxy 
MAFFT alignment tool for the classification of C. jejuni LOS biosynthesis locus. 
Table 4.1 summarises the total number of C. jejuni sequences of 125, which 
were classified using Galaxy and Megablast.  
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Figure 4.3. Illustration of trees, obtained using the Galaxy-MAFFT workflow and used to 
predict the LOS locus types in C. jejuni WG sequences 
(A). The clustering of 19 C. jejuni strains sequences (12664, 12567, 11168/lacY, 00-2426, 
IA3902, NS4-9-1, NS4-5-1, NS4-1-1, MTVDSCj07, RM1285, 11168-GSv, 11168-Kf1, 11168-
K12E5, 11168-BN148, 11168-mfK12E5, PT14, D42a, 11168H/araE, YH0002) around the 
reference class C, 2 sequences (81-176_G1_B0, RM3194) around the class B and 2 sequences 
(00-6200, RM3420) around the class A are represented. All these sequences belonged to LOS 
group 1.  
 
(B). The clustering of 5 sequences (12661, ATCC35925, 12662, 35925, S3) around the LOS 
class F and 3 sequences (HF5-7-1, HF5-5-1, F38011) around the reference LOS class K are 
depicted. All these sequences belonged to LOS group 3. 
 
(C). The clustering of RM1246-ERRC & IF1100 with class H, CG8421 & 4031 with class P, 
CJM1cam with class W, and MTVDSCj20, CJ677CC524 & CJ677CC536 around the class O are 
presented. All these sequences belonged to LOS group 2. 
 
Each blue coloured arrow represents that C. jejuni sequence for which the same LOS class was 
identified using both Megablast and Galaxy MAFFT alignment tools. Purple coloured arrows 
represent those sequences which could not be LOS classified correctly using Galaxy MAFFT, 
but correctly LOS grouped.  
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Table 4.1: Comparison of Galaxy and Megablast classified C. jejuni sequences (n=125) 
 
 
 
 
 
 
 
 
 
 
C. jejuni 
LOS locus 
class 
(Group) 
 
No. of LOS 
classified C. jejuni 
sequences by  
Galaxy 
 
 
No. of LOS 
grouped C. jejuni 
sequences  by 
Galaxy 
 
No. of LOS 
classified C. 
jejuni sequences 
by  Megablast 
 
No. of LOS 
grouped C. jejuni 
sequences  by 
Megablast 
      
      A    (1) 
      B     
      C 
      V 
      
    Total 
 
2 
2 
19 
- 
 
23 
 
 
           
 
            
              
             25 
 
11 
10 
30 
1 
 
52 
 
 
 
 
 
             
            52 
     
      E    (2) 
      H 
      O    
      P 
      W 
     
    Total 
 
- 
2 
3 
2 
1 
 
8 
 
 
  
 
 
 
           
            48 
 
1 
2 
56 
2 
1 
 
62 
 
 
 
 
 
 
             
            62 
      
      D   (3) 
      F     
      K 
     
    Total 
 
- 
5 
3 
 
8 
 
 
 
 
 
8 
 
1 
7 
3 
 
11 
 
 
 
 
            
            11 
 
 
  Sum of all 
    totals 
  
 
 
39 
 
 
81 
 
 
125 
 
 
125 
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4.3.2. C. jejuni LOS loci distribution in GenBank database and its 
comparison to C. jejuni LOS loci distribution in NGH clinical isolates  
The distribution of C. jejuni LOS locus classes and LOS groups in a collection of 
703 C. jejuni sequences available from GenBank is presented in figure 4.4. 400 
of 703 (58%) C. jejuni sequences belonged to the LOS group 1 related classes. 
The LOS classes A, B, and C with trend [B1 (n=125) > C (n=109) > A1 (n=68) > 
A2 (n=44) > B2 (n=36)] were the most common classes and the other three 
classes including R (n=10), M (n=7), and V (n=1) were rare. 214 (30%) classified 
sequences were positive for either class E (n=16), class H (n=72), class O 
(n=63), class P (n=44) or class W (n=13) and therefore, belonged to LOS group 
2. 73 (10%) C. jejuni sequences were positive for LOS group 3 related classes 
including D (n=2), F (n=36), K (n=16), Q (n=1), N (n=1), I (n=3), S (n=6), J (n=4). 
Only 16 (2%) strains belonged to group 4 related classes, where 10 were 
associated to class G and only 6 were linked to class L.  
 
A few C. jejuni sequences contained some LOS genes which had identity to the 
reference LOS genes below the cut-off value and therefore, identity scores for 
these genes were not considered to include in the Megablast score results (Table 
1 in Appendix-II). For this reason, these sequences were not linked to a particular 
class, and categorised into a mix class category within a group, such as, six to 
H/P (Group 2) and four to I/J/S (Group 3).  
 
A comparison of C. jejuni LOS class and group frequencies identified in both 
collections of clinical C. jejuni isolates and online C. jejuni sequences has been 
presented in Figure 4.5. The frequency of LOS classes within the LOS group 1 
was almost similar in both collections of C. jejuni clinical isolates [class B (22%) 
> class C (20%) > class A (14%)] and C. jejuni online sequences [class B (23%) 
> class C (16%) > class A (16%)]. Other group 1 related classes (R, V and M) 
were less frequent (~ 2.5 %) in the online C. jejuni sequence database, whereas, 
these three classes were absent in the clinical collection. 16% of LOS typed C. 
jejuni clinical strains had the LOS group 2 related class P and 10% of analysed 
C. jejuni sequences belonged to the LOS group 2 related class H, marking the 
class P in local clinical C. jejuni collection and class H in the online C. jejuni 
sequence database as the most predominant LOS group 2 classes. LOS class 
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F was the most common class of LOS group 3 among both local (6%) and global 
(5%) C. jejuni collections. A very small proportion of online C. jejuni sequences 
belonged to LOS group 2 related class W (2%), LOS group 3 related classes D 
(0.3%), N (0.1%), Q (0.1%), I (0.5%), J (0.5%), S (1%) and LOS group 4 related 
classes G (1.4%) and L (1%). These classes were all absent in the clinical 
collection of C. jejuni isolates. Finally, the trend of prevalence of LOS groups, 
group 1 > group 2 > group 3 > group 4, was similar in both types of collection of 
C. jejuni strains.  
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Figure 4.4: A Circos plot showing the distribution of C. jejuni LOS locus classes (A-W), 
subclasses (A1, A2, B1, B2) and LOS groups (1-4) in the online C. jejuni sequence 
database. 
 
Each segment of inner circle specify the total number of C. jejuni strains sequences (703) 
extracted for the LOS classification. The frequency of C. jejuni isolates classified for each 
particular LOS class/group is mentioned in numbers (n out of 703) on the top of each inner circle 
segment and presented with ribbon width. The frequency of a C. jejuni LOS class/group in percent 
is mentioned with each outer circle segment and represented by the orange or colourful blocks. 
Ribbon ends link each C. jejuni LOS class to its related LOS group. 
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Figure 4.5: A comparison of C. jejuni LOS biosynthesis locus class and group frequencies found in the 
collections of GenBank C. jejuni sequences (n=703) and C. jejuni clinical strains (n=50)  
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4.3.3. LOS locus typing of C. coli GenBank sequences and WG shotgun 
sequencing of a clinical C. coli strain  
 
The WG sequence data of 564 C. coli strains was obtained from GenBank, 
available either in the complete, annotated version or in the form of discrete 
contigs. 22 complete and 542 contig-level C. coli sequences were subjected to 
Megablast and a LOS class for each sequence was identified. The accession 
numbers for both complete and draft C. coli sequences as well as identified LOS 
containing contig numbers associated to draft sequences have been reported in 
Table 2 in Appendix-II. The identity score and query cover, both with cut-off 
values of 80%, confirmed the presence of an individual LOS gene sequence in 
a specified query sequence. On the basis of presence or absence of LOS gene 
or LOS gene combinations in a query sequence, an individual LOS class from 
already known C. coli LOS classes was identified, and assigned to the query 
sequence. Using this sequence pairwise alignment approach, sequences of 564 
C. coli strains were LOS classified (Table 2; Appendix-II).   
In the previous chapter, 50 C. jejuni clinical isolates were collected from NGH 
and the LOS type for every strain was identified using a PCR based typing 
method. C. coli strains in equal number to the C. jejuni isolates could not be 
obtained from NGH, indicating a reduced prevalence of C. coli clinically than C. 
jejuni. Due to the lack of availability of C. coli strains, a PCR typing method for 
C. coli could not be established or validated. Only one C. coli strain (C. coli 
221089) was obtained from NGH, which was WG sequenced to analyse its LOS 
biosynthesis cluster sequence. The WG sequence of C. coli 221089 was 
submitted in GenBank under the accession number, RJLP00000000. Figure 4.6 
was obtained using the Artemis comparison tool (ACT; Carver et al., 2005), 
where, C. coli 221089 and C. coli RM2228 (reference strain for C. coli LOS class 
III) LOS biosynthesis region sequences were aligned pairwise. This figure is an 
illustration of high similarity (>99%) between the LOS cluster sequences of C. 
coli 221089 and C. coli RM2228, confirming the presence of C. coli LOS type III 
in C. coli 221089 strain. 
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Figure 4.6: Pairwise comparison of C. coli RM2228 (reference strain, yellow arrow) and C. 
coli 221089 (clinical strain; red arrow) LOS cluster sequences, obtained via ACT. It shows 
the extent of similarity (green coloured area) between aligned LOS sequences (each 
containing 15,400 bases).  
Black lines link sequences present in the same orientation. Light green lines link sequences 
present in the reverse orientation. 
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4.3.4. C. coli LOS loci distribution in GenBank database  
 
The frequency of C. coli LOS locus classes in a collection of 564 GenBank C. 
coli sequences has been represented in figure 4.7. C. coli LOS class III (41%; 
n=229) was the most abundant class followed by class VIII (18%; n=103) > I 
(13%; n=70) > II (8%; n=47) > VII (7%; n=42) > IV (5%; n=27) > VI (4%; n=25) > 
V (4%; n=21) within the collection of 564 C. coli GenBank sequences.  
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Figure 4.7: Frequency of C. coli LOS locus classes within the online C. coli 
sequences GenBank database.  
 
The number of C. coli strains associated with each C. coli LOS class in column 
chart and corresponding percentages of C. coli strains in Pie chart, represent the 
frequency of C. coli LOS locus classes within the collection of C. coli online 
sequences. 
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4.3.5. C. jejuni and C. coli LOS loci distribution in different Campylobacter 
niches 
A source of microbe isolation is usually reported with each sequence of GenBank 
database. The prevalence of C. jejuni and C. coli LOS genotypes in different 
Campylobacter niches was estimated (Figure 4.8) by looking at the online 
published sources from which these C. jejuni and C. coli strains were isolated 
(Table 1 & 2, Appendix-II). C. jejuni and C. coli strains, isolated from faeces, were 
not included in this analysis as the actual source of faeces was unknown. 
Chicken and animal farm environment (water and soil) were found as the most 
common reservoir respectively for C. jejuni and C. coli. 
C. jejuni LOS group 1 associated C. jejuni strains were found mostly in humans 
[A (n=24; 6%), B (n=33; 8%), C (n=29; 7%)] and chickens [A (n=14; 3%), B (n=23; 
5%), C (n=9; 2%)]. The LOS class P (the most predominant LOS group 2 class 
among clinical isolates) associated strains (n=8 of 23) were majorly isolated from 
humans and a large proportion (n=22 of 55) of LOS class H (the most common 
LOS group 2 class in GenBank) related C. jejuni strains was obtained from milk. 
For the common LOS group 3 related class F, cows were the main source of 
isolation. Nine LOS class C linked C. jejuni strains were isolated from goats, one 
LOS class A related strain was isolated from a monkey, and five LOS class L 
related strains were from American crows. Other reservoirs of C. jejuni included 
turkey and pigeon.  
The most predominant LOS class III related C. coli strains were isolated in a high 
number from the farm environment (n=165; 37%) and humans (n=20, 5%), 
indicating that these are both the most common niches for type III LOS locus 
containing C. coli strains. The second most prevalent LOS class VIII was also 
frequent in the environment (n=31, 7%) and at similar levels to humans (n=26, 
6%) and chickens (n=25, 6%). Only one LOS class I associated C. coli strain 
was found in monkey and one LOS class II related C. coli strain was recovered 
from a dog. Rarer reservoirs of C. coli were turkey, cow, duck, pig and milk. 
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         Figure 4.8: Frequency of C. jejuni and C. coli LOS locus classes in different Campylobacter sources 
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4.3.6. Identification of novel genes in Campylobacter LOS biosynthesis loci 
By in silico analysis, LOS biosynthesis genes clusters of two C. jejuni strains, C. 
jejuni 414 (Accession no: ADGM01000014.1) and C. jejuni 1336 (Accession no: 
CM000854.1), were found with novel LOS gene content. The variable regions of 
C. jejuni 414 and 1336 LOS biosynthesis locus had 5 and 13 novel LOS genes 
of unknown functions, respectively (Figure 4.9). Further, the origin of these novel 
genes was predicted by blasting each gene against all sequences available in 
the GenBank database. Four novel LOS genes in C. jejuni 1336 locus had >99% 
similarity with the capsular polysaccharide (CPS) biosynthesis genes of other C. 
jejuni strains, suggesting a possible gene transfer from other C. jejuni strains 
CPS loci to C. jejuni 1336 LOS biosynthesis locus. Six novel LOS genes of C. 
jejuni 1336 and one gene of C. jejuni 414 did not have any identity with the 
previously known C. jejuni LOS genes. Instead, they had >99% similarity with 
various LOS biosynthesis genes of C. coli, suggesting the interspecies gene 
recombination. Another C. jejuni strain, CFSAN054107 (Accession no: 
CP028185.1), was also found with 5 previously unreported LOS genes (Figure 
4.9). One of them encodes a methlytransferase and the remaining four encode 
glycosyltranferases (data from GenBank database). In addition to looking at the 
complete novel C. jejuni LOS loci with major modifications, two C. jejuni strains’ 
(PT14 & 34288) LOS loci with a few minor gene modifications were also 
observed. C. jejuni PT14 (Accession no: CP003871.3) had a type C LOS locus 
with two modifications; deletion of ORF14 (class C related gene; cj1137c) and 
the addition of ORF48 (generally belong to LOS class L). Similarly, C. jejuni 
34288 (Accession no: CP006006.1) had a type A2 LOS locus, but with the 
duplication of a sialic acid biosynthesis gene (neuA). 
Genes present in the middle region of LOS biosynthesis cluster usually undergo 
recombination compared to those LOS genes which are present at the proximal 
and distal ends of the cluster. The cluster ends’ genes often have nucleotide 
level variations, but are less likely to vary in gene order or content (Parker et al., 
2008; Richard et al., 2013). In the current study, previously unreported LOS 
genes were identified, which were found localised at the same position in the 
distal end of five C. coli LOS biosynthesis locus types (I, II, III, V and VIII; Figure 
4.10). These were found to be extant in all those in silico typed C. coli strains 
 144 
 
sequences which had the LOS type I (n=63), II (n=43), III (n=229), V (n=3), and 
VIII (n=98) (Grey column in Table 2 in Appendix-II). These LOS genes were 
present at the same position in all five types of C. coli LOS locus, but altered in 
size and nucleotide composition from LOS class to class. The class I gene had 
a maximum size of ~1.4 kb and was distantly related to those genes which 
occurred at the same position in other C. coli LOS locus types (II, III, V & VIII). 
The class II gene had similarity (~91%) to genes present in other classes (III, V 
and VIII). The type III and VIII genes were identical (100%) to each other and the 
class V gene was partially (~51%) similar to both of these identical genes. Class 
I gene encoded the β-Kdo transferase, class II gene encoded the 
phosphoheptose isomerase and genes in other classes produced the 
glycosyltranferases for LOS synthesis (Data extracted from GenBank; Table 
4.2).  
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Figure 4.9: The illustrations of variable regions of C. jejuni 1336 (containing 13 novel LOS genes), C. jejuni 414 (containing 5 novel LOS genes), 
and C. jejuni CFSAN05410 (containing 5 previously unknown LOS genes) between the common LOS genes (lgtF, ORF17 and waaV).  
Green arrows: LOS genes common in all C. jejuni strains; Pink arrows: LOS genes originated from the LOS loci of other C. jejuni strains; Pink arrows 
with vertical lines: LOS genes originated from CPS loci of other C. jejuni strains; Purple arrows: LOS genes originated from the LOS biosynthesis region 
of C. coli strains. The direction of arrow represents the direction of gene transcription. Black star: Gene with an unknown function.  
 
 
 
C. jejuni 1336  
C. jejuni 414  
 C. jejuni CFSAN05410 
* * * * * * * * * * * * * 
* * * * * 
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Figure 4.10: Illustration of previously unreported C. coli LOS core genes 
These genes occur in C. coli LOS types (I, II, III, V and VIII) at the same location (between 
waaF and gmhA) and vary in size and nucleotide composition. The sizes of these genes, 
obtained from the GenBank database, are given in kb. Each dotted line links two genes to 
represent the similarity between them in terms of query cover score (non-bold words) and 
Megablast identity score (bold words).  
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Table 4.2: Proteins encoded by LOS genes in C. coli LOS type I, II, III, V and VIII (Data 
extracted from the GenBank) 
Gene Location  
(Strain; Accession No) 
LOS 
Class  
Protein 
Accession 
No. 
Encoded Protein 
45451-46905 
(C. coli LMG2336; 
AINM01000029) 
I EIA95603.1 Beta-Kdo transferase 
24584-25144 
(C. coli 202/04; 
AINH01000004) 
II EIA86515.1 Phosphoheptose 
isomerase 
42860- 43621 
(C. coli LMG23341; 
AINN01000020) 
III EIA96492.1 Glycosyltransferase 
35579-36334 
(C. coli 1957; 
AINF01000001) 
V EIA83727.1 Glycosyltransferase 
25177-25926 
(C. coli H9; AINV01000011) 
VIII EIB11470.1 Glycosyltransferase 
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4.4. Discussion 
 
4.4.1. Application of bioinformatics for the analysis of C. jejuni LOS 
biosynthesis cluster 
81 of 125 C. jejuni sequences obtained from GenBank were LOS grouped using 
the Galaxy built-in MAFFT multiple alignment tool, indicating that the designed 
Galaxy workflow can successfully classify the complete and annotated 
Campylobacter sequences. Similar results for 81 classified C. jejuni sequences 
were obtained by using Megablast, which validated the Galaxy workflow for the 
C. jejuni LOS locus genotyping. This Galaxy workflow extracts the approximate 
coordinates (65 kb; predicted to contain the LOS biosynthesis locus sequence) 
from the unclassified sequences. Ideally, the desire was to make it able to extract 
the sequence of variable LOS biosynthesis genes from a complete C. jejuni WG 
sequence flanking the conserved LOS biosynthesis genes. Currently, it is unable 
to detect the exact LOS biosynthesis locus sequence and therefore, it can 
sometimes extract the partial LOS sequence. This was the reason that only 
~50% sequences (39 of 81) were linked to a particular LOS class. This also 
reflects the fact that Galaxy workflow was more efficient in identifying a LOS 
group rather than the LOS class. Another limitation of the Galaxy workflow is that 
it is not applicable to draft (scaffold or contig level) sequences.  
The use of each in silico method, applied in the current study, has its own pros 
and cons. Megablast and MAFFT, both can scan a large number of sequence 
queries (McGinnis and Madden, 2004; Katoh and Toh, 2007). Gene-by-gene 
searching in a WG sequence and performing a Megablast operation repeatedly 
is a very time consuming process, however, running a Galaxy-MAFFT workflow 
once to predict the LOS types consumes less time in comparison to Megablast. 
The MAFFT progressive approach becomes less reliable when it deals with the 
aligned sequences of only 25-30% identity (Thompson et al., 1994). Megablast 
hit searching is a biased approach for Campylobacter LOS genotyping in 
contrast to MAFFT alignment in Galaxy.  It is important to be stated here that 
complete or draft sequences deposited in GenBank are also not 100% correct 
due to occurrence of errors at the experimental or sequenced data analysis 
stages (Pertsemlidis and Fondon, 2001), which may give false positive results. 
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In this study, variation in LOS biosynthesis locus was analysed at the nucleotide 
sequence level in order to determine the presence of clustered whole LOS genes 
rather than finding the modifications within the LOS gene nucleotides. The 
identification of several LOS genes within a single sequence excludes the 
possibility of false-positive results, but not 100%.  
 
4.4.2. Gene content diversity in C. jejuni LOS locus  
By analysing the distribution of C. jejuni LOS locus types within the C. jejuni 
GenBank database, LOS class B (23%) was found to be most common class, 
whereas, classes A and C (each with 16%) were the second most frequent 
classes. These findings were concordant with the C. jejuni LOS locus class 
prevalence within the clinical C. jejuni isolates, described in the previous chapter, 
where LOS class B was the most predominant followed by the LOS classes A 
and C. Class B as the most common LOS class in humans and poultry C. jejuni 
isolates has been reported previously in other studies (Quinones et al., 2007; 
Islam et al., 2018). It was discussed in the previous chapter that 50 – 64% strains 
belong to LOS group 1 related classes (A, B and C) in almost every type of C. 
jejuni population which may be human or poultry. The combined frequency of 
these three classes, identified within the online C. jejuni database (~55%), also 
falls within the same range. A very high rate of these three classes might occur 
due to distinctive ability of these classes to synthesise the sialylated LOS 
structures, which may be advantageous for pathogenesis. In contrast, the other 
three LOS group 1 related classes (R, V, & M) were absent at the clinical level 
and infrequent (~2.5%) within the C. jejuni worldwide database. Despite having 
association with the synthesis of the sialylated LOS structures (Houliston et al., 
2011), these classes were less distributed. The classes, R and M, with only 
single gene modifications are the variants of LOS type A (Parker et al., 2008) 
and class V with the absence of only one gene (cj1137c) is the variant of LOS 
class C (Richard et al., 2013). These loci can undergo gene selection and 
recombination process and re-arrange into class A, B or C, which might explain 
the reduced prevalence of these three sialylated LOS producing types.  
 150 
 
The LOS group 2 was the second most predominant group in both sorts of C. 
jejuni LOS genotypes distribution analyses. Class P within the clinical local C. 
jejuni collection, whereas, class H within the global C. jejuni collection, were 
found as the most common group 2 linked classes. These contrasting results 
might be explained because both LOS class P and H share almost similar gene 
content except for two LOS biosynthesis genes (Orf 26’ and Orf28) (Jiang et al., 
2010) and therefore few studies have ever considered these classes as two 
separate classes (Habib et al., 2009; Islam et al., 2014). The LOS class H has 
been reported previously as the most abundant class in group 2 (Quinones et 
al., 2007; Ellström et al., 2016). 
Within the LOS group 3, class F was the most prevalent class from clinical 
isolates (6%) and more globally (5%), similar to the findings of Marsden (2007) 
and Quinones et al. (2007). Class K (2%) was the second most common class 
of group 3, whereas, other LOS classes (I, S, J, D, Q, and N) were less frequent 
(˂1%). C. jejuni sequences in a very small number (< 3%) belonged to group 4 
related class G (1.4%) and class L (1%). In contrast, no group 3 related classes 
(K, I, S, J, D, Q and N) as well as group 4 related classes (G and L) were identified 
from C. jejuni clinical isolates, which may be because of the relatively small size 
of the collection. A general trend of C. jejuni LOS groups distribution (group 1 > 
group 2 > group 3 > group 4) was similar both from clinical and Genbank derived 
sequences, which agrees with the previous studies (Marsden, 2007; Quinones 
et al., 2007; Ellström et al., 2016; Islam et al., 2018).  
 
4.4.3. Gene content diversity in C. coli LOS locus  
In this study, LOS locus type III was found abundant (41%; n=229 of 564) in the 
online GenBank database of C. coli sequences. Culebro et al. (2018) also 
reported the high frequency of classes III (28%; n=72 of 261) within the 
agriculture associated C. coli strains. The class III was also found prevalent 
among those 33 C. coli strains which were collected by Richard et al. (2013) from 
different sources including human, turkey, chicken, swine and bovine. Within this 
collection of C. coli strains, LOS classes III, II and IV (21% each), I (12%), VI 
(9%), V & VIII (6% each), and VII (3%) were identified.  
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C. coli strain 76339 contains the sialic acid biosynthesis genes (cst, neuA, neuB, 
& neuC) as well as sialic acids in the LOS structure (Skarp-de Haan et al., 2014; 
Kolehmainen et al., 2019). In the current study, all C. coli sequences available in 
the GenBank database were screened for the presence of these sialic acid 
biosynthesis genes, but no other C. coli strain was found with these genes except 
the C. coli RM4661 which had three sialic acid synthesis genes (cst, neuB & 
neuC) in its LOS locus. Sialic acid synthesis related genes in C. coli strains 
(maximum one or two in each strain) are mostly located elsewhere in the genome 
rather than specifically in the LOS and CPS biosynthesis loci (Richard et al., 
2013). Despite having genes (sialyltransferases) for the synthesis of sialylated 
LOS structures, a few C. coli strains (e.g. C. coli 664H2004) are unable to initiate 
the molecular mimicry or GBS development in humans (Funakoshi et al., 2006; 
van Belkum et al., 2009; Culebro et al., 2018; Kolehmainen et al., 2019).  
 
4.4.4. Association of C. jejuni and C. coli LOS loci distribution to 
Campylobacter sources 
The frequency of LOS genotypes within the pool of human C. jejuni isolates from 
online sequences was comparable to the frequency of LOS genotypes, identified 
within the collection of C. jejuni NGH isolates (Chapter 3). For example, group 3 
related class F possessing strains were common in NGH clinical isolates and 
similarly, class F belonging GenBank C. jejuni strains were more frequently 
isolated from humans (or Campylobacter infected patients). Moreover, the 
frequency trend in LOS group 1 related classes was also similar in NGH C. jejuni 
strains [B (22%), C (20%), A (14%)] versus GenBank C. jejuni sequences [B 
(8%), C (7%), A (6%)]. Humans, chickens, and the animal farm environment were 
the common isolation sources for C. jejuni and almost every C. jejuni LOS class 
was associated with at least one of these sources. Workman et al. (2005) 
screened the faecal samples from 596 animals for the presence of 
Campylobacter species and found that C. jejuni is mostly prevalent in humans 
(63.6%) and chickens (86.6%) and can also be recovered from monkeys (17.1%) 
and sheep (4.2%).  
 152 
 
The most common C. coli LOS class III and the second most common class VIII 
linked C. coli strains were mostly isolated from humans which was concordant to 
a previous study, where half (57%) of the clinical isolates belonged to class III, 
VIII and II (Culebro et al., 2016). All C. coli classes were associated with farm 
environment, suggesting that animal farm water and soil are also important 
niches for C. coli, in addition to chickens. This was in accordance to the previous 
studies in which agriculture associated C. coli was reported as an emerging 
human pathogen (Sheppard et al., 2010, 2013).  
 
4.4.5. Novel genes in C. jejuni and C. coli LOS biosynthesis clusters 
The presence of six C. coli LOS genes in C. jejuni 1336 and one C. coli LOS 
gene in C. jejuni 414 indicated the occurrence of interspecies gene 
recombination events. C. jejuni does not only harbour the genes from C. coli, but 
C. coli can also uptake and accumulate C. jejuni DNA, especially when they are 
present in the same niche (Sheppard et al., 2013). C. jejuni and C. coli share 
71% of LOS biosynthesis genes and 65% of CPS biosynthesis genes as a 
consequence of recombination events (Richard et al., 2013). Subsequently, 
transfer of 4 genes in C. jejuni 1336 LOS locus from the CPS locus of other C. 
jejuni strains, insertion of C. jejuni class L related ORF48 to class C linked C. 
jejuni PT14, and duplication of sialic acid synthesis gene, neuA, in C. jejuni 
34288, indicated that intraspecies gene recombination events have occurred. 
The duplication phenomenon in neuA and cgtA LOS genes has been observed 
previously in C. jejuni strains (Richard et al., 2013). A few C. jejuni genes and 
their encoded enzymes are functional in both LOS and CPS biosynthesis 
clusters, for example, gmhB (cj1152c; phosphatase) gene, and therefore, they 
are subject to the horizontal transfer between LOS and CPS loci (Karlyshev et 
al., 2005). 
In this study, previously unreported LOS genes present in C. coli classes III and 
VIII, were found to be identical structurally (100% similar nucleotide content) and 
functionally (both encode the glycosyltransferase). The presence of these LOS 
core biosynthesis genes in C. coli classes, III and VIII, might be linked to the high 
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predominance of C. coli LOS type III and type VIII within the online database of 
C. coli sequences. This prediction requires verification with further research.  
 
4.5. Conclusion  
A Galaxy pipeline employing the alignment software MAFFT can predict the LOS 
type associated with a C. jejuni strain sequence. It can cluster the sequence with 
a particular C. jejuni reference LOS group where it is unable to assign an 
individual LOS class. This study validates the use of Galaxy workflow <available 
@https://usegalaxy.org/u/amberimran/w/workflow-for-Campylobacter-jejuni-
lipooliogosaccharide-biosynthesis-locus-typing> for the typing of the C. jejuni 
LOS locus. The sequence alignment tools including Megablast and MAFFT, 
used for the current in silico analysis of C. jejuni and C. coli LOS biosynthesis 
loci, are not 100% reliable and may incorporate errors in the alignment results. 
C. jejuni strains containing group I related LOS loci continue to be the most 
prevalent group in GenBank and amongst our clinical isolates. This may be due 
to the distinctive ability of these group I strains to synthesise sialylated LOS 
structures, which may be advantageous for pathogenesis. The abundance of C. 
jejuni LOS class B and trend of C. jejuni LOS group prevalence (group 1 > group 
2 > group 3 > group 4) were similar in both types of C. jejuni collections. C. coli 
strains possessing LOS class III are the most common in a worldwide database 
of C. coli and this study represents the first exploration of LOS locus genotype 
distribution in C. coli GenBank database via in silico analysis. The novel C. jejuni 
LOS types identified may have arisen due to interspecies (between C. jejuni and 
C. coli) and intraspecies LOS genes recombination. The novel C. jejuni and C. 
coli LOS genes identified in the current study need to be further characterised in 
order to understand their roles in the LOS biosynthesis. In addition to poultry, 
animal farm soil and water are also important sources of C. jejuni and C. coli 
transmission to humans.  
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CHAPTER 5 
 
         Validation of a Mutagenesis Strategy to Construct a 
Campylobacter coli RM1875 Mutant 
  
5.1. Introduction  
5.1.1. Mutagenesis strategies used previously to construct Campylobacter 
mutants  
Several mutagenesis methods have been used previously to mutate the LOS 
biosynthesis genes in Campylobacter species. The most common mutagenesis 
strategy involves the use of inverse PCR (Wren et al., 1994). In this method, a 
gene of interest is amplified using standard PCR and the produced amplicon is 
cloned into a vector. This vector is further used as a template for inverse PCR in 
order to delete the centre of the gene of interest as well as inserting one or two 
unique restriction sites. An antibiotic resistance cassette is inserted between the 
engineered, unique restriction sites and subsequently, the constructed vector is 
used to introduce a double-crossover event within the bacterial genome. This 
double-crossover event disrupts the gene of interest with the antibiotic cassette, 
resulting in defined gene mutagenesis. A cj0256 mutant in C. jejuni 81-176, galE 
mutant in C. jejuni 81116, cj1136 mutant in C. jejuni 11168, and waaF mutant in 
C. jejuni 84-25 and C. jejuni 84-19 strains have been previously constructed 
using this method to determine the functions of LOS biosynthesis genes (Fry et 
al., 2000; Cullen et al., 2010; Keo et al., 2011; Javed et al., 2012). For example, 
the role of, cj0256 encoded a lipid A phosphoethanolamine (pEtN) transferase 
(adds pEtN to LOS lipid A), galE encoded UDP-glucose 4-epimerase 
(interconverts UDP-galactose and UDP-glucose), cj1136 encoded 
galactosyltransferase (transfers a galactose), and waaF encoded 
heptosyltransferase-II (adds an heptose residue), in the biosynthesis of LOS 
structure was identified (Fry et al., 2000; Cullen et al., 2010; Keo et al., 2011; 
Javed et al., 2012).  
Another mutagenesis strategy implements the use of the overlapping extension 
PCR. In this method, upstream and downstream regions of a target gene as well 
as antibiotic cassette are amplified separately using standard PCR and these 
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three amplified DNA fragments are then joined using overlapping extension PCR 
(Horton et al., 1990). The overlapping extension PCR product is cloned into a 
vector, which is further used to introduce a double-crossover and mutagenesis 
of the gene of interest. Various LOS biosynthesis genes, gmhA, hldE, hldD, 
waaC, waaF, lgtF, cj1136 and cj1138, cj1152, and cj1165, have been mutated 
in C. jejuni 11168 and 81-176 by using this method (Iwata et al., 2013).  
Tn5 (Transposase) based in vitro transposition (Goryshin and Reznikoff, 1998) 
has also been used to construct LOS mutants. With this mutagenesis strategy, 
a plasmid containing the antibiotic cassette is used as a donor DNA and another 
plasmid comprising the cloned gene of interest is used as a target DNA. An 
antibiotic resistance cassette is transposed to the target DNA from the donor 
DNA using the Tn5 based in vitro transposition system. The resulting plasmid 
containing the antibiotic cassette is then used to introduce a double-crossover 
and mutate the gene of interest. The mutants of various LOS genes, cgtA, lgtF, 
waaC, and neuC1, in C. jejuni 81-176 have been generated using this Tn5 based 
mutagenesis strategy (Guerry et al., 2002; Kanipes et al., 2006, 2008). Mutation 
of waaC and neuC1 genes in C. jejuni 81-176, respectively, excised the terminal 
sugars and sialic acid residues from its LOS structure (Guerry et al., 2002; 
Kanipes et al., 2006). Accordingly, the role of waaC gene encoded 
heptosyltransferase-I in the addition of first heptose to Kdo-lipid A and neuC1 
function in the synthesis of sialic acids were explored. Similarly, cgtA encoded 
N-acetyl galactosaminyltransferase was examined for its role in the catalysis of 
N-acetyl galactosamine and the lgtF gene encoded glucosyltransferase was 
identified as having dual function in the transfer of a β-1,4-glucose on heptose-I 
and a β-1,2-glucose on heptose-II (Guerry et al., 2002; Kanipes et al., 2008). 
Briefly, LOS gene mutants in various C. jejuni and C. coli strains have been 
produced using different mutagenesis methods to investigate the contribution of 
Campylobacter LOS genes in the synthesis of cell-surface LOS structures. 
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5.1.2. Mutagenesis strategy used in the current study to construct a C. coli 
LOS mutant  
This strategy involves a gene, rpsL, which encodes a S12 protein - a component 
of the 30S subunit of prokaryotic ribosome (Figure 5.1) (Calidas et al., 2014). 
The nucleotide composition of the rpsL gene defines the structure of the S12 
protein, regulates the binding of streptomycin to ribosomes, and determines the 
streptomycin sensitive (strepS) or streptomycin resistant (strepR) phenotype in 
bacteria (Torii et al., 2003; Miller et al., 2016). The S12 protein amino acids 
encoded by codons 43-88 of the strepS rpsL gene produce a site in the S12 
protein for streptomycin binding (Llano-Sotelo et al., 2009). Streptomycin binds 
to the 12S protein or 16S rRNA present within the 30S subunit of the ribosome, 
stabilises the binding of aminoacyl tRNA at the 30S-ribosomal A site, reduces 
the translocation of these aminoacyl tRNA from the A to P site and consequently, 
causes mismatching between the mRNA-codons and tRNA-anticodons (Llano-
Sotelo et al., 2009; Dale et al., 2009). The misreading of codons leads to the 
synthesis of an unstable ribosome-mRNA complex and defective proteins with 
missense errors, which is detrimental to bacterial growth and causes cell death 
(Ruusala et al., 1984).  
It was identified that the strepS rpsL gene becomes dominant over the strepR 
gene and bacterial cells maintain the strepS phenotype when strepS and strepR 
rpsL genes are present together in the chromosome of prokaryotes (Lederberg, 
1951). This hypothesis was tested in strepR E. coli which became phenotypically 
strepS following the transformation with strepS gene carrying plasmids (Dean, 
1981). This principle of strepS dominance over strepR was used first time by 
Skorupski and Taylor (1995) for positive selection and construction of deletion 
mutants. For this study, a plasmid containing a strepS gene (E. coli rpsL with 
strepS phenotype) was introduced into strepR Vibrio cholerae via conjugation of 
E. coli and Vibrio cholerae strains. The occurrence of the first DNA exchange 
event between plasmid and chromosomal DNA produced the strepS phenotype 
upon a strepR background in Vibrio cholerae transconjugates. The second DNA 
exchange event caused the plasmid excision for the loss of strepS and gain of 
strepR as well as the desired mutation in Vibrio cholerae transconjugates.  
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Figure 5.1 (A): Location of the S12 protein in the 30S ribosomal subunit (B): Structure of 
ribosomal S12 protein (Reproduced from Ng et al., 2010). 
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The method introduced by Skorupski and Taylor (1995) was then applied with 
few modifications by Hendrixson et al. (2001) to construct motility gene (fliA, 
rpoN, cj1189c and cj1190c) deletion mutants in the C. jejuni 81-176 strain. In 
Hendrixson et al. (2001), two plasmids were introduced into the bacterial cells by 
electroporation step-by step rather than by conjugation. In the first step, strepR 
C. jejuni 81-176 mutant was developed by replacing its genomic rpsL with C. 
jejuni 11168 rpsL gene and a vector or suicide plasmid A (pUC19 acts as suicide 
vector in Campylobacter) containing the Cat-rpsL (conferring resistance against 
chloramphenicol and sensitivity against streptomycin) cassette flanked by 
homologous regions upstream and downstream of gene of interest was 
electroporated into strepR C. jejuni 81-176 mutant. The occurrence of 
homologous recombination excised the gene of interest and incorporated the 
Cat-rpsL cassette at the targeted gene location. The transformed C. jejuni cells 
(intermediate mutants) were selected for the chloramphenicol resistance and 
electroporated with another plasmid (suicide plasmid B) containing the 
homologous regions upstream and downstream of genes of interest. The 
occurrence of a second homologous recombination in the intermediate mutants 
excised the Cat-rpsL cassette and subsequently, final C. jejuni 81-176 deletion 
mutants were selected for the gain of strepR. Marsden et al. (2009) created 
intermediate deletion mutants of C. jejuni 11168 (Δcj1138c–cj1144c) by using 
the mutagenesis strategy of Hendrixson et al. (2001), where a Cat-rpsL cassette 
replaced the 7 LOS biosynthesis genes (cj1138c–cj1144c). In Hendrixson et al. 
(2001), Cat-rpsL cassette was subsequently removed from the intermediate 
mutants to create the final, defined deletion mutants. In comparison, Marsden et 
al., 2009 replaced the Cat-rpsL cassette in an intermediate C. jejuni 11168 
Δcj1138c–cj1144c mutant with a kanamycin cassette to construct a final, large 
deletion mutant (Δcj1132c-cj1152c).  
The approach of creating the smaller and then larger LOS cluster deletion 
mutants established by Marsden et al. (2009) and cassette eliminating rpsL-
based mutagenesis strategy developed by Hendrixson et al. (2001) are aimed to 
be used in combination in the current study to construct a LOS deletion mutant 
of C. coli RM1875 strain. Figure 5.2 explains this mutagenesis procedure, which 
will be used to generate two smaller deletion mutants (with and without Cat-rpsL 
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cassette) and two larger deletion mutants (with and without Cat-rpsL cassette) in 
C. coli. For smaller deletion, two plasmids (pAH1, pAH3) and for larger deletion, 
two plasmids (pAH2, pAH4), will be constructed. Hendrixson et al. (2001) cloned 
the C. jejuni 11168 rpsL gene with its own promoter into pUC19. In the current 
study, Helicobacter pylori rpsL gene and C. jejuni 11168 rpsL gene promoter, 
cloned into pUC19, were used. C. jejuni 11168 rpsL in the suicide plasmid was 
replaced with Helicobacter pylori rpsL gene for reducing the occurrence of false 
gene conversions during the site-directed mutagenesis in Campylobacter 
(Haigh, unpublished data).  
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                                                Figure 5.2: Strategy for rpsL-based positive selection mutagenesis (Adapted from Hendrixson et al., 2001). 
Green and pink arrows represent the cloned genes or gene sequences in suicide plasmid A & B which are homologous to the mutation site flanking gDNA 
sequences and introduce the double homologous recombination (pink and green x marks). The first double homologous recombination events between 
suicide plasmid A and bacterial DNA produce the mutation of interest and replace it with Cat-rpsL cassette. The intermediate mutant with strepS (rpsL 
domination on rpsL* gives streptomycin sensitivity) and chloramphenicol resistance is selected. Subsequently, the second double homologous 
recombination between suicide plasmid B and intermediate mutant gDNA excises the Cat-rpsL cassette from its gDNA and the final mutant with strepR 
phenotype (the presence of only rpsL* gene gives streptomycin resistance) is selected. Amp: Ampicillin resistance gene; Ori: Origin of replication (replicates 
in E. coli but do not replicate in Campylobacter). 
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5.2. Aims and Objectives 
A large deletion mutant (Δcj1132c-cj1152c) of the C. jejuni 11168 strain was 
produced previously by deletion of LOS biosynthesis gene region from cj1132c 
to cj1152c from a small deletion mutant of C. jejuni 11168 (Δcj1138c-cj1144c) 
(Marsden et al., 2009). The phenotypic characterisation of the C. jejuni Δcj1132c-
cj1152c, lacking the almost entire LOS biosynthesis gene cluster, revealed that 
cell surface LOS structures hugely impact the C. jejuni potential of invasion into 
host cells, natural transformation, and resistance against antibiotics. Similarly, 
this study aims to determine the impact of LOS gene deletion on the C. coli cell 
phenotype by validating the rpsL-based mutagenesis strategy, using this 
strategy to construct a C. coli LOS biosynthesis gene region deletion mutant, and 
characterising the constructed C. coli LOS mutants. To generate a smaller LOS 
deletion (ΔORF15-ORF4) and larger deletion (ΔwaaD-waaC) in the LOS 
biosynthesis gene region, C. coli RM1875 strain (Accession number: 
CP007183.1) will be used.
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5.3. Results 
5.3.1. Mutagenesis of C. coli RM1875 
5.3.1.1. Identification of a SNP in C. coli RM1875 rpsL gene 
The first step of the mutagenesis procedure was to introduce a spontaneous 
single-base mutation within the rpsL gene of C. coli RM1875 to establish the 
streptomycin resistance in this wild-type (WT) C. coli RM1875 strain. However, 
C. coli RM1875 strain was already resistant to streptomycin in its wild type state 
when grown on MHA with various streptomycin concentrations (100-1000 μg/ml), 
higher than its Minimum Inhibitory Concentration (MIC; 50 μg/ml). To further 
confirm that C. coli RM1875 was already resistant to streptomycin and there was 
no need to produce a spontaneous mutation in the rpsL gene, a 250 bp C. coli 
RM1875 rpsL amplicon was generated using PCR and Sanger sequenced. The 
rpsL gene specific primer and all other primers used in this chapter are given in 
Table 2 in Appendix-I. A single nucleotide polymorphism (SNP; A to G) in codon 
43 of C. coli rpsL gene was present. This change replaces a lysine with an 
arginine in the S12 protein resulting in streptomycin resistance, (Figure 5.3). In 
subsequent steps of the mutagenesis procedure, C. coli RM1875 on a strepR 
rpsL background was used. 
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 Figure 5.3 (A): Alignment between C. jejuni 11168 rpsL sequence (pink) and C. coli 
RM1875 rpsL sequence (green) for the identification of a SNP (A to G) in codon 43 of C. 
coli RM1875 rpsL gene; (B): SNP confirmation by Sanger sequencing of PCR amplified 
rpsL gene; (C): Pairwise alignment between 11168 and RM1875 S12 protein sequences; 
where the replacement of K (lysine) with R (arginine) in the amino acid sequence of S12 
protein is indicated by a blue arrow. 
GTG CCT ACC ATA AAT CAA TTG GTT AGA AAA GAG CGC AAA AAA GTT TTA GAA AAA TCT AAA TCT 
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| 
GTG CCT ACC ATA AAT CAA TTG GTT AGA AAA GAG CGC AAA AAA GTT TTA GAA AAA TCT AAA TCT 
                      
CCA GCG CTT AAA AAT TGT CCA CAA AGA AGG GGA GTT TGC ACT AGG GTT TAT ACT ACA ACA CCT 
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||  
CCA GCG CTT AAA AAT TGC CCA CAA AGA AGG GGA GTT TGC ACT AGG GTT TAT ACA ACA ACT CCT 
                     27                                              39      41 
 
AAA AAA CCA AAC TCA GCG TTA AGA AAA GTT GCC AAA GTA AGA CTT ACT AGT GGC TTT GAA GTG 
||| ||| ||| ||| ||  ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||  ||| ||| ||| ||| ||| 
AGA AAA CCA AAC TCA GCA TTA AGA AAA GTT GCC AAA GTA AGA CTT ACT AGC GGC TTT GAA GTG 
 43                  48                                          59 
 
ATC AGC TAT ATC GGC GGT GAA GGT CAT AAC TTG CAA GAA CAC AGC ATT GTT TTA GTG CGT GGT 
||| ||| ||| ||| ||| ||| ||| ||||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| 
ATT AGC TAT ATC GGC GGT GAA GGT CAC AAC CTA CAA GAA CAC AGC ATT GTT TTA GTG CGT GGG 
64                               72      74                                      84 
 
GGT AGG GTA AAA GAC TTA CCA GGG GTT AAA TAT CAC ATC GTT CGT GGT GCT CTT GAT ACA GCA 
||| ||| ||| ||  ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| 
GGT AGG GTA AAA GAC TTA CCA GGT GTG AAA TAT CAC ATC GTG CGT GGT GCG CTT GAT ACT GCG 
                            92   93                  98         101         104 105 
 
GGT GTT GCA AAA AGA ACA GTT TCT CGT TCT AAA TAT GGT GCT AAA CGT CCT AAA 
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| 
GGT GTT GCA AAA AGA ACA GTT TCT CGT TCT AAA TAT GGT GCA AAA CGC CCT AAA  
                                                    119     121 
VPTINQLVRKERKK+LEKSKSPALKNCPQRRGVCTRVYTTTPKKPNSALRKVAKVRLTSGFE 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
MPTINQLVRKERKKVLEKSKSPALKNCPQRRGVCTRVYTTTPRKPNSALRKVAKVRLTSGFE 
 
VISYIGGEGHNLQEHSIVLVRGGRVKDLPGVKYHIVRGALDTAGVAKRTVSRSKYGAKRPKA 
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
VISYIGGEGHNLQEHSIVLVRGGRVKDLPGVKYHIVRGALDTAGVAKRTVSRSKYGAKRPKA 
A A 
      
G 
A 
B 
C 
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5.3.1.2. Construction of plasmids, pAH1 and pAH2 
The plasmid pAH1 was constructed by cloning those regions of LOS biosynthesis 
genes, ORF4 and ORF15, in pUC19 which flanked the LOS gene region of 
interest to be deleted (~9 kb). The constructed pAH1 plasmid was used to 
introduce the double homologous recombination events in gDNA of C. coli 
RM1875 and generate a smaller deletion mutant (ΔORF15-ORF4) in C. coli. 
Figure 5.4 illustrates that gene sequences of the C. coli RM1875 LOS 
biosynthesis ORF15 (795 bps: 642827-643620) and ORF4 (758 bps: 652735-
653481), flanking the mutation of interest, were PCR amplified. Two restriction 
sites specific for SacI and XhoI enzymes in the amplified PCR product of ORF15 
were added correspondingly with two primers, S1-F and S1-R. Similarly, two 
sites for XhoI and KpnI restriction in the amplified PCR product of ORF4 were 
incorporated using S2-F and S2-R primers. The amplified ORF15, restricted with 
SacI and XhoI, and amplified ORF4, restricted with XhoI and KpnI, were ligated 
with common XhoI restricted, sticky ends. Simultaneously, the ligated ORF15 
and ORF4 were cloned into SacI and KpnI restricted pUC19 to construct a 
plasmid, pAH1.  
Figure 5.5 (A) represents a map of 4233 bp pAH1 and indicates the annealing 
positions of different primers (pUC-F, pUC-R, S1-F, S1-R, S2-F, S2-R), used for 
the confirmation of cloning of ORF15 and ORF4 into pUC19. PCR with pUC-F & 
pUC-R primers amplified the cloned ORF15 and ORF4 gene sequences together 
and gave a 1755 bps PCR product (Figure 5.5 B), indicating the presence of 
these two ORFs in pAH1. To further confirm the presence of these C. coli LOS 
biosynthesis gene regions into pAH1, a 1636 bps PCR product was obtained 
with pUC-F and S2-R primers and a 1684 bps PCR product was amplified using 
a set of S1-F & pUC-R primers. These PCR positive results, sequence analysis 
of PCR products, and restriction digestion of pAH1 with SacI, XhoI, and KpnI 
(Figure 5.6), confirmed the successful cloning of ORF15 and ORF4 into pUC19.  
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ORF15 (642827-643620) 
                                                                SacI 
                                                               CCCGAGCTCTAGTGGTACGAGGCTTTATC  Primer S1-F 
AGTCCGACGTTGTAAACGACGGCCAGTGAATTCGAGCTCTAGTGGTACGAGGCTTTATCCTATCACTTTAACTTTATGTAAGCAGCTTTTGCCAA
TTTATGATAAGCCCATGATTTACTATCCTCTATCTGTTTTGATGTTGGCTAAAATTCGCGAAGTCTTGATTATCTCCACGCCTAAAGATACGAGTA
AATTTCAAGAGCTTTTTGGTGATGGTTCTTGGCTTGGCATGGAAATTTCGTATTGTGTACAAGAGCAGCCAAAAGGCTTGGCAGAAGGACTTAT
TTTAGCGGATAGTTTTATAAAAAATGATGATATAGCTTTAATTTTAGGGGATAATATTTTTTATGGACAAGGATTTAGCGATTTGTTGCAAAATG
CTAAAAATGATTCTAAAAATGGCTATGCTAGTATATTTTCTTATCATGTAAAAGATCCGGATCGTTTTGGTGTAGCTGAAATTTCTAAAAATGGC
GAGGTTTTAAGTTTGGAAGAAAAACCTCAATATCCTAAGAGCAATTATGCGGTAACTGGGCTTTATTTTTATGATAACTCAGCTATTGAAATAGC
AAAAAGTGTAAAACCTAGCTCTAGAGGAGAACTTGAAATTACTGATGTTAATATAGAATATTTGAAACAAAATAGATTAAAGTCGCAAATTTTA
GGACGAGGTTTTGCTTGGATTGATACAGGTACGCATGACAGCTTAATAGAAGCTTCAGAATTTGTGCAAACAATAGAACTTAGACAAGGATACA
AGATTGCATGTTTGGAAGAAATTGCTTTTCGAAATAACTGGATAGATGAGAGAAGATTGTTAGATCGCGCAAAGCCTCGAGCGGCCTATCGAC
AATACTGATAAGATAATATGTAATTAAATACTGT  
                                                                                                     Primer S1-R   CAATCTAGCGCGTTTCGGAGCTCGCC   
                                                                                                                                                                                              XhoI 
 
ORF4 (652735-653481) 
   
                                    XhoI 
                              CCGCTCGAGTAAATCTTATTGGCGCTTGC  Primer S2-F 
CAGACAAATCCGTTAGACTCGAGTAAATCTTATTGGCGCTTGCAAAAAGAATCATACCAAAATGTATATCTTCATTGATGATATAATTTACAAAT
TTAAGTTTAATTTTCTTTAAAAAATTAAAATCAATCATCCCACCCCAACTAAAAGAAATATCTCTTGACCCAACCTCTAAAGCTCTTTTAGCATAAT
CTTTTGGGTTTATAATGCGTTCTTCTTTATAGGAGGAAATTTGCATTCTTGTTTTTCGTCCTTTATCTTCAATACCTTTTTCATAAACACACAGATGA
TCAAACCACAATACATCAACGTCTTGCATTCGTTTGGCACATTCTTCAATGCAGTTTAATTCCCAAGAATTATCAGAATCTAAGAAAATTAAATAA
TCAATATCAGGAGCTTCTAGATTTTTTTCTATAAAAGTATTTTTATTTTTGTAAATTTTATAAACATTTTGCGGATTTTCATTTGCAACGGTAAAGG
TGTAAAAACCATCAATTTCATTTGAAAAATGAGTTTCATACTCTTTGTAAAAGAATTCTATCCCTGTGTTTCTAGCTGAACTTAGTCCCCCATTTTC
TTTATCAAATAAAGTAATTCTTTTGTCTTTTAAGGCATATTCCTTAGCTATATTCAATGAATTCTCATCGGTGCTACCATCATTTACAAGTATAATTT
CTAAATTAACATAGGTTTGATTGATGACGCTTTCTAAGCATTCTCTTAAGTATTTTTCTACATTATAGATAGGGATTACTATGCCTACAGTTCGGT
ACCCGGGGATCCTCTAGAG  
                                                                                                                   Primer S2-R  CCCTAATGATACGGATGTCAAGCCATGGTGC 
                                                                                                                                                                     KpnI 
 
 
 
 
PCR amplified ORF15  
(642827-643620) 
 
 
795 bps     
ORF15 
PCR amplified ORF4  
(652735-653481) 
 
 
A 
B 
758 bps    
ORF4 
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Figure 5.4 (A): A representation of location of ORF15 (sequence from 642827 to 643620; 
upstream) and ORF4 (sequence from 652735 to 653481; downstream) in the LOS 
biosynthesis cluster of C. coli RM1875 gDNA. (B): PCR amplification of 795 bps ORF15 
and 758 bps ORF4. 
ORF15 present upstream of the point of mutation was amplified using S1-F (adding SacI 
restriction site) and S1-R (adding XhoI restriction site) primers. ORF4 present downstream of the 
point of mutation was amplified using S2-F (adding XhoI restriction site) and S2-R (adding KpnI 
restriction site). 
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Figure 5.5 (A): A map of 4233 bps pAH1, indicating the annealing positions of different primers 
(pUC-F, pUC-R, S1-F, S1-R, S2-F, and S2-R) and representing the position of cloned ORF4 and 
ORF15 in Multiple Cloning Site; (B): PCR amplicons of expected sizes on gel, obtained using 
plasmid specific primer pair (pUC-F & pUC-R), plasmid-gene specific primers sets (S1-F & pUC-
R; pUC-F & S2-R), and cloned gene specific primer pairs (S1-F & S1-R; S2-F & S2-R) to confirm 
the cloning of ORF15 and ORF4 into pUC19. 
 
 
A 
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Figure 5.6: Confirmation of ORF15 and ORF4 cloning into pUC19 by pAH1 restriction digest  
Single restriction with SacI, XhoI and KpnI linearised the plasmid (4233 bps) and digestion with 
SacI and KpnI gave two fragments (2680 bps pUC19, 1553 bps XhoI-ligated ORF15 and ORF4). 
Restriction of pAH1 with SacI, XhoI and KpnI produced three fragments (2680 bps pUC19, 795 bps 
ORF15, and 758 bps ORF4). 
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The plasmid pAH2 was also constructed to generate a larger C. coli deletion 
mutant or a mutant with deletion of those LOS biosynthesis genes (ΔwaaD-
waaC) which flanked the smaller deletion (ΔORF15-ORF4) in C. coli LOS 
biosynthesis locus. SacI & XhoI restricted waaD (620 bps: 636937-637557) and 
XhoI & XbaI restricted waaC (709 bps: 657041-657750) were ligated into pUC19 
to construct a 4007 bps plasmid, pAH2. This was also confirmed by PCR and 
restriction digests (data not shown).  
 
5.3.1.3. Inserting the Cat-rpsL cassette into pAH1 and pAH2 
A 1510 bps Cat-rpsL cassette (containing C. jejuni 11168 rpsLS gene promoter, 
Helicobacter pylori strepS rpsL gene and a chloramphenicol acyltransferase 
encoding Cat gene) was extracted from a plasmid, pRDH315, by restriction of 
pRDH315 with XhoI. Plasmids pAH1 and pAH2 were also restricted with XhoI to 
ligate with XhoI digested Cat-rpsL cassette. The plasmids, pAH1 and pAH2, after 
insertion of Cat-rpsL cassette were named as pAH3 and pAH4, respectively.  
The figure 5.7 (A) represents a map of 5743 bps pAH3 and shows the binding 
position of different primers (pUC-F, pUC-R, S1-F, S1-R, S2-F, and S2-R), most 
importantly of catR primer, which was used for the confirmation of cloning and 
right orientation of Cat-rpsL cassette into pAH1. A PCR product of expected size 
(2111 bps) amplified using plasmid specific pUC-F primer and Cat-rpsL cassette 
specific catR primer (Figure 5.7 B) and restriction digestion of pAH3 with SacI, 
XhoI, and KpnI (Figure 5.8), confirmed the presence of Cat-rpsL cassette 
between ORF15 and ORF4, as well as, its correct orientation into pAH3. The 
presence of Cat-rpsL cassette in pAH4 was confirmed similarly by performing 
PCR assays and restriction digests (data not shown). 
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Figure 5.7 (A): A map of 5743 bps pAH3, indicating the position of Cat-rpsL cassette between 
ORF 4 and ORF15 as well as annealing positions of different primers (pUC-F, pUC-R, S1-F, S1-
R, S2-F, S2-R, and cat-R); (B): Confirmation of cloning and orientation of cat-rpsL cassette 
into pAH1 by PCR, 2111 bps PCR product amplification with pUC-F and cat-R primers 
confirmed the presence of Cat-rpsL cassette in right orientation into pAH1. PCR assays 
performed with other primer pairs confirmed the intact presence of ORF15 and ORF4 into pAH3.  
 
   pAH3 
5743 bps 
ORF15 
  ORF4 
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   Figure 5.8: Confirmation of Cat-rpsL cassette insertion into pAH3 by restriction digest  
Single restriction with SacI and KpnI linearised the pAH3 (5743 bps). A single digestion with 
XhoI gave two fragments (4233 bps pAH1 and 1510 bps cat-rpsL cassette). Double digestion 
with SacI and KpnI gave two fragments (2680 bps pUC19, 3063 bps ligated ORF15, ORF4 
and cat-rpsL cassette). Restriction of pAH3 with SacI, XhoI and KpnI produced four fragments 
(2680 bps pUC19, 1510 bps cat-rpsL cassette, 795 bps ORF15, and 758 bps ORF4).   
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5.3.1.4. Integration of Cat-rpsL cassette into WT C. coli RM1875 
The integration of Cat-rpsL cassette into the C. coli RM1875 gDNA was 
confirmed by performing PCR with gDNA of C. coli RM1875 mutant strain and 
Cat-rpsL cassette specific primers (cat-F & cat-R) as it is demonstrated in figure 
5.9 (B). It was also confirmed by growing the C. coli RM1875 mutant strain on 
MHA with 20 µg/mL chloramphenicol. This chloramphenicol resistant C. coli 
strain should have exhibited strepS phenotype. Conversely, it was found strepR 
when tested at various concentrations of streptomycin (100 µg/mL-1000 µg/mL), 
which were higher than its MIC (50 µg/mL). Further, a PCR assay with cat-F and 
SS2-R primers showed positive results and indicated the presence of the Cat-
rpsL cassette upstream of the ORF4 (Figure 5.9 C). However, the position of Cat-
rpsL cassette next to the ORF15 (as demonstrated in figure 5.9 A) could not be 
confirmed using SS2-F and cat-R primers even after making many attempts and 
using alternative primer pairs. By integration of this cassette, 10 LOS 
biosynthesis genes present between ORF4 and ORF15 should have been 
deleted. Unexpectedly, all LOS genes were found present in the gDNA of C. coli 
RM1875 mutant strain after PCR based analysis of the gene deletion site. The 
positive PCR results for the presence of a LOS biosynthesis gene, YSQ_03250, 
are illustrated in figure 5.9 (D); this is only an example to illustrate that LOS genes 
were not deleted, despite the insertion of pAH3 derived Cat-rpsL cassette into 
the gDNA of C. coli RM1875 mutant. It was assumed that Cat-rpsL cassette might 
have located upstream of the ORF4 in the LOS biosynthesis gene cluster of the 
C. coli RM1875 mutant, but without deletion of any LOS biosynthesis gene.  
The gDNA of the C. coli RM1875 was WG sequenced using the Illumina platform 
to identify the point of Cat-rpsL cassette integration into it. The analysis of the C. 
coli RM1875 mutant sequence (33 contigs) demonstrated that the entire pAH3 
plasmid sequence had integrated into the chromosomal DNA. The pairwise 
alignment between reference WT C. coli LOS sequence and mutant C. coli 
sequence confirmed that ampicillin resistance gene (Amp), origin of replication 
(Ori), cat-rpsL cassette, and pAH3 derived ORF4 region, all were present intact 
in C. coli RM1875 WG sequence contig 15. The only exception was pAH3 derived 
ORF15 whose sequence was found split in contig 15. 1-129 bps at the proximal 
end of contig 15 sequence were the 1-129 bps of cloned ORF15 and 5078 to 
 173 
 
5203 bps present at the distal end of contig 15 were the 669-794 bps of cloned 
ORF15. These split ORF15 regions flanked the remaining, integrated pAH3 
sequence (Figure 5.10 B). ORF15 sequence from base 130 to 668 was missing 
in the reads of contig 15; this was the reason that LOS deletion screening SS2-F 
primer could not bind with the gDNA of mutated C. coli RM1875 strain and linkage 
of 5’ end of cat-rpsL cassette with ORF15 could not confirm by PCR. The PCR 
results (given in figure 5.9 C), indicating the location of cassette upstream of the 
ORF4, were positive because of the pAH3 integration into the gDNA. 
The exact location of the plasmid integration into the C. coli RM1875 gDNA could 
not be determined as the whole contig 15 had the plasmid sequence. The 
presence of intact LOS in another contig (contig 1) indicated no disruption in the 
LOS biosynthesis region of mutated C. coli RM1875 strain. A view of contig 1 
reads obtained using Artemis software is given in figure 5.10 (A) which shows 
that the contig 1 sequence reads containing mutant C. coli LOS locus sequence 
align to the reference or WT C. coli RM1875 LOS cluster sequence with no gap. 
This data indicate that rather than introducing a double-crossover event to 
generate a deletion in the LOS biosynthesis region, the plasmid itself has 
randomly integrated somewhere else in the gDNA of C. coli RM1875 and this 
requires further investigation.  
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Figure 5.9: Analysis of gDNA of C. coli RM1875 mutant for the presence of Cat-rpsL 
cassette and LOS gene deletion.  
(A): A representation of expected LOS region deletion (ΔORF15-ORF4) between C. coli 
RM1875 LOS biosynthesis ORF15 and ORF4 
 
(B): Amplification of a PCR product (624 bps) with cat-F and cat-R confirmed the presence of 
Cat-rpsL cassette in the gDNA of C. coli RM1875 mutant. Positive control: PCR with pAH3; 
Negative controls: PCR reactions without any DNA and WT C. coli gDNA. 
 
(C): Amplification of a PCR product (1123 bps) with cat-F and SS2-R confirmed the location of 
Cat-rpsL cassette upstream of the ORF4. Positive control: PCR reaction with pAH3; Negative 
controls: PCR reactions without any DNA and WT C. coli gDNA. 
 
(D): The PCR product (468 bps) with primers, 210-F and 210-R, confirmed the presence of a 
LOS biosynthesis gene (YSQ_03250). Positive control: PCR with WT C. coli gDNA; Negative 
control: PCR reaction without any template DNA. 
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Figure 5.10: Analysis of WG sequence of C. coli RM1875 mutant (A): The Artemis view of mutant C. coli RM1875 contig 1 showing mapping of its 
sequence reads (blue bars) against the reference C. coli LOS locus sequence (643620-652735 bps); representing that all LOS biosynthesis genes were 
present in the mutant strain. (B): A representation of entire plasmid sequence, randomly integrated into the gDNA of C. coli RM1875 mutant. All plasmid 
genes including Amp, Ori, ORF4, and Cat-rpsL cassette were consecutively present in the C. coli mutant WG sequence (contig 15: 5203 bps), whereas, ORF15 
was split. The split ORF15 sequence flanked the integrated plasmid sequence (contig 15: 1-129 bps upstream; contig 15: 5078-5203 bps downstream). Red boxes 
with ORF15 indicate the presence of partial ORF15 into the gDNA of C. coli RM1875 mutant. 
   ORF4  ORF15   ORF15 
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5.3.2. LOS analysis of C. coli RM1875 mutant  
The LOS extracted from WT C. coli RM1875 and mutant C. coli RM1875 strains 
migrated the same distance on 16 % (v/v) SDS-PAGE gel and showed no 
difference in mobility (Figure 5.11 A). This was expected because no mutation 
in C. coli RM1875 LOS biosynthesis gene cluster was produced. Similarly, no 
difference was identified when the LOS samples from WT and mutant C. coli 
RM1875 strains were dot blotted on the PVDF membrane using the peanut 
lectin (Figure 5.11 B). 
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Figure 5.11 (A): Analysis of LOS by SDS PAGE. The figure shows the mobility of WT C. coli 
RM1875 LOS (~11 kDa) and mutant C. coli RM1875 LOS (~11 kDa) bands on silver stained 16% 
(v/v) SDS-PAGE gel; Multicolour low range protein ladder (1.7- 40 kDa) was used to predict the 
size of LOS bands. (B): Analysis of LOS by Dot Blot. The figure shows the binding of WT and 
mutant C. coli RM1875 LOS with peanut lectins. Lipopolysaccharides extracted from E. coli DH5α 
was used as a positive control and endotoxin-free water (available in the Pierce LAL 
Chromogenic Endotoxin Quantitation Kit) was used as a negative control.  
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5.3.3. Impact of plasmid integration on C. coli RM1875 mutant growth and 
motility 
The C. coli RM1875 mutant strain grew differently from the WT C. coli RM1875 
strain. In comparison to the WT, the mutant C. coli entered earlier into the log 
phase and went into the final decline phase more rapidly (Figure 5.12).  
There was a significant difference (t-test; p < 0.001) in the diameter of motility 
zones between WT and mutant C. coli RM1875 indicating that compared to WT, 
the mutant was hypermotile (Figure 5.13). To determine whether motility 
associated flaA gene expression had been modulated in the mutant, expression 
of flaA was examined by qPCR. The flaA had increased expression in the 
mutant strain compared with the wild type (Figure 5.14), which might explain the 
hypermotile phenotype of C. coli mutant. 
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Figure 5.12: Comparison between WT and mutant C. coli RM1875 growth.  
The values at each time point are the means of three independent experiments 
performed in triplicate. 
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Figure 5.13: Comparison between WT and mutant C. coli RM1875 motility. 
Hypermotile C. jejuni 11168 was used as a positive control. C. jejuni 11168 mutant strain with 
flaA mutation and non-motile 11168 strain were used as negative controls. The results are the 
means + SD of three independent experiments performed in triplicate. Student’s t-test was 
performed to determine the statistical significance (p < 0.001***) between WT and mutant C. 
coli RM1875 strains. The figure showing the motility zones is given for illustration only. 
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Figure 5.14: The qPCR results showing the relative quantification (RQ) of flaA gene 
expression in WT and mutant RM1875 strains. The rpsL gene was used as an 
endogenous control to normalise the data. Values are the mean + SD of three independent 
experiments performed in triplicate. (Student’s t-test; p < 0.01**). 
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5.4. Discussion 
The first requirement of the mutagenesis strategy was to develop a spontaneous 
genomic mutation in the rpsL gene of that bacterial strain, in order to make it 
resistant to streptomycin (Hendrixson et al., 2001; Marsden et al., 2009). In this 
study, a spontaneous single base mutation in the rpsL gene of C. coli RM1875 
was not required as this strain already had a single nucleotide polymorphism (A 
to G) in the rpsL gene sequence which would result in a substitution a lysine 
(codon 43) to an arginine residue within the rpsL encoded S12 protein and confer 
streptomycin resistance to C. coli RM1875. This SNP in the rpsL gene of 
Helicobacter pylori strains, C. jejuni 14980A, and C. coli 14983A, and its link to 
streptomycin resistance have been identified previously (Torii et al., 2003; Miller 
et al., 2016). These types of spontaneous mutations in chromosomal or 
integrated rpsL genes may also occur even after the transformation or 
electroporation of bacterial strains, which further leads to the production of false 
positive strepS or strepR phenotypes (Torii et al., 2003; Tuntufye and Goddeeris, 
2011).  
A suicide plasmid, such as E. coli pUC19, is unable to replicate or propagate in 
the Campylobacter strains (Wood et al., 1999). The gene regions having a length 
of ~ >567 bps, cloned in a suicide plasmid, are considered appropriate for the 
initiation of homologous recombination and regions with 270-286 bps length are 
unable to initiate the homologous recombination in C. coli (Richardson and Park, 
1997). In the current study, two gene regions with 758 and 795 base pair lengths 
were cloned in the suicide plasmid, pAH3. This vector was supposed to create a 
deletion in LOS biosynthesis region as a consequence of a double-crossover in 
C. coli. Following the electroporation of WT C. coli RM1875 with pAH3, the entire 
pAH3 plasmid sequence was found to have integrated into the genome of C. coli 
RM1875. Generally, a single-crossover between homologous regions 
(Campbell-like recombination) and a recombination between the non-
homologous sequences (illegitimate recombination) can facilitate the integration 
of an entire plasmid DNA into Campylobacter chromosomal DNA (Wang and 
Taylor, 1990; Richardson and Park, 1997). If the former is the case in the current 
case of pAH3 integration into C. coli RM1875 chromosomal DNA, then the 
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plasmid DNA should have integrated into the LOS biosynthesis cluster even via 
a single-crossover between homologous sequences. The pAH3 sequence did 
not integrate within the LOS biosynthesis cluster and therefore, Campbell-like 
recombination may not be associated with this integration. The entire DNA of 
pAH3 is likely to have randomly integrated into the C. coli RM1875 gDNA due to 
the occurrence of illegitimate recombination events. This type of recombination 
has been observed previously in C. coli, where a suicide plasmid-derived 
tetracycline antibiotic cassette had integrated into the C. coli chromosome 
randomly and at multiple locations, despite having no sequence homology to the 
chromosomal DNA sequence (Richardson and Park, 1997). Similarly, the suicide 
plasmid’s derived streptomycin and nalidixic acid resistance genes were found 
fused into the chromosomes of C. coli and C. jejuni strains (Wang and Taylor, 
1990). A fragment of plasmid sequence was also found inserted next to the 
leucine tRNA genes in the genomic DNA (gDNA) of C. jejuni 81-176 (Hofreuter 
et al., 2006). The phenomenon of illegitimate recombination has also been 
observed in Rhodococcus fascians (Desomer et al., 1991), Bacillus subtilis 
(Hofmeister et al., 1983), Mycobacterium (Kalpana et al., 1991), and 
Streptomyces ambofaciens (Kuhstoss et al., 1989).  
Illegitimate recombination involves very short sequences of homology, which 
may ligate with intracellular nuclease-cleaved plasmid sequences during the 
DNA repair process (Desomer et al., 1991; Kalpana et al., 1991; Kusano et al., 
1997). In the current study, deletion of ~ 538 bps from the plasmid derived or 
integrated ORF15 point out the involvement of intracellular nuclease activity in 
the procedure of illegitimate recombination. This is in line with a previous study, 
where stretches of plasmid sequence were found deleted after integration into 
the C. coli chromosome (Richardson and Park, 1997). The extracellular 
nucleases, such as DNAse I, do not affect the exchange between a plasmid DNA 
and gDNA in C. jejuni (Oyarzaba et al., 2007). The suicide plasmid may 
recombine with C. coli resident plasmids in order to rescue itself (Wang and 
Taylor, 1990) and the sequence of recombined plasmids can be read possibly 
with the WG sequence of gDNA. The absence of endogenous C. coli plasmid 
sequence within the C. coli mutant WG sequence reads excludes the occurrence 
of this possibility in the current study.  
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The C. coli RM1875 mutant was resistant to streptomycin despite having pAH3 
derived strepS rpsL gene in its gDNA. It is known previously that plasmid derived 
strepS rpsL can become dominant on mutated gDNA strepR rpsL when these both 
rpsL genes exist simultaneously in the bacterial chromosome (Skorupski and 
Taylor, 1995; Hendrixson et al., 2001). In this study, gDNA strepS rpsL was not 
mutated to strepR. Instead, strepR rpsL was constitutively present in C. coli 
RM1875, which might be a reason behind the maintenance of the strepR 
phenotype in C. coli RM1875 mutant. This may also happen due to the fact that 
any unknown single-base point mutation in the rpsL gene can contribute to the 
development of a strepR phenotype. However, no SNPs in the strepR rpsL of C. 
coli RM1875 mutant were detected. 
No difference in the gel migration of WT and mutant C. coli RM1875 LOS was 
observed when they were resolved with 16% SDS-PAGE. This result is explained 
because of the lack of successful deletion of the LOS biosynthesis gene cluster. 
Only partial sequences of LOS biosynthesis ORF4 and ORF15 were cloned in 
the plasmid pAH3 and hence, off target plasmid integration into C. coli RM1875 
has not affected the cell surface LOS structure or its synthesis.  
The C. coli RM1875 mutant showed a modified growth rate, increased cell 
motility and higher flaA gene expression in comparison to the WT strain, which 
might have happened due to the insertion of the plasmid into one of the growth 
and motility regulating genes although this requires confirmation. It may also 
occur due to the phase variation in motility associated genes (Karlyshev et al., 
2002), which supports that the modifications in the growth and motility of RM1875 
mutant might not be the direct impacts of illegitimate recombination between 
pAH3 and WT RM1875 gDNA. The assimilation of the chloramphenicol cassette 
alone into the gDNA does not alter the growth rate in C. jejuni (Karlyshev and 
Wren, 2005). Full characterisation of where the pAH3 plasmid ended up is 
ongoing, but we speculate it might have affected the motility associated genes 
based on the results obtained.  
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5.5. Conclusion 
A SNP in WT C. coli RM1875 rpsL responsible for the strepR phenotype was 
confirmed. C. coli RM1875 maintained this phenotype even after integration of 
the cat-rpsL cassette in gDNA and unexpectedly, did not develop sensitivity to 
streptomycin. This may happen due to the lack of dominance of plasmid derived 
strepS rpsL on WT gDNA strepR rpsL when these both rpsL genes are present 
simultaneously in the chromosome of C. coli RM1875. The LOS mutant could 
not be constructed due to high rate of illegitimate recombination in C. coli. 
However, this study supports this fact that intracellular nuclease activity occurs 
during the illegitimate recombination. Increase in sequence homology (>1000 
bps), required to introduce the double homologous recombination, might 
decrease the chances of occurrence of illegitimate recombination, and 
subsequently, this might prove useful for the successful deletion of a long stretch 
of the C. coli LOS biosynthesis gene region.  
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CHAPTER 6 
Induction of Interleukin-1β production in the Human Monocytic  
Cell Line THP-1 by Campylobacter  
 
6.1. Introduction  
The main areas of Campylobacter localisation in humans is the lower GI tract 
including the small intestine (ileum and jejunum), caecum, and colon (van 
Spreeuwel et al., 1985; Black et al., 1988). A highly viscous mucus layer 
shielding the innermost layer of lower GI tract is a most favourable habitat for 
Campylobacter due to the low oxygen concentration and availability of nutrients  
including mucin, glycoproteins, L-fucose, galactose, sialic acid, N-acetyl 
galactosamine (GalNac), N-acetyl glucosamine, and mannose (Tu et al., 2008; 
Stahl et al., 2011). In addition to colonisation in the mucus layer, Campylobacter 
also adheres to microvilli or crypts present on the surface of the innermost layer 
of GI tract with the help of flagella and other adhesive proteins such as CadF and 
JlpA (Jin et al., 2001; Konkel et al., 2013; Baldvinsson et al., 2014). The mucus 
layer, crypts, and cell layers underneath the mucus layer (epithelium and lamina 
propria) are the main sites where Campylobacter come into contact with a range 
of human white blood cells or leukocytes (van Spreeuwel et al., 1985; Hodgson 
et al., 1998). In the first 7 days, after the onset of Campylobacter infection, acute 
inflammation is characterised by the influx of leukocytes (granulocytes, 
macrophages and lymphocytes) to the infection sites and disruption of red blood 
cells (Black et al., 1988; Samie et al., 2007).  
 
6.1.1. Campylobacter interaction with macrophages 
C. jejuni and C. coli are readily internalised by macrophages upon interaction 
(Kiehlbauch et al., 1985; Banfi et al., 1986; Watson and Galán, 2008). Earlier 
studies have demonstrated that Campylobacter cells are rapidly killed by 
endocytic lysosomes following internalisation (Wassenaar et al., 1997; Watson 
and Galán, 2008; Heikema et al., 2013), however, another earlier study showed 
that they are not rapidly killed after phagocytosis and can survive in 
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macrophages for 6-7 days (Kiehlbauch et al., 1985). It is also proposed that 
Campylobacter has the potential to produce an enzyme, catalase, which is 
encoded by a katA gene and help Campylobacter to survive within a macrophage 
(Day et al., 2000). The pathogen recognition receptors (PRRs) of human 
macrophages become activated to recognise the pathogen-associated 
molecular patterns (PAMPs) when pathogens develop interaction with a 
macrophage or survive intramacrophage subsequent to the phagocytosis (Day 
et al., 2000; Bouwman et al., 2014). Human macrophages PRRs generally 
possess cell membrane bound receptors [lectin receptors (LRs) and Toll-like 
receptors (TLRs)] and cytosolic receptors [Nucleotide-binding oligomerisation 
protein (NOD)-like receptors e.g. inflammasomes] (van Sorge et al., 2009; 
Stephenson et al., 2013; Bouwman et al., 2014).  
 
Membrane bound receptor activation by Campylobacter 
Different cellular constituents of Campylobacter such as lipoproteins, 
lipooligosaccharides, flagella, capsule, cell wall lipopolysaccharides (LPS) and 
DNA can bind to TLRs in human immune cells to activate them (de Zoete et al., 
2009; Rathinam et al., 2009; Stahl et al., 2014). Campylobacter lipoprotein, JlpA, 
dependent stimulation of TLR-2 signalling and DNA dependent activation of TLR-
9 in intestinal epithelial cells have been described by previous studies (Jin et al., 
2003; O’Hara et al., 2012). Campylobacter toxins and lipooligosaccharides are 
known to activate the TLR signalling in epithelial cells and dendritic cells (DCs) 
(Hickey et al., 2000; Hu et al., 2006; Zheng et al., 2008). Conversely, 
Campylobacter flagella help Campylobacter in evasion from the TLR-5 
recognition and its capsule is used as a TLR antagonist (Andersen-Nissen et al., 
2005; Stahl et al., 2014).  
Little is known about the correlation of Campylobacter-associated molecular 
patterns specifically with LRs and TLRs of human macrophages. Previously, C. 
jejuni N-linked glycosylated proteins and lipooligosaccharides with terminal 
GalNac have been reported as ligands of macrophage galactose-type lectin 
receptors (MGLRs), a type of LRs (van Sorge et al., 2009). Another type of 
macrophage LRs, sialoadhesin (Sn), generally recognises the sialylated ligands 
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mainly GM1 and GD1-like LOS present on the cell surface of C. jejuni to enhance 
the internalisation process of C. jejuni into the macrophages (Klaas et al., 2012; 
Heikema et al., 2013). The sialylated LOS, phosphorylated LOS as well as 
ester/amide linked LOS of C. jejuni have different capabilities towards the 
activation of TLR-4 in human primary monocytes and THP-1 cells, indicating a 
potential role of LOS in monocyte/macrophage TLR-4 signalling (Stephenson et 
al., 2013). In addition, the purified cell wall polysaccharides of C. jejuni also have 
ability to elicit the TLR-4 responses in murine macrophages (Korneev et al., 
2018).  
 
NOD-like receptors or inflammasomes induction by Campylobacter 
Currently, no C. jejuni cellular component has been defined as a ligand of human 
macrophage NOD-like receptors, however, the event of Campylobacter 
internalisation into macrophages itself and a very low intracellular level of K+ as 
a consequence of cellular damage can trigger signalling via these receptors 
(Pétrilli et al., 2007; Bouwman et al., 2014). In response to these type of stimuli 
generally NLRC4 inflammasomes for Gram-negative bacteria such as 
Salmonella Typhimurium and Pseudomonas aeruginosa and NLRP3 
inflammasomes in Neisseria gonorrhoeae activate (Lara-Tejero et al., 2006; 
Franchi et al., 2007; Duncan et al., 2009). C. jejuni are unable to induce the 
NLRC4 inflammasomes, instead, they activate the NLRP3 inflammasomes in 
human macrophages (Bouwman et al., 2014). The NLRC4 or NLRP3 
inflammasome mediated signalling in almost all gram-negative bacteria 
consequently leads to the pyroptosis (programmed cell death) of macrophages 
to enhance the inflammatory responses. In contrast, NLRP3 inflammasome 
activation in C. jejuni does not contribute to apoptosis or pyroptosis of human 
macrophages (Bouwman et al., 2014; Siegesmund et al., 2004). 
 
 
6.1.2. Signalling pathways for cytokines induction in human macrophages  
Macrophages respond to infection and produce a range of pro-inflammatory 
cytokines including TNFα, Interleukin (IL)-1 (surface bound IL-1α, secretory IL-
1α, and secretory IL-1β), IL-6, IL-12, IL-18, IL-23, IL-27 (Baer et al., 1998; 
 190 
 
Schindler et al., 2001; Verreck et al., 2004; Robinson and Nau, 2008; 
Fettelschoss et al., 2011; Fernando et al., 2014) and anti-inflammatory cytokines 
such as TGFβ and IL-10 (Chadban et al., 1998; Gong et al., 2012).  
Intestinal inflammation is a hallmark of Campylobacter infection (Black et al., 
1988). The signalling pathways (Figure 6.1), which are elicited due to the 
Campylobacter-macrophage interaction, ultimately induce the secretion of 
several pro-inflammatory cytokines such as IL-1α, IL-1β, IL-6, IL-8, and TNFα 
from macrophages, indicating a significant role of monocytes or macrophages in 
the development of intestinal inflammation (Jones et al., 2003; Hamza et al., 
2017). These signalling pathways activate due to PAMPs, specifically LOS in 
case of C. jejuni, binding to TLR1/2/6, TLR-4 and TLR-9 which recruits an 
adaptor protein, MyD88, to interact with IRK (IL-1 receptor–associated kinase) 
complex and TNF receptor-associated factor 6 (TRAF6) (Kawai et al., 1999; 
Wesche at al., 2001; Verstak et al., 2009). This interaction induces the two 
closely related kinases: (1). TGF beta-activated kinase 1 (TAK-1); and (2). 
Mitogen activated protein 3 kinase (MAP3K) (Baud et al., 1999; Irie et al., 2000). 
TAK-1 phosphorylates IKK which further phosphorylates the NFKß inhibitor (IKB) 
and consequently leads to the translocation of NFKß to the nucleus to induce the 
transcription of pro-inflammatory cytokines (TNFα, IL-6 and IL-1β) (Wesche et 
al., 2001; Verstak et al., 2009). The MyD88 activated kinase, MAP3K, further 
stimulates the MAP-1 kinases (MAP1K) including extracellular signal-regulated 
kinase (ERK), c-jun N-terminal kinase (JNK) and p38 induction. These MAP1K 
translocate to the nucleus, act as transcription factors, and regulate the 
transcription of NFKß as well as synthesis of pro-inflammatory cytokines (Baud 
et al., 1999; Feng et al., 1999). This type of MyD88 dependent signalling occurs 
downstream the TLR as well as Sn and is crucial for initiating the transcription of 
pro-inflammatory cytokines (Kawai et al., 1999; Klaas et al., 2012).   
Macrophage TLRs, mainly TLR-2 and TLR-4, also involve the MyD88 
independent signalling (Figure 6.1) where they interact with adaptor proteins, 
TRAM and TRIF, and activate the interferon regulatory factor 3 (IRF-3) (Kawai 
et al., 1999; Yamamoto et al., 2002; Nilsen et al., 2014). IRF-3 accumulates in 
the macrophage nuclei and stimulates the synthesis of pro-inflammatory 
cytokines (e.g. IL-1α) as well as regulates the synthesis of other pro-
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inflammatory cytokines via coordination with NFKß (Kawai et al., 1999; Nilsen et 
al., 2014). 
        
 
 
Figure 6.1: A representation of signalling pathways downstream the macrophage cell 
membrane receptors (TLR & Sn) and cytosolic receptors (NLRP3 inflammasome).  
Upon Campylobacter infection, TLR signals may be either MyD88 dependent or independent 
while Sn corresponds via MyD88 only. The NLRP3 inflammasomes activation can occur directly 
by the phagocytosis process after the initiation of NLRP3 and pro-IL-1β transcription by NFKß.  
 
 
NLRP3 inflammasome, a NOD-like receptor, is a macromolecular complex of 
three major proteins; NLRP3, apoptosis-associated speck-like protein containing 
a CARD (ASC; 22-kDa) and Caspase-1, and is known to induce the pro-
inflammatory cytokine IL-1β in human macrophages (Masumoto et al., 1999; 
Agostini et al., 2004). The activation of NLRP3 inflammasomes’ dependent 
signalling in human macrophages requires dual signals. Initial signalling, also 
known as priming, occurs via TLRs. TLRs get stimulation by TLR ligands or 
PAMPs (e.g. LPS) binding, TLR mediated cytokines (e.g. TNFα), and host 
factors (e.g. ATP) which further trigger the NFKß to initiate the transcription of 
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NLRP3 and pro-IL-1β. Following the TLRs stimulation, downstream signalling 
can be either MyD88 dependent or MyD88 independent (Bauernfeind et al., 
2009). The transcribed NLRP3 proteins interact with two other proteins, ASC and 
Caspase-1, to structurally assemble the NLRP3 inflammasomes. This assembly 
formation involves an initial interaction between the pyrin domains (death 
domains) of ASC and NLRP3 and then another interaction of ASC caspase 
recruitment domain (CARD) with Caspase-1 (Masumoto et al., 1999; Agostini et 
al., 2004; Bae and Park, 2011). It is demonstrated that phosphorylation of pyrin 
domains activate the assembled inflammasomes, indicating the crucial role of 
kinases and phosphatases in the inflammasomes activation (Stutz et al., 2017). 
The inflammasome remains inactivated in the cytosol and activates by a second 
signal, which may be the presence of PAMPs or ingested whole bacterial cell 
into the cytosol (Bauernfeind et al., 2009). The activated NLRP3 inflammasomes 
then elicit the Caspase-1, which further catalyses the 31 kDa pro-IL-1β (already 
located into cytosol) into mature, biologically functional 17 kDa IL-1β. The 
cleaved IL-1β is then secreted outside the cell to mediate the inflammatory 
responses (Hazuda et al., 1990; Bauernfeind et al., 2009; Bouwman et al., 2014). 
Secretory IL-1β regulates its own synthesis as well as synthesis of IL-1α (Hiscott 
et al., 1993; Fettelschoss et al., 2011).  
 
6.1.3. THP-1 cell culture as an in vitro model of human macrophages  
Macrophage can be differentiated into two forms, classically activated and 
alternatively activated, depending on the environmental conditions in their 
surroundings (Porta et al., 2009; Fernando et al., 2014). Classically activated 
macrophages produce pro-inflammatory cytokines whereas alternatively 
activated macrophages release the anti-inflammatory cytokines (Porta et al., 
2009). Figure 6.2 represents that circular THP-1 cells in suspension resemble 
human monocytes and can be differentiated into flat, adherent, classically 
activated macrophages by Phorbol 12-myristate 13-acetate (PMA) treatment 
(Tsuchiya et al., 1980, 1982; Tedesco et al., 2018). PMA treated THP-1 cells are 
phenotypically and functionally similar to the human macrophages and can be 
used as an in vitro model to study the human macrophages (Daigneault et al., 
2010; Tedesco et al., 2018). 
 193 
 
PMA is a strong inducer of Ca2+-activated, phospholipid-dependent protein 
kinase (PKC), which phosphorylates MAP1K specifically ERK. The 
phosphorylation of ERK and downstream NFKß activation do not only regulate 
the expression of p21 (a cyclin kinase inhibitor) to regulate the cell proliferation, 
but also leads to the expression of cell differentiation associated cell-surface 
markers (Castagna et al., 1982; Herrera et al., 1998). ERK signalling also 
increases the expression of adhesion molecules such as CD29, CD18 and CD11 
to enhance the cell to cell interaction (Prieto et al., 1994). ERK phosphorylation 
can be kinase independent where, rather than the MAPK, the high expression of 
a cell surface marker, CD44, stimulates the ERK phosphorylation (Zhang et al., 
2014). Briefly, ERK phosphorylation by PMA is a key event which plays an 
important role in the termination of cell proliferation and initiation of the human 
monocytes differentiation to macrophages (Herrera et al., 1998; Zhang et al., 
2014).  
The differentiated THP-1 cells were used in this study rather than the 
undifferentiated ones because of two major reasons. First, PMA differentiated 
THP-1 cells do not require priming as monocyte to macrophage differentiation 
process itself contributes to the NFKß activation (Takashiba et al., 1999). Second, 
monocytes constitutively express Caspase-1 for IL-1β cleavage and therefore, 
cannot be used for the identification of inflammasome mediated Caspase-1 
activation and IL-1β processing (Netea et al., 2009).   
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Figure 6.2: THP-1 cells before and after PMA (100 ng/mL) treatment (Current 
study) 
A). Undifferentiated THP-1 cells under inverted microscope; B). Differentiated 
THP-1 cells under inverted microscope; C). A cluster of undifferentiated THP-1 
cells under SEM; D). A differentiated THP-1 cell under SEM. Undifferentiated or 
monocytes-like cells are in suspension (before PMA treatment), whereas, 
differentiated or macrophage-like cells are adherent (after PMA treatment).  
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6.2. Aims and Objectives 
The Campylobacter LOS can bind to the membrane bound receptors (TLRs, 
MGLRs, and Sn)  of human macrophages (van Sorge et al., 2009; Klaas et al., 
2012; Heikema et al., 2013; Stephenson et al., 2013), but the role of 
Campylobacter LOS in the stimulation of human macrophages-linked cytosolic 
receptors or inflammasomes remains unidentified. For this reason, this study 
aims to elucidate the association of C. jejuni and C. coli LOS to the activation of 
inflammasome signalling in human macrophages. To investigate it, the 
expression of IL-1β and Caspase-1 will be examined as these proteins are the 
final by-products of inflammasome mediated signalling pathway in macrophages.  
The IL-1β and Caspase-1 activation downstream of the NLRP3 inflammasomes 
dependent signalling in the human macrophages in response to the Neisseria 
gonorrhoeae, Neisseria meningitidis, and C. jejuni infections has been previously 
reported (Duncan et al., 2009; Bouwman et al., 2014; John et al., 2016), but it is 
currently unknown for C. coli. Therefore, this study also aims to investigate 
whether C. coli elicits the NLRP3 inflammasomes mediated IL-1β and Caspase-
1 in macrophages and behaves similar to C. jejuni.  
In order to achieve the above aims, this study will involve the use of a mutant of 
C. jejuni 11168, C. jejuni 11168Δ32-52, which expresses a modified LOS with a 
lipid A-disaccharide backbone (attached to four phosphates, six saturated fatty 
acid chains, and two Kdo) and lack of core oligosaccharides structure (Marsden 
et al., 2009). In comparison to C. jejuni mutant strain, wild-type (WT) C. jejuni 
11168 LOS consists of a lipid A-disaccharide backbone (attached to two 
phosphates, six saturated fatty acid chains, and one Kdo), an inner core of 
tetrasaccharides, and an outer core mimicking the human ganglioside structures 
(Moran, 1997). In addition, variable LOS expressing C. coli strains, RM1875 with 
non-sialylated LOS and 76339 with sialylated LOS, will also be used. 
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6.3. Results 
6.3.1. IL-1β and Caspase-1 induction in THP-1 cells using extracted LOS 
from Campylobacter  
THP-1 cells were incubated with WT C. jejuni 11168 LOS, C. coli RM1875 LOS 
(non-sialylated), and C. coli 76339 LOS (sialylated), to determine the impact of 
LOS on the induction of Caspase-1 and IL-1β secretion in macrophages. The 
modified LOS structures extracted from C. jejuni 11168Δ32-52 were also used 
to further assess whether alteration in the LOS structure can vary the NLRP3 
inflammasomes mediated signalling in macrophages. The SDS-PAGE gel in 
figure 6.3 shows the estimated molecular weight of LOS of C. jejuni 11168, C. 
jejuni 11168Δ32-52, C. coli RM1875, and C. coli 76339. 
In comparison to PBS treated THP-1 cells, Caspase-1 was induced in THP-1 
cells upon exposure to LOS from C. jejuni 11168 (p < 0.01), C. coli RM1875 (p 
< 0.05), and C. coli 76339 (p < 0.001). However, increase in the level of Caspase-
1 was almost negligible in C. jejuni 11168Δ32-52 LOS treated THP-1 cells 
compared to PBS treated THP-1 cells (Figure 6.4 A). In addition to Caspase-1, 
WT C. jejuni 11168 LOS, C. jejuni 11168Δ32-52 LOS, C. coli RM1875 LOS, and 
C. coli 76339 LOS, all induced IL-1β production significantly (p < 0.001) in THP-
1 cells when exposed to purified LOS (Figure 6.4 B).  
The  modified LOS from C. jejuni 11168Δ32-52 induced significantly less 
Caspase-1 (p < 0.01) and IL-1β (p < 0.001) from THP1 cells in comparison to the 
WT C. jejuni 11168 LOS (Figure 6.4 A & B), indicating that LOS structural 
modifications affect the secretion of IL-1β in THP-1 cells.  
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Figure 6.3: Analysis of LOS by SDS PAGE. 
Campylobacter extracted LOS migration on silver stained 16% (v/v) SDS-
PAGE gel. (1). C. jejuni 11168 LOS (~11 kDa); (2). 11168Δ32-52 LOS (No 
detectable band); (3). C. coli RM1875 LOS (~11 kDa). (4). C. coli 76339 LOS 
(~10 kDa). Multicolour low range protein ladder (1.7- 40 kDa) was used to 
predict the size of LOS bands.  
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Figure 6.4: (A) Caspase-1 induction in LOS treated THP-1 cells at 12 hours post treatment. 
Compared to PBS treated THP-1 cells (negative control), the level of Caspase-1 increased in E. 
coli LPS (0.1 μg; positive control) and all Campylobacter LOS (1mg) treated THP-1 cells except 
those who were treated with C. jejuni 11168Δ32-52 LOS. (B) Increase in IL-1β secretion in 
THP-1 cells upon treatment with LOS of Campylobacter strains at 12 hours post treatment. 
The quantity of secreted IL-1β also significantly increased in LPS and Campylobacter LOS 
treated THP-1 cells. However, C. jejuni 11168Δ32-52 LOS induced significantly less Caspase-1 
(p < 0.01**) and IL-1β (p < 0.001***) from THP-1 cells in comparison to the WT C. jejuni 11168 
LOS. Values are the mean + SD of three independent experiments performed in triplicate. 
Student’s t-test was performed to determine the statistical significance between two experimental 
groups. 
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6.3.2. IL-1β and Caspase-1 induction using a LOS core deficient C. jejuni 
11168 mutant 
To further confirm the influence of C. jejuni LOS on IL-1β and Caspase-1 
induction, THP-1 cell culture assays were carried out with C. jejuni 11168Δ32-
52 disrupted (equivalent to ~20 μg total protein) and live cells (at MOI of  2, 50 
and  200). The results were compared with C. jejuni 11168 disrupted or live cells 
inoculated THP-1 cell cultures.  
Figure 6.5 shows that both types of C. jejuni 11168Δ32-52 cells, disrupted and 
live, significantly induced IL-1β secretion in comparison to PBS treated THP-1 
cells. The IL-1β induction intensified with increase in number of live cells of C. 
jejuni 11168Δ32-52 and was comparable with C. jejuni 11168. Compared to C. 
jejuni 11168 infection of THP-1 cells, C. jejuni 11168Δ32-52 infection did not 
show a reduction in IL-1β in THP-1 cells. These results were in contrast to those 
which were observed with C. jejuni 11168Δ32-52 LOS, where C. jejuni 
11168Δ32-52 LOS induced significantly (p < 0.001) reduced IL-1β in THP-1 cells 
in comparison to C. jejuni 11168 LOS.  
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Figure 6.5: Increase in IL-1β induction in THP-1 cells by LOS deficient C. jejuni 11168Δ32-
52 disrupted cells (A) and live cells (B) at 12 hours post treatment.  
The level of secreted IL-1β in ~1x 106 differentiated THP-1 cells raised with increase in MOI or 
number of live Campylobacter cells. THP-1 cell culture with PBS only was used as a negative 
control. THP-1 cells treated with E. coli LPS (0.1 μg) and C. jejuni 11168 (disrupted or live) were 
used as positive controls. Values are the mean + SD of three independent experiments 
performed in triplicate.  
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In comparison to PBS treated THP-1 cells, increase in Caspase-1 induction was 
observed upon infection of THP-1 cells with C. jejuni 11168 and 11168Δ32-52 
as it is demonstrated in figure 6.6 A. 
THP-1 infection assays with C. jejuni 11168 and 11168Δ32-52 were performed 
after inhibition of Caspase-1 and K+ channels in THP-1 cells. Caspase-1 
induction is coupled with the induction of IL-1β in the NLRP3 mediated signalling 
pathway (Hazuda et al., 1990; Bauernfeind et al., 2009). Therefore, Caspase-1 
inhibitor or Z-VAD-FMK treatment of both C. jejuni 11168 and C. jejuni 
11168Δ32-52 infected THP-1 cells caused decrease in the production of 
Caspase-1 (p < 0.05; Figure 6.6 A) as well as IL-1β  (p < 0.01; Figure 6.6 B). 
Inhibition of K+ channels by glyburide did not pose significant effect on IL-1β 
induction in C. jejuni 11168 infected THP-1 cells. However, it caused significant 
reduction (p < 0.05) in IL-1β induction in C. jejuni 11168Δ32-52 infected THP-1 
cells (Figure 6.6 B).   
Moreover, reduction in IL-1β due to the inhibition of K+ channels was also 
observed in those THP-1 cells, which were co-cultured with disrupted cells of C. 
jejuni 11168Δ32-52 (Figure 6.6 C).  
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Figure 6.6: (A) Induction of Caspase-1 by live C. jejuni 11168 Δ32-52 mutant (MOI=200) in 
~1x 106 THP-1 cells and its significant reduction upon treating the THP-1 cells with Z-VAD-
FMK (10 μM). The quantity of Caspase-1 in Z-VAD-FMK treated THP-1 cells significantly 
reduced and was almost equivalent to the negative control. (B) Inhibition of IL-1β secretion in 
live LOS core deficient C. jejuni 11168Δ32-52 mutant (MOI=200) infected ~1x 106 THP-1 
cells by Z-VAD-FMK (10 μM) and glyburide (50 μM) at 12 hours post inoculation. Z-VAD-
FMK and glyburide, both significantly reduced the IL-1β production in C. jejuni 11168Δ32-52 
mutant live cells infected THP-1 cells. (C) Inhibition of IL-1β secretion in C. jejuni 11168Δ32-
52 mutant disrupted cells infected ~1x 106 THP-1 cells by glyburide (50 μM) at 12 hours 
post inoculation. Glyburide reduced the IL-1β production in C. jejuni 11168Δ32-52 disrupted 
cells inoculated THP-1 cells. 
THP-1 cell culture with PBS only was used as a negative control whereas THP-1 cells stimulated 
with E. coli LPS (0.1 μg) and live C. jejuni 11168 cells (MOI=200) were used as positive controls. 
Values are the mean + SD of three independent experiments performed in triplicate; (Student’s 
t-test; p < 0.05*; p < 0.01**; p < 0.001***).  
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6.3.3. IL-1β and Caspase-1 induction by C. coli infection in THP-1 cells 
Differentiated THP-1 cells were inoculated either with C. coli disrupted cells 
(equivalent to ~20 μg total protein) or live cells at different MOI (2, 50 & 200). 
The following figures, 6.7 and 6.8, illustrate that the live cells of C. coli RM1875 
and C. coli 76339 were able to induce IL-1β secretion in THP-1 cells at levels 
comparable with E. coli LPS and C. jejuni 11168 (positive controls). The release 
of IL-1 β became intensified with increase in number of live cells of C. coli 
RM1875 and C. coli 76339. The same findings were observed following the 
incubation of THP-1 cells with disrupted cells of these C. coli strains. 
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Figure 6.7: Increase in IL-1β induction in THP-1 cells by C. coli RM1875 disrupted cells (A) 
and live cells (B) at 12 hours post treatment.  
The level of secreted IL-1β in ~1x 106 THP-1 cells raised with increase in MOI or number of live 
Campylobacter cells. THP-1 cell culture with PBS only was untreated and used as a negative 
control. THP-1 cells stimulated with E. coli LPS (0.1 μg) and C. jejuni 11168 (disrupted or live) 
were used as positive controls. Values are the mean + SD of three independent experiments 
performed in triplicate.  
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Figure 6.8: Increase in IL-1β induction in THP-1 cells by C. coli 76339 disrupted cells (A) 
and live cells (B) at 12 hours post treatment.  
The level of secreted IL-1β in ~1x 106 THP-1 cells raised with increase in MOI or number of live 
Campylobacter cells. THP-1 cell culture with PBS only was used as a negative control. THP-1 
cells treated with E. coli LPS (0.1 μg) and C. jejuni 11168 (disrupted or live) were used as positive 
controls. Values are the mean + SD of three independent experiments performed in triplicate. 
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Figure 6.9 (A) shows that in addition to IL-1β, Caspase-1 was also significantly 
induced in THP-1 cells upon infection (MOI=200) with live C. coli RM1875 (p < 
0.05) and C. coli 76339 cells (p < 0.01). 
THP-1 infection assays with C. coli RM1875 and C. coli 76339 at MOI=200 were 
further carried out in the presence of Z-VAD-FMK (10μM) and glyburide (50μM).  
The expression of Caspase-1 was inhibited in C. coli RM1875 (p < 0.01) and C. 
coli 76339 (p < 0.001) infected THP-1 cells when THP-1 cells were treated with 
Z-VAD-FMK, prior to inoculation with C. coli live cells (Figure 6.9 A). Compared 
to Z-VAD-FMK-untreated THP-1 cells, Z-VAD-FMK-treated THP-1 cells showed 
reduction in IL-1β also during infection with C. coli RM1875 (p < 0.01) and C. coli 
76339 (insignificant). However, glyburide-treated THP-1 cells following infection 
with C. coli strains did not show any significant change in IL-1β expression than 
the glyburide-untreated infected cells (Figure 6.9 B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 208 
 
 
 
 
 
 
 
 
 
Figure 6.9: (A) Induction of Caspase-1 by live C. coli RM1875 and C. coli 76339 (MOI=200) 
in ~1x 106 THP-1 cells and its significant reduction upon treating the THP-1 cells with 10 
μM Z-VAD-FMK. The quantity of Caspase-1 in Z-VAD-FMK treated THP-1 cells significantly 
reduced and was almost equivalent to the negative control. (B) Effects on IL-1β secretion in 
live C. coli RM1875 and C. coli 76339 (MOI=200) infected ~1x 106 THP-1 cells before and 
after inhibition with Z-VAD-FMK (10 μM) and glyburide (50 μM) at 12 hours post 
inoculation. Z-VAD-FMK significantly reduced the IL-1β production in C. coli infected THP-1 
cells, however, glyburide did not inhibit the IL-1β secretion in C. coli infected THP-1 cells.  
THP-1 cell culture with PBS only was used as a negative control. THP-1 cells stimulated with E. 
coli LPS (0.1 μg) and live C. jejuni 11168 cells (MOI=200) were used as positive controls. Values 
are the mean + SD of three independent experiments performed in triplicate. (Student’s t-test; p 
< 0.05*; p < 0.01**, p < 0.001***). 
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6.3.4. Increase in the LDH release in live Campylobacter infected and LOS 
treated THP-1 cells 
Measurement of increase in LDH release in THP-1 cell culture supernatants 
provides an estimation of occurrence of cell cytotoxicity (which is another cause 
of the inflammasome activation) during infection. Therefore, LDH, released in 
live strains and LOS stimulated THP-1 cell cultures, was measured relative to 
the LDH release (100%) in LPS treated THP-1 cells (positive control).  
In comparison to PBS treated THP-1 cells (negative control), relative LDH level 
did not increase in live Campylobacter infected THP-1 cells and was not in the 
detectable range (data not shown). However, in comparison to the negative 
control, a significant increase in relative LDH was present in the supernatants of 
those THP-1 cells, which were treated with WT C. jejuni 11168 LOS (p < 0.01), 
C. coli RM1875 LOS (p < 0.01), and C. coli 76339 LOS (p < 0.01) (Figure 6.10). 
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Figure 6.10: A significant increase in LDH release in Campylobacter LOS treated THP-1 
cells at 12 hours post treatment.  
LDH quantity in THP-1 cells was measured relative to the LDH release (100%) in positive control 
or E. coli LPS treated THP-1 cells. Compared to untreated THP-1 cells (negative control), the 
quantity of LDH significantly increased (Student’s t-test; p < 0.05*; p < 0.01**) in Campylobacter 
LOS (1mg) treated THP-1 cells. Values are the mean + SD of three independent experiments 
performed in triplicate. 
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6.4. Discussion  
6.4.1. Stimulation of the inflammasome dependent IL-1β secretion in 
human macrophages by Campylobacter LOS 
To investigate whether Campylobacter LOS structures can be presented as a 
contributing factor in the induction of IL-1β secretion in THP-1 cells, LOS 
extracted from C. jejuni 11168, C. coli RM1875 and C. coli 76339 were used. 
Caspase-1 induction and IL-1β secretion are the two major events, which occur 
downstream the activation of NLRP3 inflammasomes (Bauernfeind et al., 2009). 
Therefore, the Caspase-1 and IL-1β secretion in THP-1 cell cultures was 
estimated following their incubation with Campylobacter LOS extracts. LOS from 
C. jejuni 11168, C. coli RM1875 and C. coli 76339 strains induced the Caspase-
1 and IL-1β from THP-1 cells, signifying a potent link of LOS to NLRP3 
inflammasome activation. Previously, purified LOS extracted from Neisseria 
gonorrhoeae and Neisseria meningitidis have been reported to induce the 
NLRP3 inflammasomes in THP-1 cells (Duncan et al., 2009; John et al., 2016).  
Lipid A with hydroxyl-linked acyl chains in C. jejuni LOS have been found as 
more strong inducers of TLR-4 receptors than lipid A with amide-bound acyl 
chains (Moran, 1997). C. jejuni LOS structures with terminal GalNAc residues 
recognise the MGLRs whereas C. jejuni LOS with sialylated residues bind to the 
Sn on macrophages (van Sorge et al., 2009; Klaas et al., 2012; Heikema et al., 
2013). These studies have demonstrated that C. jejuni LOS lipid A and core 
oligosaccharides, both are important in the attenuation of inflammatory 
responses. In this current study, the LOS of C. jejuni mutant 11168Δ32-52 
induced the Caspase-1 and IL-1β in THP-1 cells at lower levels than C. jejuni 
11168 WT strain. C. jejuni 11168Δ32-52 LOS were deficient of core 
oligosaccharides, but had an additional Kdo and two phosphates in the lipid A 
disaccharide backbone (Marsden et al., 2009), which may have caused variation 
in the NLRP3 inflammasomes activation in THP-1 cells. It has been reported 
previously that variation in Neisseria meningitidis LOS core oligosaccharides do 
not affect the TLR-4 activation, but the removal of Kdo and phosphate groups 
from LOS-lipid A, as well as change in the number of lipid A acylated chains can 
strongly influence the TLR4 activation and cytokine induction in human 
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macrophages (John et al., 2016). Results obtained in the current study revealed 
that LOS structural modifications can vary the NLRP3 inflammasome-mediated 
Caspase-1 and functional IL-1β secretion in human macrophages, however, it 
remains unknown which component of LOS from lipid A, Kdo, and core sugars 
is actually responsible for this variation.  
Experiments with Campylobacter LOS extracts were less reliable as these LOS 
extracts were not very pure and may have carry-over of capsular saccharides 
and degraded bacterial peptidoglycans (Muramyl dipeptides). Presence of these 
types of contaminants with LOS in LOS extractions could facilitate the IL-1β 
induction in THP-1 cells and produce the false-positive results. Previously, the 
role of bacterial muramyl dipeptides in the activation of inflammasomes in 
macrophages has been observed (Martinon et al., 2004). For this reason, THP-
1 assays, performed with C. jejuni 11168 WT and mutant LOS, were replicated 
with C. jejuni 11168 WT and mutant live cells. 
 
 
6.4.2. Campylobacter LOS and intracellular K+ depletion independently 
trigger the inflammasome-mediated IL-1β secretion in human 
macrophages 
In comparison to uninfected THP-1 cells, a significant increase in Caspase-1 and 
IL-1β production was observed in THP-1 cells infected with either live or 
disrupted cells of C. jejuni 11168Δ32-52. Macrophages do not constitutively 
express Caspase-1 and are unable to process pro-IL-1β without eliciting the 
inflammasomes (Netea et al., 2009). However, some other proteases such as 
Cathepsin G, Collagenase, elastase and granzyme may be recruited to process 
the IL-1β in monocytes (Hazuda et al., 1990; Irmler et al., 1995). Therefore, to 
confirm that IL-1β is actually a by-product of Caspase-1 enzymatic activity, THP-
1 cells were incubated with a Caspase-1 inhibitor, Z-VAD-FMK, for 3 hours prior 
to infection. Caspase-1 inhibitor or Z-VAD-FMK treated THP-1 cells secreted 
significantly less Caspase-1 and IL-1β compared to Z-VAD-FMK untreated THP-
1 cells during infection with C. jejuni 11168Δ32-52, as expected.  
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C. jejuni 11168Δ32-52 mutant lacked the core oligosaccharides due to the 
deletion of LOS region (17 LOS biosynthesis genes deletion from gene cj1132-
gmhB) and had the kanamycin cassette, inserted in the replacement of deleted 
LOS gene region (Marsden et al., 2009). Despite expressing the altered LOS 
structures on the cell surface, C. jejuni 11168Δ32-52 mutant induced the IL-1β 
in THP-1 cells almost at the similar level to WT C. jejuni 11168. In an earlier 
study, infections of THP-1 cells with live C. jejuni 81116 waaF mutant (lacking 
the core oligosaccharides due to the insertion of chloramphenicol cassette in 
waaF gene) did not cause any reduction in the NLRP3 inflammasomes activation 
in comparison to its respective parent strain (Bouwman et al., 2014). Based on 
these results, it was assumed that in addition to LOS, some other factors are 
also involved in the activation of NLRP3 inflammasomes and for this reason, 
ascertaining the role of LOS in the inflammasome activation in human 
macrophages can be difficult following the infection of THP-1 cells with C. jejuni 
11168Δ32-52.  
It is well known previously that the K+ efflux, a highly conserved mechanism in 
macrophages and a major factor of inflammosome activation, occurs 
simultaneously with the internalisation of a whole-live bacterial cell, possibly by 
ATP binding to P2X7 receptors on macrophages. The exact mechanism causing 
K+ depletion or efflux in macrophages during infection is yet unknown (Pétrilli et 
al., 2007; Bouwman et al., 2014). In this study, glyburide (which inhibits the 
activation of NLRP3 inflammasomes by inhibition of K+ channels), was used to 
assess the Campylobacter LOS induced effects after inhibition of K+ efflux in 
THP-1 cells. In comparison to the glyburide-untreated infected cells, glyburide-
treated THP-1 cells had no reduction in IL-1β levels when they were infected with 
live WT C. jejuni 11168 cells, indicating that other factors in addition to K+ efflux 
were present there for the activation of NLRP3 inflammasomes. The same 
results were expected for live C. jejuni 11168Δ32-52 mutant infection. In contrast 
to the expected results, glyburide-treated THP-1 cells upon exposure to the live 
cells of C. jejuni 11168Δ32-52 mutant showed a significant decrease in IL-1β 
production. IL-1β reduction was also observed when glyburide-treated THP-1 
cells were cultured with disrupted cells of C. jejuni 11168Δ32-52 mutant. 
Blocking of K+ channels by glyburide and alteration in LOS structure at the same 
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time decreased the IL-1β production in THP-1 cells, which indicates that K+ efflux 
and LOS structures are both associated with NLRP3 inflammasome activation in 
human macrophages. These results also explained that a continuous K+ efflux 
during the infection with live and disrupted bacterial cells can mask the 
contribution of LOS structures towards the production of inflammasomes in 
human macrophages. That is why, in the absence of glyburide, C. jejuni 
11168Δ32-52 mutant live cells showed similar IL-1β induction to the WT C. jejuni 
11168 live cells.  
C. jejuni 11168Δ32-52 modified LOS showed a clear reduction in Caspase-1 and 
IL-1β secretion in THP-1 cells in comparison to C. jejuni 11168 LOS. However, 
compared to C. jejuni11168 live cells, C. jejuni 11168Δ32-52 live cells did not 
reduce the Caspase-1 and IL-1β induction from THP-1 cells, suggesting that K+ 
intracellular depletion or K+ efflux (masking LOS impact) occurred only during 
infection with live or disrupted cells and this event did not take place when  LOS 
extractions were used.  
The NFKß induction downstream of the TLR signalling is the first step of the 
inflammasomes activation to initiate the transcription of pro-IL-1β and NLRP3 
proteins (Bauernfeind et al., 2009). E. coli LPS as well as Campylobacter heat-
killed and disrupted cells, all can activate the TLRs and induce NFKß in 
macrophages via MyD88 dependent and independent signalling (Takashiba et 
al., 1999; Mellits et al., 2002; Jones et al., 2003). In this study, purified LOS and 
disrupted cells, both stimulated the inflammasomes-mediated signalling in 
macrophages. Based on our findings and previous data, it can be assumed that 
TLRs and NFKß activation may occur either upon initial interaction of 
Campylobacter with macrophage cell surface (LOS interact extracellularly with 
TLRs) or after the phagocytosis process (lysed cells including LOS interact 
intracellularly with TLRs) (Figure 6.11). Mellits et al. (2002) found that C. jejuni 
LOS preparations do not activate the NFKß in epithelial cells. Therefore, it may 
be possible that Campylobacter LOS residues directly activate the 
inflammasomes into the cytosol of macrophages, similar to the gonococcal LOS, 
which is shed through membrane blebbing by Neisseria gonorrhoeae to elicit the 
NLRP3 inflammasomes (Duncan et al., 2009). Hence, it is not known whether  
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Figure 6.11. A proposed correlation between Campylobacter live cells, disrupted cells, 
and LOS in order to induce the IL-1β secretion in human macrophages.  
Live and disrupted cells cause the intracellular K+ depletion or K+ efflux. The depletion of K+ ions 
stimulate the assembly of NLRP3 inflammasomes by an unknown mechanism. Cell surface LOS 
structures during the interaction of Campylobacter with the macrophage may activate the TLRs 
extracellularly, whereas, LOS structures released from the phagocytosed or disrupted cells may 
activate the TLR signalling intracellularly. Subsequently, Campylobacter LOS structures 
intracellularly may activate NFKß by an undefined mechanism to transcribe the NLRP3 and pro-
IL-1β, which is a first step of inflammasome activation. In the second step of inflammasomes 
dependent signalling, Caspase-1 becomes activated by NLRP3 inflammasome which further 
cleaves the pro-IL-1β into its mature form, IL-1β. Thus, Campylobacter LOS and K+ depletion 
both independently induce the inflammasome-mediated IL-1 β secretion. It is not known whether 
Campylobacter LOS elicit the inflammasomes by involving the TLRs or by direct association to 
the inflammasomes. (Arrows represent the already known events, dashed arrows represent the 
proposed events, and dashed arrows with question marks represent the unknown signalling 
pathways). 
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Campylobacter LOS stimulate the NLRP3 inflammasomes by direct association 
to the inflammasomes or/and via TLRs activation in human macrophages. 
 
6.4.3. Activation of the inflammasome-mediated IL-1β secretion in the 
human macrophages by C. coli infection 
In comparison to uninfected THP-1 cells, a significant increase in IL-1β and 
Caspase-1 production was observed when cells were treated with live cells of C. 
coli RM1875 and 76339 strains, indicating the NLRP3 inflammasomes activation 
in response to C. coli infection. IL-1β secretion in THP-1 cells induced by the 
number of C. coli live cells in a dose dependent manner. This is in line to the 
previous studies which explain that THP-1 induced IL-1β secretion depends on 
the bacterial load (Franchi et al., 2007; Duncan et al., 2009; Bouwman et al., 
2014). THP-1 induced IL-1β secretion also upon exposure to C. coli disrupted 
cells, suggesting that neither C. coli viability nor invasion is necessary to activate 
the inflammasomes. These C. coli related findings were comparable to C. jejuni 
whose invasion or viability is also not essential for the cytokine production in DCs 
and macrophages (Jones et al., 2003; Hu et al., 2006). As expected, Z-VAD-
FMK significantly inhibited the Caspase-1 and IL-1β in C. coli RM1875 infected 
THP-1 cells. It also inhibited the Caspase-1 production significantly during the 
infection of C. coli 76339, but not the IL-1β, indicating that C. coli 76339 infection 
may develop the Caspase-1 independent IL-1β stimulation in addition to the 
Caspase-1 dependent IL-1β activation in macrophages. Previously, Netea et al., 
(2010) described the occurrence of Caspase-1 independent IL-1β stimulation in 
human neutrophils. The possibility of occurrence of Caspase-1 independent IL-
1β stimulation in THP-1 cells upon infection with C. coli 76339 requires further 
investigation by using the inhibitors of other IL-1β activating enzymes, 
specifically serine protease inhibitors. Overall, these results confirmed that C. 
coli infection activates the NLRP3 inflammasomes in human macrophages.  
IL-1β levels in glyburide-treated C. coli infected cells were not significantly 
different than the glyburide-untreated infected cells, specifying that even NLRP3 
inflammasomes stimulation was inhibited following inhibition of K+ efflux, but C. 
coli LOS continued the activation of NLRP3 inflammasome dependent signalling. 
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C. coli 76339 (contained sialylated LOS) showed higher induction of IL-1β than 
C. coli RM1875 (contained non-sialylated LOS), indicating that C. coli LOS and 
its sialylation are important for IL-1β induction in macrophages.  
 
 
6.4.4. Campylobacter live cells do not cause the cell cytotoxicity  
Increase in LDH was absent in Campylobacter live cells treated THP-1 cell 
cultures, which was concordant to the findings of Bouwman et al. (2014). 
However, LDH release was high in Campylobacter LOS treated THP-1 cells, 
indicating LOS may cause cell cytotoxicity in human macrophages. It might not 
be true as cell cytotoxicity may occur due to the hypersensitivity of THP-1 cells 
in the presence of LOS and therefore, macrophages in natural settings may not 
show the same results or any cytotoxic effects. Further investigation is required 
to find out the association of Campylobacter LOS with the cytotoxicity of human 
macrophages. LDH induction by Campylobacter LOS at higher level than LPS or 
positive control may be linked to the difference in LOS (1mg) and LPS (0.001μg) 
concentrations, given to stimulate the IL-1β production in THP-1 cells.  
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6.5. Conclusion  
Activation of the NLRP3 mediated inflammatory response in human 
macrophages is a representation of a host response which develops during the 
C. coli infection. Live and disrupted C. coli cells, can both induce the production 
of NLRP3 inflammasome mediated Caspase-1 and IL-1β. The induction of 
Caspase-1 and IL-1β secretion depends on the number of C. coli live cells and 
can vary slightly between different C. coli strains. This study describes for the 
first time that C. coli is also included in the list of those bacteria which can 
stimulate the NLRP3 inflammasomes in the human macrophages during 
infection.  
In addition to live and disrupted cells, C. jejuni and C. coli cell-surface LOS 
structures can also induce the Caspase-1 and IL-1β secretion in human 
macrophages. The extent of Caspase-1 and IL-1β induction alters with variation 
in LOS structures. It is also concluded that during Campylobacter infection, 
Campylobacter-associated molecular pattern (Campylobacter LOS) and danger-
associated molecular pattern (K+ efflux), both independently trigger the activation 
of NLRP3 inflammasomes. This study is the first description which represents 
the association of Campylobacter LOS with NLRP3 mediated inflammatory 
response as well as provides new insight into the interaction of Campylobacter 
with human macrophages. 
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CHAPTER 7 
General Conclusions and Future Work 
7.1. Major findings and their integration into previous research 
7.1.1. Identification of C. jejuni LOS loci prevalence by PCR based typing 
The first aim of this study was to examine the prevalence of 23 C. jejuni LOS 
locus genotypes in a clinical cohort and analyse the extent of gene variation in 
the C. jejuni LOS biosynthesis gene cluster by LOS locus typing of clinical C. 
jejuni isolates. To achieve this, LOS class specific primer pairs were designed, 
optimised, and used for C. jejuni LOS locus typing of 50 C. jejuni clinical strains, 
isolated from faecal samples of Campylobacter infected patients at the 
Northampton General Hospital (NGH), Northampton, UK. In addition, a simplified 
LOS classification system to better understand the relationship of C. jejuni LOS 
classes with LOS groups was also presented, where LOS group 1 (with class A, 
B, C, R, V, M), group 2 (with class E, H, O, P, W), group 3 (with class D, F, K, Q, 
N, I, J, S), and group 4 (with L, G, T, U) were included. 
Previous studies have demonstrated that C. jejuni LOS group 1 and its related 
LOS classes (A, B and C) dominantly circulate amongst clinical C. jejuni isolates. 
The prevalence of this group might be due to their ability to synthesise human 
gangliosides mimicking LOS structures (Parker et al., 2005; Marsden, 2007; 
Islam et al., 2009; Ellström et al., 2013; Islam et al., 2014; Ellström et al., 2016; 
Islam et al., 2018). This study has also confirmed a high frequency of LOS group 
1 (62%) and its related classes (22% B > 20% C > 14% A). Prior published data 
has been further expanded upon in this study by identifying a hierarchy of LOS 
subclasses based on prevalence in clinical C. jejuni isolates (where B2 > A2 > 
B1 > A1). The high frequency of C. jejuni LOS classes B2 and C might be due to 
the fact that both LOS locus types exhibit high phase-variation at the gene 
sequence level and consequently, produce heterogenous LOS epitopes (or 
ganglioside mimics). For example, LOS locus type B2 present in C. jejuni strain 
81-176, can change the GM2 mimicking LOS epitope to GM3 (GM2-3) and GM2-3 
to GD (Guerry et al., 2002). Similarly, C. jejuni 11168 with LOS locus type C can 
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modify GM1 to a GM2 like LOS structure (Linton et al., 2000). Moreover, this 
thesis has also provided a comparison of current findings of C. jejuni LOS loci 
distribution with previous studies, indicating that approximately 50–65% of 
strains in most of the clinical/enteritis associated C. jejuni populations belong to 
LOS classes A, B or C.  
Compared to a high proportion of C. jejuni isolates with LOS loci (A, B and C), 
the prevalence of strains with the other three group 1 related and sialic acid 
biosynthesis genes containing loci (R, V and M) was negligible. The reasons for 
this remain unclear. However, class R strains do not produce GBS related 
ganglioside mimics (GM1, GM2, GD1, GD2) and class M strains are reported not 
to produce the ganglioside mimicking LOS structures at all despite having sialic 
acid biosynthesis genes (Houliston et al., 2011). A low frequency of these loci 
(R, V and M) from isolates as well as a low rate of GBS and MFS in 
Campylobacter infected patients (Nachamkin et al., 2002; Mortensen et al., 
2009) despite high predominance of GBS/MFS associated C. jejuni LOS A, B, 
and C loci supports the notion that LOS structure is not a sole cause of GBS/MFS 
development.   
During the collection of clinical Campylobacter strains from NGH, C. coli strains 
were much less common than C. jejuni isolates from clinical samples. This 
finding was consistent throughout the year and did not appear to vary with the 
season. Due to the lack of availability of C. coli clinical strains, a PCR based LOS 
typing assay could not be validated for C. coli in this study.  
 
7.1.2. Analysis of C. jejuni LOS loci prevalence in GenBank by using 
bioinformatics approaches 
The second aim of this study was to validate a pipeline to use for high-
throughput C. jejuni LOS locus typing. Therefore, a Galaxy pipeline employing 
the alignment software MAFFT was designed and used for the C. jejuni LOS 
locus classification and approximately 65% (n=81 of 125) C. jejuni strain 
GenBank sequences had their LOS types categorised. The pipeline allowed 
successful assignment of ~50% (n=39 of 81) of analysed sequences to 
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particular LOS classes. In the MAFFT alignment tree or in the output of Galaxy 
pipeline, unclassified sequences belonging to a particular LOS group clustered 
together, and therefore, this pipeline indicated a LOS group for each of those 
remaining 42 of 81 sequences for which a particular LOS class could not be 
identified. The same LOS class or group for these 81 C. jejuni sequences was 
identified using a manual Megablast approach, which validated the results from 
Galaxy workflow. The manual approach using Megablast, in addition to 
validating the results from Galaxy workflow, was also used to LOS classify 622 
C. jejuni sequences (44 complete and 578 draft), which could not be typed using 
the Galaxy pipeline. Blastn has been used previously to determine the LOS 
locus type in Acinetobacter baumannii genome sequences (n=234) available in 
the MLST database (Kenyon et al., 2014).  
From the LOS locus analysis of 703 C. jejuni sequences from GenBank either 
by the Galaxy pipeline or manual Megablast alignments, the frequency of 23 
different C. jejuni LOS biosynthesis locus classes (4 LOS groups) present within 
this collection was determined. The frequency of LOS classes A, B, and C was 
also high in this repository of C. jejuni online sequences [class B (23%) > class 
C (16%) > class A (16%)] similar to the collection of C. jejuni clinical isolates 
[class B (22%) > class C (20%) > class A (14%)]. Other LOS group 1 related 
classes (R, V and M) were absent from the clinical isolates and this may reflect 
the fact that even in a large repository sequences belonging to these classes 
represented only 2.5 % in the online database. The hierarchy of LOS groups 
prevalence, (group 1 > group 2 > group 3 > group 4), was similar in both C. jejuni 
clinical isolates and from the larger sequence collection. The frequency of sialic 
acid biosynthesis LOS loci in the online GenBank database was high, although 
this collection contained other C. jejuni sources (e.g. animals, birds and farm soil) 
in addition to humans. This suggests that C. jejuni strains having sialylated LOS 
structures dominantly exist perhaps not just because their LOS structures are 
important for the pathogenesis, but also because their sialylated LOS phenotype 
is advantageous for C. jejuni general survival and fitness in different niches. 
Moreover, the in silico analysis of C. jejuni sequences has identified the class 
frequency hierarchy in C. jejuni LOS group 3 (F > K > S) and group 4 (G > L) for 
the first time. 
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7.1.3. Identification of C. coli LOS loci prevalence in GenBank by using 
bioinformatics based approaches 
This study also aimed to analyse in silico the 564 C. coli online sequences 
available in GenBank to estimate the extent of gene content variation in C. coli 
LOS biosynthesis gene cluster. This study represents the first exploration of LOS 
locus genotype distribution in C. coli GenBank database via in silico analysis, 
where C. coli strains possessing LOS class III (41%; n=229 of 564) were the 
most common in GenBank. This was similar to the findings of Richard et al. 
(2013) and Culebro et al. (2018) who also reported class III as the most common 
class respectively in the collections of 33 US C. coli strains and 261 European 
Nucleotide Archive C. coli sequences. The reasons behind the high prevalence 
of LOS class III in C. coli are yet to be investigated. Moreover, the prevalence of 
C. coli LOS genotypes in different niches was estimated by looking at the online 
published sources from which these C. coli strains were isolated. The most 
common LOS types were III and VIII and tended to come from farm 
environmental niches (water and soil), as well as, humans and chickens. This 
suggests that the farm environment, in addition to poultry, is a primary source of 
C. coli transmission to humans. This was in agreement with a previous study that 
reported agriculture associated C. coli as an emerging human pathogen 
(Sheppard et al., 2010, 2013). 
 
7.1.4. In silico Identification of novel LOS biosynthesis genes  
By in silico analysis, LOS biosynthesis genes clusters of two C. jejuni strains, C. 
jejuni 414 (Accession no: ADGM01000014.1) and C. jejuni 1336 (Accession no: 
CM000854.1) were found with 5 and 13 novel LOS genes, respectively. The 
functions of these genes are not known. Four novel LOS genes in C. jejuni 1336 
locus were predicted to arise from the capsular polysaccharide biosynthesis 
genes of other C. jejuni strains, while, six novel LOS genes of C. jejuni 1336 and 
one gene of C. jejuni 414 appeared to have originated from C. coli, which 
indicates the occurrence of intraspecies and interspecies gene recombination in 
Campylobacter species.  
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Campylobacter LOS biosynthesis genes (waaC, waaM, lgtF, waaV, waaF, 
gmhA, waaE, waaD, and gmhB) are involved in the biosynthesis of the LOS inner 
core and remain present with the same order or organisation in almost all 
Campylobacter strains (Parker et al., 2008; Richard et al., 2013). This is the 
reason that the inner core of LOS does not vary enormously between 
Campylobacter strains (Gilbert et al., 2002; Kolehmainen et al., 2019). 
Previously, organisation of the inner core biosynthesis genes in two C. jejuni LOS 
loci, M and W, was found to be different from all other C. jejuni LOS loci. C. jejuni 
class M had a gene between waaM and lgtF and C. jejuni class W contained two 
genes between waaF and gmhA (Parker et al., 2008; Richard et al., 2013). 
Similarly, this thesis shows that C. coli LOS loci, I, II, III, V, and VIII contain an 
additional gene inserted between waaF and gmhA. The presence of these LOS 
genes between waaF and gmhA was confirmed in 436 C. coli GenBank 
sequences with LOS type I (n=63), II (n=43), III (n=229), V (n=3), and VIII (n=98). 
Furthermore, a clinical C. coli strain, C. coli 221089, with class III LOS locus type 
was WG sequenced using the Illumina platform and submitted in GenBank under 
the accession number, RJLP00000000 (contigs: RJLP01000001-
RJLP01000044). By pairwise alignment of these sequenced contigs with C. coli 
RM2228 (reference LOS class III strain) sequence, a class III gene, located 
between waaF and gmhA, was found present (100% query cover; 100% identity 
score) in C. coli 221089 strain.  
The identified inner core biosynthesis LOS genes in C. coli vary at the sequence 
and functional level among C. coli LOS locus classes (based on data available 
in GenBank), indicating that, in addition to the LOS outer core, the LOS inner 
core saccharides also vary amongst C. coli strains. The sequence level variation 
in these genes and their possible putative functions have been determined in 
silico but require further wet-lab based functional characterisation.  
 
7.1.5. Examination of altered motility phenotype in a mutated C. coli 
RM1875 strain 
The third aim of this study was to construct and characterise a C. coli LOS 
biosynthesis gene region deletion mutant to determine the impact of LOS gene 
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deletions on C. coli cell phenotype. This aim had not been achieved in the 
current study, which might be because deleting the LOS locus in C. coli was not 
conducive with survival. However, the whole plasmid, used to generate deletion 
in LOS, was found integrated in the gDNA of a C. coli RM1875 mutant strain at 
a non-specific site. The exact location of its integration in C. coli RM1875 has 
yet to be identified. This mutant has showed a modified growth rate, increased 
cell motility and higher flaA gene expression in comparison to the WT strain and 
therefore, it is speculated that plasmid integration might have affected the 
motility associated genes. 
 
 
7.1.6. Determination of the impact of LOS variation on IL-1β induction from 
THP-1 cells 
During infection with Campylobacter, the occurrence of continuous intracellular 
K+ ion depletion or K+ efflux contributes to the activation of the NLRP3 
inflammasome in human macrophages, possibly by ATP binding to macrophage 
P2X7 receptors (Pétrilli et al., 2007; Bouwman et al., 2014). The last aim of this 
study was to determine the in vitro impact upon the IL-1β induction of THP-1 
cells with variation of the LOS structures in C. jejuni and C. coli. 
The infection of THP-1 cells with a C. jejuni 81116 mutant lacking LOS core 
structures (waaF:cat) in a previous study demonstrated that C. jejuni LOS 
variation does not have any impact on the induction of IL-1β from THP-1 cells 
(Bouwman et al., 2014). In this thesis, similar results were observed during 
infection of THP-1 cells with a C. jejuni 11168 mutant (Δcj1132c-cj1152c) lacking 
LOS core structures. However, replication of this infection assay in the presence 
of a K+ channel inhibitor provided contrasting results. Blocking of K+ efflux with 
glyburide and simultaneously, with LOS lacking core polysaccharides, caused a 
significant decrease in IL-1β production in THP-1 cells. This explains that C. 
jejuni LOS variation can affect the extent of NLRP3 dependent IL-1β induction in 
THP-1 cells, but this minor IL-1β inducing factor (LOS) is difficult to observe due 
to simultaneous presence of another major IL-1β inducing factor (namely K+ 
efflux). The concentration of released IL-1β did not change in WT C. jejuni 11168, 
C. coli RM1875 and C. coli 76339 infected THP-1 cells following the inhibition of 
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K+ efflux, which also supports this notion that LOS and K+ efflux both contribute 
to the activation of NLRP3 inflammasome dependent signalling. This study is the 
first demonstration of an association between C. jejuni LOS and macrophage 
NLRP3 dependent IL-1β induction.  
This study has also demonstrated that, both live and disrupted cells of WT C. coli 
strains, 76339 (present sialylated LOS) and RM1875 (possess non-sialylated 
LOS), can stimulate the production of IL-1β in THP-1. C. coli 76339 infected THP-
1 cells induced IL-1β release at high level in comparison to C. coli RM1875 
infected THP-1 cells, which might be either due to the occurrence of sialylated 
LOS in C. coli 76339 or both Caspase-1 dependent and Caspase-1 independent 
IL-1β inducing mechanisms in C. coli 76339. This data suggests LOS variation 
can play an important role in modulating innate immune responses mediated 
through inflammasome activation. 
 
7.2. Research Implications and Future Work 
Our understanding of the prevalence of different C. jejuni LOS locus genotypes, 
gained from this study, could be further enhanced by coupling this genetics-
based analysis with LOS structural analysis and patient clinical data. Although, 
the analysis of the extent of gene content variation in C. jejuni LOS biosynthesis 
locus can be helpful for LOS-based Campylobacter vaccine related research in 
future. For example, it might be expected that C. jejuni strains with highly 
frequent LOS types (B and C; identified in this study) exhibit phase variable LOS 
structures (Linton et al., 2000; Guerry et al., 2002; Godschalk et al., 2004) and 
therefore might represent a challenging target for LOS based vaccine 
development (Prendergast et al., 2003). A non-phase variable, recombinant LOS 
structure engineered from the phase variation lacking LOS genes (specifically of 
highly frequent LOS locus types A, B and C), may be predicted to be good 
candidates for a Campylobacter vaccine. 
A limitation of this work is that most of the C. jejuni sequences collected were 
draft sequences from the GenBank database and may not be completely 
accurate. However, read depth coverage for most samples was >20X. In 
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addition, most of the strain sequences that have been deposited in the online 
repository were from Canada, UK or USA, and so may reflect a bias that is 
different from the overall global frequency of LOS classes/types. Further, the 
Galaxy pipeline used in this study extracted a 50KB sequence coordinate from 
the WG sequence (predict to contain LOS sequence), but for some sequences it 
could not isolate the correct 50Kb window and this is the area of the pipeline that 
needs improving. 
The rpsL based mutagenesis strategy used in the current study is complicated, 
at least for constructing the multiple gene mutation bearing mutants, as single-
nucleotide polymorphisms in rpsL genes can change the bacterial phenotype for 
streptomycin action and therefore, are likely to increase the occurrence of false 
positive results. Additionally, double-crossover events can occur between the 
plasmid and genomic rpsL genes, which can further exacerbate off-target 
mutations. Although, defined mutants with single gene deletions can be 
constructed feasibly using this strategy (Hendrixson et al., 2001). Single phase 
variation in an individual Campylobacter gene affects its phenotype enormously 
(Gilbert et al., 2002; Godschalk et al., 2004) and therefore, phenotypic 
characterisation of a Campylobacter mutant having mutation in multiple genes 
can be very complex. In the current study, an integration of a foreign plasmid 
DNA sequence into the chromosomal DNA of C. coli RM1875 was observed, 
which might be a consequence of illegitimate recombination (Richardson and 
Park, 1997). In addition, integration may be associated with the gain of antibiotic 
resistance in C. coli. A putative link between the rate of illegitimate recombination 
and gain of antibiotic resistance in C. coli can be investigated in future studies.  
This study has established a link between LOS and THP-1 induced IL-1β 
production. However, it remains unknown which LOS structural components are 
actually responsible for the increase in IL-1β induction and whether 
Campylobacter-induced cell damage during infection facilitates this. The LOS-
induced IL-1β secretion can be further investigated in other engineered NLRP3 
or Caspase-1 deficient THP-1 cell lines. The Capase-1 independent IL-1β 
induction in THP-1 cells upon infection with C. coli 76339 might be due to 
increase in expression of proteases and other pro IL-1β processing enzymes 
during this infection, which also requires further investigation. 
 227 
 
7.3. Final Conclusion 
This work extends our understanding of the C. jejuni LOS locus classification 
system, validates the potential for a bioinformatic approach to the classification 
of C. jejuni LOS locus types, and provides an overview of C. jejuni and C. coli 
LOS loci class frequencies in a worldwide database of C. jejuni and C. coli. C. 
jejuni strains having ABC LOS loci or potential to produce and modulate the 
human ganglioside-mimicking sialylated LOS structures continue to be the most 
prevalent in the online database and amongst our clinical isolates, demonstrating 
the significance of LOS in multifactorial pathogenesis of Campylobacter. This 
study also highlighted that environmental niches are a major reservoir of C. coli, 
unlike C. jejuni, whose major reservoir is in chickens. This work elucidated that 
the extent of NLRP3 dependent Caspase-1 and IL-1β induction from THP-1 cells 
alters with variation in LOS structures and demonstrated for the first time that 
purified LOS from both C. jejuni and C. coli can induce IL-1β, indicating the 
importance of LOS in the stimulation of host innate immune responses. 
Comprehensively, this work has extended our understanding of the 
Campylobacter LOS locus classification system and determined that LOS plays 
an important role in the development of host immune response during 
Campylobacter infection.  
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Appendix-I 
Table 1:  Primers for the identification of C. jejuni LOS locus classes (Classes 
given in brackets in the last column were detectable also with respective primers). 
Primer Name         Primer Properties     Target Genes Amplicon Size (bps) Class Specificity 
 
Control Primers     
1   Forward Primer: TGGGAGCAAGCCTTATCG  
  Reverse Primer:  TCCCAAGGTCTTTTTTTAATC 
          waaM       184               All 
 
 
 
 
 
 
 
 
2                 Forward Primer: TCATATCTTCCATTTGGATTAAATT 
Reverse Primer:  AAAGGCATTTTTGCTGGTC 
      waaV                   205-220                         All 
 
 
 
 
 
 
 
First Set of primers for Group 1 (Classes A, B, C, V, R, & M) 
 
Primer Name         Primer Properties     Target Genes   Amplicon Size (bps) Class Specificity 
 
A1 Forward Primer: AGCTTCTCTTGAAAGCATATTG  
Reverse Primer: ACAGGATGAAGTTGATTTAGTG  
 cgtA &  cgtB       1301                     A1 
 
 
 
 
 
 
 
 
A2 Forward Primer: ATTGCCTGCTATTCAAAGAG 
Reverse Primer:  AGGCTGTTGGTTTAATATCG 
  cgtA & cgtB      1090                            A2 
 
 
 
 
 
 
 
 
B1 Forward Primer: CCAGCTGCCTTAACTCCTTC 
Reverse Primer:  TCCTAGGGCTATGGCTACTG 
  cgtB & cst-II   764                B1 
 
 
 
 
 
 
 
 
B2 Forward Primer: TTAACAAGCACTTCATTCTTAG 
Reverse Primer:  TATAGCAAGGGCAATAGAAAG 
cgtA & cgtB    640 
 
                 B2 
 
 
 
 
 
%GC= 55                      GC clamp= 2 
Dimers= 3                     3’ Dimers= 2 
Stability= 1.8                 Tm= 56oC 
Runs= 3                        Repeats= none 
Hairpins = none 
Annealing temperature= 50 oC 
%GC= 33                         GC clamp= 1 
Dimers= 4                        3’ Dimers= 1 
Stability= 2.7                    Tm= 52oC 
 Runs= 7                           Repeats= 3 
Hairpins= none 
Annealing temperature= 50 oC 
%GC= 42                       GC clamp= 1 
Dimers= 3                      3’ Dimers= 1 
Stability= 0.7                  Tm= 52.4 oC 
Runs= 5                          Repeats= 2 
Hairpins= none 
Annealing temperature= 50 oC 
%GC= 24                      GC clamp= 0 
Dimers= 4                     3’ Dimers= 4 
Stability= 1.7                 Tm= 53.1 oC 
Runs= 3                        Repeats= 2 
Hairpins= none 
Annealing temperature= 50 oC 
%GC= 31                     GC clamp= 1 
Dimers=4                     3’ Dimers=2 
Stability=2.2                 Tm=56 oC 
Runs=2                        Repeats=none 
Hairpins= none 
Annealing temperature= 54.4oC 
%GC= 55                     GC clamp= 1 
Dimers= 6                    3’ Dimers= 1 
Stability= 1.6                Tm= 62 oC 
Runs= 2                       Repeats= none 
Hairpins= none 
Annealing temperature=54.4 oC 
%GC= 52                    GC clamp= 2 
Dimers= 2                   3’ Dimers= 1 
Stability= 3.3               Tm= 61 oC 
Runs= 3                      Repeats= none 
Hairpins= none 
Annealing temperature= 47.9 oC 
%GC= 35                    GC clamp= 2 
Dimers= 4                   3’ Dimers= 1 
Stability= 1.9               Tm= 55 oC 
Runs= 3                      Repeats= none 
Hairpins= none 
Annealing temperature= 47.9 oC 
%GC= 40                    GC clamp= 1 
Dimers= 3                   3’ Dimers= 2 
Stability= 1.9               Tm= 53.2 oC 
Runs= 3                      Repeats= 2 
Hairpins= none 
Annealing temperature= 48.2 oC 
%GC= 40                       GC clamp= 2 
Dimers= 4                      3’ Dimers= 2 
Stability= 1.9                  Tm= 53.2 oC 
 Runs= 3                        Repeats= 2 
Hairpins= none 
Annealing temperature= 48.2 oC 
%GC= 36                     GC clamp= 1 
Dimers= 2                    3’ Dimers= 2 
Stability= 1.3                Tm= 54.7 oC 
Runs= 3                       Repeats= none 
Hairpins= none 
Annealing temperature= 49.7 oC 
%GC= 36                    GC clamp= 1 
Dimers= 4                   3’ Dimers= 2 
Stability= 3.3               Tm= 54.7 oC 
Runs= 3                      Repeats= 2 
Hairpins= none 
Annealing temperature= 49.7 oC 
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C Forward Primer: GCTGCTGCTATAGTAGGAAG 
Reverse Primer:  AAATCAAAAAAACCTTTATGCTTTTC 
  neuC1 & neuA1        931                  C or V 
 
 
 
 
 
 
 
 
M Forward Primer: AGACGCTTTGCAAGTTATAATG 
Reverse Primer:  TGATGGAAGTAGCGATAATAG 
waaM & Orf51 1149               
 
              M             
 
 
 
 
 
R Forward Primer: ATAAGCAATCTTCCGAATTCAC 
Reverse Primer:  TGTTTAAGTTATGGCGAAGATG 
cj1145c & waaV         729                      R 
 
 
 
Second Set of primers for Group 2 (Classes E, H, O, P, & W) 
 
Primer Name         Primer Properties     Target Genes   Amplicon Size (bps) Class Specificity 
 
EHOP Forward Primer: TTCAAGAGCGTCCAGAAG 
Reverse Primer: CGTGAGTTCCTGTGTCAATC 
               Orf22             453 
     
  E, H, O, P 
 
 
 
 
 
 
 
 
 
26EO Forward Primer: TTGCCGTTAATTCATTACAG 
Reverse Primer:  ATGTCGCATTTATACCTTTG 
    Orf26 & Orf27 1017  E, O 
 
 
 
 
 
 
 
 
28EP Forward Primer: TCAGGTAGAGATGCATTTAG 
Reverse Primer:  CGCCTATGCAATGTTTAACC 
       Orf28 & Orf29           713 
     
  E, P 
 
 
 
 
 
 
 
 
 
26’HP Forward Primer: AAAGCAAAGAGAATGGATTAG 
Reverse Primer:  ATGTCGCATTTATACCTTTG 
Orf26 & Orf27     904        H, P 
 
 
 
 
 
 
%GC= 23                    GC clamp= 1 
Dimers= 4                   3’ Dimers= 1 
Stability= 1.2               Tm= 53.8 oC 
Runs= 7                      Repeats= 3 
Hairpins= none 
Annealing temperature= 55 oC 
%GC= 50                   GC clamp= 1 
Dimers= 6                  3’ Dimers= 2 
Stability= 1.6              Tm= 57.3 oC 
Runs= 2                     Repeats= 2 
Hairpins= none 
Annealing temperature= 55 oC 
%GC= 36                     GC clamp= 1 
Dimers= 4                    3’ Dimers= 1 
Stability= 2.6                Tm= 54.7 oC 
Runs= 3                        Repeats= none 
Hairpins= none 
Annealing temperature=49.7 oC 
%GC= 36                    GC clamp= 1 
Dimers= 6                   3’ Dimers= 1 
Stability= 1.4               Tm= 54.7oC 
Runs= 2                      Repeats= none 
Hairpins= none 
Annealing temperature= 49.7 oC 
%GC= 36                    GC clamp= 1 
Dimers= 6                   3’ Dimers= 2 
Stability= 3.0               Tm= 54.7 oC 
Runs= 3                      Repeats= 2 
Hairpins= none 
Annealing temperature=49 oC 
%GC= 38                    GC clamp= 1 
Dimers= 2                   3’ Dimers= 1 
Stability= 3.1               Tm= 54 oC  
Runs= 2                      Repeats= none 
Hairpins= none 
Annealing temperature=49 oC 
%GC= 35                    GC clamp= 1 
Dimers= 4                    3’ Dimers= 2 
Stability= 2.2               Tm= 51.1 oC 
Runs= 3                       Repeats= 2 
Hairpins= none 
Annealing temperature= 60.4 oC 
%GC= 35                   GC clamp= 1 
Dimers= 4                  3’ Dimers= 1 
Stability= 2.8              Tm= 51.1 oC 
Runs= 2                     Repeats= none 
Hairpins= none 
Annealing temperature= 60.4 oC 
%GC= 40                   GC clamp= 1 
Dimers= 6                  3’ Dimers= 1 
Stability= 2.2              Tm= 53.2 oC 
Runs= 3                     Repeats= 2 
Hairpins= none 
Annealing temperature= 57.4 oC 
%GC= 45                     GC clamp= 2 
Dimers= 4                    3’ Dimers= 1 
Stability= 2.5                Tm= 55.3 oC 
Runs= 3                       Repeats= none 
Hairpins= none 
Annealing temperature= 57.4 oC 
%GC= 35                    GC clamp= 1 
Dimers= 4                    3’ Dimers= 2 
Stability= 2.2               Tm= 51.1 oC 
Runs= 3                       Repeats= 2 
Hairpins= none 
Annealing temperature= 59.9 oC 
%GC= 33                   GC clamp= 1 
Dimers= 3                  3’ Dimers= 1 
Stability= 2.2              Tm= 52 oC 
Runs= 3                      Repeats= 2 
Hairpins= none 
Annealing temperature= 59.9 oC 
%GC= 50                    GC clamp= 1 
Dimers= 3                   3’ Dimers= 1 
Stability= 2.1               Tm= 53.7 oC 
Runs= 2                       Repeats= 2 
Hairpins= none 
Annealing temperature= 48.7 oC 
%GC= 50                   GC clamp= 1 
Dimers= 3                  3’ Dimers= 2 
Stability= 2.5              Tm= 57.3 oC 
Runs= 2                     Repeats= 2 
Hairpins= none 
Annealing temperature= 48.7 oC 
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W 
 
Forward Primer: GCTTTGGGCTTATGAGAGTG 
Reverse Primer:  GGCGAACAACTACACCCTATAC 
Orf53 & Orf54      1502            W 
 
 
 
 
 
 
 
 
Third Set of primers for Group 3 (Classes D, K, Q, N, F, I,  J, & S) 
 
Primer Name         Primer Properties     Target Genes   Amplicon Size (bps) Class Specificity 
  
D Forward Primer: TGGTTGGTGGCCTGATTATG 
Reverse Primer:  CAATGCTTGGAATGGTATAG 
Orf3 & Orf17 1221     D, (I) 
 
 
 
 
 
 
 
 
 
  F 
 
Forward Primer: ATATCAAGATCCACCCATAC 
Reverse Primer: CTCGATGCTTGTGAAATAAC 
   Orf 16 & waaV  886                                 
 
F, (D)
 
 
 
  
 
 
 
 
 
 
IS   Forward Primer: GCAAATGGGAAATCTTGATAGG 
 Reverse Primer:  GGCCCTCAGATAAACTACCC 
              Orf41 & Orf42     973   I, S 
 
 
 
 
 
 
 
 
J Forward Primer: TCATCAATACGCTTTAAATTCC 
Reverse Primer: GGCCCTCAGATAAACTACCC 
     Orf40 & Orf42            1206                    J 
 
 
 
 
K  Forward Primer: ACATAATACTCCTTGCAATC 
Reverse Primer:  TCCCAAGAATCTATAATATCAG 
                    Orf49 & waaV             3118          K 
 
 
 
 
 
 
%GC= 31                     GC clamp= 1 
Dimers= 4                     3’ Dimers= 2 
Stability= 1.5                Tm= 52.8 oC 
 Runs= 3                       Repeats= 2 
Annealing temperature=51.7 oC 
%GC= 35                   GC clamp= 1 
Dimers= 6                   3’ Dimers= 2 
Stability= 1.2              Tm= 51.1 oC 
Runs= 2                     Repeats= none 
Hairpins= none 
Annealing temperature=46.1 oC 
%GC= 40                  GC clamp= 1 
Dimers= 4                 3’ Dimers= 2 
Stability= 2.0             Tm= 53.2 oC 
 Runs= 3                   Repeats= 2 
Hairpins= none 
Annealing temperature= 51.5 oC 
%GC= 40                     GC clamp= 1 
Dimers= 4                     3’ Dimers= 1 
Stability= 2.2                Tm= 53.2 oC 
Runs= 3                       Repeats= 2 
Hairpins= none 
Annealing temperature= 51.5 oC 
%GC= 50                   GC clamp= 1 
Dimers= 4                  3’ Dimers= 1 
Stability= 3.4              Tm= 57.3 oC 
Runs= 2                     Repeats= none 
Hairpins= none 
Annealing temperature= 48.2 oC 
%GC= 40                  GC clamp= 1 
Dimers= 4                  3’ Dimers= 2 
Stability= 2.6             Tm= 53.2 oC 
 Runs= 2                    Repeats= 2 
Hairpins= none 
Annealing temperature= 48.2 oC 
%GC= 40                   GC clamp= 2 
Dimers= 3                   3’ Dimers= 1                        
Stability= 1.8              Tm= 56.5 oC 
Runs= 3                     Repeats= none 
Hairpins= none 
Annealing temperature= 51.5 oC 
%GC= 55                  GC clamp= 3 
Dimers= 4                  3’ Dimers= 1 
Stability= 2.0             Tm= 59.4 oC 
Runs= 3                    Repeats= none 
Hairpins= none 
Annealing temperature= 51.5 oC 
%GC= 50                   GC clamp= 1 
Dimers= 2                  3’ Dimers= 1 
Stability= 1.9              Tm= 57.3 oC 
Runs= 3                     Repeats= 2 
Hairpins= none 
Annealing temperature=55 oC 
%GC=50                   GC clamp=1 
Dimers=4                  3’ Dimers=1 
Stability=3.8              Tm=60.3 oC 
Runs=3                      Repeats=2 
Hairpins= none 
Annealing temperature=55 oC 
%GC= 55                   GC clamp= 3 
Dimers= 4                  3’ Dimers= 1 
Stability= 2.0              Tm= 59.4 oC 
 Runs= 3                     Repeats= none 
Annealing temperature=51.7 oC 
%GC= 31                  GC clamp= 2 
Dimers= 6                  3’ Dimers= 1 
Stability= 1.9             Tm= 52.8 oC 
Runs= 3                     Repeats= none 
Hairpins= none 
Annealing temperature=47.8 oC 
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Q Forward Primer: TGTTGCTAATTTGGCTAATTC 
Reverse Primer:  AAACGGGATTTATGGTAGTTTG 
        Orf46 & Orf16 1130                        Q 
 
 
 
 
N Forward Primer: GCACCAACTCCCAAATGTC 
Reverse Primer:  GAAAGCAGCGATGATACCC 
   Orf38 & waaV           1253               N 
 
 
 
 
 
 
 
Fourth Set of primers for Group 4 (Classes G, L, T, & U) 
 
Primer Name         Primer Properties     Target Genes   Amplicon Size (bps) Class Specificity 
 
 
G Forward Primer: TCTGATTGATACAACTTTCTATT 
Reverse Primer:  AAGATGCAAATGAAATCATACC 
 Orf37 & Orf16 776    G 
 
 
 
 
 
 
 
 
 
 
T   Forward Primer: TTGGCAAGATGATTGAAATTTTAGG 
Reverse Primer:  TTGTGAAATAGCGTTTAAAGAG 
            Orf37 & waaV  1773 
     
 T, (G, U) 
 
 
 
 
 
 
 
 
U Forward Primer: TATTCTTTGCTGCCAACC 
Reverse Primer: TTGTGAAATAGCGTTTAAAGAG 
 Orf38 & waaV 1499 U, (G) 
 
 
 
 
 
 
 
 
 
L   Forward Primer: TTTGCTTCTTCTATAAGTAATTTTC 
Reverse Primer:  TTGTGAAATAGCGTTTAAAGAG 
    Orf16 & waaV     1027         L, (F)* 
 
 
 
 
 
 
 
 
 
 
 
                                       
%GC= 52                     GC clamp= 3 
Dimers= 2                    3’ Dimers= 1 
Stability= 1.3               Tm= 56.7 oC 
Runs= 3                      Repeats= none 
Hairpins= none 
Annealing temperature=51.7 oC 
%GC= 52                  GC clamp= 1 
Dimers= 2                 3’ Dimers= 1 
Stability= 1.9             Tm= 56.7 oC 
Runs= 3                    Repeats= none 
Hairpins= none 
Annealing temperature=51.7 oC 
%GC= 33                  GC clamp= 1 
Dimers= 4                 3’ Dimers= 1 
Stability= 2.6             Tm= 52 oC 
Runs= 3                    Repeats= none 
Hairpins= none 
Annealing temperature=47 oC 
%GC= 36                     GC clamp= 1 
Dimers= 4                    3’ Dimers= 1 
Stability= 2.4                Tm= 54.7 oC 
Runs= 3                       Repeats=none 
Hairpins= none 
Annealing temperature=47 oC 
%GC= 31                     GC clamp= 2 
Dimers= 4                    3’ Dimers= 1 
Stability= 1.3                Tm= 57 oC 
Runs= 3                       Repeats= none 
Hairpins= none 
Annealing temperature= 50.5 oC 
%GC= 26                 GC clamp= 0 
Dimers= 3                3’ Dimers= 2 
Stability= 1.6           Tm= 55 oC 
Runs= 3                   Repeats= none 
Hairpins= none 
Annealing temperature= 50.5 oC 
%GC= 31                     GC clamp= 1 
Dimers= 6                     3’ Dimers= 1 
Stability= 2.1                Tm= 57 oC 
Runs= 3                       Repeats= 2 
Hairpins= none 
Annealing temperature= 47.8 oC 
%GC= 24                GC clamp= 1 
Dimers= 4                3’ Dimers= 1 
Stability= 1.6           Tm= 55 oC 
Runs= 4                   Repeats= 2 
Hairpins= none 
Annealing temperature= 47.8 oC 
%GC= 31                    GC clamp= 1 
Dimers= 6                    3’ Dimers= 1 
Stability= 2.1               Tm= 52.8 oC 
Runs= 3                       Repeats= 2 
Hairpins= none 
Annealing temperature= 47 oC 
%GC= 32                 GC clamp= 2 
Dimers= 6                3’ Dimers= 1 
Stability= 2.2           Tm= 56.4 oC 
Runs= 4                   Repeats= 2 
Hairpins= none 
Annealing temperature= 47 oC 
%GC= 31                     GC clamp= 1 
Dimers= 6                    3’ Dimers= 1 
Stability= 2.1                Tm= 52.8 oC 
Runs= 3                       Repeats= 2 
Hairpins= none 
Annealing temperature= 46.5 oC 
%GC= 44                 GC clamp= 2 
Dimers= 3                3’ Dimers= 1 
Stability= 1.3            Tm= 51.4 oC 
Runs= 3                   Repeats= none 
Hairpins= none 
Annealing temperature= 46.5 oC 
*- Classes F and L share ORF16 and waaV, 
therefore Primer L was found to be positive for 
both class F and L associated strains. 
However, it does not bind to the class F 
reference strain, RM1221. 
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                  Table 2:  Primers used for generating deletion in C. coli RM1875 and motility assay  
 
 
 
 
 
 
 
 
 
 
Primer 
 
Primer Sequence (5’-3’) 
pUC-F CTGCAAGGCGATTAAGTTGG 
pUC-R TTATGCTTCCGGCTCGTATG 
rpsL-F AACAATGCTGTGTTCTTGTAGG 
rpsL-R AAGGAATTATTGTGCCTACC 
S1-F CCCGAGCTCTAGTGGTACGAGGCTTTATC 
S1-R CCGCTCGAGGCTTTGCGCGATCTAAC 
S2-F CCGCTCGAGTAAATCTTATTGGCGCTTGC 
S2-R CGTGGTACCGAACTGTAGGCATAGTAATCCC 
cat-F TCTATGATACCGTGGACAAG 
cat-R CACTAATGCAGGTGATTTGG 
SS2-F GATACAGGTACGCATGACAG 
SS2-R GCTTTAGAGGTTGGGTCAAGAG 
210-F CCGCTCGAGAATGATACATAAAATGTCAGATGTGCAAAG 
210-R CGCGCGTGGTACCTCTAAAAAACTTTTAATATTTTACAATAATAAG 
flaA-F CCAATGTCGGCTCTGATTTG 
flaA-R GCGCAGGAAGTGGATTTTC 
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                                  Appendix-II 
Table 1: LOS types of C. jejuni complete (n=125) and draft sequences (n=597) 
Complete sequences: LOS Group 1; Classes A1, A2, B1, B2, C & V  
No. C. jejuni Strain Accession no. 51 17 14 15 5 6 7 8 9 5-II 10 11 Class Host, Country 
1 00-6200 NZ_CP010307.1     99/100 99/100 100/100 99/100 97/100  98/100 99/100 A2 Human, Canada 
2 RM3196 NZ_CP012690.1     99/100 99/100 97/100 99/100 98/100  98/100 99/100 A1 Human, South Africa  
3 
 
RM3197 NZ_CP012689.1             A1 Human, South Africa 
4 RM3420 NZ_CP017456.1     99/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Human, Canada 
5 00-1597 NZ_CP010306.1     99/98 99/100 91/100 98/100 98/99  97/100 95/100 A2 Human, Canada  
6 HF5-4A-4 NZ_CP007188.1     100/100 99/100 100/100 100/100 100/100  100/100 100/100 A1 Farm, UK 
7 FDAARGOS_262  NZ_CP022076.1     99/100 96/100 96/100 98/100 98/99  98/100 97/100 A2 Bovine, US 
8 TS1218  NZ_CP017860.1     99/100 99/100 99/100 98/100 99/99  97/100 98/99 A1 Chicken, US 
 
9 32488 NC_021834.1     99/100 99/100 95/100 97/100 97/100  97/100 95/100 A2 WITH 
DOBLE Orf 
neuA1 
Human, US 
10 M129 NZ_CP007749.1     99/100 99/100 95/100 97/100 98/99  97/100 95/100 A2 Human, US 
11 FDAARGOS_422 NZ_CP023867.1     99/100 99/100 97/100 99/100 98/100  98/100 99/100 A1 Human, US 
12 MTVDSCj13 NZ_CP017032.1     98/100 99/100 99/100 98/100 98/100 99/100 98/100 98/100 B2 Chicken, US 
13 RM3194  NZ_CP014344.1     98/100 99/100 99/100 98/100 98/100 99/100 98/100 98/100 B2 Human, South Africa 
14 MTVDSCj16  NZ_CP017033.1     96/95    98/100 99/100  97/100 B1 Chicken, US 
15 NCTC11351 NZ_LN831025.1     99/100 100/100 99/100 100/100 99/100 99/100 99/100 99/100 B1 Not Known 
16 FORC_046 NZ_CP017229.1     98/100 100/100 99/100 98/100 98/99  98/100 99/100 B2 Human, South Korea 
17 YH001 CP010058.1     98/100 98/100 93/100 99/100 98/100 99/100 98/100 99/100 B1 Beef, US 
18 Cj3 NZ_KK365768.1     98/100 98/100 93/100 98/100 98/100 99/100 98/100 98/100 B1 Human, Thailand 
19 FDAARGOS_265  NZ_CP022079.1      94/87 91/100 99/100 99/100 99/100 97/100 98/100 B1 Human, US 
20 81-176_G1_B0  NZ_CP022440.1     99/100 99/100 95/100 98/100 99/100 99/100 100/100 99/100 B2 Human, UK 
21 14980A NZ_CP017029.1     96/95    98/100 99/100 98/100 97/100 B1 Turkey, US 
22 11168-BN148 NC_018521.1   100/100 100/100  100/100 100/100 100/100 100/100  100/100 100/100 C Unknown, Finland 
23 00-2538 NC_022351.2   100/100 100/100  100/100 100/100 100/100 100/100  100/100 99/100 C Human, Canada 
24 00-2544 NC_022353.2   100/100 100/100  100/100 100/100 100/100 100/100  100/100 99/100 C Human, Canada 
25 00-2426 NC_022352.2   100/100 100/100  100/100 100/100 100/100 100/100  100/100 99/100 C Human, Canada 
26 00-2425 NC_022362.2   100/100 100/100  100/100 100/100 100/100 100/100  100/100 99/100 C Human, Canada 
27 NCTC 11168-K12E5 NZ_CP006685.1   100/100 100/100  99/100 100/100 100/100 100/100  100/100 99/100 C Human, Canada 
28 NCTC 11168-Kf1 NZ_CP006686.1   100/100 100/100  99/100 100/100 100/100 100/100  100/100 99/100 C Human, Canada 
29 D42a CP007751.1   100/100 100/100  100/100 100/100 100/100 100/100  100/100 99/100 C Chicken, US 
30 NCTC 11168-mcK12E5 NZ_CP006688.1   100/100 100/100  99/100 100/100 100/100 100/100  100/100 99/100 C Human, Canada 
31 NCTC 11168-GSv NZ_CP006689.1   100/100 100/100  100/100 100/100 100/100 100/100  100/100 99/100 C Human, Canada 
32 00-0949 NZ_CP010301.1   100/100 99/100  100/100 100/100 100/100 100/100  99/100 99/100 C Human, Canada 
33 WP2202 NZ_CP014742.1   100/100 100/100  99/100 100/100 100/100 100/100  99/100 99/100 C Chicken, US 
34 ZP3204 NZ_CP017856.1   100/100 100/100  99/100 100/100 100/100 100/100  99/100 99/100 C Chicken, US 
35 NS4-5-1 NZ_CP007192.1   100/100 99/100  99/100 100/100 99/100 100/100  100/100 99/100 C Farm, UK 
36 NS4-9-1 NZ_CP007193.1   100/100 99/100  100/100 100/100 99/100 100/100  100/100 99/100 C Farm, UK 
37 CFSAN032806 NZ_CP023543.1   99/100 99/100  99/100 100/100 100/100 100/100  99/100 99/100 C Chicken, US 
38 01-1512 NZ_CP010072.1   100/100 99/100  100/100 100/100 100/100 100/100  99/100 99/100 C Human, Canada 
39 RM1285 NZ_CP012696.1   100/100 100/100  99/100 100/100 100/100 100/100  99/100 99/100 C Chicken, US 
40 FDAARGOS_263 NZ_CP022077.1   100/100 100/100  100/100 100/100 100/100 100/100  100/100 100/100 C Human, US 
41 YQ2210 NZ_CP017859.1   100/100 100/100  99/100 100/100 100/100 100/100  99/100 99/100 C Turkey, US 
42 11168H/lacY NZ_CP022439.1   100/100 100/100  100/100 100/100 100/100 100/100  100/100 100/100 C Human, UK 
43 MTVDSCj07 NZ_CP017031.1   100/100 100/100  99/100 100/100 100/100 100/100  99/100 99/100 C Chicken, US 
44 YH002 NZ_CP020776.1   100/100 100/100  99/100 100/100 100/100 100/100  99/100 99/100 C Calf, US 
45 NS4-1-1 NZ_CP007191.1   100/100 99/100  100/100 100/100 99/100 100/100  100/100 99/100 C Farm, UK 
46 11168H/araE NZ_CP022559.1   100/100 100/100  100/100 100/100 100/100 100/100  100/100 99/100 C Human, UK 
47 NCTC 12664  NZ_CP028912.1   100/100 100/100  100/100 100/100 100/100 100/100  99/100 99/100 C Chicken, UK 
48 IA3902 NC_017279.1   100/100 99/100  100/100 100/100 100/100 100/100  99/100 99/100 C Sheep, US 
49 12567 NZ_CP028909.1   100/100 99/100  99/100 100/100 100/100 100/100  100/100 99/100 C Chicken, UK 
50 NCTC 12660  NZ_CP028910.1   100/100 99/100  99/100 100/100 100/100 100/100  100/100 99/100 C Chicken, UK 
51 OD267 NZ_CP014744.1   100/100   99/91 100/100 100/100 100/100  99/100 99/100 V Chicken, US 
52 PT14 NC_018709.4   100/100 100/100  99/100 100/100 100/100 100/100  99/100 99/100 C WITH ORF 
48L 
INSERTION 
Unknown, UK 
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Complete sequences: LOS Group 2; Classes P, H, E, O & W  
No. C. jejuni Strain Accession no. 21-25 26 26’ 27 28 29-34 Class Host, Country 
1 CG8421 NZ_CP005388.1 98/98  99/100 99/92 99/100 98/99 P Human, US 
2 4031 NC_022529.1 98/98  100/100 99/92 99/100 99/99 P Unknown, Finland 
3 MTVDSCj20 NZ_CP008787.1 98/100 99/100  100/100  100/100 O Chicken, US 
4 IF1100  NZ_CP017863.1 98/98  99/100 98/100  99/100 H Chicken, US 
5 RM1246-ERRC NZ_CP022470.1 98/98  100/100 99/100  99/100 H Human, US 
6 FDAARGOS_266 NZ_CP022080.1 96/100 99/100  98/92 99/100 98/99 E Unknown, US 
7 CJM1cam NZ_CP012149.1 99/85 99/100  99/99  98/100 W Human, UK 
8 CJ677CC519 NZ_CP010471.1 98/100 99/100  98/100  98/100 O Faeces, Finland 
9 CJ677CC002 NZ_CP010472.1 98/100 99/100  98/100  98/100 O Human, Finland 
10 CJ677CC534 NZ_CP010473.1 98/100 99/100  98/100  98/100 O Human, Finland 
11 CJ677CC536 NZ_CP010474.1 98/100 99/100  98/100  98/100 O Human, Finland 
12 CJ677CC073 NZ_CP010475.1 98/100 99/100  98/100  98/100 O Human, Finland 
13 CJ677CC521 NZ_CP010476.1 98/100 99/100  98/100  98/100 O Human, Finland 
14 CJ677CC526 NZ_CP010477.1 98/100 99/100  98/100  98/100 O Human, Finland 
15 CJ677CC036 NZ_CP010479.1 98/100 99/100  98/100  98/100 O Human, Finland 
16 CJ677CC524 NZ_CP010480.1 98/100 99/100  98/100  98/100 O Human, Finland 
17 CJ677CC016 NZ_CP010481.1 98/100 99/100  98/100  98/100 O Human, Finland 
18 CJ677CC041 NZ_CP010482.1 98/100 99/100  98/100  98/100 O Human, Finland 
19 CJ677CC535 NZ_CP010483.1 98/100 99/100  98/100  98/100 O Human, Finland 
20 CJ677CC092 NZ_CP010488.1 98/100 99/100  98/100  98/100 O Human, Finland 
21 CJ677CC530 NZ_CP010489.1 98/100 99/100  98/100  98/100 O Human, Finland 
22 CJ677CC532 NZ_CP010490.1 98/100 99/100  98/100  98/100 O Human, Finland 
23 CJ677CC529 NZ_CP010491.1 98/100 99/100  98/100  98/100 O Human, Finland 
24 CJ677CC531 NZ_CP010492.1 98/100 99/100  98/100  98/100 O Human, Finland 
25 CJ677CC062 NZ_CP010493.1 98/100 99/100  98/100  98/100 O Human, Finland 
26 CJ677CC059 NZ_CP010494.1 98/100 99/100  98/100  98/100 O Human, Finland 
27 CJ677CC032 NZ_CP010496.1 98/100 99/100  98/100  98/100 O Human, Finland 
28 CJ677CC033 NZ_CP010497.1 98/100 99/100  98/100  98/100 O Human, Finland 
29 CJ677CC537 NZ_CP010498.1 98/100 99/100  98/100  98/100 O Human, Finland 
30 CJ677CC542 NZ_CP010499.1 98/100 99/100  98/100  98/100 O Human, Finland 
31 CJ677CC528 NZ_CP010500.1 98/100 99/100  98/100  98/100 O Human, Finland 
32 CJ677CC538 NZ_CP010495.1 98/100 99/100  98/100  98/100 O Human, Finland 
33 CJ677CC520 NZ_CP010501.1 98/100 99/100  98/100  98/100 O Human, Finland 
34 CJ677CC014 NZ_CP010502.1 98/100 99/100  98/100  98/100 O Human, Finland 
35 CJ677CC039 NZ_CP010503.1 98/100 99/100  98/100  98/100 O Human, Finland 
36 CJ677CC085 NZ_CP010504.1 98/100 99/100  98/100  98/100 O Human, Finland 
37 CJ677CC052 NZ_CP010505.1 98/100 99/100  98/100  98/100 O Human, Finland 
38 CJ677CC527 NZ_CP010506.1 98/100 99/100  98/100  98/100 O Human, Finland 
39 CJ677CC078 NZ_CP010507.1 98/100 99/100  98/100  98/100 O Human, Finland 
40 CJ677CC523 NZ_CP010508.1 98/100 99/100  98/100  98/100 O Human, Finland 
41 CJ677CC540 NZ_CP010509.1 98/100 99/100  98/100  98/100 O Human, Finland 
42 CJ677CC040 NZ_CP010510.1 98/100 99/100  98/100  98/100 O Human, Finland 
43 CJ677CC061 NZ_CP010511.1 98/100 99/100  98/100  98/100 O Human, Finland 
44 CJ677CC539 NZ_CP010457.1 98/100 99/100  98/100  98/100 O Human, Finland 
45 CJ677CC533 NZ_CP010458.1 98/100 99/100  98/100  98/100 O Human, Finland 
46 CJ677CC047 NZ_CP010459.1 98/100 99/100  98/100  98/100 O Human, Finland 
47 CJ677CC058 NZ_CP010460.1 98/100 99/100  98/100  98/100 O Human, Finland 
48 CJ677CC013 NZ_CP010461.1 98/100 99/100  98/100  98/100 O Human, Finland 
49 CJ677CC100 NZ_CP010462.1 98/100 99/100  98/100  98/100 O Human, Finland 
50 CJ677CC522 NZ_CP010463.1 98/100 99/100  98/100  98/100 O Human, Finland 
51 CJ677CC094 NZ_CP010464.1 98/100 99/100  98/100  98/100 O Human, Finland 
52 CJ677CC008 NZ_CP010465.1 98/100 99/100  98/100  98/100 O Human, Finland 
53 CJ677CC541 NZ_CP010466.1 98/100 99/100  98/100  98/100 O Human, Finland 
54 CJ677CC024 NZ_CP010467.1 98/100 99/100  98/100  98/100 O Human, Finland 
55 CJ677CC064 NZ_CP010468.1 98/100 99/100  98/100  98/100 O Human, Finland 
56 CJ677CC525 NZ_CP010469.1 98/100 99/100  98/100  98/100 O Human, Finland 
57 CJ677CC026 NZ_CP010470.1 98/100 99/100  98/100  98/100 O Human, Finland 
58 CJ677CC034 NZ_CP010484.1 98/100 99/100  98/100  98/100 O Human, Finland 
59 CJ677CC086 NZ_CP010485.1 98/100 99/100  98/100  98/100 O Human, Finland 
60 CJ677CC095 NZ_CP010486.1 98/100 99/100  98/100  98/100 O Human, Finland 
61 CJ677CC012 NZ_CP010487.1 98/100 99/100  98/100  98/100 O Human, Finland 
62 CJ677CC010 CP010478.1 98/98 99/100  98/100  98/99 O Human, Finland 
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Complete sequences: LOS Group 3; Classes D, F & K  
No. C. jejuni Strain Accession no. 17 18 19 20  38 40 41 42-
45 
46 49-50 16 Class Host, Country 
1 R14 CP005081.1 99/100 99/100 100/100 100/100        100/100 D Unknown, UK 
2 S3 NC_017281.1  99/100 98/94 99/100 99/100         F Unknown, US 
3 ATCC 35925 NZ_CP020045.1 99/100 96/94 98/100 97/100         F Pigeon, Sweden 
4 35925 NZ_CP010906.1 99/100 96/94 98/100 97/100         F Human, Sweden 
5 FJ3124 NZ_CP017862.1 99/100  96/91          F Chicken, US 
6 NCTC12662 NZ_CP019965.1 99/100 96/94 98/100 97/100         F Unknown, UK 
7 NCTC 12661  NZ_CP028911.1 99/100 96/94 98/100 97/100         F Avian, UK 
8 FDAARGOS_421  NZ_CP023866.1 99/100 98/94 99/100 99/100         F Chicken, US 
9 F38011 NZ_CP006851.1 99/100 94/100 95/98        99/100 96/100 K Unknown, US 
10 HF5-5-1 NZ_CP007189.1 99/100 93/100 95/98        99/100 96/100 K Farm, UK 
11 HF5-7-1 NZ_CP007190.1 99/100 93/100 95/98        99/100 96/100 K Farm, UK 
 
Draft sequences: LOS Group 1; Classes A1, A2, B1, B2, C, V, M & R  
Class A1  
No. C. jejuni Strain Accession no. Contig no. 51 17 14 15 5 6 7 8 9 5-II 10 11 Class Host, Country 
1 ICDCCJ07002 APNP01000000 2     99/100 99/100 97/100 99/100 98/100  98/100 99/100 A1 Human, China 
2 HN-CJD07035 ARYE01000000 6     99/100 99/100 97/100 99/100 98/100  98/100 99/100 A1 Human, China 
3 BJ-CJD101 ARWV01000000 8     99/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Human, China 
4 CVM 41974 JAKS01000000 4,8     99/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Human, US 
5 HB-CJGB-QYT ATBM01000000 3     99/100 99/100 97/100 99/100 98/100  98/100 99/100 A1 Human, China 
6 BJ-CJGB96G25 ASXL01000000 3     99/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Human, China 
7 BJ-CJGB95377 ASXK01000000 2     99/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Human, China 
8 BJ-CJGB96114 ASXM01000000 2     99/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Human, China 
9 BJ-CJGB96299 ASXN01000000 3     99/100 99/100 97/100 99/100 98/100  98/100 99/100 A1 Human, China 
10 CF93-6 AANJ01000000 7     99/100 99/100 97/100 99/100 98/100  98/100 99/100 A1 Unknown 
11 LMG 23216 AIOA01000000 5     100/100 99/100 99/100 98/100 99/100  98/97  A1 Chicken, Belgium 
12 OXC6626 CUVM01000000 1     99/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Faeces, UK 
13 OXC6414 CUNR01000000 1     99/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Faeces, UK 
14 OXC6408 CUNK01000000   1     99/100 95/99 97/100 98/100 99/100  98/100 99/100 A1 Faeces, UK 
15 OXC6305 CUJN01000000    1     100/100 100/100 100/100 100/100 100/100  100/100 100/100 A1 Faeces, UK 
16 OXC6301 CUJJ01000000 1     100/100 100/100 100/100 100/100 100/100  100/100 100/100 A1 Faeces, UK 
17 OXC6406 CUNI01000000 1     100/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Faeces, UK 
18 OXC6535 CUSF01000000 1     100/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Faeces, UK 
19 OXC6397 CUNA01000000 1     100/100 100/100 100/100 100/100 100/100  100/100 100/100 A1 Faeces, UK 
20 OXC6534 CUSG01000000 1     100/100 100/100 100/100 100/100 99/100  100/100 100/100 A1 Faeces, UK 
21 OXC6641 CUWB01000000 1     99/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Faeces, UK 
22 OXC6494 CUQN01000000 2     100/100 99/100 100/100 100/100 100/100  100/100 100/100 A1 Faeces, UK 
23 OXC6264 CUHV01000000 2     99/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Faeces, UK 
24 OXC6482 CUPZ01000000 2     99/100 95/99 97/100 97/100 97/100  98/97  A1 Faeces, UK 
25 OXC6273 CUIF01000000 1     100/100 100/100 100/100 98/100 99/100  99/100 98/100 A1 Faeces, UK 
26 OXC6479 CUPX01000000 1     99/100 99/100 97/100 99/100 98/100  98/100 99/100 A1 Faeces, UK 
27 Faeces CZJF01000000 12     100/100 100/100 100/100 99/100 99/100  100/100 100/100 A1 Chicken, Spain 
28 Neck Skin CZJM01000000 2      100/100 100/100 99/100 100/100  100/100 100/100 A1 Chicken, Spain 
29 Faeces CZHY01000000 12     99/100 99/100 97/100 99/100 98/100  98/100 99/100 A1 Chicken, Spain 
30 BCW_6893 MJYX01000000 16     98/100 96/100 96/100  97/100  97/97  A1 Crow, US 
31 BCW_3804 MKAL01000000 41     100/100 100/100 100/100 98/100 99/100  99/100 98/100 A1 Crow, US 
32 BCW_4328 MKAN01000000           3     98/100 96/100 96/100 96/100 97/100  97/97  A1 Crow, US 
33 CDPHFDLB-F12M00560 MOVU01000000  1     99/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Cow, US 
34 CDPHFDLB-M00214 MOVP01000000  1     99/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Cow, US 
35 CDPHFDLB-M00224 MOVO01000000  9     99/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Cow, US 
36 CDPHFDLB-F12M00566-a2 MOVL01000000       7     99/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Cow, US 
37 BCW_6884 MKEW01000000     59     98/100 96/100 96/100 96/100 97/100  97/97  A1 Crow, US 
38 BCW_4324 MKET01000000   30     99/100 99/100 98/100 97/100 97/100  96/97  A1 Crow, US 
39 CJ096CC21 MLDN01000000   6     99/100 99/100 97/100 99/100 98/100  98/100 99/100 A1 Human, Finland 
40 W20 NFNM01000000 65     99/100 95/100 96/100 97/100 98/100  97/100 99/100 A1 Environment, Canada 
41 W16 NFNR01000000 35     99/100 95/100 96/100 97/100 98/100  97/100 99/100 A1 Environment, Canada 
42 Po_2 CCDE01000000 46     99/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Unknown, Finland 
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43 Ma_B CCDD01000000 55     99/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Unknown, Finland 
44 Le_204R CCDB01000000 45     99/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Unknown, Finland 
45 Ma_1 CCCZ01000000 47     99/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Unknown, Finland 
46 Le_755 CCDC01000000  21, 52     99/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Unknown, Finland 
47 Po_1 CCDA01000000 68     99/100 99/98 99/100 98/100 99/100  98/100 98/100 A1 Unknown, Finland 
48 P10-2209 JYEC01000000 5     99/100 95/99 97/100 97/100 97/100  98/97  A1 Pigeon, Japan 
49 P3-2209 JYEA01000000 1     99/100 95/99 97/100 97/100 97/100  98/97  A1 Pigeon, Japan 
50 P5-2209 JYEB01000000 6     99/100 95/99 97/100 97/100 97/100  98/97  A1 Pigeon, Japan 
51 OXC6521 CURR01000000       1, 16     100/100 100/100 100/100 99/100 100/100  100/100 100/100 A1 Faeces, UK 
52 OXC6525 CURV01000000 1     100/100 100/100 100/100 100/100 99/100  100/100 100/100 A1 Faeces, UK 
53 BCW_3797 MJVM01000000      31     100/100 100/100 100/100 98/100 99/100  99/100 98/100 A1 Crow, US 
54 BCW_3799 MJVO01000000    9     98/100 96/100 96/100 96/100 97/100  97/97  A1 Crow, US 
55 ICDCCJ07001 CP002029.1   -     99/100 99/100 97/100 99/100 98/100  98/100 99/100 A1 Unknown, China 
56 Faeces CZIN01000000       58, 64     99/100 99/100 99/100 99/100 99/100  100/100 100/100 A1 Chicken, Spain 
57 BCW_3797 MJVM01000000 31     100/100 100/100 100/100 98/100 99/100  99/100 98/100 A1 Crow, US 
58 OXC6525 CURV01000000 1     100/100 100/100 100/100 100/100 99/100  100/100 100/100 A1 Faeces, UK 
59 CVM N15870 JOVW01000000 2     99/100 95/100 96/100 97/100 98/100  98/100  A1 Turkey, US 
60 Water CZJO01000000 32     100/100 100/100 100/100 100/100 99/100  100/100 100/100 A1 Environment, Spain 
61 Meat CZJI01000000 43     100/100 100/100 100/100 100/100 100/100  100/100 100/100 A1 Chicken, Spain 
62 CDPHFDLB-F12M00560 MOVT01000000 8     99/100 99/100 99/100 98/100 99/100  98/100 98/100 A1 Cow, US 
 
Class A2 
No. C. jejuni Strain Accession no. Contig no. 51 17 14 15 5 6 7 8 9 5-II 10 11 Class Host, Country 
1 60004 AIOE01000000 20     100/100 100/100 100/100 100/100 100/100  99/100 95/100 A2 Chicken, US 
2 86605 AIOJ01000000 4     99/100 98/99 95/100 98/100 97/100  99/100 95/100 A2 Chicken, US 
3 2008-872 AIOR01000000 5, 31     99/100 99/100 100/100 99/100 97/100  98/100 99/100 A2 Human, France 
4 1997-7 AIOX01000000 1     99/100 99/100 100/100 99/100 97/100  98/100 98/100 A2 Human, US 
5 87459 AIPE01000000 35     99/100 98/99 99/100 98/100 99/100  99/100 95/100 A2 Chicken, US 
6 1798 AIPI01000000 21, 36     99/100 99/100 95/100 99/100 97/100  98/100 98/100 A2 Cow, US 
7 OXC6453 CURA01000000 1     99/100 99/100 100/100 99/100 97/100  98/100 99/100 A2 Faeces, UK 
8 OXC6306 CUJO01000000 1     99/100 99/100 100/100 99/100 97/100  98/100 99/100 A2 Faeces, UK 
9 OXC6579 CUTT01000000 1     99/100 99/100 100/100 99/100 97/100  98/100 99/100 A2 Faeces, UK 
10 OXC6346 CULG01000000 1     99/100 99/100 100/100 99/100 97/100  98/100 99/100 A2 Faeces, UK 
11 OXC6490 CUQJ01000000 1     99/100 99/100 100/100 99/100 97/100  98/100 99/100 A2 Faeces, UK 
12 OXC6468 CUPL01000000 1     99/100 99/100 96/100 98/100 98/100  97/100 95/100 A2 Faeces, UK 
13 OXC6402 CUNF01000000 1     99/100 99/100 100/100 99/100 97/100  98/100 99/100 A2 Faeces, UK 
14 OXC6570 CUTJ01000000 1     99/100 99/100 100/100 99/100 97/100  98/100 98/100 A2 Faeces, UK 
15 OXC6283 CUIN01000000 1     99/100 99/100 100/100 99/100 97/100  98/100 99/100 A2 Faeces, UK 
16 OXC6268 CUHZ01000000 1     99/100 99/100 100/100 99/100 97/100  98/100 99/100 A2 Faeces, UK 
17 OXC6505 CUQZ01000000 1     99/100 98/100 95/100 97/100 98/100  97/100 95/100 A2 Faeces, UK 
18 OXC6340 CULA01000000 1     99/98 99/100 91/100 98/100 98/100  98/100 96/100 A2 Faeces, UK 
19 Water CZJL01000000 12     99/100 99/100 100/100 99/100 97/100  98/100 98/100 A2 Environment, Spain 
20 CVM 41900 JAKC01000000 4     99/98 99/100 91/100 98/100 98/100  98/100 96/100 A2 Human, US 
21 CVM N534 JOUW01000000 7     99/98 99/100 91/100 98/100 97/99  97/100 95/100 A2 Chicken, US 
22 CCN25 FBJN01000000 28     99/98 99/100 91/100 98/100 98/100  98/100 96/100 A2 Poultry Environment, UK 
23 CVM N9016 JOVD01000000 12     99/100 99/100 93/100 98/100 97/99  98/100 97/100 A2 Chicken, US 
24 CVM N9095 JOVH01000000 4     99/98 99/100 99/100 98/100 98/100  97/100 95/100 A2 Chicken, US 
25 CDPHFDLB-F15M03173 MOTS01000000    8     99/100 99/100 100/100 98/100 98/100  98/100 98/100 A2 Cow, US 
26 CDPHFDLB-F15M03174 MPBJ01000000 2     99/100 99/100 100/100 98/100 98/100  98/100 98/100 A2 Milk, US 
27 BCW_5913 MKES01000000 74     99/100 98/100 91/100 98/100 97/100  98/100 99/100 A2 Monkey, US 
28 W33 NFNA01000000 92     99/100 98/100 98/100 98/100 97/100  98/100 99/100 A2 Environmental water, Canada 
29 W11 NFNW01000000 15     99/100 99/100 100/100 99/100 97/100  98/100 98/100 A2 Environmental water, Canada 
30 W10 NFNX01000000 25, 45     99/100 99/100 100/100 99/100 97/100  98/100 99/100 A2 Environmental water, Canada 
31 S1 NFOH01000000 16     99/100 98/100 98/100 98/100 97/100  98/100 99/100 A2 Environmental water, Canada 
32 H34 NFOO01000000 25, 189     99/100 99/100 100/100 99/100 97/100  98/100 99/87 A2 Human, Canada 
33 H22 NFPB01000000 41, 67     99/100 99/100 100/100 99/100 97/100  98/100 99/87 A2 Human, Canada 
34 H17 NFPG01000000 40, 42     99/98 99/100  98/100 98/100  98/100 96/100 A2 Human, Canada 
35 B2 NFQF01000000 41     99/100 99/100 100/100 99/100 97/100  98/100 98/100 A2 Cow, Canada 
36 OXC6589 CUUD01000000  1, 14     99/100 99/100 100/100 99/100 97/100  98/100 99/100 A2 Faeces, UK 
37 BCW_4727 MKAZ01000000 10     99/100 99/100 100/100 99/100 97/100  98/100 99/100 A2 Unknown, US 
38 CDPHFDL-F15M03174-
C2 
MOTQ01000000 2     99/100 99/100 100/100 98/100 98/100  98/100 98/100 A2 Cow Milk, US 
39 CVM N1630 JOUH01000000 20     99/100 99/100 93/100 98/100 98/100  98/100 96/100 A2 Chicken, US 
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Class B1 
No. C. jejuni Strain Accession no. Contig no. 51 17 14 15 5 6 7 8 9 5-II 10 11 Class Host, Country 
1 D2600 AGTF01000000 47     97/86 96/83 91/100 99/100 99/100 99/100 98/100 98/100 B1 Human, US 
2 Cj5 AUUK01000000 29     98/100 94/87 93/100 98/100 98/100 99/100 98/100 98/100 B1 Human, Thailand 
3 Cj2 AUUM01000000 34     98/100 97/83 94/100 99/100 98/100 99/100 99/100 99/100 B1 Human, Thailand 
4 P110B AEIO01000000 2, 3     98/100  93/81   99/36 98/100 99/100 B1 Chicken, New Zealand 
5 LMG 23210 AIPN01000000 30. 48     98/100 94/87 93/100 98/100 98/100 99/100 98/100 98/100 B1 Chicken, Belgium 
6 30286 AUUH01000000 4     98/100 94/87 93/100 98/100 98/100 99/100 98/100 98/100 B1 Human, Viet Nam 
7 OXC6640 CUWA01000000 2     98/100 94/87 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
8 OXC6554 CUSQ01000000 2     98/100 96/83 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
9 OXC6509 CURF01000000 1     97/86 96/83 91/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
10 OXC6341 CULB01000000 2     98/100 96/83 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
11 OXC6304 CUJM01000000 1     98/100 94/87 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
12 OXC6262 CUHT01000000   2     98/100 96/83 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
13 OXC6484 CUQC01000000 2     99/100 99/100  99/100 99/100 99/100 99/100 99/100 B1 Faeces, UK 
14 OXC6572 CUTL01000000 1     98/100 96/83 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
15 OXC6618 CUVD01000000 1     98/100 94/87 91/100 98/100 98/100 99/100 99/100 99/100 B1 Faeces, UK 
16 OXC6621 CUVH01000000 1     98/100 96/83 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
17 OXC6359 CULL01000000 2     98/100 94/87 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
18 OXC6475 CUPS01000000 1     98/100 96/83 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
19 OXC6560 CUSY01000000 2     98/100 94/87 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
20 OXC6352 CUNL01000000 2     98/100 96/83 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
21 OXC6528 CURZ01000000 1     97/86 95/83 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
22 OXC6584 CUTZ01000000 1     97/86 96/83 91/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
23 OXC6288 CUIT01000000 2     98/100 94/87 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
24 OXC6541 CUSN01000000 2     98/100 96/83 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
25 OXC6544 CUSS01000000 1     97/86 96/83 91/100 99/100 98/100 99/100 99/100 99/100 B1 Faeces, UK 
26 OXC6392 CUMV01000000 1     98/100 96/83 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
27 OXC6581 CUTV01000000 2     98/100 94/87 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
28 OXC6323 CUKJ01000000 1     98/100 94/87 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
29 OXC6361 CULN01000000 1     98/100 94/87 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
30 OXC6485 CUQD01000000 2     99/100 99/100 99/100 99/100 99/100 99/100 99/100 99/100 B1 Faeces, UK 
31 OXC6349 CUME01000000 2     99/100 99/100 99/100 99/100 99/100 100/100 100/100 100/100 B1 Faeces, UK 
32 OXC6455 CURX01000000 1     98/100 96/83 91/100 99/100 99/100 99/100 98/100 98/100 B1 Faeces, UK 
33 Faeces CZIA01000000 46     98/100 96/83 93/100 98/100 98/100 99/100 98/100 98/100 B1 Chicken, Spain 
34 Neck CZIG01000000 19     97/86 96/83 91/100 99/100 99/100 99/100 98/100 98/100 B1 Chicken, Spain 
35 CVM N9016 JOVD01000000 12     98/100 97/83 94/100 99/100 99/100 99/100 100/100 100/100 B1 Chicken, US 
36 CVM N9095 JOVH01000000 4     97/86 94/87 95/100 99/100 98/100 99/100 97/100 98/100 B1 Chicken, US 
37 CVM N534 JOUW01000000 7     97/86 94/87 91/100 99/100 99/100 99/100 98/100 97/100 B1 Chicken, US 
38 BCW_6910 MJZF01000000 43     99/100 99/100 99/100 99/100 99/100 99/100 100/100 100/100 B1 Faeces, US 
39 BCW_6956 MJZQ01000000        25     99/100 99/100 99/100 99/100 99/100 99/100 100/100 100/100 B1 Faeces, US 
40 BCW_5122 MKBQ01000000 34      100/22 95/100 98/100 98/100 99/100 98/100 98/100 B1 Human, US 
41 BCW_5129 MKBW01000000 47     98/100 94/87 93/100 98/100 98/100 99/100 98/100 98/100 B1 Human, US 
42 BCW_5135 MKCA01000000 47     98/100 94/87 93/100 98/100 98/100 99/100 98/100 98/100 B1 Human, US 
43 BCW_5136 MKCB01000000       17     98/100 94/87 93/100 98/100 98/100 99/100 98/100 98/100 B1 Human, US 
44 BCW_5144 MKCG01000000     48     98/100 96/83 93/100 98/100 98/100 99/100 98/100 98/100 B1 Human, US 
45 BCW_5148 MKCK01000000 36     98/100 96/83 93/100 98/100 98/100 99/100 98/100 98/100 B1 Human, US 
46 BCW_5151 MKCM01000000 53     98/100 94/87 93/100 98/100 98/100 99/100 98/100 98/100 B1 Human, US 
47 CDPHFDLB-F15M00516E1 MOUW01000000 2     99/100 99/100 100/100 99/100 99/100 100/100 100/100 100/36 B1 Environment, US 
48 BCW_5154 MKEZ01000000  31     98/100 96/83 93/100 98/100 98/100 99/100 98/100 98/100 B1 Human, US 
49 CAM970 BDRZ01000000  7     98/100 94/87 93/100 98/100 98/100 99/100 98/100 98/100 B1 Human, Japan 
50 W46 NFMN01000000 13     99/100 99/100 100/100 99/100 99/100 100/64   B1 Environmental water, 
Canada 
51 Isolate_1 NFQL01000000 23, 111     97/86 96/83 92/55   99/37 98/100 97/100 B1 Retail Chicken, canada 
52 OXC6391 CUMW01000000  1, 2     98/100 94/87 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
53 OXC6574 CUTO01000000 1     98/100 96/83 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
54 OXC6466 CUPJ01000000 2     98/100 94/87 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
55 OXC6550 CUUZ01000000 1     98/100 96/83 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
56 OXC6413 CUNQ01000000 1     97/86 94/87 91/100 99/100 99/100 99/100 97/100 98/100 B1 Faeces, UK 
57 OXC6635 CUVW01000000 2     98/100 94/87 93/100 98/100 98/100 99/100 98100 98/100 B1 Faeces, UK 
58 OXC6458 CUPA01000000 1     98/100 96/83 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
59 OXC6555 CUST01000000 1     98/100 96/83 93/100 98/100 98/100 99/100 98/100 98/100 B1 Faeces, UK 
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60 OXC6501 CUQU01000000 1     98/100 91/81 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
61 BJ-CJD120 LISM01000000 1     98/100 94/87 93/100 98/100 98/100 99/100 98/100 98/100 B1 Human, China 
62 BCW_5121 MKBP01000000      1     98/100 94/87 93/100 98/100 99/100 100/100 99/100 99/100 B1 Human, US 
63 BCW_5146 MKCI01000000 18     98/100 96/83 93/100 98/100 98/100 99/100 98/100 98/100 B1 Human, US 
64 BCW_5159 MKFE01000000 38     98/100 94/87 93/100 98/100 98/100 99/100 98/100 98/100 B1 Human, US 
65 FDAARGOS_264 NBTT01000000    2     97/86 96/83 91/100 99/100 99/100 99/100 97/100 98/100 B1 Human, US 
66 CVM 41922 JAKL01000000 27     98/100 91/81 93/100 99/100 98/100 99/100 98/100 99/100 B1 Human, US 
67 MEAT CZJD01000000 34     98/100 91/81 93/100 99/100 98/98 99/100 98/100 99/100 B1 Chicken, Spain 
68 BCW_4735 MKBD01000000 1     98/100 91/81 93/100 99/100 98/100 99/100 98/100 99/100 B1 Unknown, US 
69 BCW_4755 MKBN01000000      24     98/100 89/85 93/100 99/100 98/100 99/100 98/100  B1 Unknown, US 
70 Neck Skin CZIZ01000000 23     98/100 89/85 93/100 99/100 98/100 99/100 98/100 99/100 B1 Chicken, Spain 
71 OXC6477 CUPV01000000 4     98/100 89/85 93/100 99/100 98/100 99/100 98/100  B1 Faeces, UK 
72 OXC6430 CUOK01000000 1     98/100 89/85 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
73 OXC6454 CURN01000000 5     98/100 91/81 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
74 OXC6295 CUJC01000000 1, 54     98/100 89/85 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
75 H25 NFOY01000000 106     98/100 91/81 93/100 99/100 98/100 99/100 98/100 99/100 B1 Human, Canada 
76 C12 NFQA01000000 59, 69     98/100 91/81 93/100 99/100 98/100 99/100 98/100 99/99 B1 Faeces, Canada 
77 BCW_4749 MKBK01000000 16     98/100 91/81  99/100 98/100 99/100 98/100  B1 Unknown, US 
78 CCN443 FBHK01000000 16     98/100 89/85 93/100 99/100 98/100 99/100 98/100 99/100 B1 Poultry farm, UK 
79 Neck Skin CZIT01000000 12     98/100 89/85 93/100 99/100 98/100 99/100 98/100 99/100 B1 Chicken, Spain 
80 Faeces CZIP01000000 17     98/88 89/85 93/100 99/100 98/100 99/100 98/100 99/100 B1 Chicken, Spain 
81 Neck Skin CZHH01000000 31     98/100 89/85 93/100 99/100 98/100 99/90 98/100 99/100 B1 Chicken, Spain 
82 Faeces CZHM01000000 15     98/100 91/81 92/91 99/100 98/100 99/91 98/100 99/100 B1 Chicken, Spain 
83 Meat CZHQ01000000 44     98/100 89/85 93/100 99/100 98/100 99/92 98/100 99/100 B1 Chicken, Spain 
84 OXC6580 CUTU01000000 1     98/100 91/81 93/100 99/100 98/100 99/100 98/100  B1 Faeces, UK 
85 OXC6495 CUQO01000000 2     98/100 89/85 93/100 99/100 98/100 99/100 98/100  B1 Faeces, UK 
86 OXC6403 CUNE01000000 1     98/100 89/85 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
87 OXC6470 CUPN01000000 1     98/100 89/85 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
88 OXC6488 CUQH01000000 1     98/100 89/85 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
89 OXC6487 CUQG01000000 1     98/100 89/85 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
90 OXC6556 CUSU01000000 1     98/100 91/81 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
91 OXC6465 CUPH01000000  1     98/100 91/81 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
92 OXC6547 CUTX01000000 1     98/100 91/81 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
93 OXC6427 CUOE01000000 1     98/100 91/81 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
94 OXC6272 CUIE01000000 1     98/100 91/81 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
95 OXC6269 CUIC01000000 1     98/100 91/81 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
96 OXC6348 CULQ01000000 1     98/100 91/81 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
97 OXC6382 CUMK01000000 1     98/100 91/81 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
98 OXC6632 CUVS01000000 1     98/100 89/85 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
99 OXC6284 CUIS01000000 1     98/100 91/81 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
100 OXC6549 CUUQ01000000 1     98/100 89/85 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
101 OXC6638 CUVY01000000 1     98/100 89/85 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
102 OXC6422 CUOA01000000 1     98/100 91/81 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
103 OXC6354 CUOG01000000 1     98/100 91/81 93/100 99/100 98/100 99/100 98/100 99/100 B1 Faeces, UK 
104 OXC6462 CUPE01000000 1          99/100   B1 Faeces, UK 
105 OXC6411 CUNO01000000 1          99/100   B1 Faeces, UK 
106 OXC6389 CUMS01000000 1          99/100   B1 Faeces, UK 
107 OXC6421 CUNZ01000000 1          99/100   B1 Faeces, UK 
108 OXC6356 CULI01000000 1          99/100   B1 Faeces, UK 
109 OXC6345 CULF01000000 1          99/100   B1 Faeces, UK 
110 OXC6265 CUHW01000000 1          99/100   B1 Faeces, UK 
111 OXC6377 CUMF01000000 1          99/100   B1 Faeces, UK 
112 OXC6252 CUIL01000000 1          99/100   B1 Faeces, UK 
113 OXC6328 CUKM01000000 1          99/100   B1 Faeces, UK 
114 LMG 23218 AIOB01000000 3          99/100   B1 Chicken, Belgium 
115 ATCC 33560 AIOL01000000 51, 83      99/100    99/100   B1 Bovine, Belgium 
116 2008-988 AIOS01000000 46, 48          99/100   B1 Human, France 
117 1997-4 AIOW01000000 45, 62          99/100   B1 Human, France 
118 140-16 AIPF01000000 31, 53          99/100   B1 Human, US 
119 1893 AIPK01000000 12          99/100   B1 Cow, US 
 
Class B2 
No. C. jejuni Strain Accession no. Contig no. 51 17 14 15 5 6 7 8 9 5-II 10 11 Class Host, Country 
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1 10227 AUUI01000000 2     97/100 99/100 99/100 99/100 98/100 99/100 98/100 98/100 B2 Human, Viet Nam 
2 Cj1 AUUL01000000 1     97/100 99/100 99/100 99/100 98/100 99/100 98/100 98/100 B2 Human, Thailand 
3 129-258 AINY01000000 19, 62     99/100 99/100 99/100 100/100 100/100 100/100 100/100 99/100 B2 Bovine, US 
4 81-176-UMCW7 AZNS01000000 16     99/100 99/100 99/100 100/100 100/100 100/100 100/100 99/100 B2 Chicken, US 
5 OXC6333 CUKS01000000 1     100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 B2 Faeces, UK 
6 OXC6417 CUNU01000000 1     99/100 100/100 99/100 100/100 100/100 99/100 100/100 99/100 B2 Faeces, UK 
7 OXC6415 CUNS01000000 1     100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 B2 Faeces, UK 
8 OXC6409 CUNM01000000 2     99/100 100/100 99/100 100/100 100/100 99/100 100/100 99/100 B2 Faeces, UK 
9 OXC6569 CUTI01000000 1     98/100 100/100 99/100 100/100 99/100 99/100 100/100 99/100 B2 Faeces, UK 
10 OXC6350 CUMO01000000 1     100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 B2 Faeces, UK 
11 OXC6423 CUOC01000000 2     97/100 99/100 99/100 99/100 98/100 99/100 98/100 98/100 B2 Faeces, UK 
12 OXC6388 CUMR01000000 1     100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 B2 Faeces, UK 
13 OXC6271 CUID01000000 1     97/100 99/100 99/100 98/100 98/100  99/100 99/100 B2 Faeces, UK 
14 Neck CZJC01000000 16     99/100 100/100 99/100 100/100 100/100 100/100 100/100 99/100 B2 Chicken, Spain 
15 Meat CZJJ01000000 17     99/100 100/100 99/100 100/100 100/100 100/100 100/100 99/100 B2 Chicken, Spain 
16 BCW_6891 MJYW01000000 15     97/100 99/100 99/100 99/100 98/100 99/100 98/100 98/100 B2 Chicken, US 
17 BCW_6929 MKAU01000000     1     97/100 99/100 99/100 99/100 98/100 99/100 98/100 98/100 B2 Caprine, US 
18 BCW_5166 MKHU01000000        26     97/100 99/100   98/100 99/100 98/100 98/100 B2 Human, US 
19 CDPHFDLB-F15M00521-2 MOUT01000000 12     99/100 99/100 99/100 100/100 100/100 100/100 100/100 99/100 B2 Environment, US 
20 CDPHFDLB-F15M00592 MOUR01000000    1     99/100 99/100 99/100 100/100 100/100 100/100 100/100 99/100 B2 Cow, US 
21 CDPHFDLB-F15M00601 MOUO01000000 1     99/100 99/100 99/100 100/100 100/100 99/100 100/100 99/100 B2 Cow, US 
22 CDPHFDLB-F15M00602 MOUN01000000 1     99/100 99/100 99/100 100/100 100/100 99/100 100/100 99/100 B2 Cow, US 
23 CDPHFDLB-F15M00565-1 MOVQ01000000 2, 4     99/100 99/100 99/100 100/100 100/100 100/100 100/100 99/100 B2 Cow, US 
24 CDPHFDLB-F15M00565-3 MOVN01000000  3     99/100 99/100 99/100 100/100 100/100 100/100 100/100 99/100 B2 Cow, US 
25 BCW_5155 MKFA01000000  58     97/100 100/100 99/100 99/100 98/100 99/100 98/100 98/100 B2 Human, US 
26 C3 NFPV01000000 20     97/100 99/100 99/100 99/100 98/100 99/100 98/100 98/100 B2 Faeces, Canada 
27 BCW_3803 MJVR01000000 19     98/100 100/100 99/100 100/100 100/100 100/100 100/100 99/100 B2 Crow, US 
28 BCW_4456 MKAI01000000 29     97/100 - 94/100 98/100 97/100 99/100 98/100 99/100 B2 Faeces, US 
29 BCW_4734 MKBC01000000 18, 20     100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 B2 Unknown, US 
30 BCW_5170 MKHW01000000    36     97/100 99/100 99/100 99/100  99/100 98/100 98/100 B2 Human, US 
31 Faeces CZJE01000000 14     99/100 100/100 99/100 100/100 100/100 100/91 100/100 99/100 B2 Chicken, Spain 
32 OXC6512 CURH01000000 3, 4     99/100 100/100 99/100 100/100 100/100 100/100 100/100 99/100 B2 Faeces, UK 
 
Class C 
No. C. jejuni Strain Accession no. Contig no. 51 17 14 15 5 6 7 8 9 5-II 10 11 Class Host, Country 
1 FDAARGOS_263 CP022077.1    100/100 100/100  100/100 100/100 99/100 100/100  100/100 100/100 C Human, US 
2 6399 CAFT01000000 19, 22   100/100 99/100     100/17  100/100 99/100 C Unknown, 
Germany 
3 OXC6532 CUSD01000000 1   100/100 99/100  100/100 100/100  100/100  99/100 99/100 C Faeces, UK 
4 OXC6633 CUVT01000000 1   100/100 99/100  99/100 100/100  100/100  100/100 99/100 C Faeces, UK 
5 OXC6508 CURD01000000 1   100/100 99/100  100/100 100/100 99/34 100/100  100/100 99/100 C Faeces, UK 
6 OXC6538 CUSK01000000 1   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
7 OXC6257 CUKO01000000 1   100/100 99/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
8 OXC6573 CUTN01000000 1   100/100 99/100  99/100 100/100  100/100  100/100 99/100 C Faeces, UK 
9 OXC6625 CUVL01000000 1   100/100 99/100  100/100 100/100  100/100  100/100 99/100 C Faeces, UK 
10 OXC6516 CURM01000000 1   100/100 99/100  99/100   100/100  100/100 99/100 C Faeces, UK 
11 G113 AQPK01000000 8   100/100 100/100  99/100 100/100  100/100  100/100 99/100 C Unknown 
12 G1 JRLT01000000 1   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Human, UK 
13 OXC6564 CUTD01000000 1   100/100 99/100  99/100 100/100  99/100  100/100 99/100 C Faeces, UK 
14 OXC6543 CUSR01000000 1   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
15 OXC6527 CURY01000000   1   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
16 OXC6387 CUMQ01000000   1   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
17 OXC6266 CUHX01000000    1   100/100 100/100  100/100 100/100  100/100  99/100 99/100 C Faeces, UK 
18 OXC6590 CUUC01000000 1   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
19 OXC6522 CURS01000000 1   100/100 99/100  99/100   100/100  99/100 99/100 C Faeces, UK 
20 OXC6636 CTRT01000000 1   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
21 OXC6615 CUVC01000000 1   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
22 OXC6449 CUPU01000000 1   100/100 100/100  99/100 99/100  100/100  99/100 99/100 C Faeces, UK 
23 OXC6429 CUOI01000000 1   100/100 99/100  100/100 100/100  100/100  99/100 99/100 C Faeces, UK 
24 OXC6394 CUMU01000000 1   100/100 100/100  100/100 100/100  100/100  99/100 99/100 C Faeces, UK 
25 OXC6456 CUSI01000000 2   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
26 OXC6303 CUJL01000000 1   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
27 OXC6539 CUSL01000000 1   100/100 99/100  99/100 100/100  100/100  100/100 99/100 C Faeces, UK 
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28 OXC6602 CUUP01000000 1   100/100 99/100  100/100 100/100  100/100  100/100 99/100 C Faeces, UK 
29 OXC6370 CULX01000000 1   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
30 OXC6553 CUSP01000000 1   100/100 99/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
31 OXC6464 CUPG01000000 1   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
32 OXC6530 CUSB01000000 1   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
33 OXC6563 CUTC01000000 1   100/100 99/100  99/100 100/100  100/100  100/100 99/100 C Faeces, UK 
34 OXC6629 CUVP01000000 1   100/100 99/100  100/100 100/100  100/100  100/100 99/100 C Faeces, UK 
35 OXC6603 CUUR01000000 1   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
36 OXC6500 CUQV01000000 2   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
37 OXC6571 CUTK01000000 1   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
38 OXC6251 CUIA01000000 1   100/100 99/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
39 OXC6292 CUIZ01000000 1   100/100 100/100  100/100 100/100  100/100  99/100 99/100 C Faeces, UK 
40 OXC6565 CUTE01000000 1   100/100 100/100  99/100 100/100  99/100  99/100 99/100 C Faeces, UK 
41 OXC6524 CURU01000000 1   100/100 100/100  100/100 100/100  100/100  99/100 99/100 C Faeces, UK 
42 OXC6282 CUIP01000000 1   100/100 99/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK  
43 OXC6600 CUUN01000000 1   100/100 100/100  99/100 100/100  99/100  99/100 99/100 C Faeces, UK 
44 OXC6277 CUIJ01000000 1   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
45 OXC6616 CUVB01000000 1   100/100 99/100  99/100 100/100  99/100  100/100 99/100 C Faeces, UK 
46 OXC6310 CUJT01000000 1   100/100 99/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
47 CVM 41943 JAKQ01000000        3   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Human, US 
48 CDPHFDLB-F15M00600 MOUP01000000 1   100/100 100/100  100/100 99/100  100/100  99/100 99/100 C Cow, US 
49 CDPHFDLB-F15M01862-D MOUA01000000  1   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Goat Milk, US 
50 CDPHFDLB-F15M01873-A MOTZ01000000  2   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Goat Milk, US 
51 CJ003CC21 MLDJ01000000 6   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Human, Finland 
52 CJ070CC21 MLDM01000000 5   100/100 100/100  100/100 100/100 99/39 100/100  99/100 99/100 C Human, Finland 
53 CJ035CC21 MLDL01000000      6   100/100 100/100  100/100 100/100  100/100  99/100 99/100 C Human, Finland 
54 CJ507CC21 MLDP01000000     3   100/100 99/100  99/100 100/100 99/85 100/100  99/100 99/100 C Human, Finland 
55 CJ069CC21 MLDQ01000000  8   100/100 99/100  100/100 100/100  100/100  99/100 99/100 C Human, Finland 
56 CJ502CC21 MLDU01000000  1   100/100 100/100  99/100 100/100  100/100  99/100 100/100 C Human, Finland 
57 CJ503CC21 MLDV01000000  1   100/100 100/100  99/100 100/100  100/100  99/100 100/100 C Human, Finland 
58 CJ506CC21 MLDY01000000  9   100/100 100/100  100/100 100/100  100/100  99/100 99/100 C Human, Finland 
59 CJ505CC21 MLDX01000000  6   100/100 99/100  99/100 100/100  100/100  99/100 99/100 C Human, Finland 
60 CJ097CC21 MLDZ01000000  1   100/100 100/100  99/100 99/100  100/100  99/100 99/100 C Human, Finland 
61 CJ504CC21 MLDW01000000  14   100/100 99/100  99/100 100/100  100/100  99/100 99/100 C Human, Finland 
62 D7331 MORJ01000000 8   100/100 99/100  99/100 100/100  100/100  99/100 99/100 C Stool, US 
63 BCW_5157 MKFC01000000 21, 47   100/100 100/100  99/100 100/100  100/100  99/100 99/100 C Human, US 
64 Water CZJK01000000 2   100/100 100/100         C Environment, Spain 
65 CDPHFDLB-F15M01909 MOTW01000000 1   100/100 100/94         C Goat, US 
66 OXC6393 CUMX01000000 1    99/100  100/100 100/100  100/100  99/100 99/100 C Faeces, UK 
67 OXC6459 CUPC01000000 1    99/100  99/100 100/100  100/100  99/100 99/100 C Faeces, UK 
68 BCW_6920 MKAC01000000 2    100/99  100/100 100/100  100/100  99/100 99/100 C Bovine, US 
69 BCW_6922 MKAE01000000 4    99/99  99/100 100/100  100/100  99/100 99/100 C Ovine, US 
70 BCW_6925 MKAG01000000 7    99/99  99/100 100/100  100/100  99/100 99/100 C Ovine, US 
71 BCW_6933 MKIB01000000 18    100/99  100/100 100/100  100/100  99/100 99/100 C Sheep, US 
72 BCW_6931 MKIC01000000      5    100/99  99/100 100/100  100/100  99/100 99/100 C Sheep, US 
73 BCW_6932 MKID01000000 33    100/99  99/100 100/100  100/100  99/100 99/100 C Sheep, US 
74 11168H FPEE01000000    36, 37    99/100  100/100 100/100  100/100  100/100  C Laboratory, UK 
75 OXC6392 CUKN01000000     1, 17    99/100  100/100 100/100  100/100  99/100 100/100 C Faeces, UK 
76 OXC6519 CURQ01000000 1, 19    99/100  99/100 100/100  100/100  100/100 99/100 C Faeces, UK 
77 BCW_6924 MKAF01000000      16, 20    100/99  99/100 100/100  100/100  99/100 97/100 C Ovine, US 
78 BCW_6934 MKIA01000000 1, 19    99/99  99/100 100/100  100/100  99/100  C Goat, US 
79 BCW_5156 MKFB01000000  22, 42    100/99  99/100 100/100  100/100  99/100 99/100 C Human, US 
 
Class M 
No. C. jejuni Strain Accession no. Contig no. 51 17 14 15 5 6 7 8 9 5-II 10 11 Class Host, Country 
1 BCW_6896 MJYY01000000 34 99/36 96/100     96/100 98/100 99/100  97/100 98/99 M Crow, US 
2 BCW_4223 MJXU01000000  36, 70 95/95            M Crow, US 
3 BCW_6459 MJXH01000000 37, 84 95/95            M Crow, US 
4 BCW_6453 MJXC01000000 5, 68 99/98 96/99           M Crow, US 
 
5 OXC6561 CUSZ01000000 1 100/100 100/100     100/100 100/100 100/100  99/100 99/100 M Faeces, UK 
6 OXC6639 CUVZ01000000 1 100/100 100/100     100/100 100/100 100/100  99/100 99/100 M Faeces, UK 
7 OXC6364 CULS01000000 1 100/100 100/100     100/100 100/100 100/100  99/100 99/100 M Faeces, UK 
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Class R 
No. C. jejuni Strain Accession no. Contig no. 51 17 14 15 5 6 7 8 9 5-II 10 11 Class Host, Country 
1 OXC6327 CUKK01000000 1       96/100  96/100  97/100 97/100 R Faeces, UK 
2 BCW_6880 MJYO01000000 17         97/94  98/99 97/100 R Crow, US 
3 BCW_4324 MKET01000000       30     99/100 95/99 96/100 99/100 99/100  99/100 98/100 R Crow, US 
4 BCW_3791 MJVJ01000000       53       95/100       98/100 98/100  98/100 97/100 R Crow, US 
5 BCW_3807 MJVT01000000     28       96/100  98/100  98/100 97/100 R Crow, US 
6 BCW_6458 MJXG01000000     41     97/100 95/99 96/100 98/100 98/100  99/100 98/100 R Crow, US 
7 LMG 23211 AIPO01000000 10     100/100 100/100 100/100 100/100 100/100  100/100 100/100 R Chicken, Belgium 
8 CVM N15262 JOUG01000000 2      100/30 100/100  100/100  99/100 99/100 R Chicken, US 
9 CDPHFDLB-F15M01873-B MOTY01000000  1      99/83 100/100  100/100  99/100 99/100 R Goat Milk, US 
10 BCW_3799 MJVO01000000 9     97/100 95/99 96/100 98/100 98/100  99/100 98/100 R Crow, US 
 
Draft sequences: LOS Group 2; Classes P, H, E, O & W 
Class P 
No. C. jejuni Strain Accession no. Contig no. 21-25 26 26’ 27 28 29-34 Class Host, Country 
1 HB-CJGB -LL ATBJ01000000 12 98/98  100/100 99/92 100/100 97/99 P Human, China 
2 51494 AINZ01000000 9 97/98  100/100 99/92 99/100 97/99 P Chicken, US 
3 51037 AIPB01000000  12,37 98/98  100/100 99/92 99/100  P Chicken, US 
4 OXC6609 CUUU01000000 1 98/98  100/100 99/92 99/100 97/99 P Faeces, UK 
5 OXC6278 CUIK01000000 2 98/98  100/100 99/92 99/100 99/99 P Faeces, UK 
6 OXC6302 CUJK01000000 1 98/98  100/100 99/92 99/100 97/99 P Faeces, UK 
7 OXC6366 CULT01000000 1 98/98  100/100 99/92 99/100 97/99 P Faeces, UK 
8 OXC6620 CUVF01000000 1 98/98  100/100 99/92 99/100 97/99 P Faeces, UK 
9 OXC6481 CUPY01000000 1 98/98  100/100 99/92 100/100 97/99 P Faeces, UK 
10 OXC6313 CUJW01000000 2 98/98  100/100 99/92 99/100 99/99 P Faeces, UK 
11 OXC6440 CUOT01000000 1 98/98  100/100 99/92 100/100 97/99 P Faeces, UK 
12 OXC6311 CUJU01000000 1 98/98  100/100 99/92 99/100 97/99 P Faeces, UK 
13 OXC6293 CUJA01000000 1 98/98  100/100 99/92 99/100 99/99 P Faeces, UK 
14 OXC6342 CULC01000000 1 98/98  100/100 99/92 100/100 97/99 P Faeces, UK 
15 OXC6365 CULR01000000 1 98/98  100/100 99/92 99/100 99/99 P Faeces, UK 
16 OXC6503 CUQX01000000 1 98/98  99/100 99/92 100/100 97/99 P Faeces, UK 
17 OXC6339 CUKY01000000 1 98/98  100/100 99/92 99/100 99/99 P Faeces, UK 
18 OXC6357 CULJ01000000 1 98/98  100/100 99/92 99/100 97/99 P Faeces, UK 
19 OXC6351 CUMZ01000000 1 98/98  100/100 99/92 99/100 99/99 P Faeces, UK 
20 OXC6396 CUNB01000000 1 98/98  100/100 99/92 99/100 97/99 P Faeces, UK 
21 OXC6259 CUHO01000000 1 98/98  100/100 99/92 99/100 99/99 P Faeces, UK 
22 Neck Skin CZIL01000000 9   100/100 99/92 100/100  P Chicken, Spain 
23 Neck Skin CZIB01000000      11,15   100/100 99/92 99/100 97/99 P Chicken, Spain 
24 BCW_3782 MJYK01000000 17 98/98  100/100 99/92 99/100 99/99 P Crow, US 
25 BCW_6475 MJYM01000000 2 96/98  99/100 99/92 99/100 98/99 P Crow, US 
26 BCW_5132 MKBY01000000 29 98/98  100/100 99/92 100/100 97/99 P Human, US 
27 BCW_5131 MKBX01000000 101 98/98  99/100 99/92 99/100 98/99 P Human, US 
28 BCW_5147 MKCJ01000000 117 98/98  99/100 99/92 99/100 98/99 P Human, US 
29 CDPHFDLB-F15M00591 MOUS01000000 1 98/98  100/100 99/92 99/100 99/99 P Cow, US 
30 CDPHFDLB-F15M00554-a2 MOVZ01000000 1 98/98  100/100 99/92 99/100 97/99 P Water, US 
31 CDPHFDLB-F15M00554-a3 MOVY01000000  1 98/98  100/100 99/92 99/100 97/99 P Water, US 
32 CDPHFDLB-F12M00558 MOVX01000000  1 98/98  100/100 99/92 99/100 99/99 P Cow, US 
33 OXC6316 CUJZ01000000 1 98/98  100/100 99/92 99/100 97/99 P Faeces, UK 
34 OXC6274 CUIG01000000 1 98/98  100/100 99/92 99/100 97/99 P Faeces, UK 
35 BCW_4224 MJWH01000000       18 98/98  100/100 99/92 99/100 99/99 P Crow, US 
36 BCW_4757 MKBO01000000 47 98/98  100/100 99/92 99/100 99/99 P Unknown 
37 BCW_5150 MKCL01000000 69 98/98  99/100 99/92 99/100 98/99 P Human, US 
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38 W22 NFNK01000000 4 98/98  100/100 99/92 99/100 99/99 P Water, Canada 
39 C16 NFPX01000000 20 98/98  100/100 99/85 99/100 99/99 P Chicken, Canada 
40 A1 NFQG01000000      4   100/100 99/89 99/77  P Chicken, Canada 
41 H23 NFPA01000000       15 97/97  99/100 99/92 99/100 97/99 P Human, Canada 
42 K5 AUUP01000000 15, 450, 
451 
-  99/100 99/92 99/100 97/99 P Human, Pakistan 
 
Class H 
No. C. jejuni Strain Accession no. Contig no. 21-25 26 26’ 27 28 29-34 Class Host, Country 
1 30318 AUUJ01000000 26 98/98  99/100 99/100  99/100 H Human, Viet Nam 
2 HB-CJGB-LC ASXO01000000 1 98/98  100/100 99/100  98/100 H Human, China 
3 2008-894 AIOQ01000000 2 98/98  100/100 99/100  99/100 H Human, France 
4 1997-10 AIOY01000000 42, 101 98/98  99/100 99/100  99/99 H Human, US 
5 1854 AIPJ01000000 14 99/98  99/100 99/100  98/100 H Cow, US 
6 OXC6622 CUVG01000000 2 98/98  99/100 99/100  99/100 H Faeces, UK 
7 OXC6497 CUQR01000000 1 98/98  99/100 99/100  99/100 H Faeces, UK 
8 OXC6628 CUVO01000000 1 99/99  99/100 99/100  98/100 H Faeces, UK 
9 OXC6260 CUHR01000000 1 98/98  99/100 99/100  99/100 H Faeces, UK 
10 OXC6566 CUTF01000000 1 98/98  99/100 99/100  99/100 H Faeces, UK 
11 OXC6520 CURP01000000 1 98/98  99/100 99/100  99/100 H Faeces, UK 
12 OXC6478 CUPW01000000 1 98/98  99/100 99/100  99/100 H Faeces, UK 
13 OXC6611 CUUW01000000 2 98/98  99/100 99/100  99/100 H Faeces, UK 
14 OXC6473 CUPP01000000 1 98/98  99/100 99/100  99/100 H Faeces, UK 
15 OXC6585 CUUA01000000 1 98/98  99/100 99/100  99/100 H Faeces, UK 
16 OXC6438 CUOS01000000 1 98/98  99/100 99/100  99/100 H Faeces, UK 
17 OXC6575 CUTP01000000 1 98/98  99/100 99/100  99/100 H Faeces, UK 
18 OXC6591 CUUE01000000 1 98/98  99/100 99/100  99/100 H Faeces, UK 
19 Faeces CZIS01000000 78   100/97 99/92   H Chicken, Spain 
20 Meat CZHK01000000 31 99/98  100/99 99/100  98/100 H Chicken, Spain 
21 Meat CZHZ01000000 4   100/99   98/99 H Chicken, Spain 
22 Faeces CZIV01000000 34 99/96  100/99 99/100  98/100 H Chicken, Spain 
23 Meat CZHN01000000 1   99/100 99/100  99/99 H Chicken, Spain 
24 CVM 41921 JAKK01000000         34 99/96  99/100 99/100   H Human, US 
25 BCW_4230 MJWJ01000000       32 98/98  99/100 99/100  99/100 H Crow, US 
26 BCW_7692 MKAB01000000 26 98/98  99/100 99/100  99/100 H Human, US 
27 BCW_5126 MKBU01000000   52 98/98  99/100 99/100  99/100 H Human, US 
28 CDPHFDLB-F12M00584-a2 MOVC01000000 3 99/98  99/100 99/100  98/100 H Cream, US 
29 CDPHFDLB-F12M00584-a1 MOVD01000000      1 99/98  99/100 99/100  98/100 H Cream, US 
30 CDPHFDLB-F12M00585-a1 MOVB01000000      1 99/98  99/100 99/100  98/100 H Cream, US 
31 CDPHFDLB-F12M00585-a2 MOVA01000000     1 99/98  99/100 99/100  98/100 H Cream, US 
32 CDPHFDLB-F12M00589-a2 MOUY01000000      1 99/98  99/100 99/100  98/100 H Cream, US 
33 CDPHFDLB-F12M00589-a1 MOUZ01000000    1 99/98  99/100 99/100  98/100 H Cream, US 
34 CDPHFDLB-F12M00436-A MOWK01000000  1 99/98  99/100 99/100  98/100 H Cow, US 
35 CDPHFDLB-F12M00436-D MOWJ01000000     1 99/98  99/100 99/100  98/99 H Cream, US 
36 CDPHFDLB-F12M00436-H MOWI01000000  2 99/98  99/100 99/100  98/99 H Cream, US 
37 CDPHFDLB-F12M00521-3g3a MOWH01000000  1 99/98  99/100 99/100  98/100 H Milk, US 
38 CDPHFDLB-F12M00521-3g3b MOWG01000000  2 99/98  99/100 99/94   H Milk, US 
39 CDPHFDLB-F12M00521-3k2a MOWF01000000  1 99/98  99/100 99/100  98/100 H Milk, US 
40 CDPHFDLB-F12M00521-3k2b MOWE01000000  1 99/98  99/100 99/100  98/100 H Milk, US 
41 CDPHFDLB-F12M00521-8g1a MOWD01000000  4 99/98  99/100 99/100  98/100 H Milk, US 
42 CDPHFDLB-F12M00521-8g1b MOWC01000000  1 99/98  99/100 99/100  98/100 H Milk, US 
43 CDPHFDLB-F12M00521-8k1a MOWB01000000  1 99/98  99/100 99/100  98/100 H Milk, US 
44 CDPHFDLB-F12M00521-8k1a MOWA0100000  17 99/98  99/99 99/100  98/100 H Milk, US 
45 CDPHFDLB-F12M00562-b7a1 MOVS01000000  1 99/98  99/100 99/100  98/100 H Milk, US 
46 CDPHFDLB-F12M00562-b7b1 MPBL01000000  31 99/98  99/99 99/100   H Milk, US 
47 CDPHFDLB-F12M00580-a2 MOVJ01000000  1 99/98  99/100    H Milk, US 
48 CDPHFDLB-F12M00582-a1 MOVG01000000  1 99/98  99/100 99/100  98/100 H Milk, US 
49 CDPHFDLB-F12M00582-a2 MOVF01000000  1 99/98  99/100    H Milk, US 
50 CDPHFDLB-F12M00583-b1 MPBK01000000  4 99/98  99/99 99/78   H Milk, US 
51 BCW_6902 MKEU01000000  12 98/98  100/100 99/100  99/100 H Crow, US 
52 S3 NFOF01000000      35 98/98  99/100 99/100  99/100 H Environment water, Canada 
53 H27 NFOW01000000 23, 31 98/98  99/100 99/100  98/99 H Human, Canada 
54 H10 NFPM01000000  87, 98 99/98  99/100 99/100   H Human, Canada 
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55 C1 NFQC01000000    47 98/97  100/100 99/100  99/100 H Chicken, Canada 
56 W4 NFMU01000000  30, 80 99/98  99/100 99/95   H Environment water, Canada 
57 H32 NFOQ01000000 8, 72 99/98  99/100 99/100   H Human, Canada 
58 OXC6586 CTRS01000000 1 97/98  99/100 99/100  99/100 H Faeces, UK 
59 OXC6353 CUNV01000000 1 99/98  100/99 99/100  98/100 H Faeces, UK 
60 OXC6314 CUJX01000000 1 99/98  99/100 97/100  98/100 H Faeces, UK 
61 OXC6507 CURC01000000 2 98/98  99/100 99/100  99/100 H Faeces, UK 
62 RC429 CYRQ01000000 33 98/98  99/100 99/98   H Chicken, UK 
63 12502 CYRV01000000 11 98/98  99/100 99/100  99/100 H Chicken, UK 
64 BCW_4221 MJWI01000000      5 98/98  99/100 99/100  99/100 H Crow, US 
65 BCW_5125 MKBT01000000    14 98/98  99/100 99/100  99/100 H Human, US 
66 BCW_5145 MKCH01000000 42 98/98  99/100 99/100  99/100 H Human, US 
67 BCW_5161 MKHS01000000 33 98/98  99/100 99/100  99/100 H Human, US 
68 BCW_5162 MKHT01000000     31 98/98  99/100 99/100  99/100 H Human, US 
69 OXC6588 CUUG01000000    1 98/98  99/100 99/100  99/100 H Human, US 
70 BH-01-0142 ABKD01000000       1 98/98  99/100 99/100  99/100 H Human, Thailand 
 
Class E 
No. C. jejuni Strain Accession no. Contig no. 21-25 26 26’ 27 28 29-34 Class Host, Country 
1 1997-14 AIPA01000000 2, 30 98/100 99/100  98/92 99/100  E Human, US 
2 OXC6373 CUMA01000000 1 96/100 99/100  98/92 99/100 98/99 E Faeces, UK 
3 OXC6330 CUKP01000000 1 96/100 99/100  98/92 99/100 98/99 E Faeces, UK 
4 OXC6294 CUJB01000000 1 96/100 99/100  98/92 99/100 98/99 E Faeces, UK 
5 OXC6510 CURE01000000 1 96/100 99/100  98/92 99/100 98/99 E Faeces, UK 
6 OXC6511 CURG01000000 2 95/100 99/100  98/92 99/100 98/99 E Faeces, UK 
7 OXC6437 CUOQ01000000 1 96/100 99/100  98/92 99/100 98/99 E Faeces, UK 
8 OXC6369 CULV01000000 2 96/100 99/100  98/92 99/100 98/99 E Faeces, UK 
9 Faeces CZIK01000000 72 96/98 99/100  98/92 99/77  E Chicken, Spain 
10 Neck Skin CZIW01000000 31 96/98 99/100  98/92 99/100  E Chicken, Spain 
11 BCW_6898 MJZA01000000 29 96/100 99/100  98/92 99/100 98/99 E Chicken, Spain 
12 BCW_6899 MJZB01000000    17 96/100 99/100  98/92 99/100 98/99 E Chicken, Spain 
13 W38 NFMV01000000 12 96/97 99/100  98/92 99/100 98/99 E Environment water, Canada 
14 W32 NFNB01000000  24 96/100 99/100  98/92 99/100 98/99 E Environment water, Canada 
15 BCW_4743 MKBH01000000      18 96/100 99/100  98/92 99/100 98/99 E Human, US 
 
Class O 
No. C. jejuni Strain Accession no. Contig no. 21-25 26 26’ 27 28 29-34 Class Host, Country 
1 LMG 9872 AIPM01000000 11, 18 98/100 99/100  98/100  98/99 O Human, Sweden 
2 OXC6536 CUSH01000000 3 99/100 100/100  100/100  100/100 O Faeces, UK 
3 OXC6332 CUKR01000000 1 98/100 99/100  98/100  98/100 O Faeces, UK 
4 5070 CCXG01000000 6 98/100 99/100  98/100  98/100 O Chicken, Finland 
5 BCW_4753 MKBM01000000   8 99/100 100/100  100/100  99/100 O Unknown, US 
6 W27 NFNH01000000 5 96/97 99/100  98/75   O Environment water, Canada 
7 OXC6321 CUKG01000000 2 99/100 100/100  100/100  100/100 O Faeces, UK 
 
Class W 
No. C. jejuni Strain Accession no. Contig no. 21-25 26 26’ 27 28 29-34 Class Host, Country 
1 7092_1 CUPI01000000 1 99/85 100/100 99/99  99/100  W Faeces, UK 
2 CVM 41910 JAKG01000000 18 99/85 99/100 99/99  98/100  W Human, US 
3 CVM 41914 JAKI01000000 10 99/85 99/100 99/99  98/100  W Human, US 
4 CVM 41933 JAKN01000000     2 98/85 99/100 99/99  99/100  W Human, US 
5 CVM 41973 JAJF01000000 9 99/85 99/100 99/97    W Human, US 
6 CVM 41964 JAKR01000000    2 99/85 99/100 99/99  98/100  W Human, US 
7 CVM 41985 JAKU01000000   14  99/100 99/99  98/100  W Human, US 
8 BCW_4452 MJWG01000000      16 99/85 100/100 99/99  99/100  W Faeces, US 
9 BCW_6882 MJYR01000000 6 95/85 99/100 99/100  99/100  W Crow, US 
10 BCW_6886 MJYU01000000   64 95/85 99/100 99/100  99/100  W Crow, US 
11 BCW_6953 MJZN01000000   37 98/85 99/100 99/99  99/100  W Faeces, US 
12 BCW_6959 MJZT01000000   2 98/85 99/100 99/99  99/100  W Faeces, US 
 
 271 
 
 
 
 
 
LOS Group 2; Mix LOS Classes 
No. C. jejuni Strain Accession no. Contig no. 21-25 26 26’ 27 28 29-34 Class Host, Country 
1 CVM 41975 JAKT01000000 2   99/99  98/100  EHOP Human, US 
2 BCW_6883 MJYS01000000 5 95/85  99/99  99/100  EHOP Crow, US 
3 BCW_6885 MJYT01000000    58 96/85  99/99  98/100  EHOP Crow, US 
4 BCW_3781 MEIB01000000     59 95/85  99/99  99/100  EHOP Crow, US 
5 BCW_3784 MEIC01000000     25 96/85  98/99  98/100  EHOP Crow, US 
6 W9 NFMI01000000  1, 6 99/97      EHOP Environment water, Canada 
 
Draft sequences: LOS Group 3; Classes D, F, K, N, Q, I, J & S 
Class D/F 
No. C. jejuni Strain Accession no. Contig no. 17 18 19 20 38 40 41 42-45 46 49-50 16 Class Host, Country 
1 OXC6583 CUTY01000000   96/94 98/100 97/100       99/100 F Unknown, UK 
2 OXC6319 CUKC01000000   96/94 98/100 97/100       99/100 F Pigeon, Sweden 
3 OXC6254 CUJH01000000 2  98/94 99/100 98/100       99/100 F Faeces, UK 
4 OXC6582 CUTW01000000 1 100/100 100/100 100/100 100/100       99/100 D Faeces, UK 
5 CDPHFDLB-F15M00665P1 MOUL01000000        1  98/94 99/100 98/100       99/100 F Faeces, UK 
6 CDPHFDLB-F15M00667P1 MOUJ01000000       3  98/94 99/100 98/100       99/100 F Faeces, UK 
7 CDPHFDLB-F15M00668P1 MOUH01000000     1  98/94 99/100 98/100       99/100 F Cow Milk, US 
8 CDPHFDLB-F15M00669P1 MOUF01000000     1  98/94 99/100 98/100       99/100 F Cow Milk, US 
9 CDPHFDLB-F15M00562-b9b1a MOVR01000000        1  98/94 99/100 98/100       99/100 F Cow Milk, US 
10 CDPHFDLB-F12M00566-a1 MOVM01000000    1  98/94 99/100 98/100       99/100 F Cow Milk, US 
11 CDPHFDLB-F15M00668P2 MOUG01000000      2  98/94 99/100 98/100       99/100 F Cow, US 
12 RC507 CYRT01000000 1  98/86 99/100 98/100       99/100 F Cow, US 
13 W30 NFND01000000 2  98/94 99/100 98/100       99/100 F Cow Milk, US 
14 OXC6608 CUUS01000000  46, 20  98/77 99/100 99/100       99/100 F Chicken, UK 
15 OXC6432 CUOJ01000000  8  98/94 99/100 98/100       99/100 F Environment water, 
Canada 
16 OXC6412 CUNP01000000 1  98/94 99/100 99/100       99/100 F Faeces, UK 
17 OXC6491 CUQK01000000 3  98/94 99/100 99/100       99/100 F Faeces, UK 
18 OXC6250 CUHN01000000 1  98/94 99/100 98/100       99/100 F Faeces, UK 
19 OXC6450 CUQF01000000  2  98/94 99/100 98/100       99/100 F Faeces, UK 
20 OXC6401 CUND01000000  1  98/94 99/100 98/100       99/100 F Faeces, UK 
21 OXC6362 CULO01000000  2  98/94 99/100 98/100       99/100 F Faeces, UK 
22 OXC6469 CUPM01000000 1  98/94 99/100 98/100       99/100 F Faeces, UK 
23 OXC6404 CUNG01000000  1  98/94 99/100 98/100       99/100 F Faeces, UK 
24 OXC6375 CUMD01000000 2  98/94 99/100 98/100       99/100 F Faeces, UK 
25 OXC6441 CUOU01000000 1  98/94 99/100 98/100       99/100 F Faeces, UK 
26 OXC6368 CULW01000000  2  98/94 99/100 98/100       99/100 F Faeces, UK 
27 11601MD LKCR01000000 1  98/94 99/100 99/100       99/100 F Faeces, UK 
28 Faeces CZHX01000000  1  98/94 99/100 99/100       99/100 F Faeces, UK 
29 NC05-27 BCNK01000000 19  98/94 99/100        99/100 F Turkey, US 
 
Class K 
No. C. jejuni Strain Accession no. Contig no. 17 18 19 20 38 40 41 42-45 46 49-50 16 Class Host, Country 
1 7065_7 CUOO01000000 1 96/100 93/100 95/98       99/100           K Faeces, UK 
2 7213_3 CUTB01000000   1 96/100 93/100 95/98       99/100  K Faeces, UK 
3 7092_1 CURB01000000 1 96/100 93/100 95/98       99/100  K Faeces, UK 
4 7038_3 CUIM01000000 1 96/100 94/100 95/98       99/100  K Faeces, UK 
5 7065_7 CUMJ01000000 1 96/100 94/100 95/98       99/100  K Faeces, UK 
6 7065_7 CULP01000000 1 96/100 93/100 95/98       99/100  K Faeces, UK 
7 7213_3 CUVJ01000000 1 96/100 93/100 95/98       99/100  K Faeces, UK 
8 Meat CZHP01000000          32   95/98       99/100  K Chicken, Spain 
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9 CVM 41927 JAJG01000000  10, 15          99/94  K Human, US 
10 BCW_6476 MJYN01000000 39 94/100 92/100 95/98       93/100  K Crow, US 
11 BCW_6887 MKEV01000000        26  93/100 95/98       99/100  K Crow, US 
12 RC51 CYRU01000000 80 96/100  95/98       99/100  K Chicken, UK 
13 BJ-CJD39 LISI01000000 1 96/100 93/100 95/98       99/100  K Human, China 
 
Class N  
No. C. jejuni Strain Accession no. Contig no. 17 18 19 20 38 40 41 42-45 46 49-50 16 Class Host, Country 
1 BCW_5172 MKHY01000000 8     88/83      95/99 N Human, US 
 
Class Q 
No. C. jejuni Strain Accession no. Contig no. 17 18 19 20 38 40 41 42-45 46 49-50 16 Class Host, Country 
1 2871 LLWN01000000 1  91/94 91/100 93/100     99/100  79/80 Q Poultry, Malaysia 
 
Class I 
No. C. jejuni Strain Accession no. Contig no. 17 18 19 20 38 40 41 42-45 46 49-50 16 Class Host, Country 
1 LMG 23263 AIOD01000000 26, 69 99/100 99/85      99/100    I Chicken, US 
2 OXC6374 CUMB01000000 1 99/100 99/100 98/100 96/100  100/100 100/100 99/100    I Faeces, UK 
3 OXC6480 CUQA01000000 1 96/100 98/100 98/100 96/100  98/100 99/100 97/99    I Faeces, UK 
 
Class J 
No. C. jejuni Strain Accession no. Contig no. 17 18 19 20 38 40 41 42-45 46 49-50 16 Class Host, Country 
1 OXC6518 CURO01000000 1  99/92 99/100 96/90  98/98  96/100    J Faeces, UK 
2 BCW_6457 MJXF01000000          14, 62      97/100  95/99    J Crow, US 
3 BCW_4744 MKBI01000000 29  98/94 99/100 96/100  98/98  97/100    J Crow, US 
4 W13 NFNU01000000 94, 99      97/86  99/100    J Environment water, 
Canada 
 
Class S 
No. C. jejuni Strain Accession no. Contig no. 17 18 19 20 38 40 41 42-45 46 49-50 16 Class Host, Country 
1 OXC6287 CUIU01000000 1  98/94 99/100 96/100  98/100 99/100 96/100    S Faeces, UK 
2 NW AGTE01000000 2, 4      98/100 99/100 96/100    S Human, US 
3 OXC6418 CUNW01000000 1  98/94 99/100 96/100  98/100 99/100 96/100    S Faeces, UK 
4 OXC6517 CURL01000000 2  98/94 99/100 96/100  98/100 99/100 96/100    S Faeces, UK 
5 OXC6451 CUQQ01000000 2  98/94 99/100 96/100  98/100 99/100 96/100    S Faeces, UK 
6 OXC6529 CUSA01000000  1, 21  98/94 99/100 96/100  98/100 99/100 96/100    S Faeces, UK 
 
LOS Group 3; Mix LOS Classes 
No. C. jejuni Strain Accession no. Contig no. 17 18 19 20 38 40 41 42-45 46 49-50 16 Class Host, Country 
1 VA48 NACK01000000 2, 5      99/79 99/100 95/99    I/S Water, Sweden 
2 BCW_6451 MJXA01000000 7 99/100 99/100 98/100 96/100  99/100  97/100    I/J Faeces, UK 
3 BCW_6452 MJXB01000000       6 99/100 99/100 98/100 96/100  99/100  97/100    I/J Faeces, UK 
4 BCW_6954 MJZO01000000 
 
26, 27 99/100 99/100 98/100 98/100  98/98  95/100    I/J Faeces, UK 
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Draft sequences: LOS Group 4; Classes G & L 
Class G 
No. C. jejuni Strain Accession no. Contig no. 35 36 37 38 47 48 16 Class Host, Country 
1 OXC6358 CULK01000000 1 99/100 99/100 99/100 100/100   99/100 G Faeces, UK 
2 OXC6498 CUQT01000000 1 98/100 99/100 99/100 99/100   99/100 G Faeces, UK 
3 OXC6614 CUVA01000000 1 99/100 99/100 99/100 100/100   99/100 G Faeces, UK 
4 OXC6360 CULM01000000 1 98/100 99/100 99/100 99/100   99/100 G Faeces, UK 
5 OXC6322 CUKF01000000 1 98/100 99/100 99/100 99/100   99/100 G Faeces, UK 
6 OXC6410 CUNN01000000 1 99/100 99/100 99/100 99/100   99/100 G Faeces, UK 
7 OXC6486 CUQE01000000 2 98/100 99/100 99/100 99/100   99/100 G Faeces, UK 
8 OXC6256 CUKD01000000  5, 20 98/100 99/100 99/90 99/100   99/100 G Faeces, UK 
9 JL-CJHLIU1-1 LISQ01000000 2 98/100 99/100 99/100 99/100   99/100 G Chicken, China 
10 BCW_3794 MJVL01000000           3 97/100 99/100 98/100 98/100   99/100 G Crow, US 
Class L 
No. C. jejuni Strain Accession no. Contig no. 35 36 37 38 47 48 16 Class Host, Country 
1 BCW_3800 MJVP01000000 64 98/100 98/100 89/100  99/100 98/100 92/93 L Crow, US 
2 BCW_3802 MJVQ01000000       56 98/100 98/100 89/100  99/100 98/100 92/93 L Crow, US 
3 BCW_3810 MJVU01000000       57 98/100 98/100 89/100  99/100 99/100 92/93 L Crow, US 
4 BCW_4231 MJXZ01000000 65 98/100 98/100 89/100  99/100 99/100 92/93 L Crow, US 
5 BCW_6881 MJYQ01000000 89 99/100 97/100 89/100  99/100 98/100 92/93 L Crow, US 
6 OXC6631 CUVR01000000 1 97/100 96/100 89/100  99/100 99/99 91/93 L Faeces, UK 
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Table 2: LOS types of C. coli complete (n=22) and draft sequences (n=542) 
Complete sequences:  
 
LOS Class I 
 
 
LOS Class II 
No. Strain Accession # 4 5 6 7 8 9 10 11 12   Gene* Class Host 
1 JL-CDD-LMH NZ_KZ253957.1 100/100 99/100 99/100 99/100 100/100 99/99 99/100 99/100 99/100 100/100 II Unknown, China 
2 BP3183 CP017871.1 100/100 100/100 99/100 99/100 100/100 99/100 100/100 100/100 100/100 95/100 II Chicken, US 
3 WA333 CP017873.1 100/100 100/100 99/100 99/100 100/100 99/100 100/100 99/100 100/100 100/100 II Chicken, US 
4 JV20 GL405235.1 100/100 100/100 100/100 99/100 99/100 100/100 100/100 99/100 100/100 100/100 II Unknown, US 
 
LOS Class III 
 
 
 
 
 
LOS Class V 
 
 
 
LOS Class VI 
 
 
 
LOS Class VII 
No. Strain Accession# 4 5 6 7 8 9 10 11 33 34 35 36 13 14 15 Class Host 
1 OR12 NZ_CP019977.1   99/100 99/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Chicken, UK 
   22     2 CFSAN032805 CP023545.1 99/100 99/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Chicken, US 
3 CO2-160 CP013032.1 99/100 99/100 100/100 99/100 89/99 94/99 87/94       94/98 99/100 VII  Beef, US 
4 K7 NZ_KI639691.1 99/100 99/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Unknown, UK 
 
LOS Class VIII 
No. Strain Accession # 4 5 6 7 8 9 10 11 12 13 14 15 16 17   Gene* Class Host 
1 CVM N29710 NC_022347.1 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
2 15-537360 NC_022660.1 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100  94/100 VIII Human, UK 
3 FB1 CP011015.1 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Human, UK 
4 YH501 CP015528.1 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
5 CVM 41957 NZ_JAJZ01000000 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Human, US 
 
 
No. Strain  Accession # 4 5 6 7 8  Gene* Class Host 
1 YH502 CP018900.1 99/100 99/100 96/100 99/100 99/100 96/100 I Retail chicken US 
No. Strain Accession # 4 5 6 7 8 9 10 11   Gene* Class host 
1 BG2108 CP017878.1 99/100 98/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 III Chicken, US 
2 RM2228 AAFL01000002 99/100 99/100 99/100 99/100 100/100 99/100 99/100 100/100 100/100 III Unknown, US 
3 YF2105 CP017865.1 99/100 98/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 III Chicken, US 
No. Strain Accession# 4 5 6 7 8 9 10 11/11’ 12 13 14 15  Gene* Class Host 
1 RM1875 CP007183.1 99/100 99/100 100/100 99/100 99/100 99/100 96/100 99/100 100/100 93/99 95/100 98/99 99/100 V Unknown, US 
2 ZV1224 CP017875.1 99/100 99/100   99/100 100/100 100/100 99/100 99/100 98/100 96/100 99/99  V with a pseudo gene Pork, US 
No. Strain Accession# 4 5 6 7 8 9 10 11 12 31 32 14 15 Class Host 
1 RM5611 CP007179.1 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VI Unknown, US 
2 HC2-48 CP013034.1 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VI Beef, US 
3 CF2-75 CP013036.1 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VI Beef, US 
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  Draft sequences:  
 
  LOS Class I 
No. Strain  Accession # Contig # 4 5 6 7   Gene* 8 Class Host 
1 86119 AIMU01000000      31 99/100 99/100 99/100 99/100  100/100 I Chicken US   
2 OXC6372 CULY01000000      2 99/100 99/100 99/100 99/100 99/100 99/100 I Faeces UK 
3 OXC6276 CUII01000000      1 99/100 99/100 99/100 100/100 99/100 99/100 I Faeces UK 
4 OXC6378 CUMG01000000    1 99/100 99/100 99/100 99/100 99/100 99/100 I Faeces UK 
5 OXC6253 CUIX01000000      1 99/100 99/100 95/100 96/100  99/100 I Faeces UK 
6 CVM N44721 LBEL01000000 6 99/100 99/100 95/100 96/100 96/100 98/100 I Breast chicken, US 
7 CVM N46876 LBEJ01000000    4 99/100 99/100 96/100 96/100 96/100 98/100 I Breast chicken, US 
8 CVM N45714F  LBDV01000000     2 100/100 99/100 96/100 99/100  97/100 I Turkey, US 
9 CVM 41945 JAJP01000000 8 99/100 99/100 99/100 100/100  99/100 I Humans, US 
10 CVM 41970 JAJH01000000   11   99/100 99/100 96/100 97/100 I Humans, US 
11 CVM N26697 JOUO01000000   2 99/100 99/100 99/100 100/100 96/100 98/100 I Chicken, US 
12 OXC6258 CUKZ01000000 3 99/100 99/100 95/100 99/100 100/100 98/100 I FAECES, UK 
13 CVM N18323 JOUJ01000000 1 99/100 99/100 97/100 99/100 96/100 99/100 I Chicken, US 
14 CVM N26070 JOUN01000000   3 99/100 99/100 97/100 99/100 96/100 99/100 I Turkey, US 
15 H103060185 FBAG01000000 27 99/100 99/100 99/100 100/100 96/100 97/100 I Environmental WATER, UK 
16 P604D FBLZ01000000  16 99/100 99/100 99/100 99/100 96/100 97/100 I Soil, UK 
17 SS_2357 FBEC01000000    13 99/100 99/100 99/100 100/100 97/100 100/100 I Chicken, UK 
18 H093100604 FBQF01000000       19 99/100 99/100 99/100 99/100 96/100 97/100 I Environmental WATER, UK 
19 H043880651 FBNR01000000      23 99/100 99/100 99/100 100/100 96/100 95/100 I Human, UK 
20 H063800417 FBQI01000000  11 99/100 98/100 99/100 99/100 98/100 97/100 I Environmental WATER, UK 
21 H102520382 FAZD01000000   38 99/100 99/100 99/100 99/100 97/100 100/100 I Environmental WATER, UK 
22 H140200373 FBLY01000000 15 99/100 99/100 99/100 100/100 98/100 97/100 I Human, UK 
23 UNOR383B FBJO01000000 19 99/100 99/100 99/100 100/100 98/100 97/100 I Chicken, UK 
24 UNF5421c FBMG01000000 25 99/100 99/100 99/100 99/100 96/100 97/100 I Chicken, UK 
25 H094280625 FBQL01000000 28 99/100 99/100 99/100 100/100 97/100 100/100 I Environmental WATER, UK 
26 H102380405 FAYB01000000 30 99/100 99/100 99/100 99/100  99/100 I Environmental WATER, UK 
27 H132580232 FBND01000000 77 99/100 99/100 95/100 96/100 100/100 100/100 I Environmental WATER, UK 
28 H124620276b FBPL01000000 15 100/100 100/100 99/100 99/100 96/100 99/100 I Human, UK 
29 UNOR8693b FBMI01000000 14 99/100 99/100 99/100 100/100 98/100 97/100 I Chicken, UK 
30 SS_2289 FBFR01000000 16   99/100 99/100  100/100 I Chicken, UK 
31 H142080277 FBPH01000000  21 99/100 99/100 99/100 100/100 96/100 97/100 I Human, UK 
32 11601 LKCS01000000 23 100/100 99/100 96/100 99/100 96/100 97/100 I Turkey, US 
33 CVM N23392 JOUM01000000 7   99/100 99/100 100/100 100/100 I Chicken, US 
34 BCW_6860 MJYP01000000 36 99/100 99/100 99/100 99/100 96/100 97/100 I Faeces, US 
35 BCW_6914 MJZH01000000 34 99/100 99/100 99/100 99/100 96/100 97/100 I Faeces, US 
36 BCW_6948 MJZK01000000 32 99/100 99/100 99/100 99/100 96/100 97/100 I Faeces, US 
37 BCW_6950 MJZL01000000 28 99/100 99/100 99/100 99/100 96/100 97/100 I Faeces, US 
38 BCW_6958 MJZS01000000 29 99/100 99/100 99/100 99/100 96/100 97/100 I Faeces, US 
39 BCW_7437 MJZY01000000 32 99/100 99/100 99/100 99/100 96/100 97/100 I Faeces, US 
40 BCW_5818 MKAO01000000 12 99/100 99/100 99/100 99/100 96/100 97/100 I Faeces, US 
41 BCW_6946 MKEX01000000 18 99/100 99/100 99/100 99/100 96/100 97/100 I Monkey, US 
42 OXC6476 CUPT01000000 2 99/100 99/100 99/100 99/100 96/100 98/100 I Faeces, UK 
43 RC282 CYRA01000000       77   99/100 99/100 100/100 99/100 I Supermarket, UK 
44 SH-CCD11C671 LISD01000000   4 93/100 99/100 99/100 100/100 96/100 99/100 I Human, china 
45 SH-CCHF12C088 LISE01000000 5 93/100 99/100 99/100 100/100 96/100 99/100 I Chicken, china 
46 SH-CCD12C100 LISF01000000 1 93/100 99/100 99/100 99/100 96/100 99/100 I Human, china 
47 BCW_4453 MJWB01000000 34 99/100 99/100 99/100 99/100 96/100 97/100 I Faeces, US 
48 BCW_4457 MJWC01000000 35 99/100 99/100 99/100 99/100 96/100 97/100 I Faeces, US 
49 BCW_5916 MJWD01000000 32 99/100 99/100 99/100 99/100 96/100 97/100 I Faeces, US 
50 BCW_5914 MJYL01000000 36 99/100 99/100 99/100 99/100 96/100 97/100 I Faeces, US 
51 6067 LKCQ01000000 14 100/100 100/100 96/100 99/100 96/100 97/100 I Turkey house water, US 
52 BFR-CA-9557 CP011777.1            100/100 100/100 99/100 100/100 96/100 99/100 I Chicken, Germany 
53 RC182 CYQT01000000 57 99/100 99/100 99/100 99/100 100/100 99/100 I Supermarket, UK 
54 RC096 CYQI01000000 56 99/100 99/100 99/100 99/100 100/100 99/100 I Supermarket, UK 
55 RC264 CYQW01000000 106   99/100 99/100  99/100 I Supermarket, UK 
56 RC285 CYRE01000000 27 99/100 99/100 99/100 99/100 100/100 99/100 I Supermarket, UK 
57 RC126 CYQM01000000     11   99/93 99/100 100//100 99/100 I Supermarket, UK 
58 RC387 CYRK01000000   7 99/100 99/100 99/100 99/100 100/100 99/100 I Supermarket, UK 
59 RC127 CYQN01000000 85 99/100 99/100 98/100 99/100 99/100 99/100 I Supermarket, UK 
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60 RC037 CYQD01000000   27   99/94 100/100 96/100 97/100 I Supermarket, UK 
61 RC289 CYRG01000000    88 99/100 99/100 99/100 99/100 100/100 99/100 I Supermarket, UK 
62 RC415 CYRO01000000  3,81   99/86 99/100 100/100  I Supermarket, UK 
63 RC038 CYQE01000000 37 99/100 99/100 99/100 100/100 96/100 97/100 I Supermarket, UK 
64 RC428 CYRP01000000   6 99/100 99/100 99/100 99/100 100/100 99/100 I Supermarket, UK 
65 RC116 CYQL01000000            82, 91 99/100 99/100 99/100 99/100 100/100 98/90 I Supermarket, UK 
66 RC043 CYQF01000000    3 99/100 99/100 99/100 99/100 100/100 99/100 I Supermarket, UK 
67 RC281 CYQZ01000000 38   99/100 99/100 100/100 99/100 I Supermarket, UK 
68 RC284 CYRD01000000    73 99/100 99/100 99/100 99/100 100/100 99/100 I Supermarket, UK 
69 SH-CCD12C136 JXTU01000000 4 93/100 99/100 99/100 100/100 96/100 99/100 I Human, China 
 
  LOS Class II 
No. Strain Accession # Contig# 4 5 6 7 8 9 10 11 12   Gene* Class Host 
1 H8 AINU01000000 4, 27 100/100 100/100 99/100 99/100 100/100 99/100 100/100 99/100 99/100 92/100 II Human, Switzerland 
2 OXC6523 CURT01000000 1 99/100 100/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 91/100 II Faeces, UK 
3 OXC6442 CUOV01000000  1 100/100 100/100 99/100 99/100 100/100 99/100 99/100 99/100 99/100 99/100 II Faeces, UK 
4 OXC6443 CUOW01000000 1 100/100 100/100 99/100 99/100 100/100 99/100 99/100 99/100 99/100 99/100 II Faeces, UK 
5 OXC6537 CUSJ01000000 1 100/100 100/100 99/100 99/100 100/100 99/100 100/100 100/100 100/100 100/100 II Faeces, UK 
6 COL B1-266 LKIV01000000 274 100/100 100/100 99/100 99/100 100/100 99/100 100/100 100/100 100/100  II Animal, Colombia 
7 CVM N7464 JOVA01000000 1 100/84 100/100 99/100 99/100 100/100 99/100 100/100 100/100 100/100 93/100 II Chicken, US 
8 CVM N6388 JOUY01000000 4,15 100/100 100/100 99/100 99/100 100/100 99/100 100/100 100/100 99/100 100/100 II Chicken, US 
9 CVM N7454 JOUZ01000000 10 100/100 100/100 99/100 99/100 100/100 99/100 100/100 99/100   II Chicken, US 
10 CVM N9036 JOVE01000000 6, 9, 36 100/100 100/100 99/100 99/100 100/100 100/100 100/100 93/100 100/100 100/100 II Pork, US 
11 UNAJL222 FBIG01000000 25, 43 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 100/100 II Pig, UK 
12 H092660305 FBNL01000000 36 99/100 100/100 99/100 99/100 100/100 99/100 100/100 100/100 100/100 100/100 II Human, UK 
13 CCN349 FBIX01000000 28 99/100 100/100 99/100 99/100 100/100 99/100 100/100 100/100 99/100 91/99 II Chicken, UK 
14 UNNQFC9 FBLR01000000 19 99/100 100/100 99/100 99/100 100/100 99/100 99/100 100/100 100/100 95/99 II Duck, UK 
15 H060260417 FAXS01000000 11 100/100 100/100 99/100 99/100 100/100 99/100 99/100 100/100 100/90  II Human, UK 
16 UNOR581A FBHW01000000 29 99/100 100/100 99/100 99/100 100/100 99/100 99/100 100/100 100/100 95/99 II Chicken, UK 
17 H044660164 FBKS01000000 10 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 100/100 II Human, UK 
18 H063900401 FBKM01000000 26 99/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 II Human, UK 
19 H072820535 FBBC01000000 15 100/100 100/100 99/100 99/100 100/100 99/100 100/100 100/100 100/100 100/100 II Human, UK 
20 SS_2356 FBED01000000 11 100/100 100/100 99/100 99/100 100/100 99/100 100/100 100/100 100/100 91/99 II Chicken, UK 
21 H102740168 FBOG01000000 25 99/100 100/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 91/100 II Environmental water, UK 
22 UNES9 FBHB01000000 26 100/100 100/100 99/100 99/100 100/100 99/100 100/100 100/100 100/100 100/100 II Chicken, UK 
23 H063540531 FBNJ01000000 16 99/100 100/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 91/100 II Human, UK 
24 H102240159 FBQQ01000000 233 100/100 100/100 99/100 99/100 100/100 99/100 100/100 100/100 100/100 100/100 II Environmental water, UK 
25 1535 FBGC01000000 7 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 100/100 II Soil, UK 
26 EC0349 FBJR01000000 23,27 99/100 100/100 99/100 99/100 100/100 99/100 100/100 100/100 99/100 91/99 II Dairy, UK 
27 H060280132 FBNZ01000000 24 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 92/100 II Human, UK 
28 H051160594 FBPK01000000 67 100/100 100/100 99/100 99/100 100/100 99/100 100/100 100/100 100/100 100/100 II Human, UK 
29 H072820536 FBNS01000000 18 100/100 100/100 99/100 99/100 100/100 99/100 100/100 100/100 100/100 100/100 II Human, UK 
30 M1483PM LQXL01000000 23 100/100 100/100 99/100 99/100 100/100 99/100 100/100 100/100 100/100 100/100 II Chicken, Colombia 
31 M1486PM LQXK01000000 19 100/100 100/100 99/100 99/100 100/100 99/100 100/100 100/100 100/100 100/100 II Retail store, Colombia 
32 C15 NFPY01000000 99, 133 100/100 100/100 99/99 99/100 100/100 99/100 100/100 100/100 100/100 100/100 II Faeces, Canada 
33 5 NFQH01000000 62, 72 100/100 100/100 99/100 99/100 100/100 99/100 100/100 100/100 100/100 100/100 II Faeces, Canada 
34 3 NFQJ01000000 43, 50 100/100 100/100 99/97 99/100 100/100 99/100 100/100 100/100 100/100 100/100 II Retail Chicken, Canada 
35 OXC6460 CUPB01000000 2 100/100 100/100 99/100 99/100 100/100 99/100 100/100 100/100 100/100 100/100 II Faeces, UK 
36 OXC6386 CUMP01000000 1 100/100 100/100 99/100 99/100 100/100 99/100 100/100 100/100 100/100 99/100 II Faeces, UK 
37 OXC6559 CUSX01000000 1 100/100 100/100 99/100 99/100 100/100 99/100 99/100 100/100 100/100 100/100 II Faeces, UK 
38 SH-CCF11C627 LISC01000000 1 100/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 93/100 II Chicken, China 
39 BCW_5137 MKCC01000000 23 100/100 100/100 99/100 99/100 100/100 100/100 100/100 100/100 100/100 92/100 II Human, US 
40 ICDCCC-SHCCH11C314 JXAD01000000 1 100/100 100/100 100/100 99/100 99/100 100/100 100/100 99/100 100/100 93/100 II Chicken, China 
41 SH-CCH11C605 LISB01000000 1 100/100 100/100 100/100 99/100 99/100 100/100 100/100 99/100 100/100 93/100 II Chicken, China 
42 SH-CCH11C390 LISA01000000 1,6 100/100 100/100 100/100 99/100 99/100 100/100 100/100 99/100 100/100 93/100 II Chicken, China 
43 SH-CCH11C334 LIRZ01000000 1 100/100 100/100 100/100 99/100 99/100 100/100 100/100 99/100 100/100 93/100 II Chicken, China 
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  LOS Class III 
No. Strain Accession # Contig # 4 5 6 7 8 9 10 11   Gene* Class host 
1 CVM41915 JAJM01000000 55 99/100 99/100 99/100 99/100 100/100 100/100 99/100 99/100 100/100 III Human, US 
2 OXC6263 CUHU01000000 1 99/100 99/100 100/100 99/100 100/100 99/100 99/100 100/100 100/100 III Faeces, UK 
3 OXC6447 CUOY01000000 1 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Faeces, UK 
4 OXC6513 CURI01000000 1 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Faeces, UK 
5 OXC6297 CUJD01000000 2 99/100 99/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 III Faeces, UK 
6 OXC6337 CUKW01000000   1 99/100 100/100 100/100 99/100 100/100 99/100 100/100 100/100 100/100 III Faeces, UK 
7 OXC6380 CUMH01000000  2 99/100 98/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 III Faeces, UK 
8 OXC6472 CUPQ01000000 1 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Faeces, UK 
9 OXC6471 CUPO01000000 1 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Faeces, UK 
10 OXC6428 CUOH01000000 1 99/100 100/100 100/100 99/100 100/100 97/100 100/100 100/100 100/100 III Faeces, UK 
11 OXC6308 CUJQ01000000 1 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Faeces, UK 
12 OXC6267 CUHY01000000 1 99/100 100/100 100/100 100/100 100/100 97/100 100/100 100/100 100/100 III Faeces, UK 
13 CVM 41898 JAJK01000000     2, 66, 
86, 85, 
102 
99/100 100/100  99/100 100/100 100/100 99/100 100/100 100/100 III Human, US 
14 CVM N14784 JOVU01000000 37 99/100 98/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 III Chicken, US 
15 CVM N23169 JOUL01000000 15 99/100 100/100 99/100 99/100 100/100 100/100 99/100 99/100 100/100 III Chicken, US 
16 CVM N26699 JOUP01000000 5 99/100 98/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 III Chicken, US 
17 CVM N462 JOUU01000000 11 99/100 98/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 III Chicken, US 
18 CVM N9077 JOVF01000000    11 99/100 100/100 99/100 100/100 100/100 100/100 99/100 99/100 100/100 III Chicken, US 
19 CVM N3508 JOUS01000000  16 99/100 99/100 99/100 99/100 100/100 99/100 99/100 100/100 100/100 III Chicken, US 
20 CVM N9093 JOVG01000000     7, 75, 90 99/100 98/100 100/100 100/100 100/100  100/100 100/100 100/100 III Chicken, US 
21 CVM N6401 JOVZ01000000 11 99/100 99/100 100/100 99/100 100/100 100/100 99/100 99/100 100/100 III Chicken, US 
22 CCN153 FBHE01000000 20 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Chicken, UK 
23 P604B FBLL01000000 21 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Soil, UK 
24 EC3298 FBJM01000000 13 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
25 EC3529 FAZB01000000 8 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
26 EC3357 FBJD01000000 
 
20 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
27 UNOR13691b FBMF01000000 5 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Chicken, UK 
28 EC3505 FBBL01000000 19 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
29 EC3619 FAZR01000000 2 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
30 EC6049 FBFE01000000 17 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
31 CCN26 FBMP01000000 9 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
32 UNQMCIIS18a FAYE01000000 5 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Human, UK 
33 CCN181 FBJE01000000 29 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
34 EC3879 FAZZ01000000 19 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
35 EC6304 FBCC01000000 18 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
36 EC4194 FAZJ01000000 21 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
37 EC3501 FAYH01000000 22 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
38 EC3693 FBAH01000000 17 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
39 EC3615 FAYJ01000000 3 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
40 EC5259 FBBO01000000 8 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
41 EC4473 FBCJ01000000 19 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
42 EC3623 FBDC01000000 19 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
43 EC3365 FBGZ01000000 12 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
44 EC3533 FBAE01000000 1 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
45 EC6299 FBDF01000000 23 99/100 99/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
46 EC5850 FBBX01000000 4 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
47 EC6124 FBCE01000000 3 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
48 H133040289 FBBI01000000 46 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Environmental water, UK 
49 CCN265 FBJH01000000 10 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Poultry farm , UK 
50 EC3782 FBAD01000000 3 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
51 EC5923 FBBY01000000 4 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
52 H081940749 FBNA01000000 12 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Environmental water, UK 
53 UNOR10622c FBMD01000000 49 99/100 99/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 III Chicken, UK 
54 EC3478 FBHJ01000000 4 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
55 EC4593 FBDH01000000 21 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
56 EC4910 FBFH01000000 14 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
57 EC3537 FBBA01000000 2 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
58 EC3849 FAXR01000000 18 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
59 CCN123 FBIO01000000 16 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Poultry, UK 
60 EC3940 FBBK01000000 7 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Farm environment, UK 
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61 P474A FBKG01000000 18 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Soil, UK 
62 EC3146 FBGF01000000 18 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Farm environment, UK 
63 EC5721 FBFG01000000 16 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy Farm, Faeces, UK 
64 BRIS1041X FBIH01000000 15 99/100 99/100 100/100 100/100 100/100 99/100 99/100 99/100 100/100 III Soil, UK 
65 EC3627 FBAA01000000 4 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy farm, Water, UK 
66 H103480422 FBQB01000000 13 99/100 99/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 III Environmental Water, UK 
67 UNF383D FBGP01000000 49 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Chicken, UK 
68 EC3511 FBHI01000000 15 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Farm environment, UK 
69 EC3575 FBAR01000000 19 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Farm environment, UK 
70 EC3525 FAYA01000000 2 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy farm, Water, UK 
71 EC4297 FBEV01000000 17 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy Farm, Faeces, UK 
72 EC3952 FBCP01000000 2 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Farm environment, UK 
73 EC3521 FBAN01000000 15 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy farm, Water, UK 
74 H110420358 FAYG01000000 40 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 93/100 III Environmental Water, UK 
75 EC3389 FAZG01000000 5 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy farm, Water, UK 
76 H132760749 FAYP01000000 5 99/100 99/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Environmental Water, UK 
77 EC4238 FBFF01000000 18 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Environmental Water, UK 
78 CCN288 FBGL01000000 22 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Poultry farm water, UK 
79 EC6168 FBBM01000000 19 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy Farm, Faeces, UK 
80 EC3786 FBBH01000000 18 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy farm, Water, UK 
81 EC4768 FBDG01000000 22 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy Farm, Faeces, UK 
82 EC3631 FBAQ01000000 20 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy farm, Water, UK 
83 EC3731 FAZA01000000 3 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy farm, Water, UK 
84 EC4098 FBEZ01000000 16 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy farm, Water, UK 
85 P546D FBKR01000000 16 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Soil, UK 
86 H091320788 FBPN01000000 7 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Environmental Water, UK 
87 CCN154 FBHM01000000 16 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Poultry Environment, UK 
88 H140660843 FBJG01000000 14 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Human, UK 
89 EC4722 FBDA01000000 3 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Environmental Water, UK 
90 CCN71 FBIV01000000 3 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Poultry Environment, UK 
91 EC6158 FBBN01000000 18 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
92 CCN292 FBJS01000000 11 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Poultry Environment, 
Water, UK 
93 EC5240a FBBG01000000 3 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy Farm, Faeces, UK 
94 EC3607 FAYZ01000000 14 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy farm, Water, UK 
95 H065100499 FBKW01000000 23 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Environmental Water, UK 
96 EC4102 FBDR01000000 15 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy farm, Water, UK 
97 EC3390 FBHC01000000 11 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy farm, Water, UK 
98 H132580239 FBQD01000000 25 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Human, UK 
99 EC5246a FBBW01000000 5 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy Farm, Faeces, UK 
100 H132580228 FBAS01000000 67 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Environmental Water, UK 
101 EC3756 FAZK01000000 18 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Farm environment, UK 
102 EC3348 FBBD01000000 21 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy farm, Water, UK 
103 EC5183 FBDO01000000 17 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy Farm, Faeces, UK 
104 H073900238 FBOT01000000 44 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Environmental Water, UK 
105 EC6122 FBFM01000000 17 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy Farm, Faeces, UK 
106 EC5240b FBDI01000000 21 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy Farm, Faeces, UK 
107 CCN293 FBIY01000000 9 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Poultry Environment, 
Water, UK 
108 EC3361 FBIC01000000 13 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy farm, Water, UK 
109 EC5679 FBBR01000000 3 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy Farm, Faeces, UK 
110 EC4709 FBCD01000000 20 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Farm environment, UK 
111 EC4214 FAXQ01000000 1 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Dairy Farm, Faeces, UK 
112 H084040382b FBPU01000000 8 99/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 III Human, UK 
113 H132940658 FBPY01000000 23 99/100 100/100 99/100 99/100 100/100 100/100 100/100 99/100 100/100 III Human, UK 
114 EC4250 FBCS01000000 18 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
115 EC5520 FBCO01000000 3 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
116 EC4393 FBAY01000000 3 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
117 EC3956 FAZP01000000 19 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
118 EC5726 FAYM01000000 16 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
119 NCTC12570 FBHN01000000 15 - 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 III Unknown 
120 H120880380 FAYN01000000 44 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 III Human, UK 
121 P474C FBKF01000000 9, 12 - 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Soil, UK 
122 EC4258 FBCM01000000 19 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
123 EC5992 FBDL01000000 20 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
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124 EC5693 FBFN01000000 17 99/100 100/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 III Dairy Farm, Faeces, UK 
125 H130500174 FBQH01000000 39 99/100 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 III Human, UK 
126 CCN56 FBIU01000000 15 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Poultry Farm, Faeces, UK 
127 SWAN392 FBLQ01000000 17 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Duck, UK 
128 EC3721 FBDP01000000 18 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
129 EC4690 FBDB01000000 3 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
130 CCN60 FBGI01000000 5 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Poultry Farm, Faeces, UK 
131 EC4287 FBCK01000000 6 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
132 EC4946 FBCR01000000 18 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
133 EC5479 FAYI01000000 21 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
134 EC5841 FBBP01000000 4 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
135 EC3689 FBDN01000000 22 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
136 EC6173 FBCV01000000 26 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
137 H140460193 FBMV01000000 9 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Human, UK 
138 BRISLC31-1 FBGO01000000 29 99/100 99/100 100/100 100/100 100/100 99/100 99/100 100/100 100/100 III Dog, UK 
139 EC4060 FAYU01000000 20 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
140 EC3370 FAZT01000000 18 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
141 EC5905 FBCF01000000 3 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
142 EC4675 FBCY01000000 21 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
143 EC3385 FBIS01000000 15 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
144 P568B FAXX01000000 13 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Soil, UK 
145 H040680225 FAYW01000000 1 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Human, UK 
146 NCTC11438 FBMN01000000 17 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Human, UK 
147 CCN59 FBJF01000000 14 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Poultry Farm, Faeces, UK 
148 EC3727 FAZQ01000000 5 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
149 EC4242 FBCW01000000 2 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
150 EC3381 FBIN01000000 24 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
151 H053280346 FBOY01000000 15 99/100 99/100 100/100 99/100 100/100 99/100 99/100 100/100 100/100 III Human, UK 
152 EC5531 FBBZ01000000 22 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
153 EC3397 FBCQ01000000 4 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
154 EC3774 FBAJ01000000 7 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
155 EC3373 FBGU01000000 7 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
156 P635D FBKB01000000 18 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Soil, UK 
157 EC3611 FBCL01000000 21 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
158 H063800423 FBQU01000000 38 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 III Environmental Water, UK 
159 H092260569a FBNX01000000 10 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Environmental Water, UK 
160 EC3400 FBAB01000000 18 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
161 H073180384 FBJW01000000 15 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Human, UK 
162 EC4356 FBCI01000000 3 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
163 EC3444 FBBE01000000 4 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
164 P546A FBNB01000000 23 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Soil, UK 
165 CCN119 FBIL01000000 21 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Poultry Environmental, UK 
166 EC3490 FBHP01000000 23 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
167 EC4530 FBDD01000000 14 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
168 EC3344 FBJK01000000 3 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
169 EC4462 FBCH01000000 3 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
170 EC5338 FBFJ01000000 17 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
171 EC5604 FBBV01000000 21 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
172 H044040580 FAZN01000000 48 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Human, UK 
173 H111620356 FAYY01000000 3 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Environmental Water, UK 
174 EC4868 FBCB01000000 1 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
175 H062180535 FAZV01000000 1 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Human, UK 
176 P635A FBKH01000000 18 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Soil, UK 
177 EC3705 FBCZ01000000 3 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
178 EC5072 FBFL01000000 18 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
179 H114640463a FBLE01000000 20 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Human, UK 
180 EC3326 FBAC01000000 2 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
181 H053780444 FBBB01000000 19 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Human, UK 
182 EC4448 FBAZ01000000 6 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
183 EC4978 FBDJ01000000 20 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
184 EC3735 FAXT01000000 7 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
185 H132340486 FAZC01000000 3 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Environmental Water, UK 
186 CCN64 FBJU01000000 24 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Poultry Environmental, UK 
187 CCN72 FBIQ01000000 16 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Poultry Environmental, UK 
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188 H072680465 FBOF01000000 10 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Environmental Water, UK 
189 EC3322 FBJQ01000000 3 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
190 EC3725 FBAV01000000 16 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
191 EC6047 FBCA01000000 2 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
192 EC5983 FBFC01000000 18 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
193 EC6016 FBBF01000000 14 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK  
194 H132760142 FBOU01000000 73 99/100 99/100 100/100 100/100 100/100 99/100 99/100 100/100 100/100 III Environmental Water, UK 
195 H073700405 FBNF01000000 27 99/100 99/100 100/100 100/100 100/100 99/100 100/100 100/100 100/100 III Environmental Water, UK 
196 EC3356 FBJC01000000 7 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Environmental Water, UK 
197 EC4951 FBAX01000000 19 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
198 EC4383 FBCU01000000 18 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
199 EC4277 FBDE01000000 4 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
200 EC5246 FBDM01000000 3 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
201 CCN124 FBJT01000000 9 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Poultry Environmental, UK 
202 EC6203 FBBT01000000 10 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
203 EC3466 FBJJ01000000 20 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
204 EC4808 FBFD01000000 1 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
205 EC5806 FBEY01000000 15 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
206 EC4685 FBDK01000000 1 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
207 EC3748 FAYT01000000 2 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
208 EC4267 FBFB01000000 14 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
209 EC3369 FAYQ01000000 2 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
210 EC3713 FBAU01000000 18 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
211 EC3928 FBCX01000000 19 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
212 EC3875 FAZU01000000 1 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Farm environment, UK 
213 EC5899 FBEO01000000 20 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
214 CCN55 FBMM01000000 21 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Poultry Environmental, UK 
215 EC5947 FBCN01000000 3 99/100 99/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
216 EC4956 FBFK01000000 14 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy Farm, Faeces, UK 
217 EC3498 FBGS01000000 11 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
218 EC4730 FBAO01000000 18 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
219 EC3338 FAYS01000000 19 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Dairy farm, Water, UK 
220 H120880379 FAZX01000000 35 99/100 100/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 III Human, UK 
221 20A_420 MCFT01000000 1 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 III Human, UK 
222 OXC6504 CUQY01000000 1 99/100 100/100 100/100 99/100 100/100 97/100 100/100 100/100 100/100 III Faeces, UK 
223 OXC6474 CUPR01000000 1 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Faeces, UK 
224 OXC6312 CUJV01000000 1 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Faeces, UK 
225 U2 NFOA01000000 4 99/100 98/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Retail Chicken, Canada 
226 ZJ2013CCHD50 JXTV01000000 1 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 III Chicken, China 
 
  LOS Class IV 
No. Strain Accession # Contig# 4 5 6 7 8 9 10 11 12 13 14 15 Class Host 
1 LMG9860 AINS01000000 6, 47 99/100 99/100 100/100 100/100 100/100 99/100 95/82 99/100 99/100 95/99 96/100 99/100 IV Human, Canada 
2 H56 AINW01000000 6 99/100 99/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 95/99 97/100 96/100 IV Human, Switzerland 
3 OXC6425 CUOB01000000 1 99/100 100/100 100/100 100/100 100/100 99/100 99/100 99/100 99/100 95/99 95/100 99/100 IV Faeces, UK 
4 CVM 41963 JAJR01000000 16    100/100 100/100 99/100 99/100 99/100 99/100 95/99 99/100 99/100 IV Human, US 
5 CVM N18725 JOUK01000000 7 100/100 100/100 99/100 100/100 100/100 100/100 100/100 99/100 99/100 99/100 96/100 99/100 IV Chicken, US 
6 CVM N287 JOVY01000000 5 99/100 99/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 95/99 95/100 98/100 IV Pork, US 
7 H044220458 FBAP01000000 39 99/100 99/100 100/100 100/100 100/100 99/100 96/100 99/100 99/100 100/100 96/100 99/100 IV Human, UK 
8 SS_2326 FBER01000000 13 99/100 99/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 95/99 96/100 99/100 IV Chicken, UK 
9 SS_2238 FBEP01000000 35 99/100 99/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 95/99 96/100 99/100 IV Chicken, UK 
10 SS_2226 FBEF01000000 44 99/100 99/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 95/99 96/100 99/100 IV Chicken, UK 
11 H121240507 FAZF01000000 27 99/100 99/100 100/100 100/100 99/100 99/100 99/100 99/100 99/100 95/99 96/100 99/100 IV Human, UK 
12 SS_2296 FBEQ01000000 8 99/100 99/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 95/99 96/100 99/100 IV Chicken, UK 
13 SS_2318 FBEE01000000 14 99/100 99/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 95/99 96/100 99/100 IV Chicken, UK 
14 H043940494 FBNH01000000 24 99/100 99/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 95/99 95/100 98/100 IV Human, UK 
15 SS_2291 FBEN01000000 11 99/100 99/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 95/99 96/100 99/100 IV Chicken, UK 
16 SS_2230 FBEI01000000 10 99/100 99/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 95/99 96/100 99/100 IV Chicken, UK 
17 SS_2351 FBDV01000000 19 99/100 99/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 95/99 96/100 99/100 IV Chicken, UK 
18 SS_2315 FBEG01000000 39 99/100 99/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 95/99 96/100 99/100 IV Chicken, UK 
19 UNOR5482c FBME01000000 23 99/100 99/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 95/99 95/100 99/100 IV Chicken, UK 
20 H121760164 FBQE01000000 23 99/100 99/100 100/100 100/100 100/100 99/100 99/100 99/100 99/100 95/99 96/100 99/100 IV Human, UK 
21 SS_2279 FBEW01000000 13 99/100 99/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 95/99 96/100 99/100 IV Chicken, UK 
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22 SS_2325 FBEK01000000 23 99/100 99/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 95/99 96/100 99/100 IV Chicken, UK 
23 CCN264 FBMQ01000000 11 99/100 100/100 99/100 100/100 100/100 99/100 100/100 99/100 99/100 95/99 95/100 98/100 IV Poultry Environmental, UK 
24 BCW_7432 MJZU01000000 34 99/100 100/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 95/99 95/100 98/100 IV Faeces, US 
25 BCW_7435 MJZX01000000 19 99/100 100/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 95/99 95/100 98/100 IV Faeces, US 
26 BCW_6447 MJWL01000000      14 99/100 100/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 95/99 95/100 98/100 IV Faeces, US 
27 BCW_6448 MJWM01000000 14 99/100 100/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 95/99 95/100 98/100 IV Faeces, US 
 
   LOS 
Class V 
 
 
 
 
 
 
 
 
  LOS Class VI 
No. Strain Accession# Contig# 4 5 6 7 8 9 10 11 12 31 32 14 15 Class Host 
1 84-2 AIMS01000000 17 99/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 99/100 99/100 100/100 VI Swine, UK 
2 1091 AIMV01000000 2, 61 100/100 100/100 100/100 100/100 94/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VI Bovine, US 
3 LMG 9854 AINL01000000 54 99/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 VI Human, 
Canada 
4 CVM N44505F LBDX01000000 2 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VI Cow, US 
5 CVM N51226F LBDL01000000 3, 4 100/100 100/100 100/100  100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VI Cow, US 
6 CVM N13165 JAJT01000000 12 99/100 99/100 100/100 100/100 99/100 100/100 99/100 99/100 98/100 100/100 99/100 98/100 96/100 VI Chicken, US 
7 CVM N20344 JAJU01000000  27, 38, 45 100/100 100/100 100/100  100/100 100/100 100/100 100/100 100/100  100/100 100/100 100/100 VI Chicken, US 
8 CVM N20402 JAJV01000000 1 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VI Chicken, US 
9 UNAJC222 FBHF01000000 8 99/100 99/100 99/100 100/100 99/100 100/100 100/100 99/100 98/100 100/100 100/100 97/100 99/100 VI Pig, UK 
10 H130600457 FAYX01000000 18 99/100 99/100 98/100 100/100 99/100 100/100 100/100 99/100 99/100 100/100 100/100 97/100 99/100 VI Human, UK 
11 P474D FBOC01000000 22 99/100 99/100 99/100 99/100 91/100 99/100 95/100 99/100 98/100 99/100 99/100 96/100 98/100 VI Soil, UK 
12 NCTC11437 FBHL01000000 8 99/100 99/100 100/100 100/100 99/100 100/100 99/100 99/100 98/100 100/100 99/100 97/100 96/100 VI Human, UK 
13 H043920292 FBPD01000000 9 99/100 99/100 98/100 100/100 99/100 100/100 100/100 99/100 99/100 100/100 100/100 97/100 99/100 VI Human, UK 
14 UNLL3.1 FBIK01000000 4 99/100 99/100 100/100 100/100 99/100 100/100 100/100 99/100 98/100 100/100 99/100 97/100 98/100 VI Pig, UK 
15 UNQMCIIS16 FBMK01000000 14 99/100 99/100 100/100 100/100 99/100 100/100 99/100 99/100 98/100 100/100 99/100 97/100 96/100 VI Human, UK 
16 BRISPIG3 FBHR01000000 14 99/100 99/100 100/100 100/100 99/100 100/100 100/100 99/100 98/100 100/100 99/100 97/100 96/100 VI Pig, UK 
17 H125280575 FBKU01000000 19 99/100 99/100 100/100 99/100 99/100 98/90 94/94 99/100 98/100 100/100 100/100 97/100 96/100 VI Human, UK 
18 20G12 LWIH01000000  17, 130, 
132,133, 
160, 169 
99/100 99/76 73/100  99/100 100/100 96/96 99/100 98/100 100/100 100/100 96/100 99/100 VI Milk, US 
19 FNWR7B4_44 MCFS01000000 9 99/100 99/100 100/100 100/100 99/100 100/100 100/100 99/100 98/100 100/100 100/100 97/100 99/100 VI Unknown 
20 BCW_6913 MJZG01000000  22 99/100 99/100 100/100 100/100 99/100 100/100 100/100 99/100 98/100 100/100 99/100 98/100 96/100 VI Faeces, US 
21 BCW_7433 MJZV01000000 36 99/100 99/100 100/100 100/100 99/100 100/100 100/100 99/100 98/100 100/100 99/100 98/100 96/100 VI Faeces, US 
22 Tx40 MDCN01000000   8 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VI Cattle faeces, 
US 
 
No. Strain Accession# Contig# 4 5 6 7 8 9 10 11/11’ 12 13 14 15   Gene* Class Host 
1 SS_2286 FBDZ01000000 21 99/100 99/100 100/100 99/100 99/100 100/100 100/100 99/100 100/100 92/99 95/100 99/99  V Chicken, UK 
2 SS_2278 FBEL01000000 27 99/100 99/100 100/100 99/100 99/100 100/100 100/100 99/100 100/100 92/99 95/100 98/100  V Chicken, UK 
3 H132680116 FBOL01000000 34 99/100 99/100 100/100 99/100 99/100 99/100 96/100 99/100 100/100 93/99 95/100 98/99 99/100 V Environmental 
water, UK 
4 SS_2285 FBES01000000 35 99/100 99/100 100/100 99/100 99/100 100/100 100/100 99/100 100/100 92/99 95/100 98/100  V Chicken, UK 
5 SS_2266 FBEJ01000000 40 99/100 99/100 100/100 99/100 99/100 100/100 100/100 99/100 100/100 92/99 95/100 99/99  V Chicken, UK 
6 H121240502 FBPC01000000 27 100/100 99/100 100/100 99/100 99/100 99/100 96/100 99/100 100/100 93/99 95/100 99/100 100/100 V Human, UK 
7 SS_2349 FBDY01000000 35 99/100 99/100 100/100 99/100 99/100 100/100 100/100 99/100 100/100 92/99 95/100 98/100  V Chicken, UK 
8 SS_2249 FBFO01000000 5 99/100 99/100 100/100 99/100 99/100 100/100 100/100 99/100 100/100 92/99 95/100 98/100  V Chicken, UK 
9 SS_2284 FBDX01000000 49 99/100 99/100 100/100 99/100 99/100 100/100 100/100 99/100 100/100 92/99 95/100 99/99  V Chicken, UK 
10 SS_2276 FBEX01000000 40 99/100 99/100 100/100 99/100 99/100 100/100 100/100 99/100 100/100 92/99 95/100 99/99  V Chicken, UK 
11 H094560717 FBOM01000000        5 99/100 99/100 100/100 99/100 99/100 100/100 100/100 99/100 100/100 99/100 99/100 96/99  V Environmental 
water, UK 
12 SS_2352 FBEH01000000 10 99/100 99/100 100/100 99/100 99/100 100/100 100/100 99/100 100/100 92/99 95/100 98/100  V Chicken, UK 
13 p604A FBPT01000000 18 99/100 99/100 100/100 99/100 99/100 98/100 100/100 99/100 100/100 99/100 99/100 96/99  V Soil, UK 
14 H114640463b FBPS01000000 13 99/100 99/100 100/100 99/100 99/100 100/100 100/100 99/100 100/100 99/100 99/100 96/100  V Human, UK 
15 NCTC11353 FBNV01000000 29 99/100 99/100 100/100 99/100 99/100 99/100 100/100 99/100 100/100 99/100 99/100 96/100  V Pig, UK 
16 H075200514 FBLS01000000 19 99/100 99/100 100/100 99/100 99/100 100/100 100/100 99/100 100/100 99/100 99/100 96/100  V Environmental 
water, UK 
17 SS_2271 FBEU01000000 8 99/100 99/100 100/100 99/100 99/100 100/100 100/100 99/100 100/100 92/99 95/100 99/99  V Chicken, UK 
18 H061980521a FBLK01000000 15 99/100 99/100 99/100 99/100 99/100 100/100 100/100 99/100 100/100 99/100 99/100 96/100  V Environmental 
water, UK 
19 P588B FBKK01000000 17 99/100 99/100 100/100 99/100 99/100 99/100 100/100 99/100 100/100 99/100 99/100 96/99  V Soil, UK 
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  LOS Class VII 
No. Strain Accession# Contig# 4 5 6 7 8 9 10 11 33 34 35 36 13 14 15 Class Host 
1      OXC6309 CUJR01000000          1 99/100 99/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Faeces, UK 
   
22     
2 
    OXC6385 CUMN01000000       1 99/100 99/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 98/100 99/100 VII Faeces, UK 
3  OXC6376 CUMC01000000 2 99/100 99/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Faeces, UK 
4 OXC6601 CUUO01000000           1 99/100 99/100 100/100 99/100 100/100 99/100 99/100 100/100 100/100 100/100 99/100 100/100 100/100 97/100 98/100 VII Faeces, UK 
5 OXC6551 CUVK01000000 1 100/100 99/100 100/100 99/100 90/99 94/99 98/94 100/100 100/100 99/100 99/100 100/100 100/100 97/100 99/100 VII Faeces, UK 
6 OXC6587 CUUB01000000 1 99/100 99/100 100/100 99/100 99/100 100/100 99/100 100/100 100/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Faeces, UK 
7 OXC6426 CUOF01000000       1 99/100 99/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Faeces, UK 
8 OXC6371 CULZ01000000  1 99/100 99/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Faeces, UK 
9 OXC6434 CUON01000000 1 99/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 98/100 99/100 VII Faeces, UK 
10 CVMN41652 LBEQ01000000 4 99/100 99/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Chicken, US 
11 CVMN49243 LBEH01000000 4 99/100 99/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Chicken, US 
12 CVMN51619 LBEE01000000 2 99/100 99/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Chicken, US 
13 CVMN8133 JOVB01000000 8 100/100 100/100 100/100 100/100 99/100 100/100 100/100 99/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 VII Turkey, US 
14 CVMN20320 JOVX01000000 2 99/100 99/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Chicken, US 
15 H063900532 FBPQ01000000 18 99/100 99/100 99/100 99/100 100/100 100/100 100/100 100/100 100/100 99/100 99/100 100/100 100/100 99/100 99/100 VII Environmental water, UK 
16 SS_2294 FBDW01000000 7 99/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Human, UK 
17 H103600372 FBOB01000000 21 99/100 99/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Human, UK 
18 H043200357 FAYD01000000 15 99/100 99/100 99/100 99/100 99/100 100/100 99/100 100/100 100/100 100/100 99/100 100/100 100/100 98/100 99/100 VII Human, UK 
19 H121060205 FBOW01000000 9 99/100 99/100 100/100 99/100 99/100 100/100 99/100 100/100 100/100 99/100 99/100 99/100 100/100 98/100 99/100 VII Human, UK 
20 UNOR4451c FBMH01000000 60 99/100 99/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Chicken, UK 
21 UNOR532A FBIJ01000000 32 99/100 99/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Chicken, UK 
22 H132600169 FBAF01000000 28 99/100 99/100 100/100 99/100 100/100 99/100 99/100 100/100 100/100 99/100 99/100 100/100 100/100 97/100 99/100 VII Environmental water, UK 
23 SWAN331 FBGR01000000 39 93/100 93/100 98/100 99/100 99/100 96/100 99/100 99/100 99/100 99/100 96/100 91/99 98/100 96/100 93/100 VII Duck, UK 
24 SS_2295 FBDS01000000 8 99/100 99/100 100/100 99/100 100/100 99/100 99/100 100/100 100/100 99/100 99/100 100/100 100/100 97/100 99/100 VII Chicken, UK 
25 SWAN195-1 FBGK01000000 46 93/100 93/100 98/100 99/100 99/100 96/100 99/100 99/100 99/100 99/100 96/100 91/99 98/100 96/100 93/100 VII Duck, UK 
26 UNOR7592c FBMC01000000 19 99/100 99/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Chicken, UK 
27 H084040382a FBJY01000000 22 99/100 99/100 99/100 99/100 100/100 100/100 100/100 100/100 100/100 99/100 99/100 100/100 100/100 99/100 99/100 VII Human, UK 
28 H105280404 FAZS01000000 22 99/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Environmental water, UK 
29 H081820599a FAZL01000000 35 99/100 99/100 100/100 99/100 100/100 99/100 99/100 100/100 100/100 99/100 99/100 100/100 100/100 97/100 99/100 VII Environmental water, UK 
30 BCW_5918 MJVY01000000 38 99/100 99/100 100/100 99/100 100/100 99/100 100/100 100/94 100/100 99/100 99/100 100/100 99/100 97/100 99/100 VII Faeces, US 
31 BCW_4454 MJVZ01000000 39 99/100 99/100 100/100 99/100 100/100 99/100 100/100 100/94 100/100 99/100 99/100 100/100 99/100 97/100 99/100 VII Faeces, US 
32 BCW_6450 MJWA01000000 24 99/100 99/100 100/100 99/100 100/100 99/100 100/100 100/94 100/100 99/100 99/100 100/100 99/100 97/100 99/100 VII Faeces, US 
33 BCW_6949 MJZJ01000000 41 99/100 99/100 100/100 99/100 89/99 98/99 99/100 100/100 100/100 99/100 99/100 100/100 100/100 95/100 97/100 VII Faeces, US 
34 BCW_6951 MJZM01000000 9 99/100 99/100 100/100 99/100 100/100 99/100 100/100 100/94 100/100 99/100 99/100 100/100 99/100 97/100 99/100 VII Faeces, US 
35 BCW_6957 MJZR01000000 21 86/97 99/100 100/100 99/100 100/100 100/100 99/100 99/100 99/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Faeces, US 
36 CAM962 BDRY01000000 7 99/100 99/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Faeces, Japan 
37 BCW_4455 MJWE01000000 10 86/97 99/100 100/100 99/100 100/100 100/100 99/100 99/100 99/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Faeces, US 
38 CVM 41971 JAJS01000000  23, 47, 38 99/100 99/100 100/100 99/100  100/100 99/100 99/100 100/100 99/100 99/100 100/100 100/100 98/100 99/100 VII Human, US 
 
  LOS Class VIII 
No. Strain Accession # Contig# 4 5 6 7 8 9 10 11 12 13 14 15 16 17   Gene* Class Host 
1 CVM N29716 ANMS01000000   1 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
2 OXC6424 CUOD01000000    1 100/100 100/100 99/100 100/100 100/100 99/100 100/100 99/100 100/100 100/100 100/100 100/100 99/100 99/100 100/100 VIII Faeces, UK 
3 OXC6630 CUVQ01000000 1 98/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 99/100 VIII Faeces, UK 
4 OXC6568 CUTH01000000    1 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100  VIII Faeces, UK 
5 OXC6343 CULD01000000 1 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 94/100 VIII Faeces, UK 
6 OXC6577 CUTR01000000   1 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100  VIII Faeces, UK 
7 OXC6576 CUTQ01000000 2 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 100/100 99/100 91/100 VIII Faeces, UK 
8 OXC6400 CUNC01000000 1 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100  VIII Faeces, UK 
9 CVM N45963 LBEK01000000 4 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
10 CVM N44406F LBDY01000000 2 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Turkey, US 
11 CVM N44984F LBDW01000000 7 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
12 CVM N47608F LBDS01000000 2 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
13 CVM N48647F LBDR01000000 3 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
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14 CVM N49369F LBDQ01000000 35,59 100/100 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
15 CVM N51183F LBDN01000000 4 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
16 CVM N39665 LBEV01000000 10 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
17 CVM N39671 LBEU01000000 8 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
18 CVM N39677 LBET01000000  2,8 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
19 CVM N40944 LBES01000000 6, 15 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
20 CVM N40946 LBER01000000 2 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
21 CVM N41661 LBEP01000000 6 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
22 CVM N47960 LBEI01000000 1 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
23 CVM N51712 LBEB01000000 6 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
24 CVM N51987 LBEA01000000 2 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
25 CVM N44396F LBDZ01000000 2 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
26 CVM N46596F LBDT01000000 4 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
27 CVM N50039F LBDP01000000 4 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
28 CVM N51201F LBDM01000000 3, 4 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, US 
29 CVM 41917 JAJN01000000 2 100/100 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 94/100 VIII Human, US 
30 CVM 41932 JAJW01000000     1 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Human, US 
31 CVM 41939 JAJX01000000 6 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Human, US 
32 CVM 41955 JAJY01000000 2 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Human, US 
33 CVM 41958 JAKA01000000 2 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Human, US 
34 CVM 41965 JAJI01000000 6 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Human, US 
35 CVM 41976 JAKB01000000 13 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Human, US 
36 CVM 41986 JAJJ01000000 21 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/99 VIII Human, US 
37 CCN178 FBHU01000000 4 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 VIII Poultry Farm 
environment, UK 
38 H131800148 FAYF01000000 4 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 94/100 VIII Human, UK 
39 CCN397 FBGV01000000 15 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Poultry Farm 
environment, UK 
40 H054900335 FBQT01000000 6 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Human, UK 
41 P495D FBLV01000000 8 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Soil, UK 
42 H095340114b FBKC01000000 12 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 99/100 VIII Human, UK 
43 H093960099 FBPM01000000 6 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 99/100 VIII Human, UK 
44 P515A FBAM01000000 17 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Soil, UK 
45 CCN289 FBMU01000000 1 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Poultry farm water, UK 
46 H051080182 FBOQ01000000 16 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Human, UK 
47 H093580323 FBON01000000 4 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 99/100 VIII Environmental Water, 
UK 
48 CCN257 FBHS01000000 5 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 94/100 VIII Poultry farm, faeces, 
UK 
49 H042120298 FBPV01000000 30 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 94/100 VIII Human, UK 
50 H043940500 FBQK01000000 5 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 97/100 VIII Human, UK 
51 H112820480 FBPF01000000 8 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 99/100 VIII Human, UK 
52 CCN19 FBJI01000000 20 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Farm Environment, UK 
53 SWAN269 FBLP01000000 18 88/100 98/100 93/99 93/100 95/100 95/100 92/100 94/100 95/100 95/100 95/100 96/100 91/100 91/100  VIII Duck, UK 
54 CCN355 FBIR01000000 15 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 94/100 VIII Poultry farm, faeces, 
UK 
55 H123080386 FBKI01000000 10, 12 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Human, UK 
56 P515B FBKE01000000   5 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Soil, UK 
57 CCN177 FBHT01000000   6 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 VIII Farm Environment, UK 
58 H133020651a FAYK01000000 12 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Human, UK 
59 H140420240 FBMS01000000 8 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Human, UK 
60 P474B FBKX01000000 6 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Soil, UK 
61 H095340114a FAZE01000000 15 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 99/100 VIII Human, UK 
62 H083960630 FBNN01000000 6 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 99/100 VIII Human, UK 
63 CCN205 FBHO01000000 19 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Poultry Farm Water, UK  
64 P546C FBLN01000000 5 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 94/100 VIII Soil, UK 
65 SWAN350 FBLU01000000 12 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Duck, UK 
66 CCN357 FBJL01000000 14 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 VIII Poultry Farm faeces, 
UK 
67 H132480140 FBQA01000000 15 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Environmental Water, 
UK 
68 SS_2322 FBFP01000000 6 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 91/100 VIII Chicken, UK 
69 H133020651b FBLB01000000 13 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Human, UK 
70 P495B FAXU01000000 11 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Soil, UK 
71 H140420134 FBII01000000 18 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 94/100 VIII Human, UK 
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72 H092260570 FBQR01000000 18 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Environmental Water, 
UK 
73 P515D FAZH01000000 15 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Soil, UK 
74 P588D FBLA01000000 4 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Soil, UK 
75 CCN245 FBGW01000000 6 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 VIII Poultry Farm faeces, 
UK 
76 H134460277 FBPG01000000 11 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 91/100 VIII Human, UK 
77 SWAN195-3 FBLI01000000 4 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 99/100 VIII Duck, UK 
78 P494D FBMB01000000 4 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Soil, UK 
79 H090520713 FBOZ01000000 9 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 84/99 VIII Environmental Water, 
UK 
80 CCN246 FBHD01000000 14 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 VIII Poultry Farm faeces, 
UK 
81 NCTC12568 FBNI01000000 24 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 VIII Pig, UK 
82 H054000444 FBOO01000000 28 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 90/100 VIII Environmental Water, 
UK 
83 P494B FBAK01000000 15 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Soil, UK 
84 H102240161 FAYC01000000 13 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 99/100 VIII Environmental Water, 
UK 
85 H090660740 FBPI01000000 22 100/100  100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 99/100 100/100 VIII Environmental Water, 
UK 
86 H054000445 FBPB01000000 15 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Environmental Water, 
UK 
87 NCTC12567 FBGX01000000 18 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Human, UK 
88 SWAN249 FBGQ01000000 23 88/100 98/100 93/99 93/100 95/100 95/100 92/100 94/100 95/100 95/100 95/100 96/100 91/100 91/100  VIII Duck, UK 
89 H070680142 FBNW01000000 9 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/85 100/100 VIII Human, UK 
90 SS_2329 FBFS01000000 10 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 91/100 VIII Chicken, UK 
91 P495c FBQW01000000 13 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 99/100 99/100 VIII Soil, UK 
92 CCN20 FBJP01000000 6 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 VIII Farm Environment, UK 
93 UNCIC2 FBIW01000000 11 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Chicken, UK 
94 VA6 MPIQ01000000 2 88/100 98/100 93/99 93/100 96/100 95/100 92/`100 94/100 95/100 95/100 90/97 89/98 91/100 91/100  VIII Raw water, Sweden 
95 OXC6296 CUJE01000000         1 99/100 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 91/100 VIII Faeces, UK 
96 OXC6597 CUUK01000000        1 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 91/100 VIII Faeces, UK 
97 RC105 CYQJ01000000 15, 18 100/100 100/100  99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 VIII Supermarket, UK 
98 RC148 CYQO01000000 4 100/100 100/100 100/100 99/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 100/100 99/100 100/100 VIII Supermarket, UK 
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Appendix-III 
       Presentation of Abstracts  
    (Associated to unpublished manuscripts) 
 Hameed, A., Machado, L., Woodacre, A., Marsden, G. Induction of inflammasome-dependent 
signalling in the human monocytic cell line THP-1 by Campylobacter lipooligosaccharides. A 
poster presented to: ASM Microbe 2019, Moscone Center, California, US, 20 – 24 June 2019. 
 
 Hameed, A., Machado, L., Woodacre, A., Marsden, G. Interleukin-1β induction in the human 
monocytic cell line THP-1 by lipooligosaccharides of Campylobacter species. A poster 
presented to: 5th Midlands Molecular Biology Meeting (M4), University of Warwick, UK, 13 -14 
Sep 2018. 
 
 Hameed, A., Machado, L., Woodacre, A., Marsden, G. Analysis of the Genetic Diversity of 
the Campylobacter Lipooligosaccharide Biosynthesis Locus using In Silico and Molecular 
Typing. A poster presented to: 47th World Congress on Microbiology, London, UK, 10 -11 
Sep 2018. 
 
Unpublished Manuscripts 
 
 Hameed A. Human immunity against Campylobacter infection. Immune Network (A review 
article; accepted; under process). 
 
 Hameed A, Machado LR, Woodacre A, Marsden GL. An updated classification system and 
review of the lipooligosaccharide biosynthesis gene locus in Campylobacter jejuni. (A review 
article; submitted on 30th of October 2019).  
 
 Hameed A, Woodacre A, Allen S, Machado LR, Marsden GL. Analysis of the genetic 
diversity of the Campylobacter lipooligosaccharide biosynthesis locus using in silico and 
molecular typing (A research article; in preparation for submission). 
 
 Hameed A, Woodacre A, Allen S, Marsden GL, Machado LR. Induction of NLRP-3 
inflammasome-dependent signalling in the human monocytic cell line THP-1 by 
Campylobacter lipooligosaccharides (A research article; in preparation for submission). 
 
 
 
